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A new class of Cu(II) phenanthroline-phenazine complexes (developed in Dublin City 
University) have recently been reported to have the highest DNA binding constants of 
any copper therapeutic complex and at a similar level to Actinomycin. These new 
complexes show great clinical potential with their high activity against a range of in-
vitro mammalian cell lines including those with cisplatin resistance however the 
underlying biological mechanism of their action has yet to be explored in-depth. 
 
The biological data generated in this project has examined the activity of the Cu(II) 
phenanthroline-phenazine complexes in selected mammalian cells lines in-vitro and 
demonstrated that the Cu(II) complexes are highly active against cisplatin resistant 
(SKOV-3 and A2780/ Cis) cells. The use of γH2AX a DNA DSB marker demonstrated 
a high number of foci in cisplatin resistant (SKOV-3) cells compared to the cisplatin 
sensitive (MCF-7) cells. The strong detection of mitochondrial outer membrane 
potential (MoMP) decay in resistant (SKOV-3 and A2780/ Cis) cells after exposure to 
the Cu(II) phenanthroline-phenazine complexes was complemented by the potential 
disruption of mitochondrial protein homeostasis, with resultant mitochondrial toxicity 
and apoptosis induction detected by gene expression studies. The work was then 
complemented by the untargeted whole cell quantitative LFQ proteomics method. 
Proteomics of both resistant (SKOV-3) and sensitive (MCF-7) cell lines demonstrated 
increased production of metal sequestration by metallothioneins (Metallothionein-2, -
1X) and, heat shock (HSP70) and ribosomal proteins (40S and others) however, 
metabolic proteins (glycolysis/ gluconeogenesis, fatty acid synthesis and purine 
metabolism related) tended to dominate the repertoire of the resistant cells. This 
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evidence suggests the response of the cell to the Cu(II) phenanthroline-phenazine 
complexes is associated with its energy status. 
 
Parallel in-vivo studies using the G. mellonella model was carried out with the Cu(II) 
phenanthroline-phenazine complexes to examine the in-vivo biological mechanistic 
response to the Cu(II) complexes. The Cu(II) complexes presented a superior toxicity 
profile when compared to cisplatin and through high-resolution LFQ proteomics it was 
determined that the in-vivo response was characterised by metabolic enzymes 
(glycolysis/ gluconeogenesis and purine metabolism related) and detoxification 
processes (GST). Both in-vitro and in-vivo data generated in this project demonstrated 
that the mitochondria and associated metabolic factors in addition to the DNA 
interactions inducing apoptosis play a vital role in the mechanism of action of the Cu(II) 
complexes. However, this is not withstanding the fact that this work also provided clues 
to other associated mechanisms of action which warrants further investigation. This 
work demonstrated for the first time the molecular mode of action of this class of novel 
Cu(II) phenanthroline-phenazine complexes in both in-vitro and in-vivo biological 
models. The strong activity of these Cu(II) complexes against cisplatin resistant cells 
has the potential to offer a novel and alternative therapeutic option to the challenge of 
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negative control. PCA of three replicates for the negative control and three replicates of 
both test exposures. Enclosures define the different experimental conditions. Red X 
denotes the third replicates from each condition removed from the analysis due to lack 
of clustering. 
 
Fig. 3.16 Hierarchical clustering of SSDA proteins and statistically significant proteins 
with less than a 1.5 fold change in the SKOV-3 cell line after 24 h exposure to Cu-Phen 
(1) and Cu-DPQ-Phen (2) in relation to the control. Hierarchical clustering generated 
from mean Log(2) transformed values of LFQ abundance with samples clustered 
through columns. 
 
Fig. 3.17 GO analysis of biological process in SKOV-3 cells exposed to Cu-Phen (1) 
and Cu-DPQ-Phen (2) with respect to the negative control after 24 h incubation. Process 
containing more than 2 proteins was of greater interest for the analysis. 
 
Fig. 3.18 GO analysis of molecular process in SKOV-3 cells exposed to Cu-Phen (1) 
and Cu-DPQ-Phen (2) with respect to the negative control after 24 h incubation. Process 
containing more than 2 proteins was of greater interest for the analysis. 
 
Fig. 3.19 KEGG analysis of significantly upregulated proteins in glycolysis/ 
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gluconeogenesis. Phosphoglycerate kinase (2.7.2.3) (green). 
 
Fig. 3.20 STRING based protein interaction analysis of statistically significant protein 
with fold changes ≥ 1.5 in the SKOV-3 cell after 24 h exposure to Cu-Phen (1) and Cu-
DPQ-Phen (2) compared to the negative control. The STRING analysis demonstrated 
that there is not a strong clustering of proteins identified. 
 
Fig. 3.21 Principle component analysis (PCA) of whole cell lysate proteome of SKOV-
3 cells exposed to Cu-Phen (1) and Cu-DPQ-Phen (2) for 48 h in comparison to a 
negative control. PCA of three replicates for the negative control and three replicates of 
both test exposures. Enclosures define the different experimental conditions. Red X 
denotes the third replicates from each condition removed from the analysis due to lack 
of clustering. 
 
Fig. 3.22 Hierarchical clustering of SSDA proteins and statistically significant proteins 
with less than a 1.5 fold change in the SKOV-3 cell line after 48 h exposure to Cu-Phen 
(1) and Cu-DPQ-Phen (2) in relation to the control. Hierarchical clustering generated 
from mean Log(2) transformed values of LFQ abundance with samples clustered 
through columns. 
 
Fig. 3.23 GO analysis of biological process in SKOV-3 cells exposed to Cu-Phen (1) 
and Cu-DPQ-Phen (2) with respect to the negative control after 48 h incubation. Process 
containing more than 25 proteins was of greater interest for the analysis. 
 
Fig. 3.24 GO analysis of biological process in SKOV-3 cells exposed to Cu-Phen (1) 
and Cu-DPQ-Phen (2) with respect to the negative control after 48 h incubation. Process 
containing more than 20 proteins was of greater interest for the analysis. 
 
Fig. 3.25 KEGG analysis of significantly upregulated proteins in glycolysis/ 
gluconeogenesis. Glucose-6-phosphate isomerase (5.3.1.9) (red), 6-phosphofructokinase 
(2.7.1.11) (orange), fructose-bisphosphate aldolase (4.1.2.13) (yellow), triose-phosphate 
isomerase (5.3.1.1) (grey), glyceraldehyde-3-phosphate dehydrogenase (1.2.1.12) 
(pink), glyceraldehyde-3-phosphate dehydrogenase (NAD(P)+) (1.2.1.59) (wine), 
bisphosphoglycerate mutase (5.4.2.4) (purple), phosphoglycerate kinase (2.7.2.3) 
(brown) and L-lactate dehydrogenase (1.1.1.27) (blue). 
 
Fig. 3.26 KEGG analysis of significantly upregulated proteins in the pentose phosphate 
pathway. Glucose-6-phosphate isomerase (5.3.1.9) (orange), 6-phosphofructokinase 
(2.7.1.11) (brown) and fructose-bisphosphate aldolase (4.1.2.13) (yellow). 
 
Fig. 3.27 KEGG analysis of significantly upregulated proteins in fatty acid biosynthesis 
pathway. Fatty acid synthase (FASN) (red). 
 
Fig. 3.28 KEGG analysis of significantly upregulated proteins in purine metabolism. 
Nucleoside diphosphate kinase (2.7.4.6) (red). 
 
Fig. 3.29 STRING based protein interaction analysis of statistically significant protein 
with fold changes ≥ 1.5 in the SKOV-3 cell after 48 h exposure to Cu-Phen (1) and Cu-
DPQ-Phen (2) compared to the negative control. The dashed red oval highlights 




Fig. 3.30 Venn diagram illustrating the number of protein commonly upregulated in 
each of the cell lines and timepoints with all proteins abundances in each experimental 
condition of ≥ 1.5 fold change. Proteins related to the 4 major comparisons are 
displayed in Table 3.10. 
 
Fig. 4.1 Detection of changes in % MMP (ΔΨ) decay in A2780 and A2780/ Cis cells at 
24 h after exposure to IC50 concentration of Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-
Phen (3), Cu-DPPN-Phen (4), doxorubicin and cisplatin with H2O2 used as a positive 
control. All treatments have been normalized to the negative control. Baseline 
represents the negative control and no loss of mitochondrial membrane potential. 
Statistical significance set at 0.05 with Bonferroni correction performed on two-way 
ANOVA. N=8. 
 
Fig. 4.2 Detection of changes in % MMP (ΔΨ) decay in MCF-7 cell at 24 h after 
exposure to IC50 concentration of Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3), 
Cu-DPPN-Phen (4) and cisplatin with H2O2 used as a positive control. All treatments 
have been normalized to the negative control. Baseline represents the negative control 
and no loss of mitochondrial membrane potential. Statistical significance set at 0.05 
with Bonferroni correction performed on two-way ANOVA. N=7. 
 
Fig. 4.3 Gene expression of A2780 cells at 24 h following exposure to doxorubicin, 
cisplatin, Cu-Phen (1) and Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen 
(4). Error bars represent 95 % Confidence interval (N=4). 
 
Fig. 4.4 Gene expression of A2780/ Cis cells at 24 h following exposure to doxorubicin, 
cisplatin, Cu-Phen (1) and Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen 
(4). Error bars represent 95 % Confidence interval (N=4). 
 
Fig. 4.5 Mitochondrial related gene expression of MCF-7 cells at 48 h following 
exposure to cisplatin, Cu-Phen (1) and Cu-DPQ-Phen (2). Error bars represent 95 % 
Confidence interval (N=3). 
 
Fig. 4.6 Mitochondrial related gene expression of SKOV-3 cells at 48 h following 
exposure to cisplatin, Cu-Phen (1) and Cu-DPQ-Phen (2). Error bars represent 95 % 
Confidence interval (N=3). 
 
Fig. 5.1 Inoculation procedure for G. mellonella larvae. Twenty µl was injected into last 
left pro-leg. Image adapted from Cotter et al. (2000). 
 
Fig. 5.2 Living (A) (normal colour) and dead (B) (melanised) G. mellonella. Image 
adapted from Kavanagh & Fallon (Kavanagh and Fallon 2010). 
 
Fig. 5.3 Characteristic changes (A-D) in response to test inoculation. 
 
Fig. 5.4 Piercing point (anterior portion) of the G. mellonella larvae for haemocyte 
extraction indicated by the black arrow. 
 
Fig 5.5 Heatmap representation of Table 5.4 showing the mean larval mortality (%) 





Fig. 5.6 Changes in haemocyte count 24 h post inoculation with Cu-Phen (1) and Cu-
DPQ-Phen (2) and Cu-DPPZ-Phen (3). In addition to the Cu(II) phenanthroline-
phenanzine complex series the solvent, sham-inoculated and undisturbed controls were 
used for comparison. 
 
Fig. 5.7 Relative expression of (IMPI) and transferrin after 24 h exposure to LD50 value 
of Cu-Phen (1), Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3). Gene expression is 
displayed relative to the undisturbed control with the solvent control used to determine 
significance (p < 0.05) (N=4).  
 
Fig. 5.8 2D PAGE gel of separated haemolymph proteins from G. mellonella 
inoculated, (a) reference gel (control), (b) Cu-Phen (1), (c) Cu-DPQ-Phen (2) and (d) 
Cu-DPPZ-Phen (3). Circled spots excised and identified through LC/ MS and 
descriptions displayed in Table 5.7 
 
Fig. 5.9 Principle component analysis (PCA) of haemolymph proteomic profiles of 
larvae inoculated with Cu-Phen (1), Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3) versus 
the solvent control. PCA of four replicates for the solvent control and three replicates 
for each of the test exposures. Enclosures define the different experimental conditions. 
  
Fig. 5.10 Hierarchical clustering of haemolymph profiles of larvae inoculated with Cu-
Phen (1), Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3) versus the solvent control. Heat 
map generated using mean protein expression values of statistically significant 
differentially abundant proteins. Four replicates for the solvent control and three 
replicates for each of the test exposures. Samples are clustered through columns. 
 
Fig. 5.11 Volcano plots highlighting proteins altered in abundance in haemolymph of G. 
mellonella larvae following inoculation with Cu-Phen (1) (A), Cu-DPQ-Phen (2) (B) 
and Cu-DPPZ-Phen (3) (C). Plots represent protein intensity differences (-log2 mean 
intensity difference (difference)) and significance in differences (-log P-value) based on 
a two sided t-test. Points above the curve are considered statistically significant (p < 
0.05). Points above the line and to the right are present at higher levels of abundance in 
the test exposure and have a fold change ≥ 1.5. Points above the line and to the left are 
present at lower levels of abundance in the test exposure and have a fold change ≥ 1.5. 
Proteins annotated represent an example of differentially expressed proteins following 
inoculation with the test complex in comparison to the solvent control. Volcano plots 
are based on post imputated data. 
 
Fig. 5.12 Bar chart showing the different number of proteins present in a test exposure 
that is associated with selected biological processes (A) and molecular functions (B). 
Comparative bar charts represent level 4 ontology. 
 
Fig. 5.13 KEGG analysis of the metabolism of selected xenobiotics by cytochrome 
P450. Glutathione S-transferase (2.5.1.18) (pink) is shown to be significantly 
upregulated in all test exposures.  
 
Fig. 5.14 KEGG analysis of significantly upregulated proteins in glycolysis/ 
gluconeogenesis (highlighted: blue, green, grey, orange and pink) between all test 
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exposures. Cu-DPQ-Phen (2) shows no upregulation of 4.2.1.11 (phosphopyruvate 
hydratase) (pink). 
 
Fig. 5.15 KEGG analysis of significantly upregulated proteins in purine metabolism 
(highlighted: pink, yellow, blue and red). 
 
Fig. 6.1 Summary of the biological effects of the Cu(II) phenanthroline-phenazine 
complexes in both cisplatin sensitive (MCF-7 and A2780) and cisplatin resistant 
(SKOV-3 and A2780/ Cis) cells. 
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1.1 The Pharmaceutical Industry 
Pharmacology is the branch of medicinal chemistry with biology studying the users, 
effects and modes of actions of drugs (synthetic, natural or endogenous) on the body. 
Many of the disciplines can be described through the region of the body they target such 
as: neuropharmacology, psychopharmacology and cardiovascular pharmacology among 
others, with the other major disciplines concerning the use of molecular and 
epidemiological analysis on the targeting and development of drugs (Rang and Hill 
2013). The development of pharmaceuticals can trace its origins back to 1550 BC with 
the earliest known compendium of medical conditions and herbal derived remedies 
(Wreszinski 1937; Rang and Hill 2013). These earliest records of the use of remedies 
and medicines developed into a more formalised structure in the 19th and 20th century 
where the modern pharmaceutical industry was born. The pharmaceutical industry today 
is one of the largest and most powerful industries in the world with revenues from sales 
in 2015 exceeding 1 trillion dollars and projected sales to reach 1.6 trillion dollars by 
2020 (Arlington 2017). Ireland has a well-established pharmaceutical industry with over 
75 companies and annual sales exceeding 39 billion euros producing an accumulated 
total of 40 FDA approved drugs to date (Fanning 2017). While many aspects of the 
study of pharmacology overlap, the development of pharmaceuticals can be broadly 
divided into pharmaceuticals and biopharmaceuticals. The development of 
biopharmaceuticals occurred after the identification of antibody structure and the 
establishment of hybridoma technology. The use of antibodies in therapy is referred to 
as immunotherapy and is implemented by identifying disease targets that when bound 
by the therapeutic antibody, have either an agonist or antagonist function, thereby 
ameliorating the disease (Breedveld 2000). Biopharmaceuticals also descripbes a large 
array of biological products produced from recombinant DNA technologies such as 
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blood clotting factors, hormones, interferon and interleukin based products. Traditional 
pharmaceuticals are often described as “small molecules”, typically 900 Daltons in size 
which readily diffuse across the cell membrane to reach intracellular sites in the cell 
(Ganellin et al. 2013). Small molecules are developed through organic and inorganic 
synthetic medicinal chemistry and are targeted towards different cellular processes and 
biological molecules such as DNA or proteins in specific cellular and metabolic 
pathways. 
 
1.1.1 Pharmaceutical drug design process 
The pharmaceutical drug development and approval process can take between 12-15 
years and encompasses different stages, many of which overlap (FDA 2015). Broadly, 
the process can be described under three phases: discovery, development and 
commercialization (Fig. 1.1). The discovery phase usually describes the therapeutic 
concept, target selection, target validation, lead compound identification and 
optimization. The developmental phase usually includes preclinical development, 
clinical development and regulatory approval. The final commercialization phase often 
overlaps with the development phase, sharing clinical development, regulatory approval 
and finally product production (Hait 2010). The first development stage of drugs is 
often associated with the Research and Development divisions of pharmaceutical 
companies and as medicinal chemistry research projects in 3rd level academic 
Institutions. In the developmental stage the production of a small molecule drug is 
subjected to multiple iterations in design and may produce tens of thousands of 
compounds for initial screening to identify a small number of select candidates with the 
most potent therapeutic effect. The selected lead compounds then progress on to the 
clinical trial phase which can also take up to 7 years. These 2 phases can be laborious 
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and time consuming with only the possibility of one FDA approved drug at the end of 
the process (FDA 2015). Figure 1.1 illustrates the drug develop and approval process 
over time to lead to an FDA-approved medicine.  
 
Fig. 1.1 Drug development and approval process. Image adapted from FDA, (2015). 
 
The mechanism of evaluating the functional and therapeutic characteristics of lead 
compounds involves both in-vitro and in-vivo assessments. In-vitro models are the 
primary driver of research in cellular biology and were first identified by Gey and 
Colleagues (Scherer et al. 1953). Subsequent efforts were placed in the development of 
synthetic culture media and growth factors which preserved the differentiated cellular 
phenotype (Levintow and Eagle, 1961). There are now several tissue and cell culture 
repositories maintained around the world (Geraghty et al. 2014). The most prominent 
for Ireland is the European funded ECACC for Public Health England, established in 
1985 and over 40,000 accessible cell lines, representing 45 different species, 50 tissue 
types, 300 HLA types, 450 monoclonal antibodies and at least 800 genetic disorders 
(ECACC 2017). Additionally, the American Tissue Culture Collection (ATCC) is also 
available with a range of cell lines (ATCC 2017).  
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The vast collections of cell lines representing different tissue phenotypes has provided 
the essential platform to understand cellular systems and their response to novel drugs 
under development. Therefore the screening process of drug development relies heavily 
on in-vitro mammalian cell culturing. The in-vivo models are subsequently utilised after 
in-vitro mammalian cell lines have identified and characterised the candidate drug along 
with an established in-vitro efficacy. In-vitro mammalian cell line models have 
limitations such as: the testing of only a single cell type in an experiment, monolayer 
growth in comparison to 3 dimensional growth patterns, the use of artificial cell culture 
media to maintain cell growth and the loss of certain interactions between different cell 
types which effects cell growth. The in-vivo testing can utilise multiple species such as 
mice, rat, dog, chicken and monkeys all of which can be used along with different 
models of the human tumour process in anticancer pharmaceutical development. The 
combination of circulatory, immune, detoxification, excretion, musculo-skeletal and 
nervous systems provides the most comprehensive assessment of both the ability of the 
organism to tolerate and the efficacy of the developmental therapeutic. While some in-
vivo animal models can emulate certain human tumours, genetic engineering methods 
such as GEM, tumour xenograft and PDX can also be used to emulate human tumours 
for the purposes of novel pharmaceutical evaluations (Liu et al. 2017). The use of 
invertebrate models such as Drosophila melanogaster and Caenorhabditis elegans has 
been central to the study of developmental biology and genetics (Wilson-Sanders 2011). 
Other models such as Galleria mellonella has also proved to be a valuable normal tissue 
invertebrate model for evaluating potential utility and targets of therapeutic agents 
(Cotter et al. 2000; Kavanagh and Reeves 2004; Renwick and Kavanagh 2007; Rowan 
et al. 2009; Kavanagh and Fallon 2010; Browne and Kavanagh 2013; Browne et al. 
2014) and the development of models for neurological conditions (Thompson and 
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Marsh 2003; Neri 2011). Both the in-vitro and in-vivo stages in the discovery phase 
provide the critical pre-clinical data which is required to advance the candidate drug 
onto the clinical phase where human testing can begin.  
 
1.1.2 Development of chemotherapeutic drugs 
Chemotherapeutic drugs have been used for decades to treat a range of malignancies 
along with their more recent use in non-cancerous complex diseases. The designs have 
ranged from synthetic chemicals, natural product extracts to humanised monoclonal 
antibody therapies designed through recombinant DNA technologies. Chemotherapy 
was originally coined by Paul Ehrlich in the early 1900s, and is broadly defined as 
compounds that kill fast growing malignant and neoplastic cells. Chemotherapy 
originates in the use of nitrogen mustard to treat patients for non-Hodgkin’s lymphoma 
in 1942 (Krumbhaar and Krumbhaar 1919; Gilman 1946). The nitrogen mustard 
predecessor, sulphur mustard (mustard gas), was originally utilised as a chemical 
warfare agent in World War I effecting troops with disabling skin blisters and 
subsequently had a high degree of carcinogenicity. Nitrogen mustard was later found to 
result in temporary regression of lymphoid tumours. The optimism generated by the 
discovery of the therapeutic properties of nitrogen mustards Methyl-Bis(Beta-
Chloroethyl)amine Hydrochloride and Tris(Beta-Chloroethyl)amine Hydrochloride in 
1946 (Goodman et al. 1945) led to the development of cyclophosphamide, another 
DNA alkylating agent (Gross and Wulf 1959). The increasing nutritional research from 
1937 onwards had shown that deficiencies in folic acid produced the same regressive 
effect in bone marrow as had been demonstrated in lymphoid tissue with nitrogen 
mustard, precipitating the synthesis of antifolate drugs such as aminopterin and 




The founding of the National Cancer Institute (NCI) in 1937 permitted the eventual 
formulation of a systematic drug screening programme commencing after the 
identification of the thiopurine drugs, such as 5-Fluorouracil (Heidelberger et al. 1957), 
which inhibit adenine metabolism and are still widely used today. In the 1960s, the 
Food and Drug Administration (FDA) approved the use of alkylating agents, antifolates, 
fluoridated pyrimadines and vinca alkaloids in combination to treat a variety of solid 
and haematological tumours. The earliest reported combination regimens was POMP 
(6-mercaptopurine, vincristin, methotrexate and prednisone) (Rodriguez et al. 1973) for 
treating acute adult leukemia and this was followed by several others, such as COAP 
(cyclophosphamide, vincristine, cytarabine and prednisolone) and CART (cytarabine, 
asparaginase, daunorubicin and thioguanine) providing higher success rates in acute 
lymphocytic leukemia and solid tumours (Spiers et al. 1975). In 1965, cisplatin a 
platinum based drug was discovered serendipitously to inhibit cell division in E.coli and 
was later found to erradicate transplanted sarcomas in mice (Rosenberg et al. 1965). 
This was superior to mustard gas because treated cells could recover, meaning that the 
DNA targeting effects of mustard gas were more severe to cells. However, the FDA did 
not approve its use for treatment of metastatic testicular and ovarian cancer until 1978 
with further platinum analogues such as carboplatin, nedaplatin (Japan) and oxaliplatin 
approved for use in 1986, 1995 and 1996, respectively (Monneret 2011). Cisplatin was 
later found to have a broad range of activity across multiple solid tumours, cementing 
its position as one of the most indispensable chemotherapeutic agents today. Since the 
1980s a rapid increase in the use of molecular biology with advanced cell culture 
systems has allowed indentifications and characterisation of novel therapeutic agents 
resulting in faster discoveries of novel chemotherapeutic drugs. In 1989, the NCI 
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introduced the Developmental Therapeutics Programme; a 60-cell line panel, to identify 
novel drug mechanisms of action by using the known biological mechanisms from key 
cell line phenotypes, thereby accelerating their development (Shoemaker 2006). The 
introduction of the DTP NCI programme also assisted in the maturation of hybridoma 
technology which culminated in the development of the first monoclonal antibody 
therapy (Imatinib), and the subsequent hugely expanded range of other monoclonal 
therapies targeting multiple tumour types. The completion of the human genome project 
in 2003 (Human Genome Sequencing Consortium 2004) along with improvements in 
protein isolation, modifications and profiling has led to specific targeting of synthetic 
small molecules with modifications designed to specific molecules of known cell 
signalling pathways, particularly related to cell growth and development. This 
capability to target specific signal transduction events in the cell has permitted a 
refinement of drug activity and a reduction in adverse effects and toxicity to healthy 
cells, improving patient outcomes (Sever and Brugge 2015). 
 
Throughout the development of chemotherapies, DNA has remained one of the most 
sought after pharmaceutical sites to target. The initial development of alkylating agents 
such as cyclophosphamide and nitrogen mustard was complemented with folic acid and 
adenine metabolism inhibitors, all of which affect DNA replication. The discovery of 
cisplatin was shown to bind DNA specifically at guanine and purine nucleobases 
leading to DNA strand crosslinking, oxidative lesions and subsequently, damage. DNA 
is widely considered to be the main target of therapeutic action of cisplatin although 
recently, additional non-DNA mechanisms have also been proposed (St Germain et al. 
2010; Florea and Büsselberg 2011; Koch et al. 2013; Shaloam and Tchounwou 2014). 
What is clear is that cisplatin led to significant improvements in survival rates from 
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many solid tumours and has resulted in one of the few curative treatments for germline 


























1.2 Cisplatin and platinum derivatives 
1.2.1 Cisplatin discovery 
The platinum based compound, cisplatin was first described by Michele Peyrone in 
1844 (Peyrone 1844) (Fig. 1.2), however its pharmacological properties would remain 
unknown until Barnett Rosenberg’s serendipitous discovery.  
 
Fig. 1.2 Molecular structure of cisplatin. 
 
During the 1960s, Rosenberg began a series of experiments examining the effect of 
electrical currents on Escherichia coli and discovered throughout the experiments, that 
cell division was being inhibited and an escalation in filamentous growth was occurring 
(Fig. 1.3) (Rosenberg et al. 1967). 
 
The causative agent of the bacterial cell division inhibition and filamentous growth was 
determined to be (NH4)2PtCl6 under electrolysis conditions. Additionally Loretta Van 
Camp demonstrated that stock preparations of (NH4)2PtCl6 underwent photochemical 
change and became enhanced in bacterial medium. Both cis-[Pt(NH3)2Cl4] and cis-
[Pt(NH3)2Cl2] inhibited cell division in-vitro and were subsequently tested in-vivo for 






                                      A                                                                    B 
Fig. 1.3 Filamentous growth of E. coli (B) after exposure to platinated nutrient broth. 
Non-filamentous growth shown in image A adapted from Rosenberg et al. (1967). 
 
The more active cis-[Pt(NH3)2Cl2] was examined for its antitumour capability in S180 
murine sarcomas and after an initial 8 day growth period it was discovered that a single 
8 mg/kg dose resulted in successful regression of the tumours after 8 days (Fig. 1.4) 





Fig. 1.4 In-vivo study of effects of cis-[Pt(NH3)2Cl2] on the progression of S180 
sarcoma tumours in mice. Image adapted from Rosenberg and Van Camp, (1970). 
 
This key finding led to clinical trials beginning in 1971 and its later approval for use 
against testicular and ovarian adenocarcinoma in 1978. While it was initially approved 
for use against two solid tumours its approval was later incorporated into combination 
therapies for treating bladder, lung, head and neck, gastric and triple negative breast 
cancers making it the backbone of many therapeutic regimes (Chabner 2010). 
 
Since its discovery, cis-DDP (cisplatin) has remained the only stereoisomer (Fig. 1.5) to 
have biological activity and as such has had hundreds of analogoes developed. The 
trans isomer (trans-DDP) was also investigated by Rosenberg (Rosenberg et al. 1967) 
with two other series of investigation by Cleare and Hoeschele (1973a, 1973b), 




Fig. 1.5 Cis-trans isomerism structure of cisplatin. 
 
Its inactivity was explained by its weaker inhibition of DNA replication and poor 
capability of forming DNA adducts as effectively as cisplatin, greatly reducing its in-
vitro and in-vivo capability (Kalinowska-Lis et al. 2008). However, the extensive 
literature examining platinum based drugs has provided a new motivation to examine 
the effects of the trans isomer on DNA and its effect on other regulatory elements 
(Coluccia and Natile 2007; Kalinowska-Lis et al. 2008). This is due to transplatin’s 
ability to produce relevant in-vitro cytotoxicity when the amine ligands are substituted 
by aromatic N- donor heterocycles, branched aliphatic amines, or imino ligands 
(Coluccia and Natile 2007). Multiple type of ligands coordinated by platinum have been 
investigated for their cytotoxic capability and clinical efficacy such as aminoether, 
planar amines, carboxylato, non-planar heterocyclic, aliphatic, 2-phenylindole, 





The primary mechanism through which cisplatin yields its cytotoxicity in the cell is 
thought to be through DNA binding and damage (Basu and Krishnamurthy 2010), 
although more recent evidence suggests that non DNA effects may have an equally 
important role (Messori and Merlino 2016). The binding of DNA with cisplatin occurs 
following hydrolysis and the formation of the charged platinum complex, 
[Pt(NH3)2(H2O)Cl]
+. The complex interacts with DNA through the N7 position of either 
guanine or the adenine base. The remaining chloride is displaced through further 
hydrolysis allowing platinum to bind the second nucleotide base. The intra strand 
binding of the cisplatin-DNA adduct results in destacking of the nucleotide bases 
leading to the DNA helix becoming ‘kinked’ (Fig. 1.6). The ‘kinked’ DNA is then 
recognised by nuclear high-mobility group proteins which bind the lesion and prevent 







Fig. 1.6 Cisplatin forming a 1,2-intrastrand d(ApG) crosslink in DNA. Other forms of 
adduct formation produce less pharmacological active effects. Image adapted from 
Gelasco and Lippard, (1998) and Turel and Kljun, (2011).  
 
The formation of cisplatin-DNA adducts results in cell cycle arrest and cellular 
apoptosis activation. The activation of p53 remains central to the cascade of signal 
transductions which result in apoptosis (Fig. 1.7) (Basu and Krishnamurthy 2010). The 
outcome of cell death occurs through a complex series of interactions primarily 
emanating from the activation of p53 after platinum adduct formation followed by high-
mobility group proteins locating to the platinated site and subsequently an inability to 
complete DNA repair. The inherent inability of DNA repair in some prokaryotic (Beck 
and Brubaker 1973) and eukaryotic (Fraval et al. 1978) cells was shown in 1973 and 
1978, respectively, and both demonstrated accelerated cisplatin activity with 
mechanistic activity that was strongly related to DNA repair capacity. The activation of 
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p53 can precipitate the activation of cell cycle arrest through Growth Arrest and DNA 
Damage-inducible 45 (GADD45), p21 and Mouse double minute 2 homolog (Mdm2), 
and the activation of apoptosis through direct action of the Caspase cascade specifically 
with Caspase-6 and -7. Apoptosis can also be signalled with P53 induction of BCL-X 
protein where cytochrome c is released from the mitochondrial to activate Caspase-9 
and then Caspase-3 (Basu and Krishnamurthy 2010; Dasari and Tchounwou 2014). 
 
 
Fig. 1.7 Overview of the cellular response to cisplatin-induced DNA damage. Image 
adapted from Basu and Krishnamurthy, (2010). 
 
Estimates of the percentage of cisplatin bound to DNA typically record less than 5 % 
which has concentrated efforts in studying its interaction with proteins (Gullo et al. 
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1980; Eastman 1983, 1986; Messori and Merlino 2016). While the action of cisplatin 
has been widely associated with DNA interaction, cisplatin has a potent affinity for 
intracellular proteins rich in thiol and histidine residues. Indeed the interaction between 
cisplatin and proteins play a determinant role in the pharmacokinetics of cisplatin 
through cellular transport, uptake, biodistribution and toxicity profile changes (Knipp et 
al. 2007; Casini et al. 2012). Major functional classes of protein have been shown to 
interact with cisplatin such as: haemoglobin (Lammering et al. 1999), serum albumin 
(Barnes and Lippard 2004), transferrin (Khalaila et al. 2005; Zhao et al. 2005), 
glutathione (Kasherman et al. 2009), and metallothioneins (Knipp et al. 2007; Karotki 
and Vašák 2009) among others.  
 
Due to the irreversible nature of cisplatin binding to DNA and its ability to effect 
healthy tissue, the possibility of mutations and secondary tumours due to these effects is 
increased (Sakai et al. 2008; Dertinger et al. 2014). Furthermore, as described above, 
the pervasive nature of cisplatin protein interaction and consequent disruption in cellular 
function remains one of the key factors limiting prolonged use of this therapeutic. While 
cisplatin displays ototoxicity, gastrotoxicity and myelosuppression, nephrotoxicity 
remains one of the biggest rate limiting factors in its prolonged use. The kidney absorbs 
(particularly in the proximal convoluted tubule) cisplatin at higher concentrations than 
any other tissue in the body. With the accelerated uptake, a potentiation of the multitude 
of apoptotic signals results from activation of the endoplasmic reticulum, p53, Reactive 
Oxygen Species (ROS), mitochondrial cytochrome c release and TNFR (Karasawa and 
Steyger 2015). The majority of patients undergoing cisplatin therapy experience some 
form of renal dysfunction monitored through serum creatinine and blood urea nitrogen 
levels, an increase of which indicate a deterioration of renal clearance (Akcay et al. 
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2010). The uncoordinated binding of cisplatin to sulphur residues on circulating 
proteins is typically addressed by diuretics and administration of sulphur containing 
agents which provide a decoy molecule to bind the platinum agent and limit the damage 
of biologically produced sulphur rich proteins (Kröning et al. 2000; Peres and Cunha 
Júnior 2013; Rosic et al. 2017). Carboplatin and oxaliplatin, analogues of cisplatin, 
have a lower protein binding capability and consequently have become more common 
in oncology treatment than cisplatin. 
 
1.2.2 Platinum derivatives 
Carboplatin is one of the most successful analogues generated to-date and one of the 
few widely accepted for the treatment of ovarian, lung, head and neck cancers. 
Carboplatin differs from cisplatin in that it contains a bidentate carboxylate ligand in 
place of the two chloride ligands. This alteration results in slower DNA binding kinetics 
and diminished protein-carboplatin complexation. The combination of these features 
result in reduced nephrotoxicity compared to cisplatin (Dasari and Tchounwou 2014a). 
Oxaliplatin is another commonly used platinum analogue with a high degree of activity 
against colon cancer and typically used as part of a combination therapy of leucovorin 
and 5-fluorouracil (André et al. 2004; Mayer 2012). This analogue stands alongside 
several other modified platinum coordinated ligands currently undergoing clinical trials. 
Carboplatin differs from cisplatin with a bidentate carboxylate in place of the two 
chloride ligands (Fig. 1.8) and oxaliplatin contains the bidentate ligand, 1,2-






                                 
 
Fig. 1.8 Molecular structures of cisplatin (top, in dashed box) and its clinical platinum 
derivatives: carboplatin (middle left), oxaliplatin (middle right), nedaplatin (lower left), 
heptaplatin (lower right) and lobaplatin (bottom). Images adapted from Hannon, (2007). 
 
Alongside the worldwide approved carboplatin and oxaliplatin, the additional platinum 
agents; Nedaplatin (Japan) (Fig. 1.8), Lobaplatin (China) (Fig. 1.8) and Heptaplatin 
(Fig. 1.8) have gained single market approval (Wheate et al. 2010) with the hope that 
international approval will follow. Nedaplatin contains the same amine carrier ligands 
as cisplatin but with a bidentate five-membered ring structure providing the same DNA 
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binding capability as cisplatin but decreased renal and gastrointestinal toxicities 
(Kameyama et al. 1990; Niioka et al. 2007; Shimada et al. 2013). Lobaplatin contains a 
lactic acid leaving group and forms mainly GG and AG intra-strand cross links and is 
believed to influence the expression of c-myc, a key transcription factor in the 
regulation of cell proliferation (McKeage 2001). Heptaplatin development sought to 
maintain the properties of cisplatin while emulating the reduced toxicities of carboplatin 
while not demonstrating platinum cross-resistance. A combinatorial phase III study 
showed that heptaplatin with 5-fluorouracil responded similarly to cisplatin tolerable 
toxicities (Choi et al. 2004; Lee et al. 2009). The ‘traditional’ mono platinum based 
drug design are being increasingly joined by variants such as the oral delivery 
candidate, satraplatin [Pt(NH3)2(cyclohexylamine)Cl(COOCH3)2] (Lovejoy and Lippard 
2009), and the current state-of-art polyplatinum(II) compounds, TriplatinumNC-A and 
TriplatinumNC derived from the parent BBR3464 complex have shown promising 
activity in phase I and II clinical trials (Farrell 2015). Investigations are continuing on 
the monofunctional platinum complex with the recent evaluation of N-heterocyclic 
ligated phenanthriplatin. This has been reported to have promising activity exceeding 
cisplatin and oxilaplatin and an NCI-60 cell panel suggesting a different mechanism of 
action to the clinical complex (Park et al. 2012). 
 
1.2.3 Cellular resistance mechanisms to cisplatin 
Due to the ubiquitous and widespread success of cisplatin and platinum-related 
therapies, a considerable body of literature describing the numerous cisplatin resistance 
mechanisms exists. Cisplatin therapy has demonstrated a high degree of effectiveness 
against testicular germ cell cancer, with a durable complete remission rate of greater 
than 80 % (Feldman et al. 2008; Winter and Albers 2011). In contrast, rates of 
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resistance to cisplatin therapeutic regimes are considerable increased in ovarian, lung, 
prostate and colorectal cancer patients (Giaccone 2000; Köberle et al. 2010). The 
resistance mechanism are part of four main categories: pre-target (cellular transport 
mechanisms), on-target (acting on the site of DNA adduct formation), post-target 
(intracellular response to DNA adduct formation) and off-target (effects unrelated to 
DNA adduct formation) (Galluzzi et al. 2012). At the pre-target stage the expression 
level of the copper transporter 1 (CTR1) has been shown to have a strong effect on the 
active transport of cisplatin into the cytoplasm with lower expression levels resulting in 
lower intracellular accumulation of cisplatin and the consequently protective effect 
(Holzer and Howell 2006). Overexpression of the efflux transporters Adenosine 
Triphosphate 7A/ B (ATP7A/B) and Multi-Drug Resistance 2 (MRP2) also function to 
reduce the intracellular accumulation of cisplatin (Aida et al. 2005; Yamasaki et al. 
2011). Prior to DNA adduct formation the upregulated expression of glutathione S 
transferase (Chen and Kuo 2010) and metallothioneins (Notta and Koropatnick 2006) 
can result in inactivation through increased antioxidant capacity, the capture of 
superoxide and hydroxyl radicals through the presence of cysteine residues and heavy 
metal sequestration. On-target resistance at the DNA platinum adduct site can take 
many forms. The increased action of the Nucleotide Excision Repair (NER) process has 
been noted through multiple studies to increase the tendency for cisplatin resistance by 
allowing the DNA integrity to be maintained (Bellmunt et al. 2006; Olaussen et al. 
2006; Jun et al. 2008; Kim et al. 2008). The increase in Translesion Synthesis (TLS) 
which encompasses a process, which allows for platinum adduct regions to be bypassed 
by DNA Polymerase H (POLH) (Ceppi et al. 2009; Shachar et al. 2009) and the 
catalytic subunits of the TLS DNA polymerase ζ (Roos et al. 2009; Shachar et al. 
2009). In addition to the increased action of NER and TLS, deficiencies in Mismatch 
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Repair (MMR) proteins such as Methylation-dependent Silencing 1 (MLH1) (Gifford et 
al. 2004) and MutS protein Homologue 2 (MSH2) (Kamal et al. 2010) often show 
mutated or depressed activity. A large number of intracellular proteins associated with 
resistance to apoptosis are involved post-target such as BAX-like proteins, B-Cell 
Lymphoma 2 (BCL-2) like proteins, Baculoviral IAP repeat-containing protein 5 
(BIRC5), calpains, caspases, Mitogen Activated Protein Kinase (MAPKs), p53 and 
XIAP-associated factor 1 (XAF1) (Galluzzi et al. 2012). BCL-2 protein family can act 
in both a pro-apoptotic (BAX) and anti-apoptotic (BCL-2) manner. Deficiencies in 
BCL-2 associated X protein (BAX)/BCL-2 homologous antagonist killer (BAK) has 
been shown to confer resistance in in-vitro models (Kroemer et al. 2007; Tajeddine et 
al. 2008) and overexpression in BCL-2 and B-cell Lymphoma extra-large (BCL-XL) has 
been shown to increases resistance in-vitro with clinical data being currently collected 
(Michaud et al. 2009; Jain and Meyer-Hermann 2011). With regards to caspase initiated 
apoptosis, modification of the activation cascade has been shown in-vitro to increase the 
resistance profile to cisplatin (Janson et al. 2010). The overexpression of BIRC5 
proteins; X-linked inhibitor of apoptosis protein (XIAP), cytoplasmic Inhibitor of 
Apoptosis 1/ 2 (cIAP1/ 2) was shown to be associated with chemoresistance and poor 
prognosis (Altieri 2008; Ryan et al. 2009). Drug development approaches are currently 
being evaluated for BIRC5 inhibition (Groner and Weiss 2014; Hagenbuchner et al. 
2016). In relation to apoptosis, XAF1 is another protein that antagonises IAP activity 
and was reported to be at highly expressed and associated with improved progression-
free survival in bladder cancer patients (Plenchette et al. 2007; Pinho et al. 2009). The 
MAPKs such as c-Jun N-terminal Kinases (JNKs), Extracellular signal–Regulated 
Kinases (ERKs) and Stress Activated Protein Kinases (SAPK) have demonstrated 
chemoresistant and chemosensitive properties with experimental data leading to 
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uncertainty of the clinical data (Brozovic and Osmak 2007; Haagenson and Wu 2010; St 
Germain et al. 2010; Li and Melton 2012; Kong et al. 2015). Similar to MAPK related 
proteins, p53, which is a highly deterministic protein in terms of cell fate has been 
associated with both sensitivity and resistance to cisplatin therapy (Liang et al. 2011; di 
Pietro et al. 2012; Chee et al. 2013). Mechanisms of resistance not related to the site of 
cisplatin action have been associated with a cell death process such known as autophagy 
and this has been associated with cisplatin resistance (Ren et al. 2010; Yu et al. 2011; 
Xia et al. 2014), overexpression of Epidermal Growth Factor Receptor (EGFR) (Hsu et 
al. 2009; Mandic et al. 2009; Ahsan et al. 2010; Rho et al. 2011) and the association of 
Heat-Shock Proteins (HSPs) in cisplatin resistant profiles (Shen et al. 2012; Stope et al. 
2016). Due to the complex nature of cisplatin resistance and the heterogeneity of the 
cells within the tumour mass in patients, proteomic approaches alone have been unable 
to completely describe the changes generating the different response profiles. The 
analysis of glycosylation states of protein, a Post Translational Modification (PTM), is 
allowing a greater insight into the functions of proteins during resistance development, 
particularly the action of intracellular detoxification proteins (Ferreira et al. 2015). 
Extensive efforts have been placed on the understanding of biological resistance 
mechanisms and the development platinum analogues to cisplatin which do not elicit 
cross-resistance. In this effort the development of alternative metal-based drugs present 








1.3 Non-platinum based coordination compounds 
Due to the success of cisplatin and its platinum related FDA approved analogues in 
addition to multitude of other related compounds in the developmental pipeline, 
attention has been focused on the development of a non-platinum based DNA 
coordination chemotherapeutic. This is primarily to provide a new repertoire of metal-
based drugs to help treat tumours resistant to platinum based therapeutics or to help 
alleviate platinum based toxicities and adverse reactions commonly present after 
prolonged treatment regimes. Multiple transition metals (copper, ruthenium, gold, 
silver, iron, cobalt and titanium) and metalloids (gallium and arsenic) have formed the 
coordination centre of multiple ligand types and chemistries. Table 1.1 provides an 
overview of metal-based drugs currently in development. 
 
1.3.1 Ruthenium 
Ruthenium complexes have been designed in both the transition states ruthenium(II) 
and ruthenium(III) with Ru(II) capable of forming both penta- or hexa-coordination and 
Ru(III) capable of forming only hexa-coordination. The use of Ru(III) has been 
demonstrated in-vivo to be reduced to Ru(II) in hypoxic conditions, typical of the 
tumour environment (Spreckelmeyer et al. 2014). Ru(II) additionally, has recorded 
lower systematic toxicity than platinum-based compounds with Ru(II) complexes 
binding to iron-binding proteins such as transferrin and albumin, leading to increased 
accumulation in cells and upregulation of iron selective transport proteins and 
potentially redusing the overall therapeutic dose required (Guo et al. 2013). 
Ruthenium(II) has three lead complexes to-date: RM175, RAPTA-C and RDC-11, and 
Ru(III) have two lead complexes to-date: KP1019 and NAMI-A. RM175, 
[Ru(biphenyl)(en)Cl]PF6, a lead compound from the Ru(II)-arene complex family binds 
25 
 
DNA through aromatic ligand intercalation or covalent metal ion binding (Hayward et 
al. 2005). Hydrolysis reactions of [Ru(η6-p-cym)(acac)Cl] ( p-cym = para-cymene) in 
DNA binding occur through loss of the chloride ligand and the resulting species binding 
to guanine and adenine (Fernández et al. 2004). The ruthenium complex KP1019, [Ru 
(HIn)2Cl4](H2In) (HIn = indazole) which has a III transition state also binds DNA and 
induces apoptosis through the intrinsic mitochondrial pathway (Hartinger et al. 2006). 
This complex demonstrated activity against tumour cell lines which were known to 
over-express multi-drug resistance proteins (multidrug resistance protein 1 MRP1, 
breast cancer resistance protein BCRP, and lung resistance protein LRP) (Hartinger et 
al. 2006). Phase I trials began in 2003 with no dose-limiting toxicity detected (Dittrich 
et al. 2005). More recently, conjugations of Ru(III)-indazole complexed with PARP-1 
have been reported to disrupt the DNA repair process (Wang et al. 2014). Alternative 
modes of interaction have been observed with arene-ligated and water soluble 
phosphine Ru(II) complexes, [Ru(η6-p-cym)(1,3,5-triaza-7-phospha-adamantane)Cl2] 
(RAPTA-C) capable of interacting with the cysteine peptidase, cathepsin B resulting in 
the degradation of the extracellular matrix which then helps to slow down metastases 
(Casini et al. 2008; Ang et al. 2011). The [Ru(2-phenyl- pyridine)(NCMe)2phen]PF6 
(phen is 1,10-phenanthroline) (RDC-11) belongs to RDC family of organometallic 
Ru(II) compounds have been shown to induce apoptosis through activation of the pro-
apoptotic protein CHOP (CCAAT/Enhancer-Binding Protein Homologous Protein) 
which induces the unfolding stress response in the endoplasmic reticulum (Meng et al. 
2009). Another Ru(III) complex which is involved with the inhibition of the 
extracellular membrane along with other cellular functions is NAMI-A (trans-
[Ru(HIm)(DMSO)Cl4](H2Im) (Him=imidazole; DMSO=dimethylsulfoxide). Unusually, 
NAMI-A did not demonstrate strong in-vitro or in-vivo activity, it did however show 
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strong inhibition of metastases (Sava et al. 2003; Gava et al. 2006). As a result of this 
capability clinical trials began in 1999 with the phase I trials demonstrating a low 
toxicity of the complex but had no significant benefit to non-small cell lung cancer 
patients. Phase II clinical trials proceeded but combined with gemcitabine and 
ultimately demonstrated no significant efficacy beyond the use of gemcitabine alone 
(Leijen et al. 2015). Ruthenium complexes represent a highly customizable chemistry 
with partially filled 4d electronic sub-shell allowing for the tuning of reduction 
potential, ligand affinity, substitution rates and altering metal centrochirality and planar 
chirality, all the features allowing for strong future development. 
 
1.3.2 Gold 
In 1985, the phosphine ligated Au(I) complex, auranofin unexpectedly demonstrated 
decrease in the incidence of cancer in patients being treated for rheumatoid arthritis 
(Fries et al. 1985). Later their activity was linked to thioredoxin reductase inhibition, 
which is typically elevated in cancer cells (Bruijnincx and Sadler 2008a). The new 
intracellular target of phosphine ligated Au(I) prompted a more intensive study of the 
redox potential along with their strong binding affinity for thiol and sulphur containing 
proteins (Hayashi et al. 2014; Abbehausen et al. 2016; Al-Jaroudi et al. 2017; Milaeva 
et al. 2017; Reddy et al. 2017; Tavares et al. 2017). In relation to the study of adduct 
formation between gold(III) compounds/ ions, Glišić et al. has studied the oxidation 
mechanism of amino acids (glycine, methionine, histidine, cysteine etc.) using mass 
spectrometry (Glišić, Rychlewska and Djuran 2012). Au(III) complexes are another 
major group of cytotoxic active gold complexes. When Au(III) complexes were initially 
synthesised their square planar geometry and similar isoelectronic point to Pt led to the 
belief that their mode of interaction in the cell would be similar to Pt(II) complexes that 
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target DNA. However subsequent investigation failed to demonstrate a strong 
interaction between DNA and Au(III) complexes (Ronconi et al. 2006; Milacic and Dou 
2009). More recently the interaction of Au(III) complexes and the newly discovered 
telomeric G-quadruplex DNA therapeutic targets have shown to be of increased interest 
(Gratteri et al. 2015; Bertrand et al. 2017). Au(III) complexes have been bound to 
multiple ligand types such as: multidendate, bipyridine, hydroxo and amino-quinoline. 
The multidendate ligands: [Au(en)Cl2]Cl, [Au(dien) Cl]Cl2, [Au(cyclam)][ClO4]2Cl, 
[Au(terpy)Cl]Cl2, and [Au(phen)Cl2]Cl demonstrated high cytotoxicity in A2780 
ovarian adenocarcinoma cells and in addition overcame the cisplatin resistant variant 
(Gabbiani et al. 2007). The complexes were shown to have a high rate of hydrolysis and 
interestingly no renal tubular necrosis in in-vivo studies (Casini et al. 2010). The 
functionalised bipyridine complexes with the general formula [Au(N-N)Cl2][PF6] 
(where N-N = 2,2'- bipyridine, 4,4'-dimethyl-2,2'-bipyridine, 4,4'-dimethoxy-2,2'-
bipyridine, and 4,4'-diamino-2,2'-bipyridine) have demonstrated moderate cytotoxicity 
in A2780/ Cis cells which indicates that the cross resistant phenotypes typical of 
platinum cross resistance may not be effecting the activity of these Au(III) complexes 
(Rabik et al. 2007; Casini et al. 2010). A group of Au(III) ligated hydroxyl and amino-
quinoline ligands have also demonstrated anti-proliferative potency exceeding cisplatin 
in many cases. Investigations using supercoiled pBR322 plamid DNA have again 
demonstrated a weak interaction however strong interactions have been detected with 
cytochrome c suggesting a very different mechanism of action to that of Pt(II) 
complexes (Martín-Santos et al. 2015). Overall the Au complexes have shown a large 
degree of instability in aqueous solution due to their very rapid hydrolysis at 
physiological conditions which poses developmental challenges for the future, however 
their strong protein thiol binding and activity against platinum cross-resistant cells 
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Silver is a well known antimicrobial agent. However for chemotherapeutics use, the 
development of Ag(I) complexes have not demonstrated the same degree of success as 
other transition metals. In spite of this disadvantage silver has a number of advantages 
as the coordination centre of potential chemotherapeutics. While toxicity from silver is 
well known in bacteria, for humans it is uncommon which provides for the ability to use 
its capacity for coordination with a lower possibility of systemic toxicity (Hadrup and 
Lam 2014). Silver’s anticancer capability differs from platinum based-drugs in terms of 
DNA interaction, mitochondrial targeting, inhibition of thioredoxin reductase and 
potential antioxidant capability (Pellei et al. 2012), similarly to the features observed 
with gold(III) complexes (Hickey et al. 2008; Banti et al. 2012, 2014). Three primary 
design formats have been in use for Ag(I) complexes; N-hetercyclic carbenes, 
phosphines and N-heterocycles. N-hetercyclic carbene Ag(I) complexes while having a 
better response than cisplatin in certain in-vitro situations, the in-vivo situation presents 
a number of problems such as rapid clearance from the system. Ubiquitous chloride ions 
can abstract Ag in solution and sulphur rich proteins can inactivate the complexes 
(Medici et al. 2016). The use of phosphine ligands on Ag(I) complexes has been 
beneficial mostly in antimicrobial development. The development of N-heterocycles has 
typically been associated with other metal centres due to Ag(I) being more limiting. 
Positive activity has been observed in MCF-7 (breast adenocarcinoma) and HeLa 
(cervical cancer) along with an antioxidant effect and purified DNA interaction studies 
suggesting intercalation or electrostatic interactions are likely (Banti et al. 2015). 
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Recently a series of polynuclear Ag(I) dicarboxylate complexes with variable length 
linker chains demonstrated good cytotoxicity against MCF-7 and SKOV-3 (ovarian 
adenocarcinoma) cells, in addition no ROS generation or significant increase in the 
DNA double stranded break marker γH2AX was detected (Thornton et al. 2016). 
Overall, while the low or absent nature of the systemic toxicity with Ag(I) has provided 
a strong developmental incentive, challenges such as rapid clearance, Ag abstraction 
and sulphur rich protein inactivation in in-vivo environments have frustrated extensive 
assessment of this transition metal as a potential chemotherapeutic drug. 
 
1.3.4 Iron 
Iron is a trace element and is an essential component in a number of cellular processes 
such as oxygen transport, DNA synthesis, oxidation phosphorylation and cell cycle 
progression. All of these processes can be involved in carcinogenesis (Coombs et al. 
2012; Gasche 2013). The use of iron in the form of organometallic ferrocifen rings has 
been used in the clinic to treat certain forms of oestrogen receptor (ERα+) breast cancer 
cells. The ferrocifen ring has been incorporated into the existing organic drug tamoxifen 
by replacing one phenyl ring in the tamoxifen structure. The modified tamoxifen/ 
ferrocifen is highly active against breast cancer cells that are ERα-ve (ERβ+ve) as well 
as cells that are ERα+ve (Vessières et al. 2006; Lange et al. 2008; Rafique et al. 2010). 
The activity of ferrocene has also been integrated with chloroquine in the development 
of antiparasitic agents (Blackie and Chibale 2008). The chelation of iron is currently 
used for the treatment of β-thallassemia patients, where abnormal levels of intestinally 
absorbed iron occur with the subsequent increase in DNA, protein, and lipid oxidation 
(Cappellini et al. 2008). Data have shown that desferrioxamine is capable of reducing 
the incidences of neuroblastoma and leukemia (Desoize 2004). More recently, iron 
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depletion therapies have been proposed for multiple cancers (Kovacevic and Richardson 
2012; Keeler and Brookes 2013; Richardson et al. 2013; Torti and Torti 2013). 
 
1.3.5 Cobalt 
Cobalt(II) has been combined with acetylsalicylic acid which has been shown to inhibit 
Cyclooxygenase-1 and -2 (COX-1, -2) enzymes. COX1/ 2 are enzymes involved in 
prostanoid synthesis, including thromboxane and prostaglandins. COX-1 is 
constitutively expressed while COX-2 is inducible. While acetylsalicylic acid also 
inhibits COX-1 and COX-2 enzymes independent of cobalt the coordination with cobalt 
through cobalt-alkyne complexes was shown to increase enzyme inhibition and 
anticancer activity (Ott et al. 2004; Bruijnincx and Sadler 2008b; Algra et al. 2012). 
Co(III) complexes have also been explored as prodrugs which are reduced to Co(II) in 
hypoxic environments releasing their cytotoxic ligand that is destined for DNA 
alkylation or matrix metalloproteinase inhibition (Ahn et al. 2006; Failes et al. 2007; Lu 
et al. 2011). 
 
1.3.6 Gallium 
The metalloid gallium has been known to accumulate in tumour tissue and as such it has 
been used as a radio tracer using gamma cameras to diagnose lymphomas and 
osteomyelitis (Bryan 2010; Bleeker-Rovers et al. 2011). Gallium shares multiple 
similarities with iron such as similar ionic radius, ionization potential and electron 
affinities (Chitambar 2012). These similarities allow gallium to bind with transferrin, 
which can potentially allow gallium complexes to be transported via transferrin 
receptors in a similar fashion to ruthenium complexes (Chitambar and Antholine 2013). 
Gallium nitrate was the first gallium compound to be brought to phase I and phase II 
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clinical trials, with moderate success against non-Hodgkin’s lymphoma and advanced 
bladder cancer, however long intravenous infusions to prevent nephrotoxicity 
complicated the success of the formulation (Chitambar 2012). Gallium(III) complexes 
of 8-hydroxyquinoline have also been shown to interfere with the cellular transport of 
iron with its competitive binding to transferrin and thereby inhibiting the supply of iron 
to fast dividing cells. Independently, gallium(III) complexes have also been shown to 
interfere with the activity of ribonucleotide reductase, which results in an inhibition of 
DNA synthesis (Deally et al. 2012). Anti-tumour activity has also been recorded in 
phosphinoarylbisthiolato gallium(III) complexes (Fischer-Fodor et al. 2014). They 
showed strong activity against cisplatin-resistant A2780/ Cis cells and demonstrated an 
ability to bind DNA in the 7-methylguanine and 8-oxoguanine positions, oxidizing the 
pyrimidine bases and resulting in apoptosis (Fischer-Fodor et al. 2014). In addition to 
gallium nitrate, the gallium complex KP46 was also successfully brought to clinical 
trials with further studies being planned (Valiahdi et al. 2009). Owing to the success of 
the clinical trial data on gallium compounds and complexes there is a strong incentive to 




In the 1990s, Titanium in the form of titanocene dichloride entered clinical trial as an 
anticancer agent, however high toxicity related to Reactive Oxygen Species (ROS) 
production rendered it unsuitable soon afterwards (Christodoulou et al. 1998; Lümmen 
et al. 1998). Many parallels with cisplatin had been observed with this agent in relation 
to the cis-dichloride composite and its hydrolyzation with water to form a variety of 
species. The active component of the drug is still unclear and information regarding its 
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DNA binding has not yet been elucidated (Strohfeldt et al. 2007; Deally et al. 2012; 
Melendez 2012). More recently the ligand isopropoxide supported by pyrrolyl Schiff 
base ligands have been coordinated to Ti(IV) and shown cytotoxic activity towards 




The arsenic treatment, arsenic trioxide (As2O3) was approved by the FDA in 2000 for 
the treatment of acute promyelocytic leukemia demonstrating increased rates of survival 
(Douer et al. 2003; Wang and von Recum 2011). More recently darinaparsin (S-
dimethylarsino-glutathione) has been approved for use in treating T-cell lymphoma with 
evidence suggesting that the Nuclear factor (erythroid-derived 2)-like 2-Kelch-like 
ECH-associated protein 1 (Nrf2-Keap1) pathway is important in the difference between 














Table 1.1 Overview of metal-based drugs in development. 





Multiple ligands and  
 
polyplatinum complexes  
 
 Highly established clinical 
therapeutic,  
 Known toxicities. 
 Well established co-
treatment regiments. 
 High renal toxicity. 
 Cross-resistance of 
platinum therapies. 
 
 Strong potential for the 
development of new platinum 
therapies which do not suffer 









 Overcoming therapeutic 
resistance in in-vitro cells 
expressing multi-drug 
resistance protein. 
 Strong DNA intercalator 
(known chemistry). 
 Failure to demonstrate 
benefit in phase II trials 
over present therapy 
(NAMI-A). 
 Highly customizable 
chemistry: ligand affinity, 
centro and planar chirality. 
 Low toxicity in previous 
clinical trials. 
Gold: 





 Similar square planar 
geometry and isoelectric 
point to Pt. 
 Low renal tubular necrosis 
in in-vivo studies. 
 Rapid hydrolysis and 
instability in aqueous 
solution. 
 New studies assessing protein 
inhibition potential. 
 Strong thiol protein binding 
and activity against platinum 
resistance cells. 
Silver: 
Ag(I) multiple ligands 
 
 Known antimicrobial 
properties. 
 Low systemic toxicity in 
humans. 
 Different anticancer 
properties to platinum 
complexes. 
 Rapid biological 
clearance. 
 Detoxification by sulphur 
rich proteins. 
 Strong possibilities in 
antimicrobial development 
 Greater knowledge of  
mechanism of action would 
allow for more targeted 
development 
Iron: 
Fe(II) and Fe(III) 
 
 
 Complex biological 
processes for and transport 
and utilisation (reducing 
systemic toxicities). 
 Modified tamoxifen/ 
ferrocifen treating ERα-ve 
and ERα+ve. 
 Failure to demonstrate 
significant anticancer 
activity with multiple 
ligand types  
 Therapies focusing principally 





 Co(II) combined with 
acetylsalicylic acid 
inhibiting COX-1, -2 
enzymes. 
 Increased enzyme 
inhibition. 
 Limited number of ligand 
types tested. 
 Potential as pro drug (Co(III) 
→ Co(II)) releasing cytotoxic 






 Competitive binding of 
iron. 
 Similar chemistry to Iron 
 Strong therapeutic activity 
against cisplatin resistance 
cells. 
 Nephrotoxicity has been 
difficult to overcome in 
clinical trials.  





 Cytotoxicity exceed 
cisplatin in many tumour 
cell lines 
 Toxicities related to high 
ROS activity. 





 Present in current T-cell 
lymphoma therapies. 
 As2O3 in treatment of acute 
promyelocytic leukemia. 
 
 Short plasma half-life and 
narrow therapeutic 
windows. 
 Promising development in 
haematological malignancies 
Copper: 




 Well known targeting 
effects (DNA, ROS and 
enzymatic inhibition). 
 High activity against 
cisplatin resistance cancer. 
 Can become easily 
oxidized. 





1.4 Overview of copper in physiology, pathophysiology and coordination 
therapeutics 
Copper plays an essential role in the structure and activity of multiple functional protein 
classes, such as haemoglobin formation, xenobiotics and carbohydrate metabolism, 
catecholamine biosysnthesis, cross-linkage of collagen, elastin in addition to pivotal 
roles in detoxification and oxidative phosphorylation based proteins (Festa and Thiele 
2011). Antioxidant proteins such as cytochrome c oxidase, superoxide dismutase, 
ferroxidases, monoamine oxidase, and dopamine β-monooxygenase, are involved in 
neutralizing ROS or molecular oxygen and rely on copper for their functional integrity. 
Owing to the biological importance of copper, the cell employs specific copper-efflux 
transporters Adenosine Triphosphate 7A/B (ATP7A) and (ATP7B), in addition to the 
multidrug efflux pumps belonging to the ATP-Binding Cassette (ABC) superfamily (P-
glycoprotein (Pgp, ABCB1) and multi- drug resistance protein 2 (MRP2, ABCC2) 
(Safaei et al. 2004; Fontaine and Mercer 2007; Crisponi et al. 2010; Kalayda et al. 
2012). Copper enters the body through CTR1 protein on the apical membrane surface of 
enterocytes cells where it is typically converted from Cu2+→Cu+ and bound to 
Antioxidant Protein 1 (ATOX1). ATOX1 is bound for the Golgi apparatus which 
permits the export of Cu+ through the basolateral membrane located ATP7A after which 
it is bound to albumin, α2-macroglubulin and ceruloplasmin in the bloodstream. The 
transport of copper from hepatocytes to other target cells occurs after extracellular 
intake of copper at the CTR1 protein on the hepatocyte, intracellular transport with 
ATOX1 and importing into the Golgi apparatus through the ATP7B for incorporation 
into cupro-proteins (Kaplan and Lutsenko 2009; Bandmann et al. 2014). Due to the 
essential physiological requirements of copper, pathologies are associated with 
deficiencies or excesses. Wilson’s disease is one of the best known pathologies of 
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copper excess where copper primarily accumulate in the liver and brain, inducing liver 
failure and is being increasingly associated with chronic neurological disorders such as 
Alzheimer’s and Parkinson’s disease (Bandmann et al. 2014). Wilson’s disease is 
caused by autosomal recessive mutation in the ATP7B gene, encoding the copper-
transporting P-type ATPase protein. The subsequent mutated phenotype results in the 
intracellular accumulation of the copper, resulting in increased oxidative stress, free 
radical formation and mitochondrial dysfunction independent of oxidative stress (Gu et 
al. 2000; Zischka et al. 2011; Bandmann et al. 2014). Menkes disease is an X-linked 
recessive disorder resulting in copper deficiency. It is caused by a mutation of the 
ATP7A copper transporter which results in a failure to adequately absorb copper and 
resulting in deficiencies in cupro-proteins (Crisponi et al. 2010). Penicillamine is the 
current treatment standard for copper chelation therapy and results in the binding of 
copper and enhanced excretion via the kidneys (Peisach and Blumberg 1969). Recently 
trientine and 8-hydroxyquinolines have shown superior chelation capability to 
penicillamine through their copper excretion via bile in contrast penicillamine’s less 
stable excretion through urine (Říha et al. 2013). 
 
1.4.1 Copper coordinated complexes 
From a biological perspective, the endogenous nature of copper in the body is 
hypothesised to reduce the systemic toxicities that are common with many other non-
essential metals utilised in metallodrugs. In addition, the variety of N-, S-, or O-
containing ligands and the range of oxidative states permit copper to form multiple 
planar and non-planar molecular structures in addition to its ability to coordinate 
biologically active aromatic ligands, which have applications in anticancer therapeutics 
(Trudu et al. 2015). The essential nature of copper in the cell and its complex 
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homeostasis through specific transporters and trafficking proteins (Gupta and Lutsenko 
2009; Wee et al. 2013) holds a strong potential for the utilisation of it as a therapeutic 
substance, specifically as an agent to target DNA. Prior to research into copper based 
therapeutics copper was known to bind to DNA with higher affinity than many other 
divalent cation, which promoted DNA oxidation. The binding of copper to DNA and 
subsequent conformational modification of polynucleotides, proteins structures and 
membranes was shown to be dependent on the electron affinity and geometry of the 
copper ion, providing a strong basis for the development of redox active therapeutic 
designs. At present the biological targets of copper complex focus strongly on DNA 
interaction, ROS induction and protein inhibition (Trudu et al. 2015). The discovery of 
the first synthetic chemical nuclease [Cu(Phen)2]
2+ in 1979 by Sigman et al., sparked 
intensive effort toward the development of novel artificial metallonucleases with DNA 
cleavage capability (Sigman et al. 1979). The [Cu(phen)2]
2+ complex predominately 
binds DNA in the minor groove and in its reduced form abstracts a hydrogen atom 
primarily from the C1′ deoxyribose position resulting in strand damage (Sigman et al. 
1993). The [Cu(phen)2]
2+ nuclease binds both nucleic acids and proteins without 
specificity inducing a general toxicity, and is thus considered a “promiscuous” agent. 
Accordingly, manipulation of this chemotype represents an interesting developmental 
challenge. In addition to the development of the [Cu(Phen)2]
2+ chemotype, a multitude 
of other coordination chemistries are presently under investigation such as: 
thiosemicarbazones (Palanimuthu et al. 2013; Sîrbu et al. 2017), conjugated Schiff 
bases (Creaven et al. 2009; Chakraborty et al. 2010), Imidazol (and other organic 
ligands) (McGinley et al. 2013), phosphine (Kaeser et al. 2013; Małecki et al. 2015; 
Villarreal et al. 2017) and phenanthroline (Palanimuthu et al. 2013; Prisecaru et al. 




The therapeutic development of copper complexes has progressed to a more advanced 
stage with the Casiopeinas® family with the general formula [Cu(N-N)(A-A)]NO3, 
where N-N represent neutral aromatic diamine donors (phenanthroline or bipyridine) 
and A-A stands for uninegative N-O or O-O donor ligands (aminoacidates or 
acetylacetonate) being used presently in phase I clinical trials. The progress to this stage 
of development has come about through the demonstration of their cytoxicity activity 
against medulloblastoma, glioma and colorectal adenocarcinoma cell lines (Carvallo-
Chaigneau et al. 2008; Mejia and Ruiz-Azuara 2008; Serment-Guerrero et al. 2011). 
Their mechanism of action is not fully understood, however they are believed to exert 
their biological effects through DNA binding in intercalative and non-intercalative 
methods at high affinities, degrading nucleic acids through the generation of ROS, 
depleting the antioxidant systems, and inducing mitochondrial toxicity (Trejo-Solís et 
al. 2005). 
 
1.4.2 Cu(II) phenanthroline complexes 
The activity of copper phenanthroline complexes with different secondary ligands such 
as acetylacetonate and glycinate groups (Galindo-Murillo et al. 2015) to the aromatic 
ligands have shown strong cytotoxicity profiles against cancer cell lines (Kellett et al. 
2011a; Kellett et al. 2011b; Kellett et al. 2012; Prisecaru et al. 2012; Prisecaru et al. 
2013), of which endogenous reactive oxygen species was found to accompany nuclease 
activity (Kellett et al. 2011a; Kellett et al. 2012b; Prisecaru et al. 2012). Research 
conducted by the supervision team and extended research collaborators was published 
on bis-phenanthroline copper(II) phthalate complexes (Kellett et al. 2011). They were 
identified as the first such compounds in their class with “self-activating” nuclease 
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capability along with avid DNA binding properties. They demonstrated a broad 
spectrum of cytotoxic activity complemented by lack of induced cytotoxicity in the cell 
with negative expression of p53 tumour suppressor gene. These results showed toxicity 
being mediated in the reaction was of a different mechanistic pathway to that of 
Cisplatin. The research team then demonstrated that analysis of dinuclear Cu2+ and 
Mn2+ bis-phenanthroline octanedioate compounds could exhibit rapid and potent nano 
and picomolar in-vitro cytotoxicity against human-derived colorectal cancer lines (HT-
29, SW480 and SW620) and were less cytotoxic towards non-cancerous normal human 
keratinocyte cells (HaCaT) (Kellett et al. 2011). Both Cu2+ and Mn2+complexes 
displayed greater in-vivo drug tolerance compared to cisplatin when examined using the 
insect Galleria mellonella. The mechanism of action with regards to potent generation 
of intracellular reactive oxygen species and the O2–dependent cleavage of supercoiled 
pUC18 DNA was also identified (McCann et al. 2012). The activity of bleomycin as 
mentioned earlier has helped to promote the development of redox-active metal-based 
drug DNA oxidants. This work led to further studies of square-planar copper(II) 
complexes (where Phen = 1,10-phenanthroline) incorporating o-phthalate and Phen  that 
showed that a broad spectrum of chemotherapeutic potential over 24 and 96 h interval 
generated through hydroxyl related ROS mediating DNA scission from the reduction of 
Cu(II) to Cu(I) (Fig. 1.9). The copper complexes compared well with the clinical agent 
cisplatin on MCF-7 (breast adenocarcinoma), DU145 (prostate carcinoma), HT-29 
(colonic adenocarcinoma) and the intrinsically cisplatin resistant SKOV-3 (ovarian 




Fig. 1.9 ROS generation and DNA toxicity by the synthetic artificial metallonuclease 
[Cu(1, 10-phen)2]
2+. Image adapted from Kellett et al. (2012). 
 
The activity of copper(II) complexes with Phen and 1,10-phenanthroline-5,6-dione 
showed an enhanced superoxide dismutase and catalase mimetic activity in cell lines 
(McCann et al. 2012). These exposures were also carried out using in-vivo studies in 
Galleria mellonella and Mus musculus (Swiss mice). The data demonstrated a greater 
tolerance to the compounds than the equivalent use of cisplatin (McCann et al. 2012). 
Advancements from these complexes took the form of a di-copper cytotoxin, Cu(II)(μ-
terephthalate)(Phen)4]
2+. This complex was proven to be a powerful, non-sequence-
specific, minor-groove oxidizer of duplex DNA which is capable of operating 
independently of exogenous reagents. The compound also shows exceptional in-vitro 
cytotoxicity towards cisplatin resistant ovarian cancer cells, producing intracellular 
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reactive oxygen species upon nano-molar exposure (Prisecaru et al. 2012). Phen ligated 
to Cu(II) was further demonstrated in 2013 with the production of a family of sterically 
functionalized pendant carboxylates complexes. These adaptions to the ligand structure 
resulted in a 10-fold increase in dsDNA binding and a reduced incidence of bovine 
serum albumin binding. The substances recorded increased cytoselectivity between 
human cancer cells, bacteria, and fungal cells. With only a small percentage of the cells 
showing evidence of dsDNA cleavages indicated as γH2AX foci the Cu(II) bis-phen 
complex could only be described as a non-selective cytotoxin with "promiscuous" 
activity (Prisecaru et al. 2013). The study by Slator et al., (2016). was the most in-depth 
to our knowledge on the biological mechanistic activity of Cu(II) phenanthroline-based 
metallodrugs where the [Cu(o-phthalate)(phenanthroline)] complex was examined. 
Through the use of the COMPARE algorithm on the National Cancer Institute’s (NCI) 
Development Therapeutics Program, 60 human cell line screen panel, competitive 
fluorescence binding, intracellular oxidation, ROS scavenging, mitochondrial 
membrane depolarization, annexin V and caspase 3, 7, 8 and 9, a mechanism of action 
was constructed of this copper complex. Caspase 8 and 9 were activated in this study 
indicating that both the intrinsic and extrinsic apoptotic pathways were implicated along 
with mild induction of annexin V, an apoptotic marker. The generation of superoxide 
was shown to play a role in DNA oxidation along with depolarization of the 
mitochondrial membrane potential resulting in caspase mediated apoptosis. The NCI-60 
cell line panel indicated a differential mode of action to the clinical therapeutics 
cisplatin and bleomycin, while showing a similar mode of action to that of 





1.4.3 Cu(II) phenanthroline-phenazine complex development 
Cu-phenanthroline chemotype [Cu(phen)2]
2+, was capable of binding nucleic acids and 
proteins but was however unable to be directed towards specific intracellular targets 
limiting its capability. With the identification of the highly ordered intercalative DNA 
properties of the dipyridophenazine ligand bound to ruthenium(II), its ligating to the 
Cu-phenanthroline chemotype provided an opportunity to assess its intercalative 
properties and mechanism of action in the cell.  
 
The identification of the Λ-[Ru(phen)2dppz]2+ ruthenium “light switch” complex 
(Niyazi et al. 2012) (Fig. 1.10) has generated considerable interest into the nature of its 
DNA intercalative properties, with crystal structures of ruthenium complexed Λ-
[Ru(phen)2dppz]
2+ showing two intercalation modes and specific ordering of water in 
the DNA minor groove (Niyazi et al. 2012; Hall et al. 2013). The “light switch” 
properties of Λ -[Ru(phen)2dppz]2+ upon nucleotide binding have applications in both 
biosensors (Barsan et al. 2008) and therapeutics (Yu et al. 2012). Given the excellent 
intercalative properties of phenazine ligands when present within Ru(II) complexes, 
their incorporation into Cu(II) phenanthroline chemical nucleases presented us with a 




Fig 1.10 Space-filled model of a ruthenium(II) complex of dipyridophenazine (DPPZ) 
intercalating with DNA acquired from crystallographic data. Image adapted from Niyazi 
et al. (2012). 
 
The Cu(II) chemical nucleases of [Cu(phen)(N,N′)]2+ carrying designer phenazine type-
intercalators (where N,N′ represents phen = 1,10-phenanthroline, DPQ = dipyrido[3,2-
ƒ:2ʹ,3ʹ-h]quinoxaline, DPPZ = dipyrido[3,2-a:2ʹ,3ʹ-c]phenazine, DPPN = 
benzo[i]dipyrido[3,2-a:2ʹ,3ʹ-c]phenazine) (Fig. 1.11) were synthesised and examined in 
order to identify how the systematic extension of the ligated phenanthrene ligand 
influences nucleotide binding affinity, base selectivity, oxidative chemical nuclease 
activity, and cytotoxicity within human cancer cells. Examination of their DNA binding 
constants revealed the highest activity of currently known Cu(II) phenanthrene 
compounds with thermal melting experiments indicated intercalation through both 
minor and major groove of the DNA and comparable activity in SKOV3 cells to 





Fig. 1.11 Molecular Structure of the Cu(II) phenanthroline-phenazine complex series. 
Image adapted from Molphy et al. (2014). 
 
The use of pUC19 DNA showed strong nuclease ability, with an enhanced activity in G-
C rich regions of DNA. This finding has led to possibility that the complexes mode of 
action may include the targeting of cytosine-phosphate-guanine (CpG) islands, which 
are found in the promoter regions of many mammalian genes. The subsequent study 
investigation of their DNA properties demonstrated 8-oxo-2′-deoxyguanosine (8-oxo-
dG) lesions, generated from the metal-hydroxo or free hydroxyl radicals (•OH) species 
produced from hydrogen peroxide (Molphy et al. 2015). The work to date on Cu(II) 
phenanthroline-phenazine complexes has established their cytotoxic, DNA-binding and 
the ROS DNA cleavage properties. However, an in-depth biological mechanistic study 
of these complexes was required to elucidate their mechanism of action and this has 
therefore formed the basis of the research reported herein. Three candidate Cu(II) 
complexes were selected for this study from the initial biological screen on the basis of 
their potential chemotherapeutic activity. These were, dipyrido[3,2-ƒ:2ʹ,3ʹ-h]quinoxaline 
(DPQ), dipyrido[3,2-a:2ʹ,3ʹ-c]phenazine (DPPZ) and benzo[i]dipyrido[3,2-a:2ʹ,3ʹ-
c]phenazine (DPPN) present as a π-backbone extension of the aromatic phenanthroline 
ligand to the [Cu(Phen)2]
2+ scaffold (Fig. 1.9). Their structures are illustrated in Figure 
1.11 with the Cu-phenanthroline scaffold represented as Cu-Phen (1), the single 
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phenazine π-backbone extension of DPQ represented as Cu-DPQ-Phen (2), the double 
phenazine π-backbone extension of DPPZ represented as Cu-DPPZ-Phen (3) and the 
triple phenazine π-backbone extension of DPPN represented as Cu-DPPN-Phen (4). The 
numbered nomenclature of the Cu-complexes presented in Figure 1.11 are referred to in 























1.5 Biological mechanistic approaches to screening novel therapeutics 
1.5.1 Approaches to biological evaluation 
The data generated on the evaluation of Cu(II) coordinated complex as detailed above 
has extensively involved in-vitro mammalian cell models such as MCF-7, HT-29, 
SKOV-3 and PC-3 among several other cancerous immortalized tumour cell lines. The 
in-vitro mammalian cell models form the bedrock to allow therapeutic development not 
just for Cu(II) complexes and other metal-based drugs as well as the vast majority of 
pharmaceutical and biopharmaceutical development. In-vivo models are utilised 
typically after initial validation in in-vitro models to assess the activity of the 
therapeutic at the system level and in turn provide potential information regarding 
mechanism of action, clinical efficacy and toxicity.  
 
To-date the mechanistic investigations of Cu(II) complexes and indeed many other 
metal-based drugs has focused on the production of ROS (with species delineation), 
DNA binding and damage (through DNA nuclease assays and in-vitro γH2AX 
immunofluorescent detection), depolarization of the mitochondrial membrane potential, 
and the production of known markers of apoptosis. 
   
1.5.2 In-vitro and in-vivo models in therapeutic evaluation 
The key challenge for the design and testing of novel therapeutics is the ability to 
evaluate the capability of the compound in a biological environment that closely 
resembles human physiology.  In-vitro and in-vivo models are commonly used for the 
purpose of pre-clinical evaluation. The use of in-vitro mammalian cell lines forms the 
foundation of pharmaceutical evaluation with the in-vivo methodology commonly used 
to progress the stage of evaluation to more human-like physiological response. One of 
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the most common approaches (used in this study) is the identification of active 
pharmaceutical candidates through the use of in-vitro phenotypic screens. Phenotypic 
screening utilises the different properties of the tissue of origin to evaluate the response 
of the drug candidate. This approach has been extensively utilised over the last few 
decades since the isolation of the first immortal cell lines and has been formalised based 
on tissues and cell lines by the NCI (NCI-60 Therapeutics Development Program) 
(Shoemaker 2006), NIH (LINCS project) (Yu et al. 2016), Broad institute (drug 
sensitivity study) (Barretina et al. 2012), and the Wellcome Trust Sanger Institute 
(Garnett et al. 2012). With the use of phenotypic screening the effects of novel 
therapeutics can be determined by the selective cytotoxicity, inhibition of proliferation 
and decrease in the overall cancer cell size. These characteristic changes allow for the 
initial screening of the activity of the novel compound thereby permitting a more 
detailed mechanistic evaluation (Liu et al. 2017). The evaluation of Cu(II) complexes 
has utilised in-vitro mammalian cell lines to identify functional activity through 
cytotoxicity screening and mechanism of action studies of Cu(II) complexes. HT-29 
(colon carcinoma) (Kellett et al. 2011a; Kellett et al. 2011b; Kellett et al. 2012), MCF-7 
(breast adenocarcinoma) (Kellett et al. 2011b; Kellett et al. 2012), PC-3 (prostate 
carcinoma) (Prisecaru et al. 2013) and SKOV-3 (ovarian adenocarcinoma) (Kellett et al. 
2012; Prisecaru et al. 2012; Prisecaru et al. 2013; Molphy et al. 2014; Thornton et al. 
2016; Slator et al. 2017) have been extensively utilised in previous Cu(II) complex and 
other metal-based screening and mechanistic evaluation as part of the Dublin Institute of 
Technology – Dublin City University – Maynooth University collaboration.    In 
addition to their extensive prior use in this study, these four cell lines are members of 
the NCI-60 therapeutics development program, included in this panel due to their 
diverse phenotypic characteristics in the specific tissue type. In 2015 SKOV-3 cells 
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were found to provide poor genetic fidelity to their tissue of origin and atypical growth 
pattern when transplanted as subcutaneous xenografts. SKOV-3 cells however have 
maintained a strong presence in published to date in ovarian cancer research and in 
particular their use a model in testing cisplatin senstivity and resistance (Elias et al. 
2015). In-vivo models typically involve the use of mice, rats, dogs or monkeys to 
evaluate the mortality endpoints and other toxicity profiles such as hepatic, 
cardiovascular and nephrotoxicity. Along with in-vivo mortality, each of these toxicity 
profiles allows for the collection of potential adverse effects in humans. In addition to 
these assays, advanced methods of simulating the studied tumour in an in-vivo 
environment such as cell line xenografts, patient-derived xenografts and genetically 
engineered mice are being utilised to provide a more faithful testing platform for 
evaluating the efficacy of novel therapeutics (Liu et al. 2017). In-vivo evaluation of 
novel therapeutics has many advantages, however the resources required to regularly 
examine the efficacy of developmental therapeutic candidates is seldom readily 
accessible in the academic setting. Galleria mellonella larvae represent a new model for 
pre-mammalian in-vivo assessment of novel metal-based drugs. With insects being one 
of the most ubiquitous groups of invertebrates on the planet (Elzinga 2004), their use in 
the evaluation of new therapeutics is being increasingly recognised as a valuable initial 
screening step for the later evaluation in in-vivo mammalian models (e.g. Mus 
musculus). At the point of evolutionary divergence of invertebrates and vertebrates, a 
shared innate immune response was supplemented by an adaptive immune response in 
the vertebrates system (Cooper and Alder 2006; Bailey et al. 2013; Viljakainen 2015). 
The similarities of the innate immune system in the two branches of life have continued 
to be comparable (Kavanagh and Reeves 2004; Renwick et al. 2007; Kelly and 
Kavanagh 2011; Browne et al. 2013). This comparability allows insects to be used in 
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therapeutic evaluation of novel drugs and coupled with their lower financial and ethical 
drawbacks provide a good opportunity to be a predictive platform for subsequent 
mammalian studies (Kemp and Massey 2007; Cook and McArthur 2013). G. mellonella 
along with their similar innate immune system to mammals represent a basic normal 
tissue model whose results can later leed to refinement and targeting of specific 
biological process in mammalian testing. While they are not a replacement for 
mammalian in-vivo models they do offer a rapidly deployable screening system which 
can inform therapeueitc development. In addition to the biological similarities of both 
in-vivo models, international funding agencies are increasingly adopting an approach of 
Replacement, Reduction and Refinement (3R) policy whenever possible to augment the 
use of in-vivo animal models and implement valid and ethically acceptable screening 
systems (Kilkenny et al. 2010). 
 
1.5.3 In-vitro mechanistic evaluation (ROS, γH2AX, apoptosis and mitochondrial 
related toxicity) 
 
1.5.3.1 Cellular viability and ROS 
The physiological state of the cell has for decades been the basis for the evaluation of 
bio-molecular processes and has been the mainstay of pharmacological assessment of 
novel targets and treatment approaches. Viability assays such as tetrazolium salts rely 
on the metabolic capability of the cell to produce a reduction environment that can be 
measured. The MTT assay produces a formazan product from the substrate 3-(4,5-
dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide primarily through mitochondrial 
action in the cell. The production of this product occurs due to the activity of 
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mitochondrial enzymes NADPH, FADH, FMNH, NADH and other cytochromes 
(Mosmann 1983; Vega-Avila and Pugsley 2011).  
 
ROS are a collection of heterogeneous group of diatomic oxygen from free and non-free 
radical species. The activities of enzyme-catalysed reactions are a major contributor to 
the presence of ROS. With this in mind, the physiological production of ROS is 
counteracted by antioxidant enzymes such as catalase, superoxide dismutase and 
glutathione. The examination of the presence of ROS species provides important 
support information about the state of the cell and activity mechanisms of the test agents 
(Dada and Sznajder 2011). The fluorescent dye 2ʹ,7ʹ-dichlorodihydrofluorescein 
diacetate (H2DCFDA) is a reduced form of fluorescein commonly used to indicate the 
presence of ROS in cells evaluating this mechanistic quality of novel therapeutics 
(Gibson 2013). The use of the MTT cell viability assay along with ROS identification 
coupled with selection of tissue specific mammalian cell lines provides the opportunity 
to assess the potential cytoselectivity properties of novel therapeutics. A range of cell 
lines have been characterised through the MTT and 2ʹ,7ʹ-dichlorodihydrofluorescein 
diacetate assay as part of the ongoing collaboration between Dublin Institute of 
Technology – Dublin City University – Maynooth University (Kellett et al. 2011a; 
Kellett et al. 2011b; Kellett et al. 2012; Prisecaru et al. 2012; Prisecaru et al. 2013; 
Molphy et al. 2014). 
 
The production of ROS is a regulated process related to mitochondrial function. ROS 
generation in the mitochondria primarily takes the form of superoxide (O2
-˙), which is 
converted to H2O2 by either spontaneous dismutation or through the enzyme Superoxide 
Dismutase (SOD). The activity of Fenton chemistry can drive the production of OH· in 
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the presence of metal ions (Craig and Marszalek 2002). Mitochondrial ROS production 
occurs at different stages of the oxidative phosphorylation pathway. The main 
production of O2
-˙ occurs in complex III during the Q cycle at the QO site in the form of 
QH· (Turrens 1997; St-Pierre et al. 2002; Muller et al. 2003). The majority of O2-˙ from 
the QO is made facing the intermembrane space (St-Pierre et al. 2002), which has led to 
the suggestion that O2
-˙ species may transit through the Voltage-Dependent Anion 
Channel (VDAC) (Han et al. 2003), and subsequently identified to have a role in 
apoptosis (Shoshan-Barmatz et al. 2010). A central component to homeostatic balance 
is the regulation of free radical chemistry in the cell. Free radicals can be generated by 
multiple processes leading to the production of a chemical species with one or more 
unpaired electrons. ROS represents the primary speciation method with Reactive 
Nitrogen Species (RNS) also contributing. ROS are primarily produced in the 
mitochondria and by Nicotinamide Adenine Dinucleotide Phosphate (NADPH) 
oxidases. In addition to being a by-product of cellular metabolism, ROS has also been 
shown to contribute to the immune response (Dan Dunn et al. 2015). The Electron 
Transport Chain (ETC) is known to have a strong influence on the production of ROS 
with Quinlan and co-workers showing the 2-oxoacid dehydrogenase and pyruvate 
dehydrogenase complex have a strong contribution to this process (Quinlan et al. 2014). 
ROS production in the cytosol in addition to the mitochondrial derived can stimulate 
additional production through the redox sensitive Protein Kinase C (PKC) isoforms and 
the Src family of kinases following activation with angiogenesis II signalling 






1.5.3.2 Mitochondrial dysfunction and apoptosis 
Apoptosis is a major form of regulated cell death in the body and has functions ranging 
from tissue formation at embryonic stages to immune cell effector function (Green 
2011). The process of apoptosis has numerous links to pathogenic processes and has 
implication for drug action and therapeutic responses (Hassan et al. 2014; Baig et al. 
2016; Delbridge et al. 2016). Apoptosis forms one of the ‘Hallmarks’ of cancer and as 
such the targeting with therapeutics has been of considerable interest (Hanahan and 
Weinberg 2000; Hanahan et al. 2011). The process of programmed cell death 
(apoptosis) is usually described through both the intrinsic and extrinsic pathways (Fig. 
1.12). Both these pathways provide the primary means through which apoptosis occurs 
in the cell. The mitochondria is one of the primarily driver of cellular energy, central to 
this is the maintenance of its membrane potential, which permits the proton gradients to 
be maintained. The loss of the mitochondrial membrane potential which can be brought 
about through a variety of mitochondrial stressors, induces the release of Secondary 
Mitochondria-derived Activators of Caspases (SMAC) and cytochrome c which results 
in the oligomerization of Apoptotic protease activating factor-1 (Apaf-1) and the 
formation of the apoptosome. The apoptosome cleaves pro-caspases to activate the 
initiator caspase, caspase 9, ultimately resulting activation of the effector caspase, 
caspase 3 (Ichim and Tait 2016). This process constitutes the intrinsic apoptotic process 
which can also be inhibited through the action of the BCL-2 and XIAP family of 
proteins. The extrinsic pathways of apoptosis operate through the activation of cell 
surface receptor activation. The Tumor Necrosis Factor-1 (TNF-1) and Fas receptor are 
both capable of activating apoptosis through ligand binding and the subsequent cleavage 
of pro-caspase 8 and 10 resulting the activation of the effector caspases, caspase 3 and 7 
resulting in apoptosis (Ichim and Tait 2016). Both the intrinsic and extrinsic pathways 
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of apoptosis share common components and are capable of effecting each other through 
activation of the pro-apoptotic factors BAX, BH3 interacting-domain death agonist 
(BID) and BCL-2 homologous Antagonist Killer (BAK) (Ichim and Tait 2016). The 
activation of apoptosis as a mechanism of triggering cell death in relation to the 
therapeutic action of metal based drugs such as cisplatin (Kim et al. 2004; Zhang et al. 
2008; Michaud et al. 2009; Gumulec et al. 2014), has been a prominent research goal in 
drug development. The investigation of different copper coordination complexes has 
also extensively utilised apoptosis as a means to investigate the mechanism and 
therapeutic utility of novel metal-based drugs (Thati et al. 2007; Filomeni et al. 2009; 
Idan Valencia-Cruz et al. 2013; Zuo et al. 2013; Montagner et al. 2015; Fan et al. 
2017). Autophagy is another form of cell death not described until the 1990s has shown 
increased interest in its use as an endpoint for metal-based drug mechanistic assessment 
(Slator et al. 2017). Many metal-based therapeutics and other small molecules under 
evaluation are capable of generating both ROS and RNS species which ultimately 
trigger different forms of cell death which has become important to differentiate, 
especially in relation to cancer treatment (Li et al. 2012; Gibson 2013). The activity of 
the mitochondrial has important roles in the generation of oxidative radicals and a 
fundamental position in intrinsic apoptosis. To this end the monitoring of caspases 
indicative of both intrinsic and extrinsic apoptotic process (Fig. 1.12) have previously 
been examined through the use of fluorescent inhibitors specific for each of the cysteine 
endoproteases (Slator et al. 2016, 2017). In addition to the apoptotic markers the 
assessment of mitochondrial health through membrane permeability assessment using 
either 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolocarbo-cyanine iodide (JC-1) 
or Rhodamine 123, which are fluorescent cationic dyes sensitive to the proton gradient 
in the mitochondria and accumulate after the collapse of the membrane potential (Slator 
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et al. 2016, 2017). The assessment of the activation of specific apoptotic markers 
provides an avenue into the mechanism of action of metal-based drugs and additionally 
an evaluation of their mechanism of action in cisplatin resistant cell lines. 
 
Fig. 1.12 Overview of intrinsic and extrinsic apoptosis pathways. Image adapted from 
Ichim and Tait, (2016). 
 
1.5.3.3 DNA binding and damage 
The integrity of DNA is a central part of cellular homeostasis and is managed through a 
complex molecular choreography of interacting repair enzymes which respond to a 
variety of DNA damage and forms a central focus in the mechanism of action of many 
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drugs. The discovery and subsequent development of cisplatin, a DNA interacting drug 
has provided a strong developmental objective for using other transition metal-based 
coordination compounds to target DNA integrity and subsequently disrupt cellular 
survival. Many metal-based drugs function through the generation of oxidative species. 
The kinetic properties of copper metal-based drugs are believed to operate under 
Fenton-like conditions where the catalytic cycle of Cu+/Cu2+ produces different 
oxidative species (Molphy et al., 2014). The oxidative species generated are believed to 
induce oxidative DNA base modification, primarily through the formation of 8-oxo-G 
which precipitates a modification in the interstrand cross-linking and subsequent 
disruption of DNA integrity (Cadet et al., 2017). Biological nucleases such as 
endonuclease and exonucleases function by hydrolyzing internal bonds within the 
polynucleotide chain thereby separating the polynucleotide chain. Restriction 
endonucleases have been extensively used in recombinant DNA technologies. Due to 
the crucial activity that nucleases play in DNA integrity and manipulation, there has 
been considerable interest in the development of metal based drugs targeting this 
process as an alternative to the current nuclease active drug, bleomycin and the binding 
activity of cisplatin. The development of a synthetic “self-activating” metal-based drugs 
with this capability was a significant development in this level of DNA targeting in 
metal based drugs (Kellett et al. 2011b; Kellett et al. 2012). The analysis of the nuclease 
activity takes place initially against purified plasmid DNA and subsequently the effects 
on DNA in the cell are established in culture. Through the use of γH2AX fluorescent 
assays the visualisation of Double Stranded Breaks (DSB) formation can take place 





Copper complexes have been demonstrated to have nuclease cleaving abilities. With 
this process resulting in double strand DNA damage formation (Kellett et al. 2012; 
Prisecaru et al. 2013), subsequent DNA repair mechanism become active. The detection 
of DSB formation is an important metric in the effectiveness of nuclease active 
therapeutics. The fluorescent detection of γH2AX foci has been established as a strong 
indicator of the repair of DSB in DNA (Thompson 2012). The immunodetection of 
γH2AX foci through flow cytometry and confocal microscopy has been part of a 
biological evaluation of previous Cu(II) phenanthroline complexes as part of the Dublin 
Institute of Technology – Dublin City University – Maynooth University collaboration 
(Kellett et al. 2012; Prisecaru et al. 2013). 
 
1.5.3.4 Utilisation of G. mellonella for the evaluation of the Cu(II) complex series 
The use of the mortality assays has been a common tool for the evaluation of the 
tolerance and toxicity of metal-based drugs in G. mellonella for several years (Rowan et 
al. 2009; Kellett et al. 2011a; Biot et al. 2012; McCann et al. 2012; McCann et al. 
2013; McGinley et al. 2013; Browne et al. 2014). The analysis of the cellular immune 
response through the measurement of the insect haemocyte count and sub populations 
provides a useful metric of the organism’s immunogenic response to metal-based drugs. 
Previously the measurement of haemocytes have been used to evaluate immune 
response to silver SBC3 (Browne et al. 2014), in addition to other studies using the 
Lepidoptera species as model for human related infections (Cotter et al. 2000a; Coyle et 
al. 2004; Kavanagh and Reeves 2004; Renwick and Kavanagh 2007; Rowan et al. 2009; 
Kavanagh and Fallon 2010; Browne and Kavanagh 2013; Browne et al. 2014). 
Furthermore, expanding on the investigation of the immune response with humoral 
elements and in particular the examination of Inducible Metalloproteinase Inhibitor 
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(IMPI) and transferrin gene expression and proteomic analysis has expanded the 
evaluative capacity of activation of the immune system (Bergin et al. 2006; Mowlds and 
Kavanagh 2008; Mowlds et al. 2008; Kelly and Kavanagh 2011; Browne et al. 2014). 
 
The publication of the G. mellonella transcriptome in by Vogel et al, (2011) permitted 
the production of a cDNA library which could then be used to develop a proteomics 
database based on known protein homology and the opening to the application of Label 
Free Quantitative (LFQ) proteomics. The application of LFQ proteomics in the 
Lepidoptera model has permitted a higher resolution evaluation of the mechanism of 
action of novel Cu(II) complexes and in other settings such as the effects of food 
preservatives (Maguire et al. 2017) and effects of secondary metabolites of 




1.6 Thesis synopsis  
The development of chemotherapeutic drugs has produced a large repertoire of 
available therapeutics for a range of malignancies, despite this achievement resistance 
continues to be an ongoing issue in particular to the highly successful metal-based drug, 
cisplatin. The copper(II) complexes described in this PhD thesis represent a rationally 
designed suite of copper(II) coordinated phenanthroline-phenazine complexes capable 
of therapeutic action in-vitro Additionally, their biological profile of activity has been 
examined in the G. mellonella in-vivo model, developing ideas and targets for future in-
vivo mammalian work. These complexes have been synthesised and characterised by 
Molphy et al. (2014) and (2015), under the project supervision team and have 
demonstrated promising chemotherapeutic potential, exceeding that of the existing 
chemotherapeutic drugs. Overall Molphy et al. (2014) and (2015) has demonstrated the 
DNA intercalative, oxidative, redox properties and in-vitro activity of this series of 
Cu(II) complexes. While this information provides a high level assessment of the 
activity of the complexes in the cell, it is not capable of examining wider non-targeted 
changes at the genomic and proteomic levels which can provide a more comprehensive 
assessment of the mechanism of action.  
 
The biological investigations in this project sought to advance the existing mechanistic 
evaluation of Cu(II) complexes through using traditional mechanistic evaluations with 
contemporary molecular methodologies of gene expression and proteomics. The fusion 
of these two approaches has enabled an in-depth elucidation of the pathways associated 
with ROS induction, apoptosis, mitochondrial toxicity, drug sensitivity and resistance 
pathways. This project also sought to utilise the highly versatile in-vivo Lepidoptera 
model, G. mellonella as a pre-mammalian screen of the activity of the novel Cu(II) 
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complexes and identify further therapeutic targets for evaluation in in-vivo mammalian 
models. These approaches overall will expand the biological scope of the evaluations of 
developmental inorganic chemotherapeutics and identify key biological pathways and 



















Chapter 2: Screening of novel Cu(II) phenanthroline-



























The work in this chapter describes the initial in-vitro exposure of Cu(II) phenanthroline-
phenazine complexes to a group of phenotypically diverse mammalian cancer cell lines. 
The cell viability was assessed through the MTT tetrazolium dye (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) which measured the activity of 
NAD(P)H-dependent cellular oxidoreductase enzymes. The MTT assay was followed 
up using characterisation tests such as Reactive Oxygen Species (ROS) production in 
the HeLa cell line, DNA Double Strand Break (DSB) formation using γH2AX foci 
examination in both MCF-7 and SKOV-3 cell lines and activation of inflammatory and 
apoptotic markers using Reverse Transcriptase quantitative-Polymerase Chain Reaction 
(RT-qPCR) gene expression across all the cell lines.  
 
The following cell lines representing different tumour types were subjected to the MTT 
viability assay to establish the active concentration of the Cu(II) phenanthroline-
phenazine complexes for subsequent screening and characterisation experiments: MCF-
7 (breast adenocarcinoma) (Le Bivic et al. 1988), HT-29 (colonic carcinoma) (Davis et 
al. 1998), PC-3 (grade IV prostate adenocarcinoma) (Tai et al. 2011), OE-33 
(oesophageal adenocarcinoma) (Timme et al. 2013), HeLa (cervical carcinoma) 
(Masters 2002), SKOV-3 (cisplatin resistance, original ovarian origin and widly used in 
ovarian research) (O’Connor et al. 1997; O’Neill et al. 1999), A2780 (ovarian 
adenocarcinoma) (ECACC Cat. No. 93112519) and the cisplatin resistant variant 
(A2780/ Cis) (Espina et al. 2017).  
 
The HT-29, MCF-7, PC-3 and SKOV-3 cell lines are part of the NCI developmental 
therapeutics program, which provided a strong case for their use in evaluating the 
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mechanistic characteristics of these novel chemotherapeutic drugs. Additionally, 
comparability of therapeutic activity between different cell lines derived from various 
tissues has been an ongoing challenge in medicinal chemistry. With this challenge, the 
use of the ovarian cancer cell lines, A2780 and its cisplatin resistance variant (A2780/ 
Cis) provided a better platform for comparing the action of novel therapeutics against 
known resistant variants of the same cell line. 
 
The measurement of apoptosis through fluorescent detection of specific apoptotic 
markers has previously been performed with copper and manganese complexes (Slator 
et al. 2016, 2017). The apoptotic activity along with inflammation and DNA damage 
can also be monitored by qRT-PCR by assessing changes in gene expression. 
Inflammation was measured through the expression of Interleukin-6 (IL-6) and Nuclear 
Factor-κB (NF-κB). IL-6 and NF-κB are often synergistic in their response with 
activation of NF-κB in-turn leading to the upregulation of IL-6 (Aggarwal et al. 2006). 
Poly (ADP-ribose) polymerase 1 (PARP1) is a key protein involved in the repair of 
single strand breaks through Base Excision Repair (BER) (Kraus and Hottiger 2013). 
The artificial nuclease capacity of Cu(II) phenanthroline-phenazine complexes makes 
the measurement of PARP1 an important marker of DNA damage, this was utilised in 
this study. Apoptosis is a key process in controlled cell death and its measurement is an 
important process for the in-vitro mechanistic assessment of copper complexes. The 
genes used in this study are involved in regulating the switch into apoptosis (B-cell 
Lymphoma 2 (BCL-2) and Bcl-2 associated X protein (BAX)), the initiation of 
apoptosis (Caspase 9) and its execution (Caspase 3 and Second Mitochondrial-derived 
Activator of Caspases (SMAC)). BCL-2 and BAX are part of the BCL-2 family of 
regulatory apoptotic proteins. BCL-2 functions in an anti-apoptotic manner while BAX 
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is pro-apoptotic (Gross 2016). Pro-apoptotic BAX is responsible for forming the 
mitochondrial membrane transition pores that permeabilising the membrane and 
releasing cytochrome c into the cytosol. 
 
Cytochrome c is known to recruits Apoptotic Protease Activating Factor 1 (APAF-1) 
and initiator Caspase 9 to form the apoptosome. This results in the activation of the 
apoptotic executioner Caspase 3 (Würstle et al. 2012; McIlwain et al. 2013). The 
breakdown of the mitochondrial membrane also releases SMAC, potentiating the 
activation of caspases and inhibiting Inhibitors of Apoptosis (IAP’s) activity (Du et al. 
2000). The action of XIAP, IAP1 and IAP2 functions in inhibiting the pro-apoptotic 
activity of caspases. XIAP, IAP1 and IAP2 all contain ubiquitin-ligase that counteracts 
the cysteine-aspartic protease activity of caspases which promotes a strong inhibition of 
apoptosis (Estornes and Bertrand 2014). In addition to the inhibition of caspases, IAP’s 
have been demonstrated to have a pro-survival strategy activating NF-κB (Bertrand et 
al. 2008). The measurement of IAP activity provided information regarding the 
inhibition of apoptosis and whether cell survival was related to apoptosis inhibition or 
another mechanism after cellular exposure to the Cu(II) phenanthroline-phenazine 
complexes. 
 
The objective of this work was to conduct an in-vitro screen of the Cu(II) complexes on 
a range of cell lines. This initial viability screen also established the IC25/ IC50 of each 
complex that was applied to the further mechanistic studies of ROS induction, γH2AX 
DNA DSB formation and gene expression of selected markers indicative of a range of 




2.2 Material and Methods 
2.2.1 Mammalian cell culture conditions and maintenance 
The MCF-7, HT-29, OE-33, PC-3, SKOV-3, HeLa, A2780 and A2780/ Cis cell lines 
were obtained from the Radiation and Environmental Science Centre (RESC), FOCAS 
Research Institute cell bank or commercially obtained through ATCC or ECACC. Each 
cell line was stored at -80 ˚C in a cryovial containing 1 ml of cells in 10 % DMSO 
(Sigma, Ireland) (cat# 276855). Each vial was thawed slowly and placed into 20 ml of 
Roswell Park Memorial Institute (RPMI-1640) media (Sigma, Ireland) (Cat# R8758) 
supplemented with 12 % Foetal Bovine Serum (Sigma, Ireland) (Cat# F2442)  and 2 % 
L-glutamine 200mM (Sigma, Ireland) (Cat# G7513) (Appendix 1.1.1) in a T75 cell 
culture flask (Sigma, Ireland) (Cat# CLS3276). Cells were incubated for 24 h at 37 °C 
and in 5 % CO2 atmosphere to allow adherence to the base of the flask and enter the log 
growth phase. Cells were monitored each day until 85-90 % cell confluency was 
reached and they were then subcultured for routine maintenance or experimentation. 
 
Subculturing involved first removing the cell culture media from the monolayer of cells, 
then adding 10 ml of trypsin solution (Thermo, Ireland) (Cat# 15090046) (Appendix 
1.1.2) : EDTA (Sigma, Ireland Cat# E9884) (1:1) to remove any dead or detached cells 
from the population. The remaining 10 ml of trypsin solution was added and the cells 
were incubated at 37 °C for 1-2 min approximately to remove cells from their 
monolayer on the base of the flask. Cells were placed in 10 ml of fresh culture media to 
deactivate the trypsin enzyme and produce the 20 ml single cell stock suspension. This 
stock cell suspension was used to seed different cell densities in T75 stock flasks to 
maintain the cells in culture. The stock cell solution was also used for subsequent 
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experiments described below. Cells were stored in liquid nitrogen as described in 
appendix 1.1.3 when not in use.  
 
2.2.2 The MTT viability assay 
2.2.2.1 Cell counting and plating 
One ml of cell suspension was placed into 20 ml of isoton electrolyte solution (BD, 
Ireland) to conduct a cell count and determine the required volume of cell suspension 
for plating. A Beckman COULTERTM Z1 coulter®(Beckman-Coulter, USA) particle 
counter was used to count the number of cells per ml in solution. Cells were subcultured 
at different densities according to their morphology and growth characteristics and 
determined by pre-optimisation experiments. A lower number of cells were plated for 
48 h analyses compared to 24 h to allow for cell growth through the mammalian cell 
cycle. 
 
MCF-7, OE-33, SKOV-3, HeLa, A2780 and A2780/ Cis cells were plated at 5 × 102 
cells into each well for the 24 h exposure and 2.5 × 102 into the 48 h exposure on a clear 
96-well plate (Thermo Fisher Scientific, Ireland) (Cat# 167008). The HT-29 cell line 
was plated with 103 cells for 24 h and 8 × 102 cells for 48 h. The PC-3 cell line was 
plated at 2.5 × 102 cells for 24 h and 1.25 × 102 cells for 48 h experiment. The 96-well 
plate set-up is illustrated in Appendix 1.1.4 with all exposures (μM) performed in 







2.2.2.2 Drug exposure 
MCF-7, OE-33, SKOV-3, HeLa, HT-29, SKOV-3, A2780 and A2780/ Cis cell lines 
were exposed to Cu-Phen (1) (Appendix 1.1.4), Cu-DPQ-Phen (2) (Appendix 1.1.4), 
Cu-DPPZ-Phen (3) (Appendix 1.1.4), Cu-DPPN-Phen (4) (Appendix 1.1.4), cisplatin 
(Sigma, Ireland) (Cat# P4394) (Appendix 1.1.5) and doxorubicin (Sigma, Ireland) (Cat# 
D2975000) (Appendix 1.1.6). Cu(II) phenanthroline-phenazine complexes 
nomenclature refers to the Cu(II) chemical nucleases of [Cu(phen)(N,N′)]2+ carrying 
designer phenazine type-intercalators (where N,N′ represents phen = 1,10-
phenanthroline, DPQ = dipyrido[3,2-ƒ:2ʹ,3ʹ-h]quinoxaline, DPPZ = dipyrido[3,2-a:2ʹ,3ʹ-
c]phenazine, DPPN = benzo[i]dipyrido[3,2-a:2ʹ,3ʹ-c]phenazine). The Cu(II) 
phenanthroline-phenazine complexes and cisplatin were dissolved in DMSO (ACS 
grade) prior to subsequent dilution in aqueous cell culture media (200 µM). Cu-Phen (1) 
and Cu-DPQ-Phen (2) was dissolved completly while Cu-DPPZ-Phen (3) and Cu-
DPPN-Phen (4) required additional agitation to fully dissolve prior to subsequent 
dilution. Cisplatin fully dissolved in DMSO prior to subsequent dilution. Doxorubicin 
was dissolved in aqueous cell culture media (20 µM). Cu-Phen (1), Cu-DPQ-Phen (2), 
Cu-DPPZ-Phen (3) and Cu-DPPN-Phen (4) (Appendix 1.1.4) exposures were made 
with a stock of 10 µM in supplemented RPMI-1640 media and diluted further to 
produce a range of 0.25-10 µM (Appendix 1.1.7) for MCF-7, OE-33, SKOV-3, HeLa, 
HT-29 and SKOV-3 cells set up as in the 96-well plate template detailed in Appendix 
1.1.8. Cells were treated with cisplatin at a range of 0.5-200 µM (Appendix 1.1.9) in 
MCF-7, OE-33, SKOV-3, HeLa, HT-29 and SKOV-3 cells and was set up as in the 96-
well plate template detailed in Appendix 1.1.10. Cells were treated with the Cu(II) 
phenanthroline-phenazine complexes at a range of 0.156-10 µM (Appendix 1.1.11), 
doxorubicin at a range of 0.312-20 µM (Appendix 1.1.11) and cisplatin at a range of 
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3.125-200 µM (Appendix 1.1.12) in the following 96-well template: Cu(II) 
phenanthroline-phenazine complexes (Appendix 1.1.13), cisplatin (Appendix 1.1.14) 
and doxorubicin (Appendix 1.1.15). Cisplatin and doxorubicin are included as clinical 
controls due to their ability to induce their therapeutic activity primarily through DNA 
intrastrand crosslinking and interaction, respectively (Fornari et al. 1994; Jamieson and 
Lippard 1999). Following 24 h incubation at 37 °C and 5 % CO2, the cell culture media 
was replaced with the prepared solutions. All plates were then incubated for 24 or 48 h 
before methylthiazolyldiphenyl-tetrazolium bromide (MTT) (Sigma, Ireland) (Cat# 
M5655) (5 mg/ ml) was applied. Each exposure was performed on 3 separate plates. 
The triplicate plates were additionally performed 3 independent times to ensure 
statistical validity. 
 
2.2.2.3 MTT viability 
After the 24 and 48 h drug exposure a working solution of methylthiazolyldiphenyl-
tetrazolium bromide (MTT) (Sigma, Ireland) (Cat# M5655) (5 mg/ ml) (Appendix 
1.1.16) was prepared and 100 μl of the solution was added to each well of the 96-well 
plates after the exposed cell culture media was then removed. All plates were incubated 
for 3 h and afterwards each well was washed (×3) with sterilised PBS (Sigma, Ireland) 
(Cas# 806544). After the final wash, 100 μl of DMSO (ACS grade) was added to each 
well and the plates were placed on a plate shaker for 15 min to allow the coloured 
formazan crystals to develop. The plate was then read on the 1420 Multilabel Counter 
Victor3V spectrophotometer (PerkinElmer, USA) at 595 nm wavelength after 15 min on 




Based on the set-up of the 96-well plate template (Appendix 1.1.8, 1.1.10, and 1.1.13-
1.1.15) the absorbance data was analysed accordingly. The mean of each of the exposed 
concentrations was taken using the 3 independent 96-well plates along with the mean of 
the unexposed cells (Negative). Based on this experiment the highest absorbance was 
observed in the negative controls due to these cells containing the highest degree of 
viability compared to the compound exposed cells. The mean absorbance from the 
exposed cells was calculated based on the 5 replicates wells within each plate compared 
to the negative wells (unexposed cells). This same analysis was performed for each of 
the three plates in each independent experiment and an average of the 3 plates per 
triplicate experiment was calculated along with the standard deviation (S.D.). 
 
2.2.2.4 Statistical analysis of data 
The mean and standard deviation was calculated as described above. The standard 
deviation was used to measure the variability of the data set and provide information 
regarding the precision of the experiment. See Appendix 3 for raw data. Using 
Microsoft® Excel (Microsoft Corporation, USA) and the statistical package GraphPad 
Prism (Ver. 5.0) (GraphPad, USA), the IC25 and IC50 concentration was calculated for 
each cell line, time-point, complex exposure and control. The IC25 and IC50 
concentration was calculated for each cell lines/ exposed to a complex or clinical drug 
compared to the control, per timepoint. The IC25 and IC50 concentration represents the 
concentration of the test exposure which produces a 25 % and 50 % inhibition of cell 
growth respectively. The IC25 rather than the IC50 concentration was used for 
subsequent chemical exposures due to the complex and high toxicity elicited by the 
Cu(II) phenantholine-phenazine complexes. The lower level of inhibition produced in 
the experimental conditions also allowed for a more sensitive investigation of early 
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mechanistic effects on the cellular environments. Standard deviation instead of standard 
error of the mean was used as a descriptive statistic in this experiment due to the better 
representation of variability in the data set and less random nature in describing the 
sampling process. Standard deviation has also been previously used in the publications 
of in-vitro cytotoxicity data. Statistical analysis to compare the changes between the 
Cu(II) phenantholine-phenazine complexes and either cisplatin or doxorubicin (A2780 
and A2780/ Cis) was performed using one-way ANOVA with Tukey’s post-hoc test. 
 
2.2.3 Fluorescent detection of Reactive Oxygen Species (ROS) 
The HeLa cell line was used to measure ROS generation owing to its common use in 
antioxidant investigations in the published literature. ROS production was investigated 
after exposure to Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3), Cu-DPPN-Phen 
(4), cisplatin and the positive control hydrogen peroxide (H2O2) using the fluorescent 
2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) (Thermo, Ireland) (Cat# D399) 
dye. HeLa cells were sub-cultured from an 80-90 % confluency stock into 96-well 
plates at a cell density of 1 × 104 cells/ ml and incubated for 24 h to allow sufficient 
time for the cells to attach and grow. On the day of the experiment H2DCFDA was 
dissolved in DMSO (ACS grade) at a concentration of 1 mM stock and then further 
diluted to 10 µM working solution in 12 % foetal bovine serum supplemented RPMI-
1640 cell culture media. The working solution of H2DCFDA dye (10 µM) was 
incubated with the cells for 30 min in the dark at 37 °C in a 5 % CO2 atmosphere. After 
30 min the H2DCFDA working solution was removed and 20 µM of each of the Cu(II) 
phenanthroline-phenazine complexes and cisplatin with doubling dilution as in the 
template 96-well plate detailed in Appendix 1.2.1. A negative control of 12 % foetal 
bovine serum supplemented RPMI-1640 cell culture media was used for normalization 
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of ROS expression. Hydrogen peroxide (Sigma, Ireland) (Cat# 95321) at 0.312 µM was 
used as a positive control (value experimentally optimized). All 96-well plates were 
covered in tin foil and incubated as described above. Fluorescent measurements were 
taken after 15 min, 30 min, 1 h, 2 h, 3 h, 4 h and 5 h at an excitation wavelength of 495 
nm and emission of 529 nm. The production of ROS was expressed relative to the 
negative control. An unpaired t-test was performed on the average of the normalized 
fluorescent measurements of both the negative control and the highest exposed 
concentration of either the test complexes or cisplatin. A p-value of 0.05 was used to 
establish statistical significance. Each normalized average was calculated from 7 
measurements representing 15 min to 5 h (N=7). 
 
2.2.4 Immuno-detection of γH2AX foci with flow cytometry 
2.2.4.1 Cell preparation, exposure and immune-staining 
MCF-7 and SKOV-3 cell lines were selected due to their sensitivity and resistance 
respectively to the Cu(II) complexes and cisplatin as determined by their initial MTT 
cytotoxicity screen. SKOV-3 and MCF-7 cells were subcultured at 1 × 105 cells per T25 
flask (Sigma, Ireland) (Cat# CLS430639) and were incubated for 24 h to allow for 
attachment and growth. After the 24 h attachment and growth period the MCF-7 and 
SKOV-3 cells were exposed to their respective IC25 values over 24 and 48 h. Cells were 
subcultured as previously described in section 2.2.1 to generate the cell suspensions 
which were then pelleted by centrifugation at 120 g for 10 min. The supernatant was 
decanted and 200 μl of 2 % paraformaldehyde (Sigma, Ireland) (Cat# F8775) fixative 
solution (Appendix 1.3.1) was added and incubated for 10 min. A second centrifugation 
was performed at 120 g for 5 min, the supernatant removed and the cell pellet re-
suspended in ice-cold 70 % ethanol (Sigma, Ireland) (Cat# 51976). The cells were 
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centrifuged as above for 5 min with the supernatant being discarded and the cells re-
suspended in 200 μl 0.25 % Triton X-100 (Sigma, Ireland) (Cat# T8787) working 
solution (Appendix 1.3.2). A final centrifugation (as above) was conducted with the cell 
pellet then exposed to 200 μl of blocking solution (2 % BSA (Sigma, Ireland) (Cat# 
A9418) in PBS) and incubated for 30 min (Appendix 1.3.3). A separate aliquot of the 
unstained cells was placed in a new tube prior to the addition of the primary antibody 
and used as the auto fluorescent control. 
 
Blocking solution was removed as before through centrifugation and pellet was re-
suspended in 100 μl of the primary antibody (Milipore, Ireland) (Anti-phospho-Histone 
H2A.X (Ser 139), clone JBW301) (Cat# 05-636) (Lot# 2068177)) (1:500) (Appendix 1 
1.6) for 1 h at room temperature. A separate aliquot of the biological negative control 
was put into a new tube and was stained only with the primary antibody. Another 
aliquot was taken from the biological negative control and was stained only with the 
secondary antibody. The secondary antibody (Milipore, Ireland) (goat anti-mouse IgG 
Antibody, Alexa fluor 488 FITC conjugate)) (1:200) (Appendix 1.6) was applied after 
(×3) PBS washes for 1 h in the dark. Three wash steps as before were performed and the 
final pellet was re-suspended in 1 ml of PBS. The samples were centrifuged as before 
and re-suspended in a working solution of the counterstain, propidium iodide (PI) (1µg/ 
µl) (Sigma, Ireland) (Cat# P4864) (Appendix 1.3.6) for 10 min at room temperature. 







2.2.4.2 Detection of γH2AX foci by flow cytometry 
Flow cytometry utilises the properties of the scattering of light and detection of 
fluorescence in specific spectral ranges to resolve information about the cells in sheath 
fluid passing by a detector in single file (Telford et al. 2012). The BD Accuri C6 (BD 
Biosciences, USA) flow cytometer was used to detect foci formation in cells staining 
positive for γH2AX fluorescence and was resolved in the FL-1 FITC band (excited at 
495 nm and emission at 519 nm). The unstained auto fluorescent sample for both the 
MCF-7 and SKOV-3 cells was used to acquire the region of the scatter plot to be gated 
for the experimental samples. Gating is a principle in flow cytometry which uses 
defined regions in the scatter plot to examine populations of cells with common 
characteristics. Both primary and secondary only stained samples were used to set the 
positive fluorescent detection limit (to determine if either the primary or secondary 
antibodies erroneously contribute to positive detection) for the subsequent stained 
experimental samples (stained with both primary and secondary antibodies). Once the 
gated regions were set, 1 × 104 cells were acquired for each of the samples. Mean 
Fluorescent Intensity (MFI) and % positive cells were recorded from the experimentally 
determined positive gated region. An increase in the MFI is represented by a log scale 
shift to the right in the FL-1 channel histogram and the y-axis representing the number 
of cells expressing this level of fluorescence. Percentage positive is a measure of the 
number of cells expressing γH2AX foci with respect to the total number of measured 
cells in the gated region. Biological samples were performed on three independent 






2.2.4.3. Statistical processing of flow cytometry data 
MFI data for each sample was subtracted from the auto fluorescent MFI value and an 
average and standard deviation was recorded for each experimental condition (N=3). 
Percentage positive data was processed similarly to the MFI data. MFI and % positive 
results were graphed using GraphPad Prism (Ver. 5.0) and unpaired t-tests were 
performed between test complex exposure (N=3) and the negative control (N=3) with p 
value set at 0.05. 
 
2.2.5 Immunodetection of γH2AX foci with confocal microscopy 
2.2.5.1 Cytospin slide preparation 
Aliquots of 100 µl cell suspension stained with γH2AX and PI (as described above) 
were deposited onto glass slides by cytospin at 120 rpm for 5 min. Glass slides and 
cover slips (Thermo, Germany) (26x76mm, 0.8-1.0mm)  were boiled in ethanol prior to 
use to produce a clean surface. A No. 0 clover slip (Thermo, Ireland) (0.085-0.13 mm 
thick) was applied to the slides using mounting media and was sealed with clear nail 
varnish. 
 
2.2.5.2 Confocal microscope image acquisition 
The slides were read using the LSM© 510 Meta Confocal Microscope (Zeiss, Germany) 
with the negative control used to establish the minimum laser gain, amplitude and offset 
setting along with the positive control to establish the upper limits to resolve saturation 
of the images (electronic and image setting are detailed in Appendix 1.3.7). Each image 
represented a random field of view on each slide. All images were taken at 620x 
magnification with both argon and Helium-Neon lasers simultaneously scanning. 
Images were captured in TIFF format and processed with ImageJ (Open source) 
73 
 
software. ImageJ was used to split each TIFF image into its 4 component channels 
(green (γH2AX foci), red (propidium iodide), merged and brightfield). 
 
2.2.6 qRT-PCR analysis of cellular process 
2.2.6.1 Molecular targets 
The molecular gene targets of inflammation, DNA damage, apoptosis and inhibition of 
apoptosis were identified by the chosen pathway that is described in the introduction of 
this chapter. Early stage inflammation, DNA damage, apoptosis related genes and 
endogenous inhibitors of caspase action all represent a suite of functions which can 
characterise the state of the cell after exposure to Cu(II) phenanthroline-phenazine 
complexes, cisplatin and doxorubicin. See Table 2.1 contains the gene target and 
housekeeping reference genes with their primer sequences. These primer sets (forward 
and reverse) were designed in-house using Primer3PLUS programme and were 















Table 2.1 List of oligonucleotide sequences and genes used for the gene expression 
analysis. 





















Casp 9 F 
Casp 9 R 
TCCAGATTGACGACAAGTGC 
CCTACAAGTCGTGACAGGGA 
Casp 3 F 



























* Represent primers of references genes used to establish the relative expression of the target genes. 
F refers to forward primer while R refers to reverse primer. 
 
2.2.6.2 Mammalian cell sample preparation 
HT-29, PC-3, OE-33, HeLa, MCF-7, SKOV-3, A2780 and A2780/ Cis cell lines were 
exposed (1 × 104 cells) to their respective IC25 values for 24 and 48 h after allowing 24 
h for attaching and growth in the T25 flask. Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-
Phen (3) (A2780 and A2780/ Cis only), Cu-DPPN-Phen (4) (A2780 and A2780/ Cis 
only), cisplatin and doxorubicin (A2780 and A2780/ Cis only) along with a negative 
control were incubated in triplicate T25 flasks. The A2780 and A2780/ Cis were only 
examined at 24 h due to resource constraints. Following the required timepoint, the T25 
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flask was subcultured as previously described in section 2.2.1. The cell suspension was 
centrifuged at 400 g for 5 min with the cell pellet re-suspended in 5 ml of PBS as a 
wash step. Cells were centrifuged again (as before) and the pellet re-suspended in 1 ml 
of Tri-Reagent (Sigma, Ireland) (Cat# T9424). The 1 ml cell suspension in Tri-Reagent 
was allowed to stand for 2 min prior to storage at -80 ˚C in a 1.5 ml eppendorf tube 
(Thermo, USA) (Cat# AM12450). 
 
2.2.6.3 RNA extraction from samples 
Prior to the thawing of any samples all workspaces and equipment were treated with 
RNase Away (Thermo, Ireland) (Cat# 10328011) to eradicate any environmental 
RNAses and minimise RNA contamination and degradation. Two hundred µl of 
chloroform (ACS grade) (Sigma, Ireland) (Cat# 288306) was added to each of the 
samples for 5 min. Samples were centrifuged at 11,300 g for 15 min at 4 °C to separate 
the contents into 3 distinct phases. The upper phase (clear) containing the RNA was 
carefully transferred to a separate Eppendorf (taking care not to disturb the lower 
protein phase). To the upper aqueous phase 0.5 ml of 2-propanol (ACS grade) (Sigma, 
Ireland) (Cat# 278475) was added, tubes were gently inverted and incubated at room 
temperature for 10 min and then centrifuged at 4 °C for 10 min at 11,300 g. The 
supernatant was removed without disturbing the RNA pellet. The pellet was washed 
once with 1 ml of 75 % ethanol (Sigma, Ireland) (Cat# 51976) and re-suspended in 30 







2.2.6.4 RNA quantification 
The purity and concentration of the RNA samples was measured using the 
MaestroNano™ spectrophotometer (MaestroGen, USA). After an initial blank with 0.1 
% DEPC treated water the absorbance ratios (A260/A280 and A260/A230) of the 
samples was recorded to allow for the cDNA synthesis step. Impurities and 
contamination were noted from the spectrophotometer readings. RNA qualification 
using 1.5 % agrose gel was not performed.  
 
2.2.6.5 cDNA synthesis 
cDNA was synthesised from the extracted mRNA per cell line sample using the qScript 
cDNA synthesis kit (Quanta Biosciences, USA) (Cat# 733-1173). Based on the RNA 
concentrations previously obtained from the NanoDrop, a standardised value of 150 ng 
was chosen based on the smallest measured concentration. All subsequent samples were 
normalised to this concentration in a 5 µl volume. cDNA synthesis reactions was made 
and detailed in Appendix 1.4.1. Each reaction was prepared in a separate PCR reaction 
tube and placed into the Thermocycler (Techne, UK) for 5 min at 22 °C, 30 min at 42 
°C, 5 min at 85 °C followed by samples being held at 4 °C prior to the quantitative real-
time PCR. 
 
2.2.6.6 Quantitative real-time PCR 
Synthesised cDNA serve as the template for the quantitative real time PCR with the 
primers sets for each gene target. SYBR Green I (Thermo, Ireland) (Cat# 4309155) was 
used as the reaction probe for the following reaction. Master mix was made up for each 
gene target (20 µl per reaction) with 6 µl PCR-grade water, 1 µl forward primer (10 
µM), 1 µl reverse primer (10 µM) and 10 µl SYBR green MM 2x for each reaction. The 
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final 2 µl of the normalized sample was added to 18 µl of the working master mix. 
cDNA sample was normalized prior to qPCR step. A master mix for each primer was 
made up for the required number of wells. The master mix was also incubated with 
PCR-grade water to establish that there was no fluorescent signal in the absence of a 
DNA template. 
 
The samples and master mix were placed in 96 well PCR plates. The reaction for each 
sample was performed in duplicate. The PCR plate was sealed and centrifuged at 290 g 
for 2 min before being placed in the 7500 fast Real-Time PCR System (Applied 
Biosystems, USA). Details of the PCR-cycle programme are detailed in Table 2.2 
below: 
Table 2.2 Thermal cycle PCR parameters. 
Pre-incubation (1 cycle) 95 °C, 5 min, ramp 4.4 °C 
Quantification (45 cycles) 
95 °C 10 s ramp 4.4 °C, 60 °C 10 s ramp 
2.2 °C, 72 °C 10 s ramp 4.4 °C 
Melting curve (1 cycle) 
95 °C 5 s ramp 4.4 °C, 65 °C 1 min ramp 
2.2 °C, 97 °C continuous ramp 0.11 °C 
acquisition 10 per °C 
Cooling (1 cycle) 40 °C 10 s ramp 1.5 °C 
 
2.2.6.7 Statistical analysis of gene expression data 
The expression levels of each target and reference genes was measured using the Ct 
(cycle threshold) (Kurnik 2007) generated from the 7500 fast Real-Time PCR system 
(Applied Biosystems, USA). The experiment was performed 3 times (N=3) for all target 
and reference genes with the exception of A2780 and A2780/ Cis cells which was 
performed 4 times (N=4). For each PCR plate the water negative for each gene was 
used to confirm that no autofluorescence was contributing to the final value. The 
individual Ct values were recorded in Microsoft Excel™ along with average and 
standard deviation for each cDNA sample. The Ct values are related to the amount of 
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amplicon present in the reaction mix. The lower the Ct value the greater the level of 
amplicon present in the sample (Livak and Schmittgen 2001). The geometric mean of 
both actin and tubulin reference genes was used to establish a more stable normalization 
factor which has been shown to produce more consistent amplification gene expression 
data (Vandesompele et al. 2002). Target genes were compared to the geometrically 
averaged reference genes. Each sample and target gene Ct value of the reference gene 
was subtracted from the Ct value of the target gene. The delta change of target gene in 
relation to the reference Ct value is then subtracted from the biological negative control 
for that sample. This second delta value was then normalized using the following 
logarithmic formula: 2-ΔCt1(test)-ΔCt2(control) (Livak and Schmittgen 2001). The average Ct 
value for both reference and target gene was calculated along with a standard deviation. 
Both standard deviations were subjected to error propagation with the final standard 
deviation being normalized in a manner as stated in the formula above (Nordgård et al. 
2006). Both the positive and negative error bars reflects a 95 % confidence interval 














2.3.1 MTT cytotoxicity  
To examine the broad-spectrum of chemotherapeutic activities of these metal 
complexes, a range of characterisation experiments was conducted on a range of human 
cancer cell lines. The in-vitro cell lines; HT-29 (colorectal adenocarcinoma) (Table 
2.3), MCF-7 (breast adenocarcinoma) (Table 2.3), PC-3 (prostatic adenocarcinoma) 
(Table 2.3), OE-33 (oesophageal carcinoma) (Table 2.3), SKOV-3 (ovarian 
adenocarcinoma) (Table 2.3), HeLa (cervical adenocarcinoma) (Table 2.3) along with 
the cisplatin sensitive, A2780 (ovarian carcinoma) (Table 2.3) and its cisplatin resistant 
variant A2780/Cis (Table 2.3) were used to evaluate the activity of the tested complex 
using the MTT viability assay. Figure 2.1 represents a heatmap of the data from Table 
2.3. For comparison purposes, the IC50 concentration for each of the cell lines and 
timepoints was calculated and is presented in Table 2.4 with a heatmap of the data 
presented in Figure 2.2. One-way ANOVA with Tukey’s post-hoc test was used to 
compare the statistical significances of the changes between each of the Cu(II) 
phenantholine-phenazine complexes and either cisplatin or doxorubicin (A2780 and 
A2780/ Cis) (Table 2.4 – 2.5). 
 
In all cases Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3), Cu-DPPN-Phen (4) 
and cisplatin showed increased activity after 48 h of exposure when compared to 24 h 
indicating a time-dependent cytotoxic response. Cisplatin was tested over a greater 
range of 0.5-200 µM compared to Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) 




Cisplatin showed variable level of activity accross the range of tested cell lines and 
timepoints. In HT-29 cells there was a small decrease in the toxicity over the two 
timepoints. The MCF-7 cells saw an unchanged level of activity after both exposed 
timepoints possibly indicating some resistance in response. The PC-3 cell lines showed 
a large resistance to toxicity induced by the platinum agent, markedly decreasing after 
48 h of exposure. OE-33 cells showed a relatively unchanged level of toxicity while 
SKOV-3 cells displayed an indicative profile of platinum resistance as observed in prior 
studies (Beaufort et al. 2015). HeLa cells demonstrated rapid toxicity increasing over 
the two timepoints. Cisplatin displayed differential activity in both A2780 and 
A2780/Cis cell lines (Table 2.3), with the resistant variant demonstrating a higher 
concentration in relation to the sensitive variant at 24 h (> 200 µM vs. 63.10 µM). The 
IC25 concentration increased at 48 h with the resistant and sensitive characteristics 
remaining similar to the 24 h timepoint (33.22 µM vs. 3.85 µM). The chemotherapeutic, 
doxorubicin was also exposed to both the A2780 and A2780/ Cis cells. Both these cell 
lines are known to be sensitive to this clinical drug. For both cell lines, doxorubicin 
displayed time-dependant increase in toxicity from 24 to 48 h (A2780 24 h 1.13 µM → 
A2780 48 h 0.61 µM) (A2780/ Cis 24 h 1.473 µM → A2780/ Cis 48 h 0.655 µM), as 
with cisplatin. Both cell lines demonstrate no appreciable difference between the 
responses to doxorubicin when the standard deviation is taken into account. 
 
Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen (4) in Table 
2.3 all show very active IC25 concentrations values of <10 µM with the exception of 
OE-33 cells. Cu-Phen (1) represents the fundamental architecture upon which the 
phenazine π backbone is extended such as in Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and 
Cu-DPPN-Phen (4). Here, Cu-Phen (1) is shown to have significant activity of <5 µM 
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exceeding the activity of cisplatin in PC-3 (4.87 µM 24 h, 2.12 µM 48 h), OE-33 (1.76 
µM 24 h, 1.32 µM 48 h) and cisplatin resistant SKOV-3 (2.56 µM 24 h, 1.87 µM 48 h) 
cells. Cu-Phen (1), significantly exceeded the activity of cisplatin in A2780 and A2780/ 
Cis cells, along with the clinical drug doxorubicin in A2780 cells (0.39 µM vs. 1.13 
µM, 0.83 µM vs. 1.473 µM). Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-
Phen (4) represent phenazine π-backbone extended ligands of the Cu-Phen (1) 
architecture with the increasing phenazine chain lengths going from DPQ → DPPZ → 
DPPN. In most cases the extension of the phenazine complex by a single aromatic ring 
to Cu-DPQ-Phen (2) does not provide an increase in toxicity in the cell lines: HT-29, 
MCF-7, OE-33, SKOV-3 and HeLa, with the exception of PC-3 cells at 24 h (3.91 µM) 
but not at 48 h (4.41 µM). Additionally, both A2780 (except at 48 h) and A2780/ Cis 
cells demonstrate increased activity of Cu-DPQ-Phen (2) in comparison to Cu-Phen (1) 
(A2780 24 h: 0.34 µM vs. 0.39 µM) (A2780/ Cis 24 h: 0.72 µM vs. 0.83 µM, A2780/ 
Cis 48 h: 0.43 µM vs. 0.44 µM). Exposure to Cu-DPPZ-Phen (3) yields increased 
toxicity across all the different cell lines over 24- and 48-h with significant increases 
observed in PC-3, OE-33, SKOV-3, HeLa, A2780 and A2780/ Cis cells in comparison 
to cisplatin. With Cu-DPPZ-Phen (3) many of the IC25 concentrations are reduced to ≤1 
µM after 24 h. Cu-DPPZ-Phen (3) (except in the case of the MCF-7 cells) provide a 
significant increase over the chemotherapeutic activity of cisplatin and doxorubicin in 
the A2780/ Cis cell line. The activity of Cu-DPPN-Phen (4) in the HT-29, MCF-7, PC-
3, OE-33 and HeLa cells showed a significant decrease in activity compared to the 
activity of cisplatin over 24- and 48- h. The activity of Cu-DPPN-Phen (4) at both 24- 
and 48- h in the A2780 and A2780/ Cis cell line in contrast to the other cell lines 
demonstrated a significant increase in activity in comparison to cisplatin and in the case 
of doxorubicin, A2780 48 h and A2780/ Cis 24 h. The IC25 values (except in the case of 
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the A2780 and A2780/ Cis cells) of Cu-Phen (1), Cu-DPQ-Phen (2) and Cu-DPPZ-Phen 
(3) show superior activity for all cell lines at both 24- and 48- h in comparison to Cu-
DPPN-Phen (4). In contrast the A2780 and A2780/ Cis cell only demonstrated superior 
toxicity to the Cu-DPPN-Phen (4) complex at 24 h in the A2780 (Cu-Phen (1)), 48 h in 
the A2780 (Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3)), in the A2780/ Cis 
cells at 24 h (Cu-Phen (1) and Cu-DPQ-Phen (2)) and at 48 h in A2780/ Cis (Cu-Phen 
(1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3)). Both known cisplatin sensitive cell lines 
(MCF-7 and A2780) demonstrate higher toxicity towards the Cu(II) phenanthroline-
phenazine complexes in comparison to both known cisplatin resistant cell lines (SKOV-
3 and A2780/ Cis). In general the activity of the copper complexes is similar with Cu-
Phen (1) and Cu-DPQ-Phen (2) showing a high degree of homology. Some 
improvements in cytotoxic response are seen for the Cu-DPPZ-Phen (3) complex while 
activity recedes with the introduction of Cu-DPPN-Phen (4), possibility due to its larger 




Table 2.3 IC25 values for HT-29, MCF-7, PC-3, OE-33, SKOV-3, HeLa, A2780 and A2780/ Cis cells when exposed to Cu-Phen (1), Cu-
DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen (4), cisplatin and doxorubicin over 24 and 48 h.  
IC25 values represent the mean ± standard deviation (N=3). 
‡ denotes reduced number of replicates.  
* denotes p < 0.05 in comparison to cisplatin. 
** denotes p < 0.01 in comparison to cisplatin. 
*** denotes p < 0.001 in comparison to cisplatin. 
‽ denotes p < 0.05 in comparison to doxorubicin. 
‽‽ denotes p < 0.01 in comparison to doxorubicin. 
‽‽‽ denotes p < 0.001 in comparison to doxorubicin. 





Compound IC25 (μM) ± S.D. 
 HT-29 MCF-7 PC-3 OE-33 SKOV-3 HeLa A2780 A2780/ Cisplatin 






































































































































































































Fig. 2.1 Heatmap representing the results of IC25 values generated from the tested cell lines using 
the MTT assay (Table 2.3). Details of the concentrations range and its relation to the colour is 
displayed in the legend (right). N.P. indicates test not performed. 
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Table 2.4 IC50 values for HT-29, MCF-7, PC-3, OE-33, SKOV-3, HeLa, A2780 and A2780/ Cis cells when exposed to Cu-Phen (1), Cu-
DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen (4), cisplatin and doxorubicin over 24 and 48 h.  
Compound IC50 (μM) ± S.D. 
 HT-29 MCF-7 PC-3 OE-33 SKOV-3 HeLa A2780 A2780/ Cisplatin 













































































































































































































IC25 values represent the mean ± standard deviation (N=3). 
* denotes p < 0.05 in comparison to cisplatin. 
** denotes p < 0.01 in comparison to cisplatin. 
*** denotes p < 0.001 in comparison to cisplatin. 
‽ denotes p < 0.05 in comparison to doxorubicin. 
‽‽ denotes p < 0.01 in comparison to doxorubicin. 
‽‽‽ denotes p < 0.001 in comparison to doxorubicin. 






Fig. 2.2 Heatmap representing the results of IC50 values generated from the tested cell lines using the 
MTT assay (Table 2.4). Details of the concentrations range and its relation to the colour is displayed in 
the legend (right). N.P. indicates test not performed. 
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2.3.2 Fluorescent detection of Reactive Oxygen Species 
ROS production was assessed through the fluorescent dye, 2ʹ7ʹ-dichlorofluorescein 
diacetate (H2DCFDA). HeLa cells were assessed for the presence of ROS at a doubling 
concentration of cisplatin (0.195-50 µM) (Fig. 2.3 E), Cu-Phen (1), Cu-DPQ-Phen (2), 
Cu-DPPZ-Phen (3), Cu-DPPN-Phen (4) (1-4: 0.078-20 µM) (Fig. 2.3 A-D) over a 5 h 
period. Hydrogen peroxide (H2O2) was used as a positive control. The negative control 
remained unexposed to any of the drugs and was used to establish the relative increase 
in endogenous ROS generation. H2O2 showed a strong time-dependent increase in ROS 
generation in all experiments accross the 5 h exposure period. Exposure to Cu-Phen (1) 
(0.078-20 µM) (Fig. 2.3 A) produced a significant time-dependent increase in ROS 
generation at 20 µM and down to 0.312 µM. Exposure to Cu-DPQ-Phen (2) (0.078-20 
µM) (Fig. 2.3 B) produced a smaller (than Cu-Phen (1)) but significant overall increase 
in ROS generation as the concentration was increased however over the increasing 
timepoints, ROS generation decreased slightly, potentially due to ETC impairment or 
cell death. Exposure to Cu-DPPZ-Phen (3) (0.078-20 µM) (Fig. 2.3 C) produced a 
significant but smaller (than Cu-Phen (1)) time-dependent increase in ROS generation at 
20 µM. Smaller changes in ROS generation were observed in all lower exposed 
concentrations with relatively little change over the time course. Exposure to Cu-DPPN-
Phen (4) (0.078-20 µM) (Fig. 2.3 D) produced a significant but small time-dependent 
increase in ROS generation at 20 µM and below. Smaller changes in ROS generation 
were observed in all lower exposed concentrations with a small increase over the 
timepoints. Overall the exposure to Cu-Phen (1) demonstrated an increase in ROS 
production over the timeperiod while Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-
DPPN-Phen (4) ROS production decreased or stayed that same over the timeperiod. 
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Cisplatin demonstrated a concentration-dependent significant increase in ROS at 50 µM 









Fig. 2.3 (A-E) Fluorescent detection of ROS using DCF/DA in HeLa cells after exposure to Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-
Phen (3), Cu-DPPN-Phen (4) and cisplatin over a period of 5 h. H2O2 used as positive control. * Statistically significant (p < 0.05) 
difference between highest exposed concentration of the test complexes/ cisplatin and the negative control. N=8. 
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2.3.3 Immuno-detection of γH2AX foci using flow cytometry 
2.3.3.1 Immuno-detection of γH2AX foci in MCF-7 and SKOV-3 cells 
 
The γH2AX foci formation in the MCF-7 and SKOV-3 cells was examined by flow 
cytometry after exposure to IC25 concentrations to assess the impact of lower Inhibitory 
Concentrations (IC) of the Cu(II) phenanthroline-phenazine complexes and cisplatin in 
relation to the unexposed negative control over both 24 and 48 h. γH2AX foci was 
expressed as Mean Fluorescent Intensity (MFI) for MCF-7 (Fig. 2.4) and SKOV-3 cells 
(Fig. 2.5). γH2AX foci was also expressed through % positive cells in MCF-7 (Fig. 2.6) 
and SKOV-3 cells (Fig. 2.7).  
 
Foci formation in the MCF-7 cells (Fig. 2.4) indicates that exposure to cisplatin, a 
known DNA damaging agent, produces a characteristic increase in fluorescence in 
comparison to the negative control. Exposure to the IC25 concentration of Cu-Phen (1), 
Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen (4) result in increased foci 
formation with respect to the negative control. A significant increase (p ≤ 0.05) was 
seen in the 24 h exposure of Cu-Phen (1) and Cu-DPQ-Phen (2), additionally a 
significant increase (p ≤ 0.05) was seen with both 24 and 48 h exposures to Cu-DPPN-
Phen (4) in comparison to the negative control. In the SKOV-3 cell line at both 24 and 
48 h, γH2AX foci formation measured through MFI (Fig. 2.5) showed a significant 
increase (p ≤ 0.05) after incubation with Cu-Phen (1), Cu-DPQ-Phen (2) and Cu-DPPN-
Phen (4) while a non-significant (p ≤ 0.05) increase occurs after exposure to Cu-DPPZ-
Phen (3). The positive control, cisplatin demonstrated a marginal increase in γH2AX 
foci formation over the negative control. With the exception of Cu-DPPZ-Phen (3) all 
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other Cu(II) phenanthroline-phenazine complexes induced higher foci formation than 
the cisplatin exposure at both timepoints. 
 
Similarly to the measurement of γH2AX foci through MFI, the MCF-7 % positive cells 
(Fig. 2.6) for γH2AX foci formation indicate double stranded DNA damage in a similar 
pattern to the MFI results (Fig. 2.4). Cisplatin demonstrates increased foci formation as 
previously described. Exposures to Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) 
and Cu-DPPN-Phen (4) all show significantly increased (p ≤ 0.05) incidences of foci 
formation after both 24 and 48 h exposures. The incidence of γH2AX foci formation 
measured through % positive cells (Fig. 2.7) in the SKOV-3 cell lines after exposure to 
Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3), Cu-DPPN-Phen (4) and cisplatin 
at both timepoints produces a measurement profile similar to the MFI (Fig. 2.5). A 
significant increase (p ≤ 0.05) is observed in the % positive cells after exposure to Cu-
Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen (4) at both 
timepoints. The positive control, cisplatin induced double stranded DNA damage at 
both timepoints. All Cu(II) phenanthroline-phenazine complexes and cisplatin produced 
a decreased % positive response at 48 h in relation to their 24 h result. 
 
Overall the MCF-7 cell measurement of γH2AX foci formation through both MFI and 
% positive show a similar pattern of results between both analysis methods. The SKOV-
3 cell measurement of γH2AX foci formation through both MFI and % positive show a 
similar pattern of results. The exposure of Cu-DPPZ-Phen (3) produced lower foci 
formation in comparison to Cu-Phen (1), Cu-DPQ-Phen (2) and Cu-DPPN-Phen (4) 




Fig. 2.4 Immuno-detection of γH2AX recorded through mean 
fluorescence intensity of MCF-7 cells exposed to Cu-Phen (1), Cu-
DPQ-Phen (2), Cu-DPPZ-Phen (3), Cu-DPPN-Phen (4) and cisplatin 
at their respective IC25 concentration for both 24 and 48 h. * 
indicated significant (p < 0.05) (N=3) increase in MFI in comparison 
to the negative control. 
Fig. 2.5 Immuno-detection of γH2AX recorded through mean 
fluorescence intensity of SKOV-3 cells exposed to Cu-Phen (1), 
Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3), Cu-DPPN-Phen (4) and 
cisplatin at their respective IC25 concentration for both 24 and 48 h. 
* indicated significant (p < 0.05) (N=3) increase in MFI in 







Fig. 2.6 Immuno-detection of γH2AX recorded through % positive 
cells. MCF-7 cells exposed to Cu-Phen (1), Cu-DPQ-Phen (2), Cu-
DPPZ-Phen (3), Cu-DPPN-Phen (4) and cisplatin at their respective 
IC25 concentration for both 24 and 48 h. * indicated significant 
increase (p < 0.05) (N=3) in % positive cells in comparison to the 
negative control. 
Fig 2.7 Immuno-detection of γH2AX recorded through % positive 
cells. SKOV-3 cells exposed to Cu-Phen (1), Cu-DPQ-Phen (2), Cu-
DPPZ-Phen (3), Cu-DPPN-Phen (4) and cisplatin at their respective 
IC25 concentration for both 24 and 48 h. * indicated significant 





2.3.4 Immuno-detection of γH2AX foci using confocal microscopy 
MCF-7 (Fig. 2.8-2.9) and SKOV-3 cells (Fig. 2.10-2.11) were analysed for the presence 
of γH2AX foci using confocal microscopy after both 24- and 48- h exposures to the IC25 
concentrations of cisplatin, Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-
DPPN-Phen (4). γH2AX foci were determined using both a primary and a FITC 
labelled secondary antibody. Propidium iodide (PI) was used as a nuclear counterstain. 
A merged green and red channel image was displayed along with a brightfield image to 
give a non-fluorescent context to the images. The overlapping of primary stain (green) 
with the counterstain (red) on the merged image produced a yellow colour.  
 
Figure 2.8 shows the production of γH2AX foci in MCF-7 cells following 24- and 48- 
h respectively exposure of IC25 values of cisplatin, Cu-Phen (1), Cu-DPQ-Phen (2), Cu-
DPPZ-Phen (3) and Cu-DPPN-Phen (4). The negative control indicates no appreciable 
increase in γH2AX foci while the positive control, cisplatin indicates an appreciable 
increase. Cisplatin, Cu-Phen (1) and Cu-DPQ-Phen (2) exposures produce more 
concentrated foci formation, while Cu-DPPN-Phen (4) tends to be more diffuse. Cu-
DPPZ-Phen (3) induces no detectable foci formation, however a smaller number of cells 
were intact for confocal analysis. Overall, while strong foci formation was found in 
specific cells, the number of cells displaying foci formation was small after the 24 h 
exposure to cisplatin and the Cu(II) phenanthroline-phenanzine complex series. Figure 
2.9 shows the production of γH2AX foci in MCF-7 cells following 48 h exposure of 
IC25 values of cisplatin, Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-
DPPN-Phen (4). The negative control indicates no appreciable increase in γH2AX foci 
while the positive control, cisplatin indicates a strong increase in specific cells. Cu-Phen 
(1) induces diffuse foci formation in a smaller number of cells, similarly to the cisplatin 
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exposure. Cu-DPQ-Phen (2) and Cu-DPPN-Phen (4) produce more concentrated foci in 
the cells, with Cu-DPPN-Phen (4) inducing γH2AX foci in a larger number of cells. 
Exposure to Cu-DPPZ-Phen (3) induced a small number of foci in the observed cells, 
although only a small number of cells remained intact for confocal analysis. Overall, 
while strong foci formation was found in specific cells, the number of cells displaying 
foci formation was small after the 48 h exposure to cisplatin and the Cu(II) 
phenanthroline-phenanzine complex series. 
 
Figure 2.10 shows the production of γH2AX foci in SKOV-3 cells following 24- and 
48- h exposure of IC25 values of cisplatin, Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-
Phen (3) and Cu-DPPN-Phen (4). The negative control indicates a very small increase 
in γH2AX foci while the positive control, cisplatin indicates a strong increase in most 
cells. Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen (4), all 
show a strong increase in both diffuse and concentrated foci formation in cells. Cu-Phen 
(1), Cu-DPQ-Phen (2) and Cu-DPPN-Phen (4) demonstrated the strongest increases in 
foci formation while exposure to Cu-DPPZ-Phen (3) induced an appreciable smaller 
number of foci. Overall, an strong level of foci formation was observed after exposures 
to cisplatin, Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen 
(4) in SKOV-3 cells at 24 h. Figure 2.11 shows the production of γH2AX foci in 
SKOV-3 cells following 48 h exposure of IC25 values of cisplatin, Cu-Phen (1), Cu-
DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen (4). The negative control 
indicates a very small increase in γH2AX foci while the positive control, cisplatin 
induces a stronger increase in a small number of cells. Cu-Phen (1), Cu-DPQ-Phen (2), 
Cu-DPPZ-Phen (3) and Cu-DPPN-Phen (4), all show a strong increase in both diffuse 
and concentrated foci formation in cells. Cu-Phen (1), Cu-DPQ-Phen (2) and Cu-DPPN-
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Phen (4) demonstrated the strongest increases in foci formation while exposure to Cu-
DPPZ-Phen (3) induced an appreciable smaller and more diffuse number of foci 
formation. Overall, an intense level of foci formation was observed after exposures to 
cisplatin, Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen (4) 
in SKOV-3 cells at 48 h. 
 
Between both MCF-7 and SKOV-3 cells a strong difference in both the concentration of 
foci and the number of cells present with foci was observed. MCF-7 cells demonstrated 
both a smaller number of cells with induced foci and a smaller number of foci formation 
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Fig. 2.8 MCF-7 cells exposed to the IC25 24 h concentrations of cisplatin, Cu-Phen (1), 
Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen (4) in comparison to the 
negative control. γH2AX foci determined using primary antibody stain with fluorescent 
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Fig. 2.9 MCF-7 cells exposed to the IC25 48 h concentrations of cisplatin, Cu-Phen (1), 
Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen (4) in comparison to the 
negative control. γH2AX foci determined using primary antibody stain with fluorescent 





γH2AX foci (green) Propidium iodide (red) Merged Brightfield 
Neg 
control 
    
Cis-
platin 



















    
Fig. 2.10 SKOV-3 cells exposed to the IC25 24 h values of cisplatin, Cu-Phen (1), Cu-
DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen (4) in comparison to the 
negative control. γH2AX foci determined using primary antibody stain with fluorescent 
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Fig. 2.11 SKOV-3 cells exposed to the IC25 48 h values of cisplatin, Cu-Phen (1), Cu-
DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen (4) in comparison to the 
negative control. γH2AX foci determined using primary antibody stain with fluorescent 
FITC secondary label and propidium iodide used as a nuclear counter stain. 
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2.3.5 qRT-PCR analysis of cellular processes 
The differences in gene expression between the two timepoints of each of the cell lines 
will be discussed separately. The level of activity of each target was assessed by the 
relative expression of the specific mRNA representative of the cDNA of the target gene 
being assayed. The expression of the target gene was made in relation to geometric 
mean expression level of the two reference genes, actin and tubulin. The standard 
deviation of the means calculated from both the reference gene and target gene was 
error propagated and subsequently Log(2) transformed to produce a 95 % confidence 
interval range around the log(2) transformed mean double delta Ct value. Grouped 
columns in Figure 2.12 to Figure 2.25 display the log(2) transformed mean expression 
value relative to the biological negative control with the broken line at y = 1 indicating 
negative expression below and positive expression above. 
 
Figure 2.12 and Figure 2.13 shows the expression of genes outlined in Table 2.1 
relative to the geometric mean of the references genes, actin and tubulin in the HT-29 
cell line at 24- and 48- h exposures respectively. Twenty four hours after exposure to 
cisplatin the HT-29 cells demonstrate a strong apoptotic initiator (Caspase 9) and 
executioner (Caspase 3) activity and a moderate increase in SMAC activity this was 
contrasted with a strong activity of the apoptotic inhibitor XIAP and low activity of 
IAP1 and IAP2. Gene expression at 48 h after exposure to cisplatin presents a different 
profile with only the elevation of SMAC presenting. Exposure to Cu-Phen (1) at 24 h 
activates a strong executioner caspase (Caspase 3) but not the initiator (Caspase 9). The 
apoptosis related SMAC and anti-apoptotic IAP2 are also strongly upregulated. At 48 h 
exposure, Cu-Phen (1) initiates an inflammatory response (IL-6) with low level of 
Caspases 9 and 3 but is characterised by an anti-apoptotic response of high XIAP and 
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moderately elevated IAP1 and IAP2. Exposure to Cu-DPQ-Phen (2) at 24 h initiates a 
low level inflammatory (IL-6) and apoptotic response (Caspase 3 and SMAC). The 48 h 
response of HT-29 to Cu-DPQ-Phen (2) is characterised by a strong inflammatory (IL-
6) and anti-apoptotic (XIAP and IAP2) response.  
 
Figure 2.14 and Figure 2.15 shows the expression of genes outlined in Table 2.1 
relative to the geometric mean of the references genes, actin and tubulin in the PC-3 cell 
line at 24- and 48- h exposure respectively. Twenty four hours after exposure to 
cisplatin an early stage inflammatory response (IL-6) with a small increase in the 
initiator caspase (Caspase 9) and executioner (Caspase 3) is observed. At 48 h the 
inflammatory response (IL-6 and NF-kB) was increased with a small upregulation of 
caspase activity and a larger increase in IAP2. The profile of activity of Cu-Phen (1) is 
similar to the profile of cisplatin at 24 h with increased activity of IAP2. In contrast, the 
effects of Cu-Phen (1) at 48 h demonstrated no appreciable increase in the measured 
processes except for a mild increase in the anti-apoptotic gene (XIAP). Exposure to Cu-
DPQ-Phen (2) at 24 h again produces a similar profile to that of cisplatin and Cu-Phen 
(1) with increased activation of Caspase 3 and IAP2. At 48 h exposure to Cu-DPQ-Phen 
(2) continues with an upregulated inflammatory process (IL-6) but had no upregulated 
apoptotic markers and a small upregulation of IAP2. The error bars represent a 95 % 
confidence interval and was large for some of the MCF-7 24 h measurements indicating 








Fig. 2.12 Gene expression of HT-29 cells at 24 h following 
exposure to cisplatin, Cu-Phen (1) and Cu-DPQ-Phen (2). Error bars 
represent 95 % Confidence interval (N=3). Relative expression of 
target genes calculated in relation to the geometric mean of the 
references genes, actin and tubulin. 
Fig. 2.13 Gene expression of HT-29 cells at 48 h following 
exposure to cisplatin, Cu-Phen (1) and Cu-DPQ-Phen (2). Error bars 
represent 95 % Confidence interval (N=3). Relative expression of 
target genes calculated in relation to the geometric mean of the 







Fig. 2.14 Gene expression of PC-3 cells at 24 h following 
exposure to cisplatin, Cu-Phen (1) and Cu-DPQ-Phen (2). Error 
bars represent 95 % Confidence interval (N=3). Relative 
expression of target genes calculated in relation to the geometric 
mean of the references genes, actin and tubulin. 
Fig. 2.15 Gene expression of PC-3 cells at 48 h following exposure to 
cisplatin, Cu-Phen (1) and Cu-DPQ-Phen (2). Error bars represent 95 
% Confidence interval (N=3). Relative expression of target genes 
calculated in relation to the geometric mean of the references genes, 




Figure 2.16 and Figure 2.17 shows the expression of genes outlined in Table 2.1 
relative to the geometric mean of the references genes, actin and tubulin in the OE-33 
cell line in 24- and 48- h exposures respectively. 24 h after exposure to cisplatin a large 
upregulation was observed in the expression of inflammatory genes (IL-6 and NF-kB), 
single strand DNA break (PARP), executioner Caspase 3 and IAP1. This is in contrast 
to the 48 h profile of the cisplatin exposure which showed no upregulation of 
inflammatory, DNA damage and apoptotic processes genes with only the anti-apoptotic 
XIAP upregulated. Exposure to Cu-Phen (1) at 24 h produces a small inflammatory 
(NF-kB) response. This profile changes after the 48 h exposure with an upregulation of 
apoptotic (Caspase 9, Caspase 3 and SMAC) and anti-apoptotic (XIAP) markers. 
Exposure to Cu-DPQ-Phen (2) after 24 h showed a large upregulation of apoptotic 
(Caspase 3) and anti-apoptotic (XIAP) response with a low level activity of apoptotic 
(Caspase 9 and SMAC) and anti-apoptotic (XIAP) factors at 48 h. 
 
Figure 2.18 and Figure 2.19 shows the expression of genes outlined in Table 2.1 
relative to the geometric mean of the references genes, actin and tubulin in the HeLa 
cell line in 24- and 48- h exposures respectively. Exposure to cisplatin at 24 h induced 
the expression of the inflammatory marker (IL-6) with a small increase in NF-κB. 
Apoptotic marker, Caspase 3 was upregulated with moderate upregulation of anti-
apoptotic factors (XIAP, IAP1 and IAP2). In contrast, at 48 h cisplatin exposure 
induced no upregulation in any of the measured processes. Exposure to Cu-Phen (1) at 
24 h resulted in the upregulation of Caspase 9 and SMAC with a progressively larger 
increase in anti-apoptotic factor, the largest increase occured in IAP2. In contrast, the 48 
h exposure of Cu-Phen (1) produces no appreciable upregulation in any of the measured 
processes. Exposure to Cu-DPQ-Phen (2) at 24 h induced a small upregulation in 
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inflammatory markers (IL-6 and NF-kB) and a large increase in anti-apoptotic factors 
(IAP1 and IAP2). Again in contrast, the 48 h exposure of Cu-DPQ-Phen (2) induced no 

























Fig. 2.16 Gene expression of OE-33 cells at 24 h following exposure 
to cisplatin, Cu-Phen (1) and Cu-DPQ-Phen (2). Error bars represent 
95 % Confidence interval (N=3). Relative expression of target genes 
calculated in relation to the geometric mean of the references genes, 
actin and tubulin. 
Fig. 2.17 Gene expression of OE-33 cells at 48 h following 
exposure to cisplatin, Cu-Phen (1) and Cu-DPQ-Phen (2). Error bars 
represent 95 % Confidence interval (N=3). Relative expression of 
target genes calculated in relation to the geometric mean of the 






Fig. 2.18 Gene expression of HeLa cells at 24 h following exposure 
to cisplatin, Cu-Phen (1) and Cu-DPQ-Phen (2). Error bars 
represent 95 % Confidence interval (N=3). Relative expression of 
target genes calculated in relation to the geometric mean of the 
references genes, actin and tubulin. 
Fig. 2.19 Gene expression of HeLa cells at 48 h following exposure 
to cisplatin, Cu-Phen (1) and Cu-DPQ-Phen (2). Error bars represent 
95 % Confidence interval (N=3). Relative expression of target genes 
calculated in relation to the geometric mean of the references genes, 
actin and tubulin. 
110 
 
Figure 2.20 and Figure 2.21 shows the expression of genes outlined in Table 2.1 
relative to the geometric mean of the references genes, actin and tubulin in the MCF-7 
cell line in 24- and 48- h exposures respectively. MCF-7 cells after exposure to cisplatin 
after 24 h produced an increase in the early stage inflammatory marker, NF-κB and no 
appreciable up regulation of any other measured process. At 48 h the exposure to 
cisplatin induced an increase in the anti-apoptotic gene IAP1. Cu-Phen (1) exposure 
over 24 h induced a similar upregulation of the early stage inflammatory marker, NF-kB 
and a small increase in the anti-apoptotic gene IAP2. At 48 h an increase in the 
apoptotic factor BAX was observed along with other process. Exposure to Cu-DPQ-
Phen (2) for 48 h resulted in a similar upregulation of NF-κB to cisplatin and Cu-Phen 
(1). A small increase of Caspase 9 and XIAP was observed at 24 h with no other 
appreciable increase observed in any other process at 24 h. After Cu-DPQ-Phen (2) was 
exposed for 48 h BAX expression was induced, similarly to the exposure to Cu-Phen (1) 
indicating apoptotic induction in the MCF-7 cells.  
 
Figure 2.22 and Figure 2.23 shows the expression of genes outlined in Table 2.1 
relative to the geometric mean of the references genes, actin and tubulin in the SKOV-3 
cell line in 24- and 48- h exposures respectively. Exposure to cisplatin after 24 h 
induced a small increase in the apoptotic gene, Caspase 3 and BAX. No other gene 
demonstrated an appreciable increase in expression. In contrast, at 48 h, cisplatin did not 
induce Caspase 3 and BAX expression, with only a small increase in BCL-2. Cu-Phen 
(1) induced a small increase in the early stage inflammatory marker, IL-6 and an equally 
small increase in the apoptotic genes, Caspase 9 and BAX. At 48 h a small increase in 
the early stage inflammatory marker, IL-6 and NF-kB was coupled with a small increase 
in PARP and the apoptotic related genes, SMAC and BCL-2. Exposure to Cu-DPQ-
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Phen (2) induced a moderate to large increase in Caspase 3 and BAX respectively. At 
48 h a increase in the early stage inflammatory marker, IL-6 was observed, with no 

























Fig. 2.20 Gene expression of MCF-7 cells at 24 h following 
exposure to cisplatin, Cu-Phen (1) and Cu-DPQ-Phen (2). Error 
bars represent 95 % Confidence Interval (N=3). Relative 
expression of target genes calculated in relation to the geometric 
mean of the references genes, actin and tubulin. 
Fig. 2.21 Gene expression of MCF-7 cells at 48 h following exposure 
to cisplatin, Cu-Phen (1) and Cu-DPQ-Phen (2). Error bars represent 
95 % Confidence Interval (N=3). Relative expression of target genes 
calculated in relation to the geometric mean of the references genes, 







Fig. 2.22 Gene expression of SKOV-3 cells at 24 h following exposure to 
cisplatin, Cu-Phen (1) and Cu-DPQ-Phen (2). Error bars represent 95 % 
Confidence Interval (N=3). Relative expression of target genes calculated 
in relation to the geometric mean of the references genes, actin and 
tubulin. 
Fig. 2.23 Gene expression of SKOV-3 cells at 48 h following 
exposure to cisplatin, Cu-Phen (1) and Cu-DPQ-Phen (2). Error 
bars represent 95 % Confidence Interval (N=3). Relative 
expression of target genes calculated in relation to the 




Figure 2.24 shows the expression of genes outlined in Table 2.1 relative to the 
geometric mean of the references genes, actin and tubulin in the A2780 cell line. 
Exposure to doxorubicin upregulated apoptotic processes, such as Caspase 9, BCL-2 
and BAX. XIAP, an inhibitor of apoptosis was also upregulated. Cisplatin induced a 
large increase in the expression of the anti-apoptotic gene, XIAP. Cu-Phen (1) exposure 
induced a moderate increase in the expression of the apoptotic related genes, Caspase 9, 
BCL-2 and BAX. A large increase in the anti-apoptotic, XIAP was observed. Cu-Phen 
(1) induces a moderate increase in the expression of the apoptotic related genes, 
Caspase 9, BCL-2 and BAX. A large increase in the anti-apoptotic, XIAP was observed. 
Exposure to Cu-DPQ-Phen (2) shows no appreciable increase in any of the apoptotic 
process. Cu-DPPZ-Phen (3) induced a small increase in the apoptotic gene BAX. 
Exposure to Cu-DPPN-Phen (4) induced only a small increase in the expression of the 
anti-apoptotic gene, XIAP. All other genes were either not detected or not increased in 
expression. 
 
Figure 2.24 shows the expression of genes outlined in Table 2.1 after a 24 h exposure, 
relative to the geometric mean of the references genes, actin and tubulin in the A2780/ 
Cis cell line. Exposure to doxorubicin induced a decrease or undetectable change in the 
apoptotic genes and related processes. Cisplatin exposure induced a strong increase in 
the apoptotic related factor, BCL-2. Exposure to Cu-Phen (1) induced a decrease or 
undetectable change in the apoptotic related genes. Cu-DPQ-Phen (2) induced a strong 
apoptotic activation of Caspase 3 while Cu-DPPZ-Phen (3) induced a strong increase in 
the apoptotic factors, Caspase 9 and BAX. The exposure to Cu-DPPN-Phen (4) induced 
a large response across all of the measured processes. Apoptosis related factors showed 






Fig. 2.24 Gene expression of A2780 and A2780/ Cis cells at 24 h following exposure to doxorubicin, cisplatin, Cu-Phen (1) and Cu-DPQ-Phen (2), Cu-
DPPZ-Phen (3) and Cu-DPPN-Phen (4). Error bars represent 95 % Confidence Interval (N=4). Relative expression of target genes calculated in relation 




The experimental work detailed in this Chapter describes the fundamental evaluation of 
the Cu(II) phenanthroline-phenazine complex series and compares them to the clinical 
therapeutics, cisplatin and doxorubicin. A range of cell lines derived from different solid 
tumours were used to evaluate the activity of the drugs across a broad range of 
phenotypes. A range of sensitivities was detected in all of the cell lines to cisplatin and 
the Cu(II) phenanthroline-phenazine complex series, demonstrating the potential of anti-
cancer activity. ROS (H2DCFDA), DNA DSB formation (γH2AX), inflammation and 
the apoptosis (gene expression) were used to provide a screen of the mechanisms of 
action which will be expanded on in subsequent chapters. 
 
Throughout viability testing the novel Cu(II) complexes were shown to exert time-
dependent, superior toxicity in comparison to cisplatin and doxorubicin (except where 
N.P. is indicated). Overall a viability profile with the following cadence was 
demonstrated, with some exceptions: Cu-DPPZ-Phen (3) (greatest toxicity) > Cu-Phen 
(1) > Cu-DPQ-Phen (2) > Cu-DPPN-Phen (4) (lowest toxicity). The extension of the 
phenazine ligand generally resulted in increased loss of cell viability. In particular, Cu-
DPPZ-Phen (3) demonstrated the lowest viability at both 24- and 48- h in the tested cell 
lines, with Cu-DPPN-Phen (4) demonstrating the highest viability. With the exception 
of the cisplatin sensitive MCF-7 cell line one or more of the Cu(II) complex series 
exceeded the activity of cisplatin in all cell lines thereby demonstrating their further 
developmental potential. A key finding of this investigation through multiple cell lines 
was the demonstration of the superior inhibition of viability of the Cu(II) complex series 
to cisplatin in all the cisplatin resistant cell lines (PC-3, SKOV-3 and A2780/ Cis). The 
activity of the Cu(II) complex series in SKOV-3 cells was previously demonstrated with 
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a similar result profile in the study by Molphy et al. (2014). The results from the Cu(II) 
complexes in the cisplatin resistant cell lines may indicate that they have a different 
mechanism of action to cisplatin, which is a key therapeutic objective in inorganic 
medicinal chemistry. Many of the sensitive cell lines demonstrated very little difference 
between the response to cisplatin and the Cu(II) complexes. 
 
ROS generation as a therapeutic characteristic has proven to be a strong developmental 
objective in metal-based drugs (Cadet et al. 2017). The previous study by Molphy et al. 
(2015), demonstrated that Cu-DPQ-Phen (2), Cu-Phen (1) and Cu-DPPZ-Phen (3) 
resulted in the production of metal-hydroxo or free hydroxyl radicals (•OH) as the 
predominant oxidative species and in-turn produced DNA oxidation of 8-oxo-2′-
deoxyguanosine (8-oxo-dG) lesion with strong evidence that singlet oxygen generation 
is the causative factor (Frelon et al. 2003). These conditions were however examined on 
purified pUC19 plasmid DNA and not in-vitro. Here the in-vitro studies on HeLa cells 
demonstrated moderate ROS production after exposure to Cu-Phen (1) but weaker 
production after exposure to Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen 
(4). Cu-Phen (1) has been previously demonstrated as a chemical nuclease, capable of 
abstracting hydrogen (•H) from the pentose ring of DNA in the presence of both 
exogenous reductant (Cu(II) → Cu(I)) and oxidant (O2 or H2O2) (Sigman et al. 1979; 
Chen et al. 2001; Santini et al. 2014). The results of the weaker ROS production from 
the phenazine π-backbone extended ligands demonstrate that the toxicity in the cells 
may not be entirely a result of ROS generation. 
 
One of the primary developmental objectives in inorganic medicinal chemistry is the 
establishment of an alternative DNA interacting metal-based drug, with the hope of 
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emulating and expanding of the therapeutic success of the platinum-based cisplatin. The 
study by Molphy et al. (2014), established that the Cu(II) phenanthroline-phenazine 
complexes bound to calf thymus DNA as follows: Cu-DPQ-Phen (2) ~ Cu-DPPZ-Phen 
(3) (strongest) > Cu-DPPN-Phen (4) > Cu-Phen (1) (weakest) and additionally was 
found to interact with DNA through intercalation of both the minor and major grooves. 
In all tested cell lines, the lowest viability was observed after exposure to Cu-DPPZ-
Phen (3) with the highest being Cu-DPPN-Phen (4). This published data suggests that 
the intercalation capability of the Cu(II) phenanthroline-phenazine complexes may not 
have sole responsibility for inducing the toxicity in the cell. In this study both MCF-7 
and SKOV-3 cells induced the production of γH2AX foci after exposure to cisplatin, 
Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen (4), however 
at different intensities. MCF-7 cells demonstrated γH2AX foci formation but with a low 
% of cells effected, while SKOV-3 cells demonstrated γH2AX foci formation with a 
much higher % cell affected. Based on the lower viability values of the MCF-7 
compared to SKOV-3 cells when exposed to the Cu(II) phenanthroline-phenazine 
complex series, the lower percentage of γH2AX foci formation of effected cells may 
have a greater role in the toxicity of the cisplatin sensitive, MCF-7 cells in comparison 
to the higher percentage of γH2AX foci cisplatin resistant, SKOV-3 cells. 
 
Apoptosis, as a means through which programmed cell death occurs, is a common 
feature of the mechanism of action of cisplatin (Dasari and Tchounwou 2014). Due to 
its investigation in relation to cisplatin, the Cu(II) complex, 
[Cu(o‑phthalate)(phenanthroline)] has also been studied both from the intrinsic and 




The cisplatin sensitive cell lines: HT-29, MCF-7, OE-33, HeLa and A2780 generally 
responded to the exposure of cisplatin and the Cu(II) phenanthroline-phenanzine 
complexes with the upregulation of both apoptotic and anti-apoptotic process over both 
24- and 48- h timepoints. In addition to apoptosis, a mild to strong upregulation in the 
anti-apoptotic genes was observed in the HT-29, OE-33, HeLa and MCF-7 cells 
demonstrating that the apoptotic process may not have sole responsibility for cell death 
after exposure to Cu-Phen (1). Exposure to Cu-DPQ-Phen (2) was characterised by a 
time-dependent inflammatory response coupled to a time-dependent apoptotic response 
in the HT-29, OE-33 and MCF-7 cell lines. The response to cisplatin was characterised 
by a strong apoptotic activation in contrast to the more complex response to the Cu(II) 
phenanthroline-phenanzine complexes. The cisplatin resistant cells: PC-3, SKOV3 and 
A2780/ Cis responded to the cisplatin exposure with a similar exposure to the cisplatin 
sensitive cells lines however the response to the Cu(II) phenanthroline-phenanzine 
complexes was more complex. The response of both SKOV-3 and A2780/ Cis to Cu-
Phen (1) showed no upregulation of apoptotic and anti-apoptotic processes, indicating 
that these may not be part of its resistance mechanism. In contrast, SKOV-3 cells 
exposure to Cu-DPQ-Phen (2) demonstrated an apoptotic response at 24 h which was 
lost at 48 h, similarly to the SKOV-3 exposure to Cu-Phen (1). Exposure of Cu-DPQ-
Phen (2) in the A2780/ Cis cells induced a strong executioner caspase response but no 
other apoptotic marker. The upregulation of IAP’s has been a well documented 
resistance factor in therapeutics and is a potential factor in these results (Li et al. 2001; 
Nomura et al. 2005; Zhang et al. 2008; Del Bello et al. 2013). The activation of 
apoptotic markers was observed following Cu-DPPZ-Phen (3) and Cu-DPPN-Phen (4) 
exposures with progressive expansion of apoptosis signature, as the phenazine π-
backbone was extended.  
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Further in-vitro mechanistic investigations carried out in Chapter 3 and 4 
Cisplatin sensitive cells (MCF-7 and A2780) Cisplatin resistance cells (SKOV-3 and A2780/ Cis) 
Label free Quantitative proteomic (MCF-7 and SKOV-3 only) 
Mitochondrial membrane potential decay 
Mitochondrial related gene expression 
N.P. Not Performed 
 
The work described in this chapter and summarised in Table 2.5 identified the activity 
and initial characterisation of the mechanisms of action of the novel Cu(II) 
phenanthroline-phenazine complexes with the clinical drugs, cisplatin and doxorubicin 
in a series of tumorigenic cell lines. The MCF-7, A2780 cells were shown to be 
sensitive to cisplatin while SKOV-3, A2780/ Cis cells were shown to be resistant. The 
Cu(II) phenanthroline-phenazine complexes strongly exceeded the activity of cisplatin 
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in the resistant cells. Intracellular ROS generation was found to vary between mild to 
moderate levels of generation. DNA DSB formation indicated by γH2AX foci was 
found weakly positive in the MCF-7 compared to SKOV-3 cells. Both the MCF-7 and 
SKOV-3 have demonstrated good comparative profiles through cell viability/ toxicity 
and DNA DSB assays. Additionally, they have demonstrated using gene expression that 
the process of apoptosis was not a prominent feature of the MCF-7 and A2780 cell lines 
while the apoptotic process featured more prominently in the SKOV-3 and A2780/ Cis 
cells.  
 
The contrasting results between the MCF-7 and SKOV-3 cells demonstrated that a 
proteomic level evaluation (Chapter 3) of both these cell lines would give new insights 
into their responses. The evaluation of MCF-7 and SKOV-3 cells for mitochondrial 
related gene expression along with A2780 and A2780/ Cis cells (Chapter 4) allowed for 













Chapter 3: In-vitro mammalian cell proteomic responses to 



























Mass spectrometry based proteomics has emerged in the past two decades due to 
advances in chromatographic and mass spectrometric detection technology and has 
greatly benefitted research into intracellular signalling, biomarker discovery, infection 
classification and characterisation and recently, drug target evaluation (Dias et al. 
2016). With the sequencing of the first cancer genome in 2008 (Ley et al. 2008), a large 
quantity of tumorigenic information was acquired which aided in drug target selection 
and prognostic evaluation. Similarily to genomic sequencing technologies, the 
exapansion of modern proteomic technologies has opened up a new avenue into 
evaluating response of the cell at protein level to therapeutic action. 
 
Mass spectrometry and Two Dimensional (2D)-gel based analysis platforms are the two 
main methodologies used for quantitative proteomics. Two-dimensional gel 
electrophoresis utilises polyacrylamide gels to separate proteins by pH and size, with 
comparisons between gel spots revealing relative fold changes in protein expression. 
The spots of interest can then be excised, chemically digested and identified using 
LC/MS and protein sequence alignment (Dias et al. 2016). Mass spectrometry based 
quantitative proteomics is accomplished using several peptide spectral identification 
methods. The use of chemical labelling such as isobaric Tags for Relative and Absolute 
Quantification (iTRAQ), Tandem Mass Tags (TMT) and dimethyl labelling are used to 
label different biological samples to measure the relative abundance of peptides.  
 
Over the past few decades the development of metal-based drugs has occurred through 
the evaluation of purified biomolecules extracts. The results from these investigations 
have been further enhanced using stratified experiments in in-vitro mammalian models 
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with successful candidates progressing to murine models. Many metal-based drugs 
including copper-based coordinated complexes are designed to target DNA and as such 
the evaluation of their capabilities has been restricted to non-cell-based assays and only 
later in-vitro evaluation. Additionally, ROS production has been classified as a major 
contributing factor towards their therapeutic effects on the cell. While this reductionist 
approach is valuable in defining the potential mechanism of action, it is limited by an 
inability to take into account other contributing factors contributing to the observed 
cellular effects. The effects of metal-based drugs, principally cisplatin on proteins, and 
in particular their preponderance to form adducts in sulphur rich sequences have been 
the subject of studies (Florea and Büsselberg 2011; Trudu et al. 2015). Recently, a more 
concerted effort has been placed on establishing the interaction of metal-based drugs 
with proteins on the overall therapeutic outcome of the cell and also resistance profiles 
(Mena et al. 2013; Moraleja et al. 2014; Giner Martínez-Sierra et al. 2015; Kullmann et 
al. 2015). Examination of platinum and other metal content in the cell utilising ICP-MS 
and ESI LTQ technologies investigate the degree to which platinum content is forming 
DNA adducts, (Harrington et al. 2010; Corte-Rodríguez et al. 2015), the interaction of 
platinum with other proteins (Timerbaev et al. 2012; Moraleja et al. 2014) and effects 
on the cellular metalloproteome (Timerbaev et al. 2012). The interaction of a metal 
complex with epigenetic regulators such as histone deacetylases (HDAC), BRD4 and 
JMJD2 has also gained prominence (Leung et al. 2016). Copper complexes have 
demonstrated DNA double strand break (γH2AX) (Kellett et al. 2012; Prisecaru et al. 
2013) and topoisomerase-like activity (Slator et al. 2016) as part of their mechanism of 
action. The addition of proteomics to these mechanistic studies will provide new insight 
into protein interaction and potential epigenetic effects which provide a more 
comprehensive analysis of the in-vitro mechanistic effects. The proteomic evaluation of 
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organogold(III) (Gamberi et al. 2014) and titanium dioxide (Vuong et al. 2016) 
demonstrated changes in multiple protein functional classes such as stress response, 
metabolic, transport and protein synthetic process. The analysis of these individual 
protein expression changes in addition to wider changes across functional classifications 
give significant information regarding the response of the cell to the therapeutics. 
Proteomic approaches to mechanism of action studies can also be integrated into 
transcriptomic and metabolomics data sets (Cho et al. 2012; Wilmes et al. 2013) to 
produce a highly integrated assessment of the potential success of a candidate 
therapeutic and also can identify alternative drug targets not previously envisaged in the 
initial workup. 
 
The work described in this chapter uses label free quantitative proteomics to identify 
and assess the quantitative changes in proteins following treatment with Cu(II) 
phenanthroline-phenazine complexes in cisplatin sensitive and resistant cell lines. This 
comparison will help identify potential mechanisms of action resulting from changes in 












3.2 Material and methods 
3.2.1 Cell preparation, exposure and processing 
The cisplatin sensitive, MCF-7 and cisplatin resistant, SKOV-3 cells were chosen for 
the LFQ proteomics study due to their differential response to cisplatin and their 
sensitivity to Cu-Phen (1) and Cu-DPQ-Phen (2). Both cell lines were subcultured into 
T25 flasks at a density of 1 × 105 cells. After 24 h cells were exposed to their respective 
IC25 concentrations (as in the gene expression and γH2AX studies in Chapter 2) of Cu-
Phen (1) and Cu-DPQ-Phen (2) for a 24- and 48- h timepoints. While both Cu-DPPZ-
Phen (3) and Cu-DPPN-Phen (4) demonstrated good toxicity in Chapter 2, an increased 
variability in results, cost and complexity of processing the generated data excluded 
them from analysis in this chapter. After 24- and 48- h, 500 µl of cell lysis buffer 
(Sigma, Ireland) (6 M Urea, 2 M Thiourea, 0.1 M Tris-HCl (pH 8.0)) (Appendix 1.5.1) 
(Cat# U5378, Cat# T8656, Cat# T3038 respectively) was added to each flask and left to 
incubate for 1 h. Lysed cellular components were then transferred to an Eppendorf tube 
(Thermo, USA) (Cat# 90410) and were incubated for a further 3 h on a rotary mixer. 
Following this the samples were centrifuged at 6000 g. The supernatant was then 
transferred to a new tube and stored at -20 ˚C until required. 
 
3.2.2 In-solution digestion protocol using ProteaseMAX 
The samples were thawed on the day of the digestion procedure. The Bradford assay 
(BioRad, USA) (Cat# G-250) (Appendix 1.5.2) was used to determine the concentration 
of protein in each sample. Sixty µg of protein in 25 µl of cell lysis buffer was removed 
and subjected to the in-solution protein digestion protocol using ProteaseMAX 
(Promega, USA) (Cat# V2071) (Appendix 1.5.3). Samples were re-suspended in sample 
re-suspension buffer with the proteolytic inhibitors; Aprotinin (Sigma, Ireland) (10 
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mg/mL) (Cat# A6106), Leupeptin (Sigma, Ireland) (Cat# L5793), Pepstatin (Sigma, 
Ireland) (Cat# P5318) and TLCK (Sigma, Ireland) (Cat# T7254) added. One hundred 
and twenty five µl of ammonium bicarbonate (50 mM) (Sigma, Ireland) (Cat# 09830) 
was added to the sample along with 1 µl of DTT (0.5 M) (Sigma, Ireland) (Cat# 
D0632). Samples were incubated at 56 °C for 20 min. Once samples had cooled 2.7 µl 
of IAA (0.55 M) (Sigma, Ireland) (Cat# I4386) was added, followed by incubation at 
room temperature for 15 min in the dark. A working solution of ProteaseMAX (1 % 
(w/v stock) (Promega, USA) (Cat# V2071) and sequence grade Trypsin (0.5 µg/µl) 
(Promega, USA) (Cat# V5111) (Appendix 1.5.3) was added to each of the samples with 
a subsequent overnight incubation at 37 °C. Following the overnight incubation the 
samples were acidified with 1 µl of TFA (Sigma, Ireland) (Cat# 8.08260), vortexed and 
incubated at room temperature for 5 min and subsequently centrifuged at 13,000 g for 
10 min at room temperature. See Appendix 1.5.3 for further details of in-solution 
protein digestion. Following the in-solution digestion protocol one of the aliquots from 
each biological sample was subjected to the C18 spin columns (Thermo, USA) (Cat# 
89870) (Appendix 1.5.4 and 1.5.5) which used reverse phase chromatography to enrich 
the hydrophobic peptides before mass spectrometric analysis.  
 
3.2.3 Sample clean-up using C18 spin-columns 
C18 spin-columns (Thermo, USA) (Cat# 89870) were used to enrich the hydrophobic 
peptides and desalt the eluted peptides prior to mass spectrometric analysis. Samples 
were mixed with the sample buffer 1 (Appendix 1.5.4). Two hundred µl of activation 
solution (Appendix 1.5.4) was added to each of the columns to rinse and wet the 
separating resin. Columns were centrifuged at 1500 g for 1 min and flow-through was 
discarded. This process was repeated once. Two hundred µl of equilibrium solution 
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(Appendix 1.5.4) was added to each of the columns and centrifuged at 1500 g for 1 min 
and flow-through was discarded. This process was repeated once. Samples (10-150 µl; 
up to 30 µg) were loaded to the top of the resin bed and the columns were placed in new 
receiver tubes. Samples were centrifuged at 1500 g for 1 min, the flow-through was 
recovered and re-applied to the column. This step was repeated twice more to ensure 
complete sample binding. The columns were transferred into new receiver tubes and 
200 µl of wash buffer (Appendix 1.5.4) was added. The columns were centrifuged at 
1500 g for 1 min and the flow-through was discarded. This step was repeated twice 
more to remove high levels of contaminants. The columns were placed in new receiver 
tubes and 25 µl of elution buffer (Appendix 1.5.4) was applied to the top of the resin 
bed. The columns were centrifuged at 1500 g for 1 min. This step was repeated twice 
more using the same receiver tube to collect a total ~75 µl of eluant. The resulting 
samples were dried out in a SpeedyVac (Thermo, USA) at medium heat for 1 h. 
Samples were stored at -20 °C until loading onto the Q Exactive™ (Thermo, USA). The 
constituents and procedure for the C18 reverse phase chromatography columns is 
detailed in Appendix 1.5.4-1.5.5.  
 
3.2.4 Q Exactive analysis 
Dried samples were re-suspended in 32 µl of Q Exactive buffer (Appendix 1.5.5) on day 
of analysis. Samples were placed in a sonication bath for 5 min to aid peptide re-
suspension. Samples were subsequently centrifuged at 13,000 g for 5 min at RT to 
pellet any insoluble material. The supernatant was transferred to LC MS/ MS vials 
(Thermo, Ireland) (Cat# 60180-508). A peptide mix was separated on a Dionex 
Ultimate 3000 (RSLC nano, Thermo, USA)) chromatography system with increasing 
gradient of acetonitrile on a Biobasic C18 Picofrit TM column (100 mm length, 75 mm 
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ID), using a 180 min reverse phase gradient at a flow rate of 250 nl min-1.  High 
resolution MS scan (300-2000 Da) was performed using the Orbitrap to select the 15 
most intense ions prior to MS/ MS. Each sample was run 3 times for technical 
comparison and a 3 h blank was run between each biological sample. 
 
3.2.5 Computational and statistical processing of LC-MS data 
Label free LC-MS data analysis was performed on Progenesis QI for Proteomics 
(Nonlinear Dynamics, USA) package with subsequent identification using Proteome 
Discoverer (Thermo Fischer Scientific, USA). Spectral files were aligned in Progenesis 
QI for Proteomics using retention time from the LC and m/z peak height, from the 
peptides in the replicate samples to produces consensus peak ion intensity. Differential 
analysis was performed on the peak height at the specific retention time between 
biological samples. The experimental comparison was divided up into 4 separate 
analyses as follows as outlined in Table 3.1. 
Table 3.1 Set-up for the LFQ proteomics experimental conditions. 
Experimental designation Experimental condition 
(A) 
MCF-7 24 h exposure to Cu-Phen (1) and Cu-
DPQ-Phen (2) in comparison to the negative 
control 
(B) 
MCF-7 48 h exposure to Cu-Phen (1) and Cu-
DPQ-Phen (2) in comparison to the negative 
control 
(C) 
SKOV-3 24 h exposure to Cu-Phen (1) and 
Cu-DPQ-Phen (2) in comparison to the 
negative control 
(D) 
SKOV-3 48 h exposure to Cu-Phen (1) and 
Cu-DPQ-Phen (2) in comparison to the 
negative control 
 
Ion intensity peaks were identified after meeting the following criteria: ANOVA p-
value ≤ 0.05, minimum fold-change between experimental groups of 1.5 and a ≥ 2 
peptides contributing to the protein identification. Proteins which meet the inclusion 
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criteria were identified using the software, Proteome Discoverer. Proteins were 
identified through a consensus workflow comparing the results of both the SEQUEST 
and MASCOT algorithms and using the following identification parameters: peptide 
mass tolerance at 20 ppm with the fragment tolerance set at 0.02 Da, up to 2 missed 
cleavages, a static modification of cysteine carboxymethylation and dynamic 
modification of methionein oxidation, MASCOT ion score was set at a minimum of 40, 
and SEQUEST HT XCorr was set at minimum 1.5 and FDR for PSMs and peptides set 
for strict at 0.01 and relaxed at 0.05. See appendix 1.5.6 for further details. Principle 
Component Analysis (PCA) uses orthogonal transformation to convert a set of 
potentially correlated variables into a smaller number of uncorrelated variables 
(principle components). This statistical procedure is used to reduce a large set of 
variable into a smaller set while preserving the trends and patterns present in the 
original dataset. PCA was performed on each of the experimental designs to establish 
the protein abundance variation between the different experimental exposures and 
examine the variation within each experimental group. Tight clustering indicated similar 
protein abundance while dispersed data points indicated dissimilar protein abundance. 
Dispersion of the data points on the x-axis (Component 1) represented the largest 
difference in protein abundance while dispersion of data points on the y-axis 
(Component 2) represented the next largest difference in protein abundance. Proteins 
with statistical significant expression and ≥ 1.5 fold change between the test exposure 
and the negative control were labelled, Statistically Significant Differentially Abundant 
(SSDA) proteins. Proteins with statistically significant changes in relation to the 
negative control but < 1.5 protein fold change were included and tabulated separately. 
Statistically significant changes in protein abundance between both Cu-Phen (1) and 
Cu-DPQ-Phen (2) treated cells were not included in the analysis. All fold changes were 
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calculated based on mean normalized abundances of the test exposures with the 
negative control. Hierarchical clustering was performed on all statistically significant 
proteins with log(2) transformed raw abundance values processed in Perseus software 
package (ver. 1.5.0.31). 
 
The Blast2GO suite (www.blast2GO.com) of software tools was used to assign 
annotation, enzyme code, KEGG and Gene Ontology mapping on SSDA proteins. GO 
mapping for biological processes and molecular functions was graphed at level 4 
ontology. Due to the different number of proteins detected in each of the experimental 
conditions, arbitrary thresholds were used to discuss the results of the GO analysis. 
Proteins of interest in both MCF-7 48 h and SKOV-3 48 h exposures were further 
analysed using Pathway Studio which used supervised text mining of published journal 
article along with the production of directional specific regulation proteins networks and 
their associated cell processes. Pathway Studio analysis was performed by Dr. Padraig 
Doolan in the National Institute for Cellular Biotechnology, Dublin City University, as 













3.3.1 (A) MCF-7 24 h exposure to Cu-Phen (1) and Cu-DPQ-Phen (2) in 
comparison to the negative control 
 
The cell lysate from the MCF-7 cell line was extracted after a 24 h exposure to Cu-Phen 
(1) and Cu-DPQ-Phen (2) along with a negative control for comparison. A total of 42 
Statistically Significant Differentially Abundant (SSDA) proteins (Table 3.2) were 
found to meet the following criteria: containing ≥ 2 unique peptide from the identified 
protein, showed a significant change (ANOVA) in comparison to the negative control, 
had ≥ 1.5 fold change in relation to the negative control (a fold change of ˂ 1.5 was also 
included if the same protein was expressed at ≥ 1.5 fold change in another exposure). A 
total of 159 proteins (Table 3.3) were found to be statistically significant but had a ˂ 
1.5 fold change in protein expression in relation to the negative control. Principle 
component analysis (PCA) (Fig. 3.1) was used to visualise the variation in protein 
abundance across individual replicates. In each of the exposed (Cu-Phen (1) and Cu-
DPQ-Phen (2)) and unexposed cells (negative control), a single replicates was excluded 
from the subsequent analysis. Both the negative control and Cu-Phen (1) exposed cells 
showed close clustering, indicating a similar protein expression pattern. This is in 
contrast to the separation observed in the negative control and Cu-DPQ-Phen (2). Cu-
Phen (1) and Cu-DPQ-Phen (2) treated cells show closer clustering to each other 
through both component 1 and 2. Hierarchical clustering was generated through the 
mean of the Log(2) transformed LFQ abundances (Fig. 3.2) and indicated a closer 
clustering of both Cu-Phen (1) and Cu-DPQ-Phen (2) results, similarly to the PCA in 
Figure 3.1. Table 3.2 represents a diverse functional classification of proteins with 
roles in metal based detoxification and signalling (metallothioneins), heat shock 
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signalling (HSP’s), DNA modification (histones), ribosomal related (60S, 40S etc.) and 
metabolic related proteins which are the principle focus of this analysis. Table 3.3 
additionally, detailed further proteins in these classes at lower fold changes in relation 
to the negative control. Many of the functional processes these proteins are associated 
with are similar to Table 3.2. Gene Ontology (GO) biological process (Fig. 3.3) 
indicated a large increase in biosynthetic, primary metabolic, organic substance 
metabolic and nitrogen compound metabolic processes. The processes containing more 
than 25 proteins were of greater interest for the analysis. GO molecular process analysis 
revealed large numbers of proteins associated with binding of ions, small molecules, 
organic cyclic compounds, heterocyclic compounds and drugs. The processes 
containing more than 20 proteins formed the main focus of the analysis. KEGG analysis 
highlighted several pathways with associated proteins (Table 3.2). While additional 
KEGG pathways were identified but not included in this chapter the pathways presented 
below represent pathways that were highlighted across multiple experimental conditions 
and in many cases contained multiple protein identification within the same pathways. 
Fatty acid biosynthesis: fatty-acid synthase (FASN) (Fig. 3.5). Glycolysis/ 
gluconeogenesis: 6-phosphofructokinase (2.7.1.11) and L-lactate dehydrogenase 
(1.1.1.27) (Fig. 3.6). Nucleoside diphosphate kinase B and purine nucleoside 
phosphorylase are associated with purine metabolism but had a low fold change after 
both exposures. STRING protein network analysis (Fig. 3.7) demonstrates putative 





Fig. 3.1 Principle component analysis of whole cell lysate proteome of MCF-7 cells exposed to Cu-Phen (1) and Cu-DPQ-Phen (2) for 24 h 
in comparison to the negative control. PCA of three replicates for the negative control and three replicates (N=3) of both test exposures. 
Enclosures define the different experimental conditions. Red X denotes the third replicates from each condition removed from the analysis 








Fig. 3.2: Hierarchical clustering of SSDA proteins and statistically significant proteins 
with less than a 1.5 fold change in the MCF-7 cell line after 24 h exposure to Cu-Phen 
(1) and Cu-DPQ-Phen (2) in relation to the control. Hierarchical clustering generated 
from mean Log(2) transformed values of LFQ abundance with samples clustered 






Table 3.2 Statistically significant differentially abundant (SSDA) proteins (42) after 
exposure of Cu-Phen (1) and Cu-DPQ-Phen (2) in the MCF-7 cell line after 24h 
incubation.  











Metallothionein-1F P04733 2 2.09E-04 121.17 85.66 
Metallothionein-1X P80297 4 8.01E-06 74.59 75.32 
Metallothionein-2 P02795 3 1.66E-04 25.65 21.78 
Protein NDRG1 Q92597 2 3.55E-04 3.60 1.00 
BAG family molecular chaperone 
regulator 3 
O95817 2 1.63E-03 2.27 1.10 
Thioredoxin reductase 1, cytoplasmic Q16881 3 3.97E-03 2.21 1.54 
60S ribosomal protein L14 P50914 2 2.36E-02 1.96 2.47 
L-lactate dehydrogenase A chain P00338 10 6.11E-05 1.95 0.95 
Ubiquitin-60S ribosomal protein L40 P62987 3 3.16E-04 1.89 1.23 
Sequestosome-1 Q13501 4 2.80E-06 1.86 1.17 
cAMP-dependent protein kinase type I-
alpha regulatory subunit 
P10644 2 3.46E-03 1.73 1.68 
Golgin subfamily B member 1 Q14789 2 1.70E-02 1.72 1.43 
26S protease regulatory subunit 6A P17980 6 1.19E-02 1.69 1.40 
ATP-dependent 6-phosphofructokinase, 
platelet type 
Q01813 2 4.08E-03 1.64 1.32 
Paxillin P49023 2 4.67E-04 1.62 0.89 
Ras GTPase-activating protein-binding 
protein 1 
Q13283 2 7.22E-03 1.60 1.05 
60 kDa heat shock protein, mitochondrial P10809 8 1.04E-03 1.58 1.08 
Clathrin heavy chain 1 Q00610 3 1.24E-04 1.55 0.89 
Bcl-2-associated transcription factor 1 Q9NYF8 2 5.01E-03 1.54 1.13 
Serum albumin P02768 3 6.01E-05 1.54 0.63 
DNA replication licensing factor MCM3 P25205 2 8.22E-03 1.52 1.83 
Transaldolase P37837 2 2.92E-02 1.50 1.58 
Annexin A4 P09525 2 3.19E-02 1.36 1.56 
T-complex protein 1 subunit alpha P17987 2 1.46E-02 1.27 1.61 
Heat shock protein HSP 90-alpha P07900 16 2.68E-03 1.26 1.58 
60S ribosomal protein L28 P46779 4 6.07E-03 1.14 1.83 
Heat shock protein beta-8 Q9UJY1 3 6.69E-04 1.14 1.70 
Ubiquitin carboxyl-terminal hydrolase 14 P54578 4 1.44E-03 1.12 1.62 
Actin-related protein 2 P61160 2 1.09E-03 1.11 1.61 
Histone H3.1 P68431 4 1.01E-04 1.05 2.27 
Adenosylhomocysteinase P23526 3 1.14E-02 1.04 1.54 
Heat shock protein HSP 90-beta P08238 16 7.64E-03 1.01 1.61 
Fatty acid synthase P49327 3 3.25E-03 0.97 1.51 
Proteasome subunit alpha type-5 P28066 2 1.23E-02 0.95 1.62 
Protein LSM14 homolog B Q9BX40 2 2.78E-03 0.87 1.64 
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60S ribosomal protein L32 P62910 3 5.98E-03 0.86 1.57 
40S ribosomal protein S25 P62851 4 6.49E-05 0.83 2.08 
60S ribosomal protein L8 P62917 4 1.25E-02 0.82 1.94 
60S ribosomal protein L23a P62750 3 1.62E-04 0.80 1.70 
D-3-phosphoglycerate dehydrogenase O43175 2 4.85E-03 0.79 1.52 
60S ribosomal protein L35a P18077 4 6.92E-04 0.74 1.58 
Histone H2A type 1-B/E P04908 4 1.10E-04 0.62 1.95 
Relative fold changes are given for each test exposure in comparison to the negative control.  
Fold changes of ˂ 1.5 were included when expression in other test exposure was ≥ 1.5 fold change.  
Proteins (highlighted in grey) involved in metal based detoxification and signalling (metallothioneins), 
heat shock signalling (HSP’s), DNA modification (histones), ribosomal related (60S, 40S etc.) and 




































Table 3.3 Statistically significant proteins (159) with fold changes < 1.5 fold change 
after exposure of Cu-Phen (1) and Cu-DPQ-Phen (2) in the MCF-7 cell line after 24 h 
incubation.  
















Heat shock 70 kDa protein 1B P0DMV9 17 3.13E-03 1.49 1.31 
Nuclear migration protein nudC Q9Y266 2 3.32E-03 1.48 0.97 
Glucose-6-phosphate 1-dehydrogenase P11413 9 9.15E-05 1.47 1.17 
Fructose-bisphosphate aldolase A P04075 19 1.94E-04 1.43 0.84 
6-phosphogluconate dehydrogenase, decarboxylating P52209 2 2.21E-03 1.41 0.74 
Heterogeneous nuclear ribonucleoprotein A0 Q13151 2 4.87E-03 1.41 0.90 
Ubiquitin carboxyl-terminal hydrolase 5 P45974 2 9.08E-03 1.40 0.87 
LIM and SH3 domain protein 1 Q14847 2 6.83E-04 1.39 0.70 
Guanine nucleotide-binding protein subunit beta-2-like 1 P63244 5 3.05E-05 1.31 0.84 
Isocitrate dehydrogenase [NADP], mitochondrial P48735 2 1.98E-03 1.28 0.72 
Stress-70 protein, mitochondrial P38646 8 1.37E-03 1.28 0.72 
Nucleosome assembly protein 1-like 1 P55209 2 8.52E-03 1.26 0.71 
Protein disulfide-isomerase A3 P30101 6 1.93E-03 1.26 0.81 
Chromobox protein homolog 5 P45973 3 1.79E-03 1.26 0.76 
Elongation factor Tu, mitochondrial P49411 4 7.31E-04 1.25 0.83 
Transcriptional repressor p66-alpha Q86YP4 2 7.35E-05 1.25 0.71 
Small glutamine-rich tetratricopeptide repeat-containing 
protein alpha 
O43765 2 3.01E-03 1.23 0.66 
Translationally-controlled tumor protein P13693 3 1.89E-02 1.23 0.76 
Calreticulin P27797 2 5.14E-03 1.22 0.68 
DnaJ homolog subfamily B member 1 P25685 3 1.51E-03 1.22 0.73 
Thioredoxin domain-containing protein 5 Q8NBS9 3 8.59E-05 1.18 0.37 
Protein disulfide-isomerase P07237 2 2.28E-04 1.18 0.36 
Endophilin-B2 Q9NR46 3 1.84E-03 1.17 0.74 
10 kDa heat shock protein, mitochondrial P61604 8 3.33E-03 1.16 0.77 
S-adenosylmethionine synthase isoform type-2 P31153 2 8.16E-03 1.16 0.70 
Serine/arginine-rich splicing factor 2 Q01130 2 9.69E-03 1.16 0.76 
Poly(rC)-binding protein 2 Q15366 6 2.05E-05 1.15 0.68 
Calcyclin-binding protein Q9HB71 6 2.69E-03 1.14 0.77 
Phosphoglycerate mutase 1 P18669 7 4.44E-04 1.11 0.68 
40S ribosomal protein S12 P25398 3 5.15E-03 1.11 0.72 
40S ribosomal protein S9 P46781 2 1.00E-02 1.10 0.71 
Galectin-1 P09382 3 9.59E-04 1.09 0.46 
Ras-related protein Rap-1b P61224 3 1.76E-03 1.07 0.70 
Cysteine-rich protein 2 P52943 2 2.00E-02 1.06 0.69 
ATP synthase subunit beta, mitochondrial P06576 7 6.93E-04 1.06 0.65 
N-alpha-acetyltransferase 10 P41227 2 5.79E-04 1.05 0.68 
Glyceraldehyde-3-phosphate dehydrogenase P04406 20 1.67E-03 1.04 0.67 
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Proteasome subunit alpha type-1 P25786 5 2.38E-04 1.04 1.46 
78 kDa glucose-regulated protein P11021 14 4.95E-04 1.03 0.68 
Cofilin-1 P23528 7 6.34E-05 1.02 0.61 
40S ribosomal protein S3 P23396 3 2.63E-03 1.02 0.61 
Heterogeneous nuclear ribonucleoprotein D0 Q14103 4 7.47E-04 1.02 0.59 
Destrin P60981 3 3.27E-04 1.02 0.60 
Poly(rC)-binding protein 1 Q15365 7 1.05E-02 1.02 0.78 
Acidic leucine-rich nuclear phosphoprotein 32 family 
member A 
P39687 2 3.05E-03 1.02 0.61 
Alpha-enolase P06733 21 1.84E-03 1.00 0.77 
Ubiquitin-40S ribosomal protein S27a P62979 2 4.55E-04 0.98 0.66 
40S ribosomal protein S23 P62266 2 1.67E-03 0.98 0.66 
Peroxiredoxin-6 P30041 5 4.36E-02 0.97 1.44 
26S protease regulatory subunit 8 P62195 5 1.52E-03 0.95 1.45 
Voltage-dependent anion-selective channel protein 2 P45880 4 1.16E-02 0.95 0.58 
Eukaryotic initiation factor 4A-III P38919 2 1.79E-02 0.94 1.41 
Prefoldin subunit 2 Q9UHV9 2 1.31E-02 0.94 0.52 
Transgelin-2 P37802 7 7.37E-05 0.93 0.67 
Lysine--tRNA ligase Q15046 2 1.75E-02 0.93 0.62 
60S ribosomal protein L13 P26373 5 5.40E-04 0.92 1.40 
Myosin light polypeptide 6 P60660 6 9.12E-04 0.92 0.66 
rRNA 2'-O-methyltransferase fibrillarin P22087 2 4.55E-03 0.92 0.47 
Heterogeneous nuclear ribonucleoprotein A/B Q99729 7 7.62E-04 0.92 0.54 
High mobility group protein B1 P09429 4 1.23E-04 0.92 0.52 
mRNA export factor P78406 3 3.98E-02 0.91 0.61 
Serine/threonine-protein phosphatase PP1-alpha catalytic 
subunit 
P62136 2 3.43E-03 0.91 0.58 
Histone H4 P62805 4 1.26E-02 0.91 1.40 
Protein CDV3 homolog Q9UKY7 2 6.12E-03 0.90 0.62 
Aspartate aminotransferase, cytoplasmic P17174 2 1.72E-03 0.90 1.39 
Splicing factor U2AF 65 kDa subunit P26368 2 1.45E-03 0.90 0.57 
Non-POU domain-containing octamer-binding protein Q15233 10 5.59E-06 0.89 0.72 
Serine/arginine-rich splicing factor 1 Q07955 2 3.35E-03 0.89 0.56 
Voltage-dependent anion-selective channel protein 1 P21796 3 2.41E-03 0.89 0.59 
Hematological and neurological expressed 1-like protein Q9H910 5 5.32E-04 0.89 1.40 
Na(+)/H(+) exchange regulatory cofactor NHE-RF1 O14745 5 9.72E-03 0.88 0.67 
Chloride intracellular channel protein 1 O00299 11 1.88E-03 0.88 0.64 
Heat shock protein beta-1 P04792 7 3.20E-02 0.88 1.28 
Heterogeneous nuclear ribonucleoproteins A2/B1 P22626 9 6.08E-03 0.88 1.25 
Acyl-CoA-binding protein P07108 2 4.15E-04 0.88 0.54 
Serine/threonine-protein phosphatase 2A 65 kDa 
regulatory subunit A alpha isoform 
P30153 3 2.41E-03 0.87 1.38 
Endoplasmic reticulum resident protein 29 P30040 3 3.40E-03 0.87 0.58 
Fructose-1,6-bisphosphatase 1 P09467 4 7.77E-03 0.87 0.52 
Serpin H1 P50454 4 3.09E-03 0.86 0.66 
Lupus La protein P05455 3 5.26E-04 0.85 0.52 
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Inorganic pyrophosphatase Q15181 5 3.05E-04 0.83 0.53 
Adenylyl cyclase-associated protein 1 Q01518 2 5.65E-03 0.83 0.57 
40S ribosomal protein S16 P62249 3 7.02E-03 0.81 1.22 
T-complex protein 1 subunit eta Q99832 7 4.73E-03 0.81 1.11 
Ubiquitin carboxyl-terminal hydrolase 10 Q14694 2 1.31E-02 0.80 0.45 
Alpha-actinin-4 O43707 12 1.65E-02 0.80 1.19 
Prohibitin P35232 6 1.52E-03 0.79 1.29 
RNA-binding protein EWS Q01844 2 5.07E-03 0.79 0.59 
6-phosphogluconolactonase O95336 2 6.65E-03 0.79 1.19 
Neuroblast differentiation-associated protein AHNAK Q09666 6 1.88E-02 0.79 0.61 
Keratin, type II cytoskeletal 80 Q6KB66 2 3.94E-02 0.78 1.31 
Hepatoma-derived growth factor P51858 3 1.24E-02 0.78 0.59 
Peptidyl-prolyl cis-trans isomerase A P62937 16 5.21E-04 0.78 0.66 
Myosin-9 P35579 6 4.03E-03 0.77 0.86 
60S ribosomal protein L9 P32969 2 6.31E-03 0.77 1.34 
60S ribosomal protein L34 P49207 3 4.93E-03 0.77 1.26 
60S ribosomal protein L5 P46777 2 1.55E-03 0.77 0.59 
Desmoplakin P15924 3 3.17E-03 0.77 0.45 
Tubulin beta-3 chain Q13509 16 1.12E-02 0.77 1.03 
Macrophage migration inhibitory factor P14174 6 3.44E-03 0.77 1.26 
Plakophilin-3 Q9Y446 3 4.65E-02 0.77 1.26 
Proteasome subunit alpha type-2 P25787 3 2.73E-02 0.76 1.22 
Nuclear mitotic apparatus protein 1 Q14980 4 3.17E-02 0.75 1.19 
Coronin-1B Q9BR76 5 1.50E-03 0.75 1.13 
40S ribosomal protein S8 P62241 4 4.56E-03 0.75 1.21 
Zinc finger protein 185 O15231 2 7.29E-03 0.74 0.55 
60S ribosomal protein L21 P46778 4 6.48E-04 0.74 1.16 
Heterogeneous nuclear ribonucleoprotein K P61978 10 3.24E-03 0.73 0.97 
60S ribosomal protein L10a P62906 2 1.66E-02 0.73 0.60 
4F2 cell-surface antigen heavy chain P08195 3 9.42E-03 0.71 1.22 
40S ribosomal protein S21 P63220 10 5.03E-03 0.71 1.10 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit beta-2 
P62879 2 9.21E-04 0.71 0.66 
Transitional endoplasmic reticulum ATPase P55072 16 1.16E-02 0.71 0.85 
60S acidic ribosomal protein P2 P05387 3 3.72E-03 0.71 0.42 
Cold-inducible RNA-binding protein Q14011 4 6.55E-03 0.70 1.04 
RNA-binding protein 4 Q9BWF3 4 4.57E-03 0.70 0.61 
60S ribosomal protein L6 Q02878 4 1.38E-03 0.69 1.31 
Heterogeneous nuclear ribonucleoprotein Q O60506 5 2.01E-03 0.69 0.57 
RuvB-like 2 Q9Y230 3 6.89E-03 0.69 1.22 
Proliferating cell nuclear antigen P12004 3 2.09E-03 0.69 1.15 
S-formylglutathione hydrolase P10768 4 5.36E-03 0.68 0.63 
60S ribosomal protein L24 P83731 4 5.82E-04 0.68 1.05 
Sialic acid synthase Q9NR45 4 4.65E-04 0.67 0.59 
Emerin P50402 2 1.13E-02 0.66 0.45 
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40S ribosomal protein S6 P62753 4 1.02E-02 0.65 1.31 
Heterogeneous nuclear ribonucleoprotein H2 P55795 3 2.32E-04 0.65 0.48 
Anterior gradient protein 2 homolog O95994 4 3.38E-03 0.65 0.64 
Annexin A11 P50995 4 1.06E-03 0.64 0.83 
Histone H2B type 3-B Q8N257 3 5.63E-03 0.64 0.66 
Flap endonuclease 1 P39748 2 2.06E-03 0.64 0.72 
Nucleophosmin P06748 11 1.13E-03 0.64 1.18 
Rab GDP dissociation inhibitor beta P50395 6 8.30E-03 0.64 1.17 
Mitochondrial import receptor subunit TOM34 Q15785 2 6.60E-03 0.62 1.12 
Hematological and neurological expressed 1 protein Q9UK76 4 8.27E-04 0.62 0.86 
Eukaryotic translation initiation factor 4H Q15056 2 3.06E-03 0.62 1.02 
Tubulin beta chain P07437 11 1.72E-02 0.62 0.82 
Serine/arginine-rich splicing factor 5 Q13243 4 1.11E-02 0.62 0.88 
Acidic leucine-rich nuclear phosphoprotein 32 family 
member B 
Q92688 2 2.56E-02 0.61 0.71 
Methionine aminopeptidase 1 P53582 2 1.29E-02 0.61 0.98 
40S ribosomal protein S7 P62081 6 7.53E-03 0.61 1.16 
Structural maintenance of chromosomes protein 1A Q14683 2 3.39E-03 0.60 0.68 
Cytochrome c oxidase subunit 6B1 P14854 5 3.52E-03 0.59 0.86 
Ladinin-1 O00515 3 3.01E-02 0.58 1.08 
Gelsolin P06396 3 1.02E-02 0.58 0.77 
Importin subunit alpha-1 P52292 5 3.00E-03 0.57 0.64 
Phosphatidylethanolamine-binding protein 1 P30086 3 3.46E-05 0.56 0.57 
Ubiquitin fusion degradation protein 1 homolog Q92890 2 1.03E-02 0.54 0.94 
Polypyrimidine tract-binding protein 1 P26599 4 9.65E-04 0.53 0.74 
Poly(U)-binding-splicing factor PUF60 Q9UHX1 4 3.85E-03 0.52 0.52 
RNA-binding protein 3 P98179 4 1.14E-02 0.51 0.86 
Histone H2B type 1-D P58876 15 1.20E-03 0.50 1.17 
Tubulin beta-6 chain Q9BUF5 5 1.68E-04 0.49 0.85 
Ribosome biogenesis regulatory protein homolog Q15050 2 7.88E-06 0.45 0.67 
tRNA-splicing endonuclease subunit Sen34 Q9BSV6 2 2.23E-03 0.43 0.86 
CUGBP Elav-like family member 1 Q92879 2 4.30E-04 0.42 0.96 
Purine nucleoside phosphorylase P00491 2 3.51E-03 0.38 0.59 
Annexin A5 P08758 2 2.17E-03 0.32 0.52 
Rac GTPase-activating protein 1 Q9H0H5 2 1.77E-03 0.30 0.44 
Nucleoside diphosphate kinase B P22392 3 1.07E-04 0.09 0.73 






Fig. 3.3 GO analysis of biological process in MCF-7 cells exposed to Cu-Phen (1) and 
Cu-DPQ-Phen (2) with respect to the negative control after 24 h incubation. Process 






Fig. 3.4 GO analysis of molecular process in MCF-7 cells exposed to Cu-Phen (1) and 
Cu-DPQ-Phen (2) with respect to the negative control after 24 h incubation. Process 

































Fig. 3.6 KEGG analysis of significantly upregulated proteins in glycolysis/ 
gluconeogenesis. 6-phosphofructokinase (2.7.1.11) (orange) and L-lactate 







Fig. 3.7 STRING based protein interaction analysis of statistically significant protein 
with fold changes ≥ 1.5 in the MCF-7 cell after 24 h exposure to Cu-Phen (1) and Cu-
DPQ-Phen (2) compared to the negative control. The dashed red oval highlights 






3.3.2 (B) MCF-7 48 h exposure to Cu-Phen (1) and Cu-DPQ-Phen (2) in 
comparison to the negative control  
 
Cell lysates from MCF-7 cells were extracted after a 48 h exposure to Cu-Phen (1) and 
Cu-DPQ-Phen (2) along with a negative control for comparison. A total of 12 
Statistically Significant Differentially Abundant (SSDA) proteins (Table 3.4) were 
found to meet the following criteria: containing ≥ 2 unique peptide from the identified 
protein, showed a significant change (ANOVA) in comparison to the negative control, 
had ≥ 1.5 fold change in relation to the negative control (a fold change of ˂ 1.5 was also 
included if the same protein was expressed at ≥ 1.5 fold change in another exposure). A 
total of 5 proteins (Table 3.5) were found to be statistically significant but were ˂ 1.5 
fold change in protein expression in relation to the negative control. PCA (Fig. 3.8) was 
used to visualise the variation in protein abundance across individual replicates. In each 
of the exposure and negative control a single replicate was excluded from the 
subsequent analysis. Both the negative control and Cu-DPQ-Phen (2) treatments 
showed close clustering, indicating a similar protein profile while Cu-Phen (1) was 
largely separated from the other 2 by component 2. Hierarchical clustering was 
generated through the mean of the Log(2) transformed LFQ abundances (Fig 3.9) and 
indicates the separation of both complexes from the negative control, similarly to the 
PCA in Figure 3.8. Table 3.4 represents significant differentially abundant proteins 
with multiple functional classes from metal detoxification and signalling 
(metallothionein), cytoskeletal (Tubulin), metabolic (Pyruvate kinase) and ribosomal 
(40S). Table 3.5 additionally, detailed further proteins at lower differentially abundant 
to the negative control. Gene Ontology (GO) biological process (Fig. 3.10) indicated a 
large increase in biosynthetic, primary metabolic, organic substance metabolic and 
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nitrogen compound metabolic processes. Processes that contained more than 6 proteins 
were of greater interest in the analysis. GO molecular process (Fig. 3.11) analysis 
revealed increased numbers of proteins associated with binding of ions, small 
molecules, organic cyclic compounds and heterocyclic compounds. Processes that 
contained more than 6 proteins were of greater interest in the analysis. KEGG analysis 
highlighted 2 pathways with associated proteins (Table 3.4). While additional KEGG 
pathways were identified but not included in this chapter the pathways presented below 
represent pathways that were highlighted across multiple experimental conditions and in 
many cases contained multiple protein identification within the same pathways. Purine 
metabolism (Fig. 3.12) highlighted the following proteins: pyruvate kinase (2.7.1.40). 
Glycolysis/ gluconeogenesis (Fig. 3.13): phosphoglycerate kinase (2.7.2.3) and 
pyruvate kinase (2.7.1.40). STRING protein interaction network (Fig. 3.14) showed 
















Fig. 3.8 Principle component analysis (PCA) of whole cell lysate proteomes of MCF-7 cell exposed to Cu-Phen (1) and Cu-DPQ-Phen (2) 
for 48 h in comparison to a negative control. PCA of three replicates for the negative control and three replicates of both test exposures. 
Enclosures define the different experimental conditions. Red X denotes the third replicates from each condition removed from the analysis 








Fig. 3.9 Hierarchical clustering of SSDA proteins and statistically significant proteins 
with less than a 1.5 fold change in the MCF-7 cell line after 48 h exposure to Cu-Phen 
(1) and Cu-DPQ-Phen (2) in relation to the control. Hierarchical clustering generated 






Table 3.4 Statistically significant differentially abundant (SSDA) proteins (12) after 
exposure of Cu-Phen (1) and Cu-DPQ-Phen (2) in the MCF-7 cell line after 48 h 
incubation.  











Metallothionein-2 P02795 3 2.35E-05 42.56 58.51 
40S ribosomal protein S7 P62081 2 1.41E-02 3.60 1.97 
Filamin-A P21333 3 3.55E-02 2.61 1.36 
60S acidic ribosomal protein 
P0 
P05388 2 2.98E-02 2.15 1.21 
Tubulin beta-4A chain P04350 2 9.25E-04 1.95 1.20 
Phosphoglycerate kinase 1 P00558 3 1.64E-04 1.92 1.01 
Tubulin beta chain P07437 2 3.02E-04 1.87 1.15 
Tubulin beta-3 chain Q13509 3 3.29E-05 1.78 1.08 
GTP-binding nuclear protein 
Ran 
P62826 2 1.31E-05 1.72 1.30 
Annexin A2 P07355 2 1.36E-03 1.61 1.07 
Pyruvate kinase PKM P14618 5 1.50E-02 1.59 1.02 
Ubiquitin-40S ribosomal 
protein S27a 
P62979 2 9.22E-03 0.89 1.85 
Relative fold changes are given for each test exposure in comparison to the negative control.  
Fold changes of ˂ 1.5 were included when expression in other test exposure was ≥ 1.5 fold change.  
Proteins (highlighted in grey) involved in metal detoxification and signalling (metallothionein), 
cytoskeletal (Tubulin), metabolic (Pyruvate kinase) and ribosomal (40S) were the principle focus of this 
analysis. 
 
Table 3.5 Statistically significant proteins (5) with fold changes <1.5 fold change after 
exposure of Cu-Phen (1) and Cu-DPQ-Phen (2) in the MCF-7 cell line after 48 h 
incubation.  












Plectin Q15149 2 3.14E-02 0.76 1.33 
Protein RCC2 Q9P258 2 1.98E-02 0.71 1.14 
Proteasome subunit alpha type-1 P25786 2 2.83E-02 0.68 1.06 
Cold-inducible RNA-binding protein Q14011 2 1.72E-02 0.52 0.92 
Serum albumin P02768 3 1.54E-02 0.45 0.93 







Fig. 3.10 GO analysis of biological process in MCF-7 cells exposed to Cu-Phen (1) and 
Cu-DPQ-Phen (2) with respect to the negative control after 48 h incubation. Process 






Fig. 3.11 GO analysis of molecular process in MCF-7 cells exposed to Cu-Phen (1) and 
Cu-DPQ-Phen (2) with respect to the negative control after 48 h incubation. Process 

































Fig. 3.13 KEGG analysis of significantly upregulated proteins in glycolysis/ 






Fig. 3.14 STRING based protein interaction analysis of statistically significant protein 
with fold changes ≥ 1.5 in the MCF-7 cell after 48 h exposure to Cu-Phen (1) and Cu-
DPQ-Phen (2) compared to the negative control. The STRING analysis demonstrated 














3.3.3 (C) SKOV-3 24 h exposure to Cu-Phen (1) and Cu-DPQ-Phen (2) in 
comparison to the negative control 
Cell lysates from SKOV-3 cells were extracted after a 24 h exposure to Cu-Phen (1) and 
Cu-DPQ-Phen (2) along with a negative control for comparison. A total of 7 
Statistically Significant Differentially Abundant (SSDA) proteins (Table 3.6) were 
found to meet the following criteria: containing ≥ 2 unique peptide from the identified 
protein, showed a significant change (ANOVA) in comparison to the negative control, 
had ≥ 1.5 fold change in relation to the negative control (a fold change of ˂ 1.5 was also 
included if the same protein was expressed at ≥ 1.5 fold change in another exposure). A 
total of 26 proteins (Table 3.7) were found to be statistically significant but were ˂ 1.5 
fold change in protein expression in relation to the negative control. PCA (Fig. 3.15) 
was used to visualise the variation in protein abundance across individual replicates. In 
each of the complex exposures and negative control, a single replicate was excluded 
from the subsequent analysis due to lack of clustering. PCA showed separation of the 
negative control, Cu-Phen (1) and Cu-DPQ-Phen (2) with Cu-Phen (1) being separated 
more strongly by component 2. However hierarchical clustering using Log(2) 
transformed LFQ abundances (Fig. 3.16) of the all protein showed an absence of profile 
clustering in both Cu-Phen (1) and Cu-DPQ-Phen (2), indicating their similar protein 
expression pattern. Table 3.6 contains significantly differentially abundant proteins 
from multiple functional classes of which include metal detoxification and signalling 
(metallothioneins), signalling and chaperones (heat shock proteins) and metabolic 
(phosphoglycerate kinase 1). Table 3.7 contains lower differentially abundant protein in 
relation to the negative control. Gene Ontology (GO) biological process (Fig. 3.17) 
indicates proteins associated with the following functions: primary metabolic, organic 
substance metabolic and nitrogen compound metabolic processes. Processes that 
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contained more than 2 proteins were of greater interest in the analysis. GO molecular 
process. (Fig. 3.18) indicated proteins associated with the following functions: 
heterocyclic compound, organic cyclic compound, small molecule, protein and ion 
binding. Processes that contained more than 2 proteins were of greater interest in the 
analysis. KEGG analysis demonstrated involvement of phosphoglycerate kinase 
(2.7.2.3) in Glycolysis/ gluconeogenesis (Fig. 3.19) pathway. Additionally, nucleoside 
diphosphate kinase A was upregulated ≤ 1.5 fold change, a protein involved in purine 
metabolism. While additional KEGG pathways were identified but not included in this 
chapter the pathways presented below represent pathways that were highlighted across 
multiple experimental conditions and in many cases contained multiple protein 
identification within the same pathways. STRING protein interaction network described 
only two interactions between heat shock protein and metabolic proteins and between 





Fig. 3.15 Principle component analysis (PCA) of whole cell lysate proteome of SKOV-3 cells exposed to Cu-Phen (1) and Cu-DPQ-Phen 
(2) for 24 h in comparison to a negative control. PCA of three replicates for the negative control and three replicates of both test exposures. 
Enclosures define the different experimental conditions. Red X denotes the third replicates from each condition removed from the analysis 






Fig. 3.16 Hierarchical clustering of SSDA proteins and statistically significant proteins 
with less than a 1.5 fold change in the SKOV-3 cell line after 24 h exposure to Cu-Phen 
(1) and Cu-DPQ-Phen (2) in relation to the control. Hierarchical clustering generated 









Table 3.6 Statistically significant differentially abundant (SSDA) proteins (7) after 
exposure of Cu-Phen (1) and Cu-DPQ-Phen (2) in the SKOV-3 cell line after 24 h 
incubation.  












Metallothionein-1X P80297 5 2.82E-03 14.72 17.63 
Metallothionein-2 P02795 5 3.97E-03 4.77 5.87 
Heat shock 70 kDa protein 6 P17066 9 6.25E-04 4.56 2.04 
Heat shock 70 kDa protein 1B P0DMV9 11 2.07E-03 4.04 1.92 
Tumor protein D54 O43399 2 1.04E-02 1.68 1.47 
Ubiquitin-40S ribosomal protein 
S27a 
P62979 2 7.84E-03 1.60 1.19 
Phosphoglycerate kinase 1 P00558 4 5.27E-03 1.50 1.00 
Relative fold changes are given for each test exposure in comparison to the negative control.  
Fold changes of ˂ 1.5 were included when expression in other test exposure was ≥ 1.5 fold change.  
Proteins (highlighted in grey) involved in metal detoxification and signalling (metallothioneins), 
signalling and chaperones (heat shock proteins) and metabolic (phosphoglycerate kinase 1) were the 



























Table 3.7 Statistically significant proteins (26) with fold changes < 1.5 fold change 
after exposure of Cu-Phen (1) and Cu-DPQ-Phen (2) in the SKOV-3 cell line after 24 h 
incubation.  












60S ribosomal protein L24 P83731 2 1.65E-02 0.90 0.65 
60S ribosomal protein L29 P47914 2 2.50E-02 0.74 0.55 
Talin-1 Q9Y490 2 1.24E-03 0.68 0.59 
Heterogeneous nuclear ribonucleoproteins A2/B1 P22626 3 3.69E-03 0.67 0.64 
Ezrin P15311 2 3.13E-02 0.67 0.64 
Elongation factor 2 P13639 6 5.24E-03 0.66 0.76 
Polypyrimidine tract-binding protein 1 P26599 2 5.94E-03 0.65 0.62 
Triosephosphate isomerase P60174 2 2.54E-02 0.64 0.68 
GMP synthase [glutamine-hydrolyzing] P49915 3 2.27E-02 0.63 0.70 
Nucleophosmin P06748 6 1.98E-02 0.63 0.61 
60S ribosomal protein L4 P36578 2 5.83E-05 0.62 0.58 
Myosin-9 P35579 3 5.94E-04 0.59 0.61 
Tubulin beta-4A chain P04350 2 9.56E-03 0.58 0.59 
ATP synthase subunit beta, mitochondrial P06576 2 5.63E-03 0.58 0.76 
40S ribosomal protein S7 P62081 2 2.34E-02 0.58 0.57 
Stress-70 protein, mitochondrial P38646 2 7.22E-03 0.57 0.70 
Carbonyl reductase [NADPH] 1 P16152 2 1.07E-03 0.57 0.58 
Alpha-actinin-1 P12814 2 1.11E-02 0.56 0.65 
Thioredoxin-like protein 1 O43396 2 1.19E-02 0.52 0.76 
Nucleoside diphosphate kinase A P15531 2 1.15E-02 0.52 0.54 
Plectin Q15149 5 2.14E-03 0.51 0.66 
Keratin, type I cytoskeletal 17 Q04695 4 1.17E-03 0.48 0.55 
Importin subunit alpha-1 P52292 2 5.04E-03 0.47 0.59 
Histone H2B type 1-D P58876 7 3.12E-03 0.46 0.58 
Histone H1.3 P16402 3 1.11E-02 0.45 0.67 
Tubulin alpha-1B chain P68363 2 2.75E-03 0.03 0.05 




Fig. 3.17 GO analysis of biological process in SKOV-3 cells exposed to Cu-Phen (1) 
and Cu-DPQ-Phen (2) with respect to the negative control after 24 h incubation. Process 






Fig. 3.18 GO analysis of molecular process in SKOV-3 cells exposed to Cu-Phen (1) 
and Cu-DPQ-Phen (2) with respect to the negative control after 24 h incubation. Process 
















Fig. 3.19 KEGG analysis of significantly upregulated proteins in glycolysis/ 






Fig. 3.20 STRING based protein interaction analysis of statistically significant protein 
with fold changes ≥ 1.5 in the SKOV-3 cell after 24 h exposure to Cu-Phen (1) and Cu-
DPQ-Phen (2) compared to the negative control. The STRING analysis demonstrated 




















3.3.4 (D) SKOV-3 48 h exposure to Cu-Phen (1) and Cu-DPQ-Phen (2) in 
comparison to the negative control  
 
Cell lysates from SKOV-3 cells were extracted after a 48 h exposure to Cu-Phen (1) and 
Cu-DPQ-Phen (2) along with a negative control for comparison. A total of 44 
Statistically Significant Differentially Abundant (SSDA) proteins (Table 3.8) were 
found to meet the following criteria: containing ≥ 2 unique peptide from the identified 
protein, showed a significant change (ANOVA) in comparison to the negative control, 
had ≥ 1.5 fold change in relation to the negative control (a fold change of ˂ 1.5 was also 
included if the same protein was expressed at ≥ 1.5 fold change in another exposure). A 
total of 90 proteins (Table 3.9) were found to be statistically significant but were ˂ 1.5 
fold change in protein expression in relation to the negative control. PCA (Fig. 3.21) 
was used to visualise the variation in protein abundance across individual replicates. 
Both Cu-Phen (1) and Cu-DPQ-Phen (2) show separation from each other primarily 
through component 2 while the negative control and Cu-DPQ-Phen (2) show close 
clustering indicating a similar protein expression profile. Hierarchical clustering (Fig. 
3.22) indicates separation of all experimental conditions with the negative control and 
Cu-DPQ-Phen (2) showing closer association than Cu-Phen (1), similarly to PCA in 
Figure 3.21. In each of the complex exposures and negative control, a single replicate 
was excluded from the subsequent analysis due to lack of clustering. PCA shows 
separation of the negative control, Cu-Phen (1) and Cu-DPQ-Phen (2) with Cu-Phen (1) 
being separated more strongly by component 2. However hierarchical clustering using 
Log(2) transformed LFQ abundances (Fig. 3.22) of the all protein showed the absence 
of profile clustering in both Cu-Phen (1) and Cu-DPQ-Phen (2), indicating their similar 
protein expression pattern. Table 3.8 indicates significant differentially abundant 
proteins with multiple functional protein classes in relation to the negative control. 
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Protein functional classes, such as detoxification and signalling (e.g. metallothioneins), 
metabolic (e.g. glucose-6-phosphate isomerase), transcription factor related (e.g.pre-
mRNA-processing factor), ribosomal (e.g. 40S) and chaperones/ signalling (e.g. heat-
shock proteins) among others. Table 3.9 also detailed significant lower differentially 
expressed proteins with multiple protein functional classes in comparison to the 
negative control. GO analysis of biological processes (Fig. 3.23) indicated a large 
number of proteins associated with the following processes: cellular metabolic, organic 
substance metabolic and nitrogen compound metabolic processes. Processes that 
contained more than 25 proteins were of greater interest to the analysis. GO analysis of 
molecular processes (Fig. 3.24) indicated a large number of proteins associated with the 
following processes: small molecule, organic cyclic compound, heterocyclic, ion and 
protein binding. Processes that contained more than 20 proteins were of greater interest 
in the analysis.  KEGG analysis highlighted several pathways containing identified 
protein. While additional KEGG pathways were identified but not included in this 
chapter the pathways presented below represent pathways that were highlighted across 
multiple experimental conditions and in many cases contained multiple protein 
identification within the same pathways. Glycolysis/ gluconeogenesis (Fig. 3.25): 
glucose-6-phosphate isomerase (5.3.1.9), 6-phosphofructokinase (2.7.1.11), fructose-
bisphosphate aldolase (4.1.2.13), triose-phosphate isomerase (5.3.1.1), glyceraldehyde-
3-phosphate dehydrogenase (1.2.1.12), glyceraldehyde-3-phosphate dehydrogenase 
(NAD(P)+) (1.2.1.59), bisphosphoglycerate mutase (5.4.2.4), phosphoglycerate kinase 
(2.7.2.3) and L-lactate dehydrogenase (1.1.1.27). Pentose phosphate pathway (Fig. 
3.26): glucose-6-phosphate isomerase (5.3.1.9), 6-phosphofructokinase (2.7.1.11) and 
fructose-bisphosphate aldolase (4.1.2.13). Fatty acid biosynthesis (Fig. 3.27): fatty-acid 
synthase (FasN). Purine metabolism (Fig. 3.28): nucleoside-diphosphate kinase 
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(2.7.4.6). STRING protein interaction network (Fig. 3.29) demonstrated strong 








Fig. 3.21 Principle component analysis (PCA) of whole cell lysate proteome of SKOV-3 cells exposed to Cu-Phen (1) and Cu-DPQ-Phen 
(2) for 48 h in comparison to a negative control. PCA of three replicates for the negative control and three replicates of both test exposures. 
Enclosures define the different experimental conditions. Red X denotes the third replicates from each condition removed from the analysis 






Fig. 3.22 Hierarchical clustering of SSDA proteins and statistically significant proteins 
with less than a 1.5 fold change in the SKOV-3 cell line after 48 h exposure to Cu-Phen 
(1) and Cu-DPQ-Phen (2) in relation to the control. Hierarchical clustering generated 




Table 3.8 Statistically significant differentially abundant (SSDA) proteins (44) after 
exposure of Cu-Phen (1) and Cu-DPQ-Phen (2) in the SKOV-3 cell line after 48 h 
incubation.  












Metallothionein-1X P80297 5 1.37E-05 32.12 32.12 
Fructose-bisphosphate aldolase C P09972 2 1.26E-03 14.89 1.57 
Prolyl 4-hydroxylase subunit alpha-2 O15460 2 7.00E-03 13.75 1.29 
Protein NDRG1 Q92597 6 2.28E-04 6.51 1.29 
Metallothionein-2 P02795 5 3.17E-04 4.92 5.45 
Procollagen-lysine,2-oxoglutarate 5-
dioxygenase 2 
O00469 2 1.88E-02 4.43 1.25 
Rab GDP dissociation inhibitor alpha P31150 2 2.08E-03 3.66 2.21 
Importin subunit beta-1 Q14974 3 1.12E-03 3.39 2.10 
Tubulin beta chain P07437 3 1.84E-04 3.27 2.09 
Cathepsin Z Q9UBR2 2 3.59E-02 2.96 1.12 
Pre-mRNA-processing factor 19 Q9UMS4 2 1.39E-03 2.71 3.48 
Alpha-actinin-1 P12814 3 3.31E-03 2.64 2.26 
L-lactate dehydrogenase A chain P00338 10 1.41E-03 2.52 1.09 
Glucose-6-phosphate isomerase P06744 3 7.17E-04 2.46 1.20 
Neutral alpha-glucosidase AB Q14697 5 1.30E-03 2.36 0.96 
Phosphoglycerate kinase 1 P00558 16 2.69E-05 2.30 1.01 
Alpha-actinin-4 O43707 2 3.30E-05 2.26 1.37 
Histone H2B type 1-K O60814 11 2.95E-04 2.21 2.12 
ATP-dependent 6-phosphofructokinase, 
platelet type 
Q01813 2 1.31E-02 2.03 1.05 
40S ribosomal protein S7 P62081 4 1.30E-03 2.02 1.82 
Calponin-3 Q15417 2 3.54E-03 1.96 2.42 
Tubulin beta-3 chain Q13509 4 1.21E-03 1.96 1.23 
Proteasome subunit alpha type-1 P25786 2 1.36E-04 1.95 0.99 
Nucleoside diphosphate kinase A P15531 2 1.86E-03 1.95 1.97 
Fatty acid synthase P49327 2 2.86E-03 1.94 1.34 
Nucleoside diphosphate kinase B P22392 2 1.64E-03 1.93 1.66 
Phosphoglycerate mutase 1 P18669 6 6.96E-04 1.90 0.95 
Macrophage migration inhibitory factor P14174 8 1.52E-04 1.83 1.00 
Triosephosphate isomerase P60174 7 1.52E-04 1.83 1.15 
Heat shock 70 kDa protein 1B P0DMV9 9 4.30E-05 1.77 1.21 
Fructose-bisphosphate aldolase A P04075 12 1.73E-04 1.75 0.88 
Protein disulfide-isomerase P07237 2 8.61E-04 1.73 0.68 
Nucleophosmin P06748 8 2.53E-05 1.66 1.74 
Endoplasmin P14625 7 1.39E-04 1.64 0.83 
Tubulin beta-2A chain Q13885 14 1.97E-03 1.64 1.19 
Hematological and neurological 
expressed 1-like protein 
Q9H910 2 2.40E-03 1.62 0.89 
Phosphoserine aminotransferase Q9Y617 3 1.57E-03 1.61 1.01 
173 
 
Alanine--tRNA ligase, cytoplasmic P49588 2 3.74E-03 1.59 0.90 
Ubiquitin-like modifier-activating 
enzyme 1 
P22314 2 4.57E-03 1.59 1.08 
Microtubule-associated protein 1B P46821 2 2.50E-03 1.56 1.04 
Tubulin beta-6 chain Q9BUF5 5 3.77E-03 1.56 1.00 
Myosin-9 P35579 4 1.42E-03 1.53 1.30 
Protein BRICK1 Q8WUW1 2 2.41E-02 1.52 0.96 
Glyceraldehyde-3-phosphate 
dehydrogenase 
P04406 6 3.50E-06 1.51 0.95 
Relative fold changes are given for each test exposure in comparison to the negative control.  
Fold changes of ˂ 1.5 were included when expression in other test exposure was ≥ 1.5 fold change.  
The proteins (highlighted in grey) relate to detoxification and signalling (e.g. metallothioneins), metabolic 
(e.g. glucose-6-phosphate isomerase), transcription factor related (e.g.pre-mRNA-processing factor), 


































Table 3.9 Statistically significant proteins (90) with fold changes <1.5 fold change after 
exposure of Cu-Phen (1) and Cu-DPQ-Phen (2) in the SKOV-3 cell line after 48 h 
incubation.  












Actin-related protein 2 P61160 2 2.82E-02 1.49 0.91 
Serine/threonine-protein phosphatase 2A 65 
kDa regulatory subunit A alpha isoform 
P30153 4 2.02E-03 1.48 0.76 
Macrophage-capping protein P40121 2 1.31E-02 1.47 0.89 
Transitional endoplasmic reticulum ATPase P55072 9 1.14E-03 1.44 0.92 
Vinculin P18206 4 4.92E-04 1.44 0.91 
Adenosylhomocysteinase P23526 2 3.65E-02 1.44 0.89 
Protein disulfide-isomerase A3 P30101 4 1.09E-04 1.42 0.79 
78 kDa glucose-regulated protein P11021 9 1.60E-04 1.40 0.81 
40S ribosomal protein S28 P62857 2 7.48E-04 1.38 0.91 
Cytidine deaminase P32320 4 8.69E-03 1.37 0.86 
Thioredoxin domain-containing protein 5 Q8NBS9 2 1.10E-02 1.35 0.82 
PDZ and LIM domain protein 1 O00151 2 5.87E-03 1.35 0.83 
Protein AHNAK2 Q8IVF2 2 6.30E-03 1.34 0.56 
Nuclear mitotic apparatus protein 1 Q14980 2 3.33E-02 1.31 0.83 
Alpha-enolase P06733 11 2.68E-03 1.31 0.85 
Protein kinase C delta-binding protein Q969G5 2 3.45E-03 1.31 0.79 
Epidermal growth factor receptor kinase 
substrate 8-like protein 2 
Q9H6S3 2 1.34E-03 1.31 0.77 
Gelsolin P06396 2 6.48E-04 1.31 0.66 
Major vault protein Q14764 2 3.31E-03 1.28 0.75 
Pyruvate kinase PKM P14618 9 4.21E-04 1.27 0.81 
Pyridoxal kinase O00764 3 2.14E-03 1.26 0.78 
Protein disulfide-isomerase A6 Q15084 2 1.25E-03 1.26 0.60 
Tubulin beta-4A chain P04350 3 1.39E-04 1.21 0.58 
WASH complex subunit CCDC53 Q9Y3C0 2 3.53E-03 1.10 0.73 
Annexin A11 P50995 2 6.30E-03 1.09 0.70 
Prohibitin P35232 2 4.58E-02 1.07 0.54 
Sorting nexin-3 O60493 2 2.35E-05 0.88 0.49 
Vasodilator-stimulated phosphoprotein P50552 2 1.13E-02 0.77 1.31 
Histone H4 P62805 2 5.86E-03 0.72 0.56 
Prelamin-A/C P02545 8 3.53E-04 0.71 1.07 
60S ribosomal protein L30 P62888 4 1.09E-02 0.70 1.10 
Proteasome subunit alpha type-6 P60900 2 6.70E-03 0.67 1.06 
Voltage-dependent anion-selective channel 
protein 1 
P21796 4 2.03E-02 0.66 0.65 
14-3-3 protein zeta/delta P63104 3 1.41E-02 0.66 0.88 
Poly(rC)-binding protein 2 Q15366 4 1.34E-03 0.65 1.14 
Nucleosome assembly protein 1-like 4 Q99733 2 1.95E-03 0.65 1.02 
40S ribosomal protein S14 P62263 3 1.21E-03 0.65 1.11 
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T-complex protein 1 subunit epsilon P48643 6 2.33E-04 0.65 1.05 
60S ribosomal protein L3 P39023 2 3.78E-02 0.64 1.15 
Elongation factor 2 P13639 11 5.64E-04 0.64 0.80 
Splicing factor 3B subunit 2 Q13435 3 2.42E-05 0.63 0.93 
Ubiquitin-40S ribosomal protein S27a P62979 3 2.93E-05 0.63 1.02 
GTP-binding nuclear protein Ran P62826 3 2.46E-03 0.63 0.94 
60S acidic ribosomal protein P0 P05388 2 3.31E-02 0.63 0.94 
T-complex protein 1 subunit zeta P40227 3 5.18E-04 0.62 1.01 
Plectin Q15149 16 6.09E-04 0.62 0.88 
Heterogeneous nuclear ribonucleoprotein K P61978 4 6.34E-04 0.61 0.97 
LIM and SH3 domain protein 1 Q14847 3 9.70E-03 0.61 1.14 
Importin subunit alpha-1 P52292 5 9.15E-04 0.61 0.84 
Eukaryotic translation initiation factor 6 P56537 2 2.61E-02 0.61 0.76 
Ran-binding protein 3 Q9H6Z4 2 2.10E-04 0.61 1.01 
ATP-dependent RNA helicase DDX1 Q92499 3 1.30E-02 0.61 1.25 
Far upstream element-binding protein 1 Q96AE4 4 3.29E-04 0.60 0.99 
Nucleolin P19338 4 3.70E-03 0.60 0.81 
Eukaryotic translation initiation factor 5 P55010 2 7.02E-04 0.60 0.81 
60S ribosomal protein L7 P18124 2 2.12E-02 0.59 1.22 
Ran GTPase-activating protein 1 P46060 2 5.10E-03 0.59 0.95 
60S ribosomal protein L13 P26373 2 3.79E-04 0.58 1.03 
Apoptotic chromatin condensation inducer in 
the nucleus 
Q9UKV3 3 2.48E-03 0.58 1.24 
Probable ATP-dependent RNA helicase 
DDX17 
Q92841 2 2.39E-03 0.58 0.94 
Scaffold attachment factor B1 Q15424 2 3.96E-03 0.58 0.88 
Protein S100-A6 P06703 3 3.69E-03 0.56 0.98 
DNA replication licensing factor MCM7 P33993 2 8.95E-03 0.56 0.84 
Elongation factor 1-alpha 2 Q05639 6 1.75E-05 0.56 0.87 
KH domain-containing, RNA-binding, signal 
transduction-associated protein 1 
Q07666 2 5.80E-04 0.56 1.09 
60S ribosomal protein L15 P61313 2 4.63E-03 0.54 0.71 
Stathmin P16949 4 2.79E-04 0.54 0.85 
Heterogeneous nuclear ribonucleoprotein A0 Q13151 2 2.18E-03 0.53 1.05 
Probable ATP-dependent RNA helicase DDX5 P17844 4 2.83E-03 0.53 0.87 
Splicing factor, proline- and glutamine-rich P23246 5 5.12E-05 0.53 0.96 
Histone H1.3 P16402 3 2.06E-03 0.53 0.98 
Chromobox protein homolog 3 Q13185 3 1.03E-03 0.52 0.70 
Serum albumin P02768 2 5.02E-05 0.52 1.02 
60S ribosomal protein L22 P35268 2 1.16E-03 0.52 1.09 
Cold-inducible RNA-binding protein Q14011 2 3.01E-03 0.51 0.90 
ATP-dependent RNA helicase DDX3X O00571 4 3.93E-03 0.51 0.97 
Polyadenylate-binding protein 1 P11940 5 2.93E-03 0.50 0.84 
Heterogeneous nuclear ribonucleoprotein D0 Q14103 2 1.59E-02 0.50 0.89 
Proliferation-associated protein 2G4 Q9UQ80 4 1.69E-04 0.50 1.05 
Heterogeneous nuclear ribonucleoprotein A1 P09651 5 3.16E-03 0.50 1.47 
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Serine/arginine-rich splicing factor 1 Q07955 2 4.16E-04 0.49 0.90 
Proteasome subunit alpha type-7 O14818 2 1.47E-03 0.49 0.96 
Nuclear migration protein nudC Q9Y266 2 2.72E-04 0.47 1.12 
Bcl-2-associated transcription factor 1 Q9NYF8 2 1.62E-03 0.47 1.05 
Matrin-3 P43243 2 2.53E-03 0.46 1.01 
DnaJ homolog subfamily A member 1 P31689 2 6.53E-04 0.45 1.05 
Histone H1.5 P16401 3 3.50E-04 0.41 1.07 
60S ribosomal protein L29 P47914 2 7.11E-04 0.35 0.98 
Eukaryotic translation initiation factor 5A-1 P63241 2 1.16E-02 0.32 1.06 
Heterogeneous nuclear ribonucleoprotein D-
like 
O14979 2 2.45E-03 0.24 0.75 








Fig 3.23 GO analysis of biological process in SKOV-3 cells exposed to Cu-Phen (1) 
and Cu-DPQ-Phen (2) with respect to the negative control after 48 h incubation. Process 







Fig 3.24 GO analysis of biological process in SKOV-3 cells exposed to Cu-Phen (1) 
and Cu-DPQ-Phen (2) with respect to the negative control after 48 h incubation. Process 






Fig. 3.25 KEGG analysis of significantly upregulated proteins in glycolysis/ 
gluconeogenesis. Glucose-6-phosphate isomerase (5.3.1.9) (red), 6-phosphofructokinase 
(2.7.1.11) (orange), fructose-bisphosphate aldolase (4.1.2.13) (yellow), triose-phosphate 
isomerase (5.3.1.1) (grey), glyceraldehyde-3-phosphate dehydrogenase (1.2.1.12) 
(pink), glyceraldehyde-3-phosphate dehydrogenase (NAD(P)+) (1.2.1.59) (wine), 
bisphosphoglycerate mutase (5.4.2.4) (purple), phosphoglycerate kinase (2.7.2.3) 





Fig. 3.26 KEGG analysis of significantly upregulated proteins in the pentose phosphate pathway. Glucose-6-phosphate isomerase (5.3.1.9) 














Fig. 3.29 STRING based protein interaction analysis of statistically significant protein 
with fold changes ≥ 1.5 in the SKOV-3 cell after 48 h exposure to Cu-Phen (1) and Cu-
DPQ-Phen (2) compared to the negative control. The dashed red oval highlights 




Commonly upregulated proteins from four experimental conditions 
 
Multiple proteins observed at ≥ 1.5 fold change were commonly upregulated throughout 
the experimental conditions. Table 3.10 and Figure 3.30 detail the commonly 
expressed proteins in each of the experimental conditions. 
 
Table 3.10. Common upregulated proteins (SSDA) with fold change ≥ 1.5 between 
both cell lines and Cu-Phen (1) and Cu-DPQ-Phen (2) exposures.  
MCF-7 24 h 
+ 
SKOV-3 24 h 
MCF-7 48 h 
+ 
SKOV-3 48 h 
MCF-7 24 h 
+ 
MCF-7 48 h 
SKOV-3 24 h 
+ 
























shock 70 kDa 
protein 1B) 
 
Commonly upregulated in all: P02795 (Metallothionein-2) 
Proteins detailed in table above are reflected in the Venn diagram (Fig. 3.30) along with number of 




Fig. 3.30 Venn diagram illustrating the number of protein commonly upregulated in 
each of the cell lines and timepoints with all proteins abundances in each experimental 
condition ≥ 1.5 fold change. Proteins related to the 4 major comparisons are displayed 












The work outlined in this Chapter describes the whole-cell proteomic response of the 
MCF-7 and SKOV-3 cell lines at both 24- and 48- h to Cu-Phen (1) and Cu-DPQ-Phen 
(2) in comparison to the negative control. Both cisplatin sensitive MCF-7 and cisplatin 
resistant SKOV-3 cell lines were used in this study as in Chapter 2. 
 
Overall, across the experimental conditions upregulation of metabolic, heat shock, 
cytoskeletal, ribosomal and metal chelation (metallothioneins) proteins were a common 
characteristic feature of the mechanistic response of the cells to the Cu(II) 
phenanthroline-phenazine complex series. With the MCF-7 24 h exposure, differences 
were observed between the abundance levels of proteins between both exposures to Cu-
Phen (1) and Cu-DPQ-Phen (2). Cu-Phen (1) tended to illicit higher abundance changes 
in the metabolic and ribosomal proteins while Cu-DPQ-Phen (2) induced higher 
abundance changes in heat shock and related proteins. This trend continued at the 48 h 
exposure although there were less proteins detected. An increased abundance in 
cytoskeletal proteins was also detected in the Cu-Phen (1) exposure in contrast to lower 
abundance detected after exposre to Cu-DPQ-Phen (2). 
 
Cisplatin resistant SKOV-3 cells at 24 h exposure were similar to the MCF-7 cells at 24 
h in regards to the higher upregulation of heat-shock, ribosomal and metabolic proteins 
after exposure to Cu-Phen (1). This same functional protein expression portfolio was 
also present in the SKOV-3 48 h exposure, however, a large increase in the amount of 
cytoskeletal and RNA binding proteins were identified in the 48 h exposure with the 




STRING analysis provided a means to assess the clustering and potential functional 
interactions in each of the experiments. In the two larger networks (MCF-7 24 h and 
SKOV-3 48 h) both metabolic and heat shock-related proteins were shown to be a 
strong focal point for potential mechanistic interactions. The two smaller networks 
(MCF-7 48 h and SKOV-3 24 h) did not form around a common functional protein class 
but contained elements of ribosomal, cytoskeletal and heat shock protein as potential 
mechanistic interactions. Overall, the experimental conditions, metallothionein-2 was 
observed to be upregulated in all cases. Metallothioneins are typically stimulated 
through metal ions, cytokines and growth factors and normally function in the control of 
oxidative stress and promote factors to reduce cellular stress. Metallothioneins have also 
been associated with drug resistance, tumour survival and cell proliferation through NF-
κB and p53 regulatory proteins (Notta and Koropatnick 2006; Ruttkay-Nedecky et al. 
2013). Metallothioneins have previously been associated with mediating cisplatin 
resistance (Andrews et al. 1987), but more recent studies have established reactivity’s 
between the protein and platinum and ruthenium complexes (Casini et al. 2009; Karotki 
and Vašák 2009). With a growing body of knowledge regarding its interaction with 
therapeutics directly and cellular regulatory functions, there is a strong possibility that 
the protein interacts with the novel Cu(II) complexes and assists in the cellular 
mechanistic response. The metal chelators remained the most prominent of all 
upregulated proteins in terms of fold changes in relation to the negative control, 
demonstrating the importance of copper sequestration and potential other regulatory 
functions. It is however not clear as to what degree the level of copper sequestration has 
on the mechanism of action in the cell and the subsequent toxicity. Interestingly, across 
all the experimental conditions there were no appreciable increases in specific drug 
detoxification proteins, typical of many xenobiotic exposures. Overall, both cell lines 
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share common increases in heat shock and ribosomal proteins, however, metabolic 
related proteins tended to dominate the response of the cisplatin resistant cell line, 
























Chapter 4: In-vitro mammalian cell mechanisms of action: 



























The work described in the 2 preceding Chapters have detailed the results of screening 
assays and proteomics evaluations of the Cu(II) phenanthroline-phenanzine complexes. 
The work in Chapter 2 and Chapter 3 detailed the process of apoptosis and the 
proteomics expression response respectively of both the MCF-7 and SKOV-3 cells after 
exposure to the Cu(II) phenanthroline-phenazine complexes. Both these preceding 
chapters identified apoptosis and metabolic enzymes as potentially playing a part in the 
mechanism of action of the Cu(II) phenanthroline-phenazine complexes. Therefore the 
work detailed this Chapter 4 explores the role of the mitochondria as a target for the 
action of Cu(II) phenanthroline-phenazine complexes. 
 
The MCF-7 and SKOV-3 cell lines were used as well as A2780 and its cisplatin and 
doxorubicin resistant variant, A2780/ Cis representing a sensitive and resistant cisplatin 
profile respectively in each cell lines set. The A2780 (ovarian adenocarcinoma) and 
cisplatin and doxorubicin variant, A2780/ Cis have been widely used to examine the 
cisplatin mechanisms of resistance and evaluation of other metal-based drugs (Gamberi 
et al. 2014; Bashford and Cooper 2016). An additional advantage to their inclusion in 
this research is that both the sensitive and resistant variants are derived from the same 
cell and as such will have a similar gene and protein expression profile, unlike the 
MCF-7 and SKOV-3 cell lines previously used. 
 
Mitochondria-related gene expression and associated signalling involves multiple 
processes, all of which may contribute to the mechanism of action of the Cu(II) 
phenanthroline phenazine complexes. Heme Oxygenase (HMOX-1) is a member of the 
phase II antioxidant enzymes and is primarily involved in the removal of iron based 
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porphyrin, heme from the non-protein moiety of haemoglobin (Tebay et al. 2015). 
Nuclear factor (erythroid-derived 2)-like 2 (Nrf-2) is closely involved with the induction 
of HMOX-1 through the Antioxidant Response Element (ARE) transcription region. In 
addition to the involvement of HMOX-1, another suite of antioxidant enzymes such as 
NAD(P)H quinine oxidoreductase 1 (NQO1), glutamate-cystein ligase (GCL) and 
glutathione S-transferases (GST) (Kansanen et al. 2012, 2013) play a role in antioxidant 
response by activation of their ARE transcription region. Nrf-2 also forms part of the 
transcriptional regulation of Transcription factor B1/2, mitochondrial (TFB1M) and 
(TFB2M) which in turn regulates the transcription of the general mitochondrial 
transcription factor, Transcription Factor A (TFAM) (Gleyzer et al. 2005; Litonin et al. 
2010; Shi et al. 2012). 
 
The genes ATP-dependent Clp protease proteolytic subunit (CLPP), Lon protease 
homolog 1 (LON1), paraplegin matrix AAA peptidase subunit (SPG7) and ATP-
dependent metalloprotease YME1L1 (YME1L1) are involved in the regulation of 
mitochondrial quality control. Both LON and CLPP are present in the mitochondrial 
matrix and are involved in the proteolysis of oxidised proteins from ROS damage and 
misfolded protein due to damage respectively. Both CLPP and LON are potential 
targets for degenerative conditions (Cole et al. 2015; Quirós et al. 2015; Bota and 
Davies 2016). In addition to LON and CLPP, SPG7 and the AAA metalloprotease, 
YME1L1 are embedded in the inner mitochondrial forming components of the 
permeability transition pore complex with functions in both protein quality control and 
the maintenance of the respiratory chain complexes (Shanmughapriya et al. 2015; 




Dynamin-Related Protein (DRP1), Mitofusin-1/-2 (MFN1), (MFN2) and Dynamin-like 
120 kDa protein (OPA1) are involved in the control of mitochondrial fission and fusion. 
The process of mitochondrial fission is largely controlled by DRP1, which is 
translocated to the outer membrane of the mitochondria to bring about fission (Reddy 
2014). The process of mitochondrial fusion involves OPA1 in concert with MFN1 and 
MFN2 which regulate mitochondrial fusion from the inner mitochondrial membrane 
and is essential for the cristae remodelling which also has a regulatory function in 
oxidative phosphorylation (Patten et al. 2014; Reddy 2014). 
 
In addition to examining the relative changes in gene expression related to apoptosis 
and mitochondrial function, measurement of the changes in the mitochondrial 
membrane potential (ΔΨ) should help complement the mechanistic assessment of the 
Cu(II) complexes. Rhodamine 123 is a cell-permeable, monovalent cationic, fluorescent 
dye which accumulates in energized mitochondria, a feature which allows the detection 
of depolarization of the mitochondrial membrane potential (ΔΨ) (Chalovich and 
Eisenberg 2005). The dye, 5,5′,6,6′-tetrachloro-1,1′,3,3′-
tetraethylbenzimidazolcarbocyanine iodide (JC-1) also performs the same function 
(Cossarizza et al. 1993). The loss of the mitochondrial membrane potential (ΔΨ) is a 
key indicator of the loss of mitochondrial function and toxicity. Coupled to the role the 
mitochondrial plays in intrinsic apoptosis the measurement of mitochondrial membrane 
potential is an important way to assess the activity of novel metal-based drugs, such as 
in cisplatin (Choi et al. 2015) and copper complexes (Slator et al. 2016). 
 
The genes above control the regulation of protein quality, misfolding and regulation of 
mitofission/ mitofusion have been associated with neurodegenerative, metabolic 
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syndromes and cancer (Quirós et al. 2015). In addition, the regulation of mitochondria 
function has a direct effect on the activation of apoptosis and as such, cell survival. The 
connection between apoptosis, mitochondrial related gene expression and mitochondrial 
membrane potential (ΔΨ) provide a strong framework for the evaluation of the 
mechanism of action of the novel Cu(II) phenanthroline-phenazine complexes. 
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4.2 Material and methods 
4.2.1 Detection of mitochondrial membrane potential decay (ΔΨ) 
4.2.1.1 Cell preparation 
The A2780, A2780/ Cis, MCF-7 and SKOV-3 cell lines were used to assess whether 
changes in mitochondrial membrane potential due to their can explain their drug 
sensitivity profile. The loss of the mitochondrial membrane potential is a strong 
indicator of loss of mitochondrial function and mitochondrial toxicity. Cells were 
prepared as described previously in section 2.2.1. 
 
4.2.1.2 Subculturing and compound exposure 
Cells were subcultured and seeded into clear 96-well plates as described in section 
2.2.2.1. The 88 wells in each plate were inoculated with 1 × 104 cells as shown in the 
template in Appendix 1.7.1. Cells were incubated at 37 °C in 5 % CO2 atmosphere for 
24 h to allow for attachment and growth. A2780 cells were exposed to the following 
IC50 concentrations of the clinical controls and Cu(II) phenanthroline-phenazine 
complexes: cisplatin (200 µM) (Sigma, Ireland) (cis-Diamineplatinum(II) dichloride, 
CAS: 15663-27-1) (Cat# P4394), doxorubicin (2.20 µM) (Doxorubicin hydrochloride, 
CAS: 25316-40-9) (Cat# D2975000), Cu-Phen (1) (0.56 µM), Cu-DPQ-Phen (2) (0.62 
µM), Cu-DPPZ-Phen (3) (0.43 µM) and Cu-DPPN-Phen (4) (0.09 µM) (Table 2.4). 
A2780/ Cis cells were exposed to the following IC50 concentrations of the clinical 
controls and Cu(II) phenanthroline-phenazine complexes: cisplatin (200 µM), 
doxorubicin (2.35 µM), Cu-Phen (1) (1.07 µM), Cu-DPQ-Phen (2) (1.14 µM), Cu-
DPPZ-Phen (3) (0.97 µM) and Cu-DPPN-Phen (4) (1.13 µM) (Table 2.4). MCF-7 cells 
were exposed to the following IC50 concentrations of the clinical control and Cu(II) 
phenanthroline-phenazine complexes: cisplatin (0.53 µM), Cu-Phen (1) (1.78 µM), Cu-
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DPQ-Phen (2) (2.03 µM), Cu-DPPZ-Phen (3) (1.01 µM) and Cu-DPPN-Phen (4) (2.60 
µM) (Table 2.4). SKOV-3 cells were exposed to the following IC50 concentrations of 
the clinical control and Cu(II) phenanthroline-phenazine complexes: cisplatin (53.44 
µM), Cu-Phen (1) (3.05 µM), Cu-DPQ-Phen (2) (2.92 µM), Cu-DPPZ-Phen (3) (0.76 
µM) and Cu-DPPN-Phen (4) (7.45 µM) (Table 2.4). The clinical controls and Cu(II) 
phenanthroline-phenazine complexes were made up at the concentrations described 
above in 12 % supplemented (Cat# F2442) (Sigma, Ireland) RPMI-1640 (Sigma, 
Ireland) (Cat# R8758) cell culture media and were double diluted using cell culture 
media as per the 96-well plate template in Appendix 1.7.1. Doubling dilutions of each 
of the compounds was used to examine the response of different concentrations of the 
compounds within the biologically relevant IC50 concentrations. Hydrogen peroxide 
(Hydrogen peroxide solution, 30 % w/w), (Sigma, Ireland) (Cat# H1009) was used as a 
positive control at 10 µM (value experimentally determined). 
 
4.2.1.3 Rhodamine 123 dye application and fluorescent measurement 
Rhodamine 123 (1 mg/ml) (Sigma, Ireland) (Cat# R8004) was dissolved in ethanol and 
made up to a concentration of 10 µg/ml in PBS. Upon completion of the 24 h exposure 
to either cisplatin, doxorubicin, Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and 
Cu-DPPN-Phen (4), the exposed cell culture media was removed and the cells washed 3 
times with PBS. After the final wash, 100 µl of the rhodamine 123 working solution 
was placed on the cells. The 96-well plates were quickly wrapped in tin foil as the dye 
is photosensitive and they were incubated at 37 ˚C in 5 % CO2 atmosphere for 30 min. 
The rhodamine 123 working solution was removed and the cells washed twice with 
PBS. Cells were covered with 100 µl PBS after the final wash prior to measurement. 
Fluorescence was measured on the SpectraMax M3 Multi-Mode Microplate Reader 
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(Molecular Devices, USA) with an excitation of 485 nm and emission wavelength of 
530 nm. Fluorescence of the IC50 concentration exposed cells was displayed relative to 
the negative control (cell culture media). The mean and standard deviation from 8 
replicate wells (N=8) were used to represent the relative change between the exposed 
cells and the negative control. Two-way ANOVA with Bonferroni correction was 
performed between MCF-7/ SKOV-3 and A2780/A2780/Cis to establish statistically 
significant (p < 0.05) changes after exposure to test complexes. 
 
4.2.2 Gene expression analysis of molecular targets 
4.2.2.1 Primer design and synthesis of molecular targets 
Mitochondrial-related gene transcription factors, mitochondrial proteases and 
mitochondrial fission/ fusion regulation genes all represent a suite of functions which 
can characterise the state of the cell after exposure to the Cu(II) phenanthroline-
phenazine complexes, cisplatin and doxorubicin. Forward and reverse primer sequences 
per molecular target were designed in-house using Primer3PLUS programme and were 
synthesised by Sigma. The primer sequence for each target and reference genes are 
















Table 4.1 List of primers and oligonucleotide sequence used to examine mitochondrial-
related gene expression in MCF-7, SKOV-3, A2780 and A2780/ Cis mammalian cell 
lines after exposure to Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3), Cu-DPPN-
Phen (4), doxorubicin and cisplatin for 24 h (A2780 and A2780/ Cis) and 48 h (MCF-7 
and SKOV-3).  





























































* Represent primers of references genes used to establish the relative expression of the target genes. 
 
4.2.2.2 Gene expression of molecular targets 
A2780 and A2780/ Cis (105 cells) were exposed in T25 flasks after an initial 24 h 
attachment and growth period to their respective IC25 concentrations of cisplatin, 
doxorubicin, Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen 
(4) for 24 h. The MCF-7 and SKOV-3 (1 × 105 cells) were exposed in T25 flasks after 
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an initial 24 h attachment and growth period to their respective IC25 concentrations of 
cisplatin, Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen (4) 
for 48 h. Cells were incubated in triplicate for their required timepoint in T25 flasks and 
subcultured and Tri-reagent extracted as described in section 2.2.6.2. 
 
4.2.2.3 Processing of RNA sample to qRT-PCR analysis 
RNA extraction from samples performed as described in section 2.2.6.3. RNA 
concentration established as described in section 2.2.6.4. RNA concentration 
standardised as described in section 2.2.6.5. Quantitative real time PCR was performed 
as described in section 2.2.6.6. Relative expression of target genes was determined as 


















4.3.1 Detection of mitochondrial membrane potential decay (ΔΨ) 
Rhodamine 123 is a cationic non-toxic cell dye which is actively sequestered from 
active mitochondria. Loss of mitochondrial membrane potential is a key indicator of the 
loss of mitochondrial function and toxicity. Cells were normalized against a negative 
control with mitochondrial membrane potential decay represented a positive potential 
above the negative control baseline. The A2780, A2780/ Cis, MCF-7 and SKOV-3 cells 
were exposed to the IC50 concentrations of the Cu-Phen (1), Cu-DPQ-Phen (2), Cu-
DPPZ-Phen (3), Cu-DPPN-Phen (4), cisplatin and doxorubicin (for A2780 and A2780/ 
Cis) for 24 h. Hydrogen peroxide (H2O2) was used as a positive control. 
 
4.3.1.1 Changes in mitochondrial membrane potential (MMP) in the A2780 and A2780/ 
Cis cells 
Exposure to the IC50 concentration of Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen 
(3), Cu-DPPN-Phen (4), cisplatin and doxorubicin over 24 h induced different 
intensities of MMP decay relative to the negative control baseline in A2780 cells (Fig. 
4.1). Both cisplatin and doxorubicin induced similar levels of MMP decay while Cu-
Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen (4) induced higher 
levels of decay with Cu-Phen (1) and Cu-DPQ-Phen (2) inducing the highest level of 
MMP decay. H2O2 induced an increase in MMP decay. Exposure to the IC50 
concentration of Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3), Cu-DPPN-Phen 
(4), cisplatin and doxorubicin over 24 h induced different intensities of MMP decay 
relative to the negative control baseline in A2780/ Cis cells (Fig. 4.1). Exposure to 
doxorubicin induced a higher level of MMP decay than cisplatin. Exposure to the IC50 
concentration of Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-
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Phen (4) induced MMP decay with the highest levels observed after exposure to Cu-
DPQ-Phen (2) and Cu-DPPZ-Phen (3). H2O2 induced an increase in MMP decay. 
 
Between both A2780 and A2780/ Cis cells, differences between levels of MMP decay 
remain relatively unchanged after exposure to cisplatin. However, significant increases 
in the level of MMP decay were observed after exposure to Cu-DPQ-Phen (2) and Cu-
DPPZ-Phen (3) in A2780/ Cis cells and in contrast, a significant decrease was observed 
in levels of MMP decay after exposure to Cu-Phen (1). Generally exposure to the 
clinical controls and Cu(II) phenanthroline-phenanzine complexes resulted in an 





Fig. 4.1 Detection of changes in % MMP (ΔΨ) decay in A2780 and A2780/ Cis cells at 24 h after exposure to IC50 
concentration of Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3), Cu-DPPN-Phen (4), doxorubicin and cisplatin 
with H2O2 used as a positive control. All treatments have been normalized to the negative control. Baseline represents 
the negative control and no loss of mitochondrial membrane potential. Statistical significance set at 0.05 with Bonferroni 
correction performed on two-way ANOVA. N=8. 
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4.3.1.2 Changes in mitochondrial membrane potential (MMP) (ΔΨ) in the MCF-7 and 
SKOV-3 cells 
Exposure to the IC50 concentration of Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen 
(3), Cu-DPPN-Phen (4) and cisplatin over 24 h induced different intensities of MMP 
decay relative to the negative control baseline in MCF-7 cells (Fig. 4.2). Exposure to 
the IC50 concentration of Cu-Phen (1), Cu-DPQ-Phen (2), and Cu-DPPN-Phen (4) 
induced similar levels of MMP decay while Cu-DPPZ-Phen (3) induced a much smaller 
change relative to the negative control baseline. Cisplatin and H2O2, both induced MMP 
decay at similar levels to Cu-Phen (1), Cu-DPQ-Phen (2), and Cu-DPPN-Phen (4) 
exposure. Exposure to the IC50 concentration of Cu-Phen (1), Cu-DPQ-Phen (2), Cu-
DPPZ-Phen (3), Cu-DPPN-Phen (4) and cisplatin over 24 h induced different intensities 
of MMP decay relative to the negative control baseline in SKOV-3 cells (Fig. 4.2). 
Exposure to the IC50 concentration Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) 
and Cu-DPPN-Phen (4) induced MMP decay with the lowest recorded after exposure to 
Cu-Phen (1) relative to the negative control baseline. Both cisplatin and H2O2 induced 
MMP decay strongly above the negative control baseline. 
 
Exposure to Cu-DPPZ-Phen (3) in the cisplatin resistant SKOV-3 cell line induced a 
significant increase in MMP decay compared to the MCF-7 cells. Exposure to Cu-DPQ-
Phen (2) resulted in non-significant increase in MMP decay while a significant 
increases in MMP decay occured after exposure to Cu-DPPZ-Phen (3) in A2780/ Cis 
compared to A2780 cells. Across all tested cell lines exposure to Cu-Phen (1), Cu-DPQ-
Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen (4) induced increases in MMP decay. 
With the exception of Cu-Phen (1) the level of MMP decay was increased or marginally 
changed in the cisplatin resistant SKOV-3 cells after exposure to cisplatin and the 
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Fig. 4.2 Detection of changes in % MMP (ΔΨ) decay in MCF-7 cell at 24 h after exposure to IC50 concentration of 
Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3), Cu-DPPN-Phen (4) and cisplatin with H2O2 used as a 
positive control. All treatments have been normalized to the negative control. Baseline represents the negative 
control and no loss of mitochondrial membrane potential. Statistical significance set at 0.05 with Bonferroni 
correction performed on two-way ANOVA. N=7. 
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4.3.2 Gene expression analysis 
The level of activity of each gene target was assessed by the relative expression of the 
specific mRNA representative of the cDNA of the target gene being assayed. The 
expression of the target gene was made in relation to geometric mean expression level 
of the two housekeeping genes, actin and tubulin. The standard deviation of both the 
reference gene mean and target gene mean were error propagated and subsequently 
Log(2) transformed to produce a 95 % confidence interval range around the log(2) 
transformed mean double delta Ct value. Grouped columns in Fig. 4.3-4.6 display the 
log(2) transformed mean expression value relative to the biological negative control 
with the broken line at y = 1 indicating negative expression below and positive 
expression above. 
 
Figure 4.3 shows the expression of genes outlined in Table 4.1 relative to the 
geometric mean of the references genes, actin and tubulin in the A2780 cell line. 
Exposure to doxorubicin resulted in a marginal increase in the antioxidant enzyme, 
HMOX with a larger increase observed in the mitochondrial transcription regulators, 
TFAM, TFB1M and NRF-2. Mitochondrial protease regulators show no increased 
activity or were undetected. Regulators of the mitochondrial fission/ fusion process 
demonstrated progressive increases. Exposure to cisplatin resulted in only a moderate 
upregulation in the serine protease, CLPP, and a small increase in dynamin fusion, 
OPA1. Exposure to Cu-Phen (1) resulted in an upregulation in the antioxidant, HMOX. 
Similarly to doxorubicin the mitochondrial related transcription factors, TFAM, TFB2M 
and NRF-2 are upregulated after exposure. Mitochondrial related protease genes show 
no increase or were undetectable. Again, similarly to doxorubicin but at a lower 
magnitude a stepwise increase was observed in the expression of fission/ fusion 
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regulation genes from DRP1, MFN1, MFN2 to OPA1. Exposure to Cu-DPQ-Phen (2) 
showed no appreciable increase in any of the process with the exception to the serine 
protease, CLPP, which recorded a small increase. Exposure to Cu-DPPZ-Phen (3) 
resulted in a large increase in the fission/ fusion processes, OPA1 but also an increasing 
trend, although still negative when compared to the biological negative in DRP1, MFN1 
and MFN2. Exposure to Cu-DPPN-Phen (4) resulted in no detectable or downregulated 
gene expression across all the measured processes. The error bars representing a 95 % 
confidence interval demonstrated a high degree of variability particularly in the target 
genes representing mitochondrial related transcription. 
 
Figure 4.4 shows the expression of genes outlined in Table 4.1 after a 24 h exposure, 
relative to the geometric mean of the references genes, actin and tubulin in the A2780/ 
Cis cell line. Exposure to doxorubicin induced a small to moderate upregulation in the 
antioxidant enzyme, HMOX and mitochondrial transcription factor, TFAM. The largest 
increase was observed in the serine-threonine kinase regulators of mitochondrial 
oxidative stress response, DRP1 with no other genes showing appreciable upregulation. 
Exposure to cisplatin induced a slight increase in the mitochondrial transcription 
related, TFB1M and NRF-2. A large increase was recorded in the serine-threonine 
kinase regulators of mitochondrial oxidative stress response, DRP1 and a small increase 
in MFN1, MFN2 and OPA1. Exposure to Cu-Phen (1) induced a small increase in the 
mitochondrial transcription factors, TFB1M and TFB2M. A moderate increase was 
observed with the protease and structural gene, LON and YME1L1, which respond to 
oxidatively damaged protein and an AAA metallo-protease respectively. Similarly to 
doxorubicin and cisplatin a large increase was observed in the gene DRP1 and a small 
increase in MFN1. Exposure to Cu-DPQ-Phen (2) induced a strong increase in the 
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antioxidant enzyme, HMOX and the mitochondrial transcription factors, TFB1M and 
TFB2M. A moderate to small increase was recorded with the mitochondrial protease 
and structural related genes, CLPP, LON and SPG7. Again, similarly to the previous 
exposures of cisplatin, doxorubicin and Cu-Phen (1), a large increase was recorded in 
the serine threonine kinase; DRP1. Exposure to Cu-DPPZ-Phen (3) induced a strong 
increase in the transcription regulator; NRF-2 demonstrated a strong increase in contrast 
to previous exposures. Again, DRP1 showed a strong increase, as with previous 
exposures. The exposure to Cu-DPPN-Phen (4) induced a large response across all of 
the measured processes. A strong increase in the antioxidant enzyme, HMOX and the 
mitochondrial transcription factors, TFB1M and TFB2M and NRF-2 were 
demonstrated. A strong increase was recorded with the mitochondrial protease and 
structural related genes, CLPP, LON, SPG7 and YME1L1. Finally, similarly to the 
other exposures a strong increase was recorded in the activity of DRP1 and in addition 





Fig. 4.3 Gene expression of A2780 cells at 24 h following exposure to doxorubicin, cisplatin, Cu-Phen (1) and Cu-DPQ-Phen (2), Cu-





Fig. 4.4 Gene expression of A2780/ Cis cells at 24 h following exposure to doxorubicin, cisplatin, Cu-Phen (1) and Cu-DPQ-Phen (2), Cu-




Figure 4.5 shows the expression of genes outlined in Table 4.1 relative to the 
geometric mean of the references genes, actin and tubulin in the MCF-7 cell line. 
Exposure to cisplatin induced the expression of the mitochondrial transcription 
regulator, TFAM and the mitochondrial serine protease, CLPP. Exposure to Cu-Phen 
(1) induced expression of the phase I enzyme, HMOX. Expression of all other 
mitochondrial related processes was either downregulated or not detected. Exposure to 
Cu-DPQ-Phen (2) induces upregulation of the serine protease, CLPP. Expression of all 
other mitochondrial related processes was either downregulated or not detected. 
  
Figure 4.6 shows the expression of genes outlined in Table 4.1 relative to the 
geometric mean of the references genes, actin and tubulin in the SKOV-3 cell line.  
Exposure to cisplatin resulted in a large increase in mitochondrial related transcription 
from TFAM and TFB1M. Exposure to cisplatin also showed a large increase in the 
AAA Metallo-protease; YME1L1 along with increases in the fission/ fusion genes; 
MFN1, MFN2 and to a lesser extent OPA1. Exposure to Cu-Phen (1) did not 
demonstrate the same increase in mitochondrial related transcription from TFAM but 
did show similar expression levels in YME1L1 and MFN2 to that of cisplatin. Exposure 
to Cu-DPQ-Phen (2) only induced an appreciable increase in the serine protease, CLPP 






Fig. 4.5 Mitochondrial related gene expression of MCF-7 cells at 
48 h following exposure to cisplatin, Cu-Phen (1) and Cu-DPQ-
Phen (2). Error bars represent 95 % Confidence interval (N=3). 
Fig. 4.6 Mitochondrial related gene expression of SKOV-3 cells at 
48 h following exposure to cisplatin, Cu-Phen (1) and Cu-DPQ-Phen 





The work described in this Chapter examines the decay of the mitochondrial membrane 
potential (ΔΨ) and alterations in gene expression related to mitochondrial transcription, 
mitochondrial protease function and mitochondrial fission/ fusion. Both mitochondrial 
membrane potential and mitochondrial related gene expression are closely associated 
with the apoptotic process described in Chapter 2 and as such facilitate a more complete 
picture of the mechanism of action of the Cu(II) phenanthroline-phenazine complexes. 
Chapter 2 identified the cisplatin sensitive cells, MCF-7 and A2780 and the cisplatin 
resistant cells, SKOV-3 and A2780/ Cis as being strongly susceptible to the activity of 
Cu(II) phenanthroline-phenazine complexes exceeding the activity of the clinical 
therapeutics and demonstrating evidence of apoptosis through the apoptosis molecular 
targets in Chapter 2. The evaluation of mitochondrial membrane potential changes and 
mitochondrial related gene expression in this Chapter helped to examine the 
mitochondrial contribution to the mechanism of action. 
 
The mitochondrial membrane potential has previously been used to examine 
mitochondrial toxicity of [Cu(o-phthalate)(phenanthroline)] and di-manganese(II) 
complexes (Slator et al. 2016, 2017). The result of the Mitochondrial Membrane 
Potential (MMP) decay assay indicated that all of the tested cell lines demonstrated 
different degree of MMP decay after exposure to cisplatin, doxorubicin (A2780 and 
A2780/ Cis) (A2780 and A2780/ Cis) and the Cu(II) phenanthroline-phenazine series in 
the A2780, A2780/ Cis, MCF-7 and SKOV-3 cells. The A2780 and A2780/ Cis 
demonstrated contrasting activity in terms of MMP decay with a general increase of 
MMP after exposure to most of the Cu(II) phenanthroline-phenazine complexes in the 
A2780/ Cis cells. The profile of increase MMP decay after exposure to Cu(II) 
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phenanthroline-phenazine complexes was demonstrated similarly SKOV-3 cells in 
comparison to the MCF-7 cells. The increased MMP decay in resistant phenotypes after 
exposure to the Cu(II) phenanthroline-phenazine complexes in comparison to the 
relatively unchanged cisplatin values may potentially indicate that the breakdown of the 
mitochondrial membrane potential has a role in the mechanisms of action of  the Cu(II) 
phenanthroline-phenazine complexes. The intrinsic apoptotic pathway is initiated 
through a breakdown in mitochondrial function. The results of Chapter 2 demonstrated 
a profile of apoptosis activation after exposure to the Cu(II) phenanthroline-phenazine 
complexes. With the breakdown of the mitochondrial membrane potential demonstrated 
in this Chapter and the activation of apoptosis demonstrated in Chapter 2, there is a 
strong association which may contribute to the mechanism of action of the Cu(II) 
phenanthroline-phenazine complexes.  
 
The mitochondrial related gene expression panel was examined through antioxidant 
enzyme production, HMOX, while mitochondrial related transcription was monitored 
through TFAM, TFB1M, TFB2M and NRF-2. Mitochondrial protease genes were 
monitored through CLPP, LON, SPG7 and YME1L1. The process of fission/ fusion of 
the mitochondria were monitored through DRP1, MFN1, MFN2 and OPA1.  
 
The A2780 and A2780/ Cis cells demonstrated contrasting gene expression profiles 
with the antioxidant and mitochondrial related transcription along with the protease, 
CLPP characterising the gene expression response. The cisplatin and doxorubicin 
resistant, A2780/ Cis is characterised by the upregulation of mitochondrial transcription, 
proteases and the mitochondrial fission regulator, DRP1. The activity of transcription 
factors and fission/ fusion regulators are known to be involved in drug resistance 
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mechanisms (Chiang et al. 2009; Thomas and Jacobson 2012; Kashatus et al. 2015; Cai 
et al. 2016). Doxorubicin interacts with DNA through intercalation, similarly to the 
proposed interaction mechanism of the Cu(II) phenanthroline-phenazine complexes 
(Molphy et al. 2014, 2015). The Cu-DPPZ-Phen (3) exposure which is known to have 
the highest DNA binding constant produced a similar gene expression profile to 
doxorubicin. Cu-DPPN-Phen (4) with a much lower DNA binding capability induces no 
change in any target genes. Large error bars in the A2780 24 h exposures demonstrated 
that a high degree of variability particularly in mitochondrial related trandcription. This 
may have been due to changing rates of transcription of these genes at the time point. In 
A2780/ Cis cells, exposures to both doxorubicin and cisplatin were shown to strongly 
upregulate DRP1 in addition to all of the Cu(II) phenanthroline-phenazine complexes. 
DRP1 is strongly associated with mitochondrial membrane impairment and resulting 
loss of the oxidative phosphorylation pathway and in the cases of low expression, a drug 
resistance factor (Bras et al. 2007; Thomas and Jacobson 2012). The MCF-7 and 
SKOV-3 cells present contrasting gene expression profiles with MCF-7 cells 
demonstrating antioxidant and the mitochondrial protease, CLPP being upregulated 
after exposure to Cu-Phen (1) and Cu-DPQ-Phen (2). The response of the cisplatin 
resistant SKOV-3 cells to Cu-Phen (1) and Cu-DPQ-Phen (2) is characterised by a 
protease and mitochondrial related transcription response. The increase in protease 
activity which is present in the SKOV-3 cells after exposure to the Cu(II) 
phenanthroline-phenazine complexes, has been associated with HSP proteins and 
protein unfolding in the mitochondria (Jovaisaite et al. 2014). 
 
The work detailed in this Chapter utilised the cisplatin sensitive and resistant cell lines 
to examine the differences in mitochondrial related effects both at the membrane 
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potential and the mitochondrial related gene expression. The A2780 and its cisplatin and 
doxorubicin resistant variant, A2780/ Cis were included in this Chapter due to their 
identical lineage and similar genomic expression profile, allowing them to be 
differentiated by only their resistant features. Overall both the sensitive (MCF-7 and 
A2780) and resistant (SKOV-3 and A2780/ Cis) cells demonstrated some degree of 
impairment of the mitochondrial membrane potential, with the resistant cells generally 
demonstrating higher levels of mitochondrial membrane potential decay. Gene 
expression analysis demonstrated that mitochondrial related transcription factors and 
proteases may be involved in the mechanism of action of Cu-Phen (1) and Cu-DPQ-
Phen (2) in A2780/ Cis cisplatin resistant cells. The cisplatin resistant SKOV-3 cells 
were also characterised by an increase in mitochondrial related transcription factors and 
proteases, both of which are involved in the control of oxidatively and misfolded 
protein damage in the mitochondria. In addition to the transcription and proteases gene 
expression profile the resistant A2780/ Cis cells demonstrated strong upregulation of the 
mitochondrial fission regulator, DRP1 in all exposures. Upregulation of DRP1 has been 
shown to protect from damage-induced fission events in the mitochondria and may 









Chapter 5: In-vivo evaluation of response of Galleria 
mellonella larvae to novel copper(II) phenanthroline-
phenazine complexes 
The work outlined in the following chapter appears in-part in the article entitled “In-
vivo evaluation of response of Galleria mellonella larvae to novel copper(II) 






















Insects represent one of the most phenotypically diverse classes of organism, with 
habitats occupying every ecological niche across the planet, apart from the sea (Elzinga 
2004). Additionally, insects such as Drosophila melanogaster have been pivotal in the 
study of genetics and developmental biology (Jennings 2011). The insect innate 
immune system is one of the key features of an insect’s ability to inhabit such a wide 
variety of habitats. While vertebrates have developed a strong adaptive immune 
response over millions of years of evolution, much of their innate immune systems 
shows structural and functional similarities to the insect immune system (Kavanagh and 
Reeves 2004; Renwick et al. 2007; Kelly and Kavanagh 2011; Browne and Kavanagh 
2013). In many cases insect models can provide comparable immunological response to 
higher mammals and therefore are useful option to assess new therapeutics without the 
financial implications and have a lower ethical threshold (Kemp and Massey 2007; 
Cook and McArthur 2013). 
 
Insects also provide a powerful tool for the evaluation of potential novel drug and other 
immunological based therapeutic candidates. The larvae of the greater wax moth 
(Galleria mellonella) provide a useful opportunity to study the toxicological profile of 
the copper complex studied in the in-vitro mammalian cell lines in Chapter 2. The 
physical size of the larvae allows for an easy inoculation procedure and the effects of 
the exposure can be measured visually, cellularly and at a molecular level with 
alterations in gene and protein expression. The amenable nature of G. mellonella to 
pharmacodynamics studies allows investigation into the larval immune response when 




G. mellonella larvae were first used to examine the pathogenic properties of wild-type 
and lipopolysaccharide deficient mutants of Pseudomonas aeruginosa (Dunphy et al. 
1986) and in studies incorporating Proteus mirabilis, Escherichia coli and Bacillus 
cereus (Walters and Ratcliffe 1983; Paterson et al. 1987; Cotter et al. 2000). The 
similarity of the immune response to that of mammals centres on structural and passive 
barriers as well as cellular and humoral responses. Haemocytes are responsible for the 
cellular immune response in G. melleonlla larvae and many other invertebrates. 
Haemocytes perform similar functions to polymorphonuclear cells in mammals and can 
be functionally sub-catagorised. Sub-categories of haemocytes identified are believed to 
perform different function such as phagocytosis, encapsulation and nodule formation 
(Matha and Acek 1984). Research has shown that the production of superoxide in larval 
haemocytes originates from NADPH oxidase complex which contains two proteins, 67-
kDa and 47-kDa, which have significant regional homology to human derived p67phox 
and p47phox proteins found in neutrophils (Bergin et al. 2005; Renwick et al. 2007).  
 
The cellular insect immune response is characterised by lectin-mediated phagocytosis 
and oxidative burst, similarly to the vertebrate system (Bergin et al. 2005; Browne et al. 
2013). The humoral element of the insect immune response centres on the production of 
antimicrobial peptides (AMPs) which provide a competent defence mechanism for the 
insect. To this end, two common AMP genes; inducible metalloproteinase inhibitor 
(IMPI) and transferrin are typically up regulated during in larval immune responses. 
IMPI was the first metalloproteinase inhibitor characterised in invertebrates and was 
purified from G. mellonella. It functions by inhibiting the action of enzymes secreted by 
pathogenic microbes (Clermont et al. 2004; Vertyporokh and Wojda 2016). Transferrin 
was identified in D. melanogaster after bacterial infection and has also shown increases 
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in expression. These increases have also been seen in sham inoculations and are 
believed to be caused by a priming effect (Yoshiga et al. 1999). For many pathogens 
iron is an important growth factor, its sequestration from the mammalian system has 
been strongly associated with improved survival (Iglesias-Osma et al. 1995). With such 
homology present it is likely that it functions in the invertebrate model in the same way 
(Kelly and Kavanagh 2011). The immunogenicity of therapeutics is an important 
characteristic in the evaluation and development process. The G. mellonella model 
provides a basic platform to assess potential immunogenic response in later higher 
mammal testing. The evaluation of the proteomic response provides another vital 
avenue into the evaluation of the larval immune response to infection and foreign 
agents. Presently multiple proteins have been observed in haemolymph, some of which 
can be described as non-specific responses. Ferritin subunit is a protein commonly 
observed in protein responses. Its importance in iron homeostasis is mirrored in the 
mammalian response to infection. Prophenoloxidase is a common protein in insects 
which is directly involved in melanin synthesis, a key defence strategy in insects. 
Juvenile hormone binding protein is also another common protein seen after the G. 
mellonella exposure to an environmental stressor (Banville et al. 2012). It is important 
in regulating growth of the insect and can also function as protection from non-specific 
esterase action (Kramer and Childs 1977; Zalewska et al. 2009). Arginine kinase is 
another protein involved in the transfer of phosphates from ATP. These examples above 
represent a small list of proteins found to have significant homology to other organisms, 
and from this, their functionality is determined. The type of functionalities of these 
proteins is usually associated with antimicrobial or metabolic function. With the 
publishing of the G. mellonella transcriptome by Vogel et al (2011), the capability of 
high throughput proteomics such as Label-Free Quantification (LFQ) has permitted a 
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larger scale assessment of the proteomics response of the larvae to experimental 
conditions such as responses to food preservatives (Maguire et al. 2017). 
 
With the host/ pathogen evaluation platform well established in the G. mellonella 
model, there remains an important opportunity to explore the capacity of the 
Lepidoptera model for metal-based drugs as an initial pre-screening in-vivo model. To 
this effect a group of studies have previously used G. mellonella to evaluate the in-vivo 
activity of a variety of metal-based drugs (Kavanagh and Fallon 2010; Kellett et al. 
2011b; McCann et al. 2012). Cu(II) bis-phen complexes showed tolerance exceeding 
that of cisplatin in the G. mellonella model (Kellett et al. 2011) with phendione 
modifications to the copper(II) showing well tolerated exposures in both the larval 
model and Swiss mice (McCann et al. 2012). Multiple copper and other metal-based 
complexes have been developed as part of the Kellett group, Dublin City University and 
have established good biological potential not just according to the chemical activity of 
the novel complexes on DNA integrity and radical species of oxygen and nitrogen 
production but also due to the ability of G. mellonella to biologically tolerate them.  
 
To date, the work on G. mellonella has stemmed from a host-pathogenicity or infection-
treatment model. This has provided invaluable information regarding the response of 
the larvae to certain infection that pertain to humans and how these infections are 
altered by certain novel metal-based drugs and microbiologically derived agents. This 
study will examine the effects of the novel Cu(II) phenanthroline-phenazine complex 
series on larvae through mortality assays, gene expression and high resolution LFQ 
proteomics. While in the absence of a antimicrobial derived focus, this study, given the 
promising activity of Cu(II) phenanthroline-phenazine complexes (Molphy et al. 2014, 
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2015), will provide valuable insight into the in-vivo activity of these novel series of 
Cu(II) complexes and identify therapeutic targets and mode of action information for 

























5.2 Material and Methods 
5.2.1 Galleria mellonella in-vivo toxicity assay and cuticle changes 
In-vivo cytotoxicity testing of Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and 
Cu-DPPN-Phen (4) and cisplatin were performed on G. mellonella larvae in the 6th 
developmental stage sourced from the Meal Worm Company, (Sheffield, UK). The 
phenazine ligands: DPQ, DPPZ and DPPN were in addition, separately exposed to the 
larvae. All larvae were stored in the dark at 15 ⁰C in wood shaving prior to testing. 
Thirty three larvae (average weight 0.3±0.05 g) with no cuticle decolouration were used 
for each experiment. Thirty three larvae were allocated for each toxicity experiment. All 
solutions were prepared fresh before use as detailed in Appendix 1.6.1.  Larvae were 
inoculated (20 μl) by injection (BD Ultra-Fine™ Insulin Syringe) into their haemocoel 
through the last pro-leg (Fig. 5.1) (Cotter et al. 2000). Solvent control (8.92 % DMSO) 
(Sigma, Ireland) (Cat# 276855) was also inoculated in the same manner along with 
sham-inoculations and undisturbed controls. Larval toxicity after exposure was 
monitored at 4, 24, 48 and 72 h.  
 
Visual changes were recorded throughout the course of the experiment. The onset of 
melanisation, characterised by the larvae turning brown/ black was recorded after the 
inoculations. The onset of melanisation occurred due to the insect immune response 
driven by the cleavage of prophenoloxidase to active phenoloxidase. The chemical 
cleavage of prophenoloxidase is driven generalised damage to the organisms where it 
responds to limit the growth of a potential pathogen within the haemocoel (Kavanagh 
and Reeves 2004). Dead larvae usually appeard black (Fig. 5.2) however this did not 




Fig. 5.1 Inoculation procedure for G. mellonella larvae. Twenty µl was injected into last 
left pro-leg. Image adapted from Cotter et al. (2000). 
 
 
Fig. 5.2 Living (A) (normal colour) and dead (B) (melanised) G. mellonella. Image 






















    
Fig. 5.3 Characteristic changes (A-D) in response to test inoculation 
 
5.2.1.1 Measurement of haemocyte count 
Haemocyte count was measured 24 h post inoculation with the LD50 value of Cu-Phen 
(1) (8.94 µg), Cu-DPQ-Phen (2) (11.47 µg) and Cu-DPPZ-Phen (3) (25.05 µg) along 
with a solvent control (8.94 % DMSO in MilliQ water), sham-inoculated and 
undisturbed control. Five larvae representing each condition were bled through the 
anterior region of the head (Fig. 5.4), with the inoculation and bleeding performed on 4 
separate occasions (N=4). The extracted haemolymph was diluted 1:10 with 
mercaptoethanol (0.37 %) (ACS grade) (Sigma, Ireland) (Cat# M6250). Cell counts 
were performed using a haemocytometer. 
 
Fig. 5.4 Piercing point (anterior portion) of the G. mellonella larvae for haemocyte 
extraction indicated by the black arrow. 
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5.2.2 Measurement of immune related gene expression by Quantitative Real Time 
– PCR (qRT-PCR) 
5.2.2.1 Sample preparation 
Larvae were inoculated with Cu-Phen (1) (8.94 µg), Cu-DPQ-Phen (2) (11.47 µg) and 
Cu-DPPZ-Phen (3) (25.05 µg) along with solvent, sham-inoculation and undisturbed 
controls for 24 h. After 24 h, 3 larvae representing each experimental condition were 
immersed in liquid nitrogen in a sterile mortar and ground-up with a sterile pestle into a 
fine powder. The mortar was allowed to warm for a few minutes before 1 ml of tri-
reagent (Sigma, Ireland) (Cat# T9424) was added to the powdered remains. The mixture 
was carefully transferred to an RNase free Eppendorf. The sample was allowed to stand 
for 2 min before being centrifuged at 2000 g for 2 min. Here, all the insoluble material 
from the sample was pelleted. The supernatant was transferred to a new Eppendorf and 
stored at -80 ˚C.  
 
5.2.2.2 RNA extraction to qRT-PCR 
RNA extraction was performed as described in section 2.2.6.3. RNA quantification was 
performed as described in 2.2.6.4. cDNA synthesis of RNA templates was performed as 
described in section 2.2.6.5. Quantitative real-time PCR was performed as described in 
section 2.2.6.6. Primer sequences were designed and obtained from the medical 
mycology lab in Maynooth University. Both forward and reverse primers for each target 
and reference gene are detailed in Table 5.2. Each probe and primer was mixed with 
molecular grade water to check for autofluorescence. The samples and master mix were 
placed in 96-well PCR plates. Assay was performed in quadruplicate. PCR plate was 
sealed and centrifuged at 1200 g for 2 min before being placed in the 7500 Fast Real-
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Time PCR System (Applied Biosystems, USA). Thermal cycling parameters are 
detailed in Table 5.1 below. 
 
Table 5.1 Thermal cycling parameters 
Pre-incubation (1 cycle) 95 °C, 10 min, ramp 4.4°C 
Quantification (45 cycles) 
95 °C 10 sec ramp 4.4 °C, 60 °C 30 sec 
ramp 2.2 °C, 72 °C 30 sec ramp 4.4 °C 
Melting curve (1 cycle) 
95 °C 5 sec ramp 4.4 °C, 65 °C 1 min 
ramp 2.2°C, 97 °C continuous ramp 0.11 
°C acquisition 5 per °C 
Cooling (1 cycle) 37 °C 11 sec ramp 2.2 °C 
 
 
Table 5.2 Forward and reverse primer sequences for genes related to immune activity in 
G. mellonella.  
Primer name Oligonucleotides (5'-3') 

















*Represents primers of reference gene, S7e (ribosomal related). 
 
5.2.2.3 Statistical analysis of gene expression data 
The expression levels of each target and reference gene was measured using Ct values 
(Cycle threshold) (Kurnik 2007). For each PCR plate the water negative for each gene 
was used to confirm that autofluorescence was not contributing to the final reading. The 
individual Ct values were recorded in Microsoft Excel™ (Microsoft Corporation, USA) 
along with average and standard deviation for each cDNA sample. The Ct values are 
related to the amount of amplicon present in the reaction mix. The lower the Ct value 
the greater the level of amplicon present in the sample. For each sample and target gene 
the Ct value of the reference gene (S7e) (Browne 2014) was subtracted from the Ct 
value of the target gene. The delta change of target gene in relation to the S7e Ct value 
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is then subtracted from the biological negative control for that sample. The second delta 
value is then normalized using the following logarithmic formula: 2-ΔCt1(test)-ΔCt2(control). 
The average Ct value for both reference and target gene was calculated along with the 
standard deviation. Both standard deviations were subjected to error propagation with 
the final standard deviation being normalized in a manner as stated in the formula above 
(Nordgård et al. 2006). Both positive and negative range reflects a 95 % confidence 
interval around the mean normalized gene expression value. 
 
5.2.3 2D SDS-PAGE analysis of protein expression 
5.2.3.1 Sample collection, Bradford assay and protein precipitation 
Larvae were inoculated with the LD50 value of Cu-Phen (1) (8.94 µg), Cu-DPQ-Phen 
(2) (11.47 µg) and Cu-DPPZ-Phen (3) (25.05 µg) along with a solvent control (8.94 % 
in MilliQ water) for 24 h. Haemolymph (~100 µl) was collected from 5 larvae in a 
similar manner to the haemocyte density count. Haemolymph was collected into pre-
chilled eppendorf and a 1/10 dilution with PBS was performed. The collection of 
haemolymph (5 larvae each) was performed on 3 separate occasions for each of the 
experimental conditions. The sample was centrifuged at 1500 g for 5 min in order to 
pellet the collected haemocytes. The supernatant was transferred to a new Eppendorf 
and further diluted 1:10. Protein was quantified using the Bradford assay (Bio-Rad 
Munich, Germany) (Cat# G-250) (Appendix 1.5.2).  Protein concentration was diluted 
to 200 µg per sample. Following the Bradford assay an acetone (Sigma, Ireland) (Cat# 
V800023) precipitation was performed at a ratio of 1:4 sample to acetone. The acetone 
was ice-cold before being added to the protein samples. Protein/ acetone solution was 
then incubated -20 °C for 1 h. Following the 1 h incubation samples were spun for 30 
min, 13,000 g at 4 °C. Pelleted samples were then re-suspended in 100 µl of IEF buffer 
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(appendix 1.7.2) and 2 µl of DTT (Sigma, Ireland) Cat# 43815) and ampholytes (pH 4-
7) were added. Samples were mixed and 150 µl of IEF buffer was added on top of the 
samples along with 1 µl of bromoplenol blue. Samples were let stand for 15 min at 
room temperature. 
 
5.2.3.2 1D gel set-up 
One dimensional IEF gel strips pH 4-7 (Thermo, Ireland) (Cat# ZM0012) were removed 
from the freezer and gel strip retainers with lids were rinsed with deionised water and 
dried prior to use. Two hundred and fifty µl of the sample was added to the positive end 
of the coffin and pH strip was peeled apart carefully. The coffin was gently tilted as the 
strip was laid down into the coffin allowing the strip to be evenly submerged. A Pasteur 
pipette was used to cover the pH strip with Plus One dry strip cover fluid (GE 
Healthcare, Ireland). Isoelectric focusing was performed on the EttanIPGphore II 
(Amersham Biosciences, USA) using the following programme (Table 5.3). Resulting 
gel strips were stored at -70 °C before 2D gel electrophoresis. 
 
Table 5.3 EttanIPGphore II electrical separation parameters. 
Step 1 50 Volts, step and hold for 10 h 
Step 2 250 Volts, step and hold for 15 min 
Step 3 8000 Volts, gradient for 5 h 
Step 4 8000 Volts, step and hold for 8 h 
 
5.2.3.3 2D-PAGE set-up (separating gel) 
Equilibrium buffer X2 (Appendix 1.7.3) was thawed and brought to 37°C and place 10 
ml in individual test tubes. DTT (Sigma, Ireland) (Cat# D0632) (1 g) was added to each 
10 ml of equilibrium buffer and 1D gel strips were immerse in individual test tubes. 
IAA (Sigma, Ireland) (Cat# I4386) (0.25 g) was added with 1 µl of bromophenol blue 
(Sigma, Ireland) (Cat# B8026) to each tube and was then sealed with parfilm and 
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protected from light with tin foil. The tubes were placed horizontally on a plate rocker 
for 20 min to incubate. Separating gel (Appendix 1.7.4) was made up with the TEMED 
(Sigma, Ireland) (Cat# T9281) excluded until later polymerization. A 1 ml solution of 
200 µl 5X Solubilisation Buffer (Appendix 1.7.5), 800 µl deionised water, 10 µl of 
marker + 190 µl 5X solubilisation buffer was boiled at 95 °C for 5 min. A 1 % agrose 
gel in 1X running buffer (appendix 1.7.6) + and 1 µl of bromophenol blue was produced 
with the solution being heated in a microwave for 1 min. TEMED was added to the 
separating gel and the gel was set in a pre-cleaned plate of approximately 1.5 mm 
thickness. The 1D gel strips were taken out of IAA with a tweezers and washed in 10X 
electrode running buffer (Appendix 1.7.6). The gel strip was orientated facing away 
from the glass and plastic side against glass. The positive side was placed to the left and 
a straw was used to push the strip down to the surface of the set gel. A Pasteur pipette 
was used to cover the top of the strip with blue (tipped with bromophenol blue) agrose 
gel and was subsequently allowed to set. Each plate was then connected to the 
electrophoresis rig with Vaseline around the corners to prevent drying. The chambers 
were filled with 10 X running buffer to the top and the chambers on the outside were 
filled with 1 X running buffer (Appendix 1.7.6). The electrophoresis rig was run at 30 V 
overnight. After the electrophoresis run, the gel is carefully removed with a plastic 
wedge and a mark placed in the gel to aid in later orientation. The gels were placed in 
Coomassie Brilliant Blue stain (Appendix 1.7.7) for 1 h followed by Coomassie Destain 
(Appendix 1.7.8) for 1 h.  
 
5.2.3.4 Progenesis SameSpot analysis and protein spot picking 
Each gel was scanned using a Hewlett Packard scanjet 5100c scanner (HP, USA) and 
images were orientated with Microsoft Office™ Powerpoint (Microsoft Corporation, 
230 
 
USA) and analysed using Progenesis SameSpot (Nonlinear Dynamics, USA) software. 
Progenesis software allows for the analysis of protein expression changes between 
replicates with significance determined through ANOVA. A table of protein spots was 
built with an annotated gel image to provide a final check on gel alignment before spot 
excision. Important spots were identified using the Progenesis SameSpot. The truncated 
pipette tip was used produce a clean circular cut in the desired gel. The 2D gel was 
rinsed with water for 2 h and placed on a light box to visualise the proteins spots. The 
required spot was cut with the tip and placed into a labelled Eppendorf.  
 
5.2.3.5 In-gel digestion of excised protein spots 
Ammonium bicarbonate/ acetonitrile (Sigma, Ireland) (Cat# 09830/Cat# 271004) (100 
µl) (1:1 v/ v) 10 mM was added to the Eppendorf, sample was incubated and stored at 
room temperature for 10 min. Acetonitrile (500 µl) was added to gel spots until gel 
became white and shrunk, following this acetonitrile was removed (samples were then 
stored at -20 °C). The sample was saturated with Trypsin (0.5 µg/µl) (Promega, USA) 
(Cat# V5111) making sure the spot was covered and incubated for 2 h in the fridge. 
Ammonium bicarbonate (10 µl) buffer was added to the spot pieces and left at 37 °C for 
24 h. Trypsin digestion similar to (Shevchenko et al. 2006) was performed. Following 
24 h digestion the sample was centrifuge and 50 µl of the supernatant was removed and 
place into a labelled tube. To the gel piece, 100 µl of extraction buffer (1:2 v/ v 5 % 
formic acid/ acetonitrile) (Sigma, Ireland) was added to each tube and incubated at 37 
°C for 15 min. The supernatant was removed with a small pipette tip to avoid aspirating 
pieces of the remaining gel. The supernatant was placed into a separate Eppendorf and 
dried down in a vacuum centrifuge. The samples were re-dissolved with 20 µl of 0.1 % 
(v/ v) formic acid then vortexed for 5 min and placed in a sonication bath for 5 min. 
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Each sample was centrifuged at 10,000 g for 15 min and transferred to a spin filters and 
repeated. The eluant was placed into acetonitrile washed vials and the lid labelled to 
ensure that no keratin contamination occurred. 
 
5.2.3.6 LC/MS analysis of protein spots 
The fragmented protein samples were eluted by Agilent 6340 Ion trap LC/ MS (Waters, 
USA). A run table was produced with blanks dividing up each sample and a BSA 
standard to check the performance of the instrument prior to sample injection. All 
samples were run for 20 min and the resulting data was analysed using the Mascot 
search engine (http://www.matrixscience.com).  
 
5.2.3.7 Statistical analysis of LC/ MS protein spots identifications  
Three independent gels from 3 individual biological experiments were used to examine 
each experimental condition. Protein fold changes between 2D gels were determined 
with the Progenesis SameSpot software. Their significance was determined through 
ANOVA testing and choice of picking for LC/ MS analysis made accordingly. A 
MASCOT score above 67 was deemed to be a significant match (p ≤ 0.05) (MASCOT 
2017). MASCOT programme search parameters are detailed in Appendix 1.6.9. A mass 
error tolerance of 1 Dalton was allowed for a maximum of no more than two missed 
cleavages. Protein sequences were verified by blasting the protein sequences on the 







5.2.4 Label Free Quantification of larval haemolymph protein using Q Exactive 
LC/ MS 
5.2.4.1 Protein preparation and processing for Q Exactive analysis 
Samples for Q Exactive analysis were processed from the same haemolymph extracts 
for 2D PAGE analysis detailed in section 5.2.3.1. An additional replicate was included 
from each experimental condition for Q Exactive analysis bringing the total number of 
independent replicates to 4. Samples were normalized to 100 µg and stored at -20 °C 
prior to the in-solution digestion protocol using ProteaseMAX (Promega, USA) (Cat# 
V2071). The protein samples were digested as described in the in-solution digestion 
protocol using ProteaseMAX in section 3.2.2. Samples were cleaned-up using the 
reverse phase C18 spin-column. The protocol is described in section 3.2.3. 
 
5.2.4.2 Q Exactive analysis 
Dried samples were re-suspended in 32 µl of Q Exactive buffer (Appendix 1.3.4) on day 
of analysis. Samples were placed in a sonication bath for 5 min to aid peptide re-
suspension. Samples were subsequently centrifuged at 13,000 g for 5 min at room 
temperature to pellet any insoluble material. The supernatant was transferred to LC 
MS/MS vials. Peptide mix was separated on a Dionex Ultimate 3000 (Thermo Fisher 
Scientific, USA) chromatrgraphy system with increasing gradient of acetonitrile on a 
Biobasic C18 Picofrit TM column (100 mm length, 75 mm ID), using a 60 min reverse 
phase gradient at a flow rate of 250 nl min-1.  High resolution MS scan (300-2000 Da) 
was performed using the Orbitrap to select the 15 most intense ions prior to MS/MS. A 





5.2.4.3 Computational identification of ion peaks 
MS/ MS ion peaks were identified using MaxQuant (open source,ver. 1.2.2.5, 
http://maxquant.org/) through the use of the incorporated Andromeda search engine 
(Cox et al. 2011) and correlated against a 6-frame translation of the EST contigs 
identified for G. mellonella (Vogel et al. 2011). The following search parameters were 
set for identification of proteins in MaxQuant: First peptide tolerance was set at 20 ppm, 
second peptide tolerance was set at 4.5 ppm, cysteine carbamidomethylation set as a 
fixed modification, N-acetylation of proteins and oxidation of methionine as a variable 
modification, and a maximum of 2 missed cleavage sites allowed. Search results were 
challenged with a target decoy database and False Discovery Rate (FDR) was set to 1 % 
for both peptide and proteins. Identified peptides contained a minimum of 7 amino acids 
and proteins were only considered identified when 2 or more unique constituent 
peptides were observed. 
 
5.2.4.4 Statistical and visual processing of identified proteins 
Identified proteins were processed using Perseus (open source, ver. 1.5.6, 
http://www.perseus-framework.org). LFQ intensities were subjected to log(2) 
transformation. Proteins were only processed when they were present in at least 3 of 4 
biological replicates. Proteins that contained LFQ intensity values of zero (NaN) were 
included in the results when they were absent in 1 group and present in at least 3 
replicates of another group. Subsequently, replicate samples that were missing from one 
group were imputated based on Gaussian distribution using the value for each dataset, 
which was calculated as being a 1.75 downshift from the mean value and a 0.25 width 
downshift for the standard deviation. Unpaired t-tests between the solvent control and 
each of the test complexes were performed with a p-value of 0.05 set with FDR 
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correction (Benjamini-Hochberg). Principle Component Analysis (PCA) was performed 
on each of the experimental designs to establish the protein abundance variation 
between the different experimental exposures and examine the variation within each 
experimental group. Tight clustering indicated similar protein abundance while 
dispersed data points indicated dissimilar protein abundance. Dispersion of the data 
points on the x-axis (Component 1) represented the largest difference in protein 
abundance while dispersion of data points on the y-axis (Component 2) represented the 
next largest difference in protein abundance. Hierarchical clustering and volcano plots 
were generated between each of the test complexes and the solvent control from the 
imputated dataset. Proteins with statistical significant expression (p ≤ 0.05) and ≥ 1.5 
fold change between the test exposure and the negative control were referred to as 
Statistically Significant Differentially Abundant (SSDA) proteins. The Blast2GO suite 
(BioBam Bioinformatics, Spain) of software tools was used to assign annotation, 
enzyme code, KEGG and Gene Ontology mapping on SSDA proteins. GO mapping for 














5.3.1 Galleria mellonella in-vivo toxicity assay and cuticle changes 
G. mellonella larvae were exposed to Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen 
(3) and cisplatin and the level of toxicity was assessed by the mean mortality (%) over 
72 h (Table 5.4 – 5.5). No mortality (data not shown) was recorded at any timepoint 
after incubation of solvent (8.94% DMSO in MilliQ water), sham inoculated and 
undisturbed controls. The results of the individual larval responses to the inoculated 
doses and timepoints are detailed Table 5.4 – 5.5.  In the case of Cu-Phen (1) (Table 
5.4), the onset of toxicity occurs rapidly with inoculation in excess of 10 µg at 24 h and 
after, with inoculation dose of under 10 µg producing no appreciable increase in 
mortality over the subsequent timepoints. 
 
The inoculation of the larvae with Cu-DPQ-Phen (2) (Table 5.4) produced a different 
effect in comparison to inoculation with Cu-Phen (1). At the 4 h timepoint mortality 
was not observed until 20 µg in comparison to 10 µg with Cu-Phen (1). Mortality 
increases at both 24 and 48 h and increases marginally again at 72 h with toxicity 
beginning to appear at 8 µg. Cu-Phen (1) and Cu-DPQ-Phen (2) differ in terms of their 
toxicity to the larvae both in relation to the dose administration and the rate of increase 
in mortality with Cu-Phen (1) producing a superior toxicity profile in all cases in 
comparison to Cu-DPQ-Phen (2). 
 
Inoculation of larvae with Cu-DPPZ-Phen (3) (Table 5.4) produces a different profile to 
that of Cu-Phen (1) and Cu-DPQ-Phen (2). Mortality was restricted to the 12-30 µg 
range until the 72 h timepoint where it was observed at 40 % in the 10 µg inoculation. 
The inoculation with Cu-DPPZ-Phen (3) also showed very little increase in the level of 
mortality over time in contrast to Cu-Phen (1) and Cu-DPQ-Phen (2). Cu-DPPZ-Phen 
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(3) was injected in micro-suspension which may partially explain the profile of early 
toxicity followed by a very marginal increase in mortality over time. Figure 5.5 
presents the results from Table 5.4 as a heatmap. 
Table 5.4 Mean larval mortality (%) after 4, 24, 48 and 72 h inoculations with Cu-Phen 
(1), Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3) at the required doses. 
 Larval dose 
(μg) 














































































































































































































































































































































































Fig 5.5 Heatmap representation of Table 5.4 showing the mean larval mortality (%) 
after 4, 24, 48 and 72 h inoculations with Cu-Phen (1), Cu-DPQ-Phen (2) and Cu-
DPPZ-Phen (3). 
 
The pharmacological reference drug, cisplatin produced far lower levels of toxicity 
(Table 5.5) than Cu-Phen (1), Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3) over 3 
timepoints. An additional high dose inoculation (100 µg) was performed to demonstrate 
maximal toxicity which was previously demonstrated by (McCann et al. 2012). Cu-
Phen (1), Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3) exceed the toxicity of cisplatin over 
a 72 h period. The DPQ and DPPZ ligands independent of the Cu-Phen scaffold 
complex was administered at a range of 2-10 µg but no mortality was observed at any 
dose or timepoint due to lack of solubility in the required solution. 
238 
 
Table 5.5 Mean larval mortality (%) after 24, 48 and 72 h inoculation with 20 µl of 











































































The LD50 values (Table 5.6) from Cu-Phen (1), Cu-DPQ-Phen (2) and Cu-DPPZ-Phen 
(3) decrease over the increasing timepoints with Cu-Phen (1) showing superior toxicity 
to Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3) at all timepoints. All complexes 
demonstrated time-dependent toxicity. Mild orange discoloration was observed after 
exposure Cu-Phen (1) at 24 h with no other remarkable colour changes apparent except 























Table 5.6 Calculated LD50 values and the representation of cuticle presentation post 
exposure.  
 LD50 (µg) ± S.D. 
 4 h 24 h 48 h 72 h 
Cu-Phen 
(1) 









26.07±0.312 25.05±0.312 25.05±0.312 16.81±0.236 
 Treatment images after 24 h exposure 






(3) (24 h)* 
Cuticle 
response 
    






















5.3.2 Measurement of haemocyte count 
Haemocytes count (Fig. 5.6) was performed from the haemolymph extracted from 5 
larvae per treatment (LD50 value at 24 h). This procedure was replicated × 4 for 
statistical validity. No significant changes were observed between any of the controls 
and test complex exposures. 
 
Fig. 5.6 Changes in haemocyte count 24 h post inoculation with Cu-Phen (1) and Cu-
DPQ-Phen (2) and Cu-DPPZ-Phen (3). In addition to the Cu(II) phenanthroline-
phenanzine complex series the solvent, sham-inoculated and undisturbed controls were 








5.3.3 Measurement of IMPI and Transferrin by qRT-PCR 
Larvae were exposed to the 24 h LD50 value of Cu-Phen (1) (8.94 µg), Cu-DPQ-Phen 
(2) (11.47 µg) and Cu-DPPZ-Phen (3) (25.05 µg). Solvent control, sham-inoculation 
and undisturbed control were utilised as previously described. Both transferrin and 
IMPI were normalised against the expression of S7e reference gene and all larval 
treatments were compared to the undisturbed control. Both sham-inoculation and 
undisturbed controls produced similar expression levels (data not shown). Fig. 5.7 
demonstrates the expression of both genes. A significant decrease in IMPI expression 
was observed in Cu-Phen (1), Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3) treated larvae 
in comparison to the solvent control. In all LD50 complex exposures there was a 
significant decrease in transferrin activity with respect to the solvent control.  
 
Fig. 5.7 Relative expression of (IMPI) and transferrin after 24 h exposure to LD50 value 
of Cu-Phen (1), Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3). Gene expression is 
displayed relative to the undisturbed control with the solvent control used to determine 




5.3.4 2D SDS-PAGE analysis of protein expression 
2D PAGE gels were produced by separating proteins on the basis of size after IEF 1D 
gel strips separated proteins based on a pH gradient. Progenesis SameSpot (Nonlinear 
Dynamics, USA) software was used to compare the density of protein spots across the 
different exposures and in relation to the solvent control (Table 5.7), spots were then 
excised from the reference gel (Fig. 5.8 (a)) and subsequent LC/MS identification. 
Table 5.7 details 10 protein spots which had a ≥ 1.5 fold change in expression between 
the control (reference gel) and test exposures with Cu-Phen (1), Cu-DPQ-Phen (2) and 
Cu-DPPZ-Phen (3). The location of the spots is shown in Fig. 5.8 (a). Table 5.7 
displays the spots 1-10 identifications based on LC/MS (Mascot) analysis. Asterisks 
denote significant changes (p ≤ 0.05) in protein abundance as determined by ANOVA 
compared to the solvent control.  
 
Spots 2, 7, 3, 6, 8 and 9 have all been identified to function in the immune response as 
well as other capabilities. Spot 2 represents apolipophorin-III. Apolipophorin-III is a 
pattern recognition receptor, a fundamental component of the innate immune response 
in mammals and insects involved in recognition of foreign antigens. A significant 
increase in apolipophorin-III was observed when exposed to Cu-Phen (1) but is 
significantly decreased upon inoculation with Cu-DPQ-Phen (2) or Cu-DPPZ-Phen (3) 
relative to the solvent control.  Spot 7 represents apolipophorin which is a precursor of 
apolipophorin-III and is involved in the transport of lipids and activation of the innate 
immune response. A non-significant decrease was observed upon exposure to all the test 
complexes relative to the solvent control. Spot 3 was identified as storage protein 1, a 
close analogue of arylophorin which functions in amino acid storage and immune 
functioning. A significant increase in arylophorin was observed when the larvae were 
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exposed to all of the test complexes relative to the solvent control. Spot 6 represents 
transferrin precursor, the precursor to transferrin, which is involved in iron storage and 
transport. A non-significant decrease was observed in all exposure to the test complexes 
relative to the solvent control. Both spot 8 and 9 represent two subunits of ferritin. 
Ferritin is found in all eukaryotic cells and functions in iron storage, transport and 
antioxidant activity and is commonly elevated in response to infection. A non-
significant decrease was seen in both these subunits following exposure to the test 
complexes relative to the solvent control. 
 
Spots 1, 4, 5 and 10 relates to the proteins identified to have metabolic, adaptor and 
signaling functions. Spot 1 was identified as 27 kDa hemolymph protein which is 
secreted and functions in signaling. Significant decreases in this protein were seen after 
inoculation with all of the complex series relative to the solvent control. Spot 4 
represents a phosphotidylserine receptor (GL24169) identified through homology to 
Drosophila melanogaster in Flybase (www.flybase.org). A significant increase was 
observed with this protein in response to all the test complexes with the strongest 
increase observed with Cu-DPPZ-Phen (3) relative to the solvent control. Spot 5 was 
identified as juvenile hormone binding protein which is involved in the regulation of 
embryogenesis and reproduction. A non-significant decrease was seen with this protein 
in response to inoculation with all the test complexes, the strongest of which was seen 
in Cu-DPQ-Phen (2) relative to the solvent control. Spot 10 represents imaginal disc 
growth factor (partial) which is important in regulating cell proliferation and growth. In 
all exposure the protein was non-significantly decreased relative to the solvent control 
with the greatest amplitude of the response with the exposure to Cu-DPQ-Phen (2). 
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Table 5.7 Protein identifications from MASCOT analysis after spot picking from reference gel (a), trypsin digestion and LC/MS analysis. 
Fold changes of proteins are presented relative to solvent control.  
*indicates statistically significant (p ≤ 0.05) fold changes using ANOVA (N=3).  
¥ Denotes proteins and expression profile expressed in both 2D PAGE and LFQ proteomics (Table 4.8-4.10). 
 






























26374 5.17 258 16 P83632 1 -1.86 -6.35 -4.34¥ 
2 (65)* Apolipophorin-III 
G. 
mellonella 
20498 8.59 184 18 P80703 1 +1.25 -3.65¥ -3.28¥ 
3 (11)* Storage protein 1 
Omphisa 
fuscidentalis 













27469 6.84 346 33 AAN06604 1 -1.13 -2.24 -1.56¥ 
6 (23) Transferrin precursor 
G. 
mellonella 






168310 6.25 549 10 AAT76806 1 -1.00 -2.11 -2.01 
8 (48) 




26727 5.69 85 4 AAL47694 1 -1.54 -2.40 -1.50 
9 (56) 




23932 6.22 186 9 AAG41120 1 -1.48 -1.85 -2.45 
10 (34) 









Fig. 5.8 2D PAGE gel of separated haemolymph proteins from G. mellonella inoculated, (a) reference gel (control), (b) Cu-Phen (1), (c) 




5.3.5 LFQ proteomics between Cu(II) complex exposures and control 
The haemolymph of larvae was extracted after the 24 h exposure to the LD50 value of 
the complex series in order to assess the difference in protein abundance between the 
treated and control larvae. Table 5.8 displays statistically significant proteins which 
were ≥ 1.5 fold change in relation to the solvent control after exposure to Cu-Phen (1). 
Table 5.9 displays statistically significant proteins which were ≥ 1.5 fold change in 
relation to the solvent control after exposure to Cu-DPQ-Phen (2). Table 5.10 displays 
statistically significant proteins which were ≥ 1.5 fold change in relation to the solvent 
control after exposure to Cu-DPPZ-Phen (3). A total of 299 proteins were detected with 
2 or more peptides. One hundred and four proteins were found to be significantly 
altered in abundance or uniquely detected across the 4 conditions (Table 5.11). Nine 
proteins were found to be absent or below the limit of detection following exposure to 
Cu-DPQ-Phen (2). Twelve proteins were found to be absent or below the detection limit 
following exposure to Cu-Phen (1). Four proteins were found to be absent or below the 
limit of detection after exposure to Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3). One 
protein was found to be absent or below the limit of detection after exposure to Cu-Phen 
(1) and Cu-DPPZ-Phen (3). Twenty three proteins were found to be absent or below the 
limit of detection after exposure to Cu-Phen (1) and Cu-DPQ-Phen (2). Principle 
component analysis (PCA) (Fig. 5.9) was used to visualise the variation in protein 
abundance across the individual replicates. The proteomes of larvae exposed to the 
solvent control and Cu-DPPZ-Phen (3) showed clustering that was widely separated by 
component 1, however Cu-Phen (1) and Cu-DPQ-Phen (2) were closely clustered. 
Hierarchical clustering (Fig. 5.10) similarly reflected the PCA analysis. Four replicates 
were included for the solvent control and one replicate was removed from each of the 
test exposures due to lack of clustering with the parent group. Volcano plots (Fig. 5.11 
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(A), (B) and (C)) show the increasing number of significantly up regulated proteins in 
the following pattern: Cu-Phen (1) < Cu-DPQ-Phen (2) < Cu-DPPZ-Phen (3). In the 
case of Cu-DPPZ-Phen (3) exposure, a greater number of antimicrobial proteins were 
observed to be significantly downregulated while a greater number of metabolic 
proteins and proteins containing calcium binding sites were up regulated. Gene 
Ontology (GO) terms were categorised by both biological processes (Fig. 5.12 (A)) and 
molecular function (Fig. 5.12 (B)) with categorisations being performed at level 4 
ontology. The biological process analysis (Fig. 5.12 (A)) does not show any major 
changes in larvae inoculated with the different complexes. Protein groups such as 
precursor metabolites, organonitrogen and cellular nitrogen associated proteins were 
more prominent in terms of observed proteins. An overall increase was observed in the 
number of proteins recorded after exposure to Cu-DPQ-Phen (2) and Cu-DPPZ-Phen 
(3) with the number of proteins increasing as the ligated phenazine π-backbone was 
extended. However, the number of proteins associated with each GO process 
proportionally increased in comparison to Cu-Phen (1). Interestingly, proteins 
associated with sulphur compounds and cellular aldehyde processes were only present 
after exposure to Cu-DPPZ-Phen (3).  Analysis of molecular functions (Fig. 5.12 (B)) 
also showed a similar trend of increasing number of proteins involved in the 
functionally categorised processes as the Cu(II) series progressed from Cu-Phen > Cu-
DPQ-Phen > Cu-DPPZ-Phen. Proteins associated with coenzyme binding, 
oxidoreductases acting on CH-OH and peptidase activity was only associated with 
exposure of Cu-Phen (1), while all other protein groups were co-expressed by all three 
test complexes. Glutathione S-transferase (GST) highlighted in the KEGG analysis 
(Fig. 5.13), exhibited an increased relative abundance following exposure to Cu-Phen 
(1), Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3) in comparison to the control. KEGG 
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glycolysis/ gluconeogenesis analysis (Fig. 5.14) of all three complex exposures showed 
an upregulation of several proteins: fructose bisphosphate, triose phosphate isomerase, 
glyceraldehydes-3-phosphate dehydrogenase and phosphopyruvate hydratase (enolase). 
KEGG analysis of purine metabolism (Fig. 5.15) showed increased relative abundance 
of 6 proteins after exposure to all test complexes: 
phosphoribosylaminoimidazolesuccinocarboxamide synthase (SAICAR), 
phosphoribosylaminoimidazolecarboxamide formyltransferase (AICAR), IMP 
cyclohydrolase, nucleoside-diphosphate kinase, nucleoside-triphosphate phosphatise 



















Table 5.8 Identities and relative expression values for proteins that were identified as 
being significantly higher and lower in abundance in the larvae inoculated with the LD50 
dose of Cu-Phen (1) compared to the negative control. 











chitin deacetylase 1 35 63.3 0.00E+00 1.65E+10 6.88 
dihydropteridine reductase 30 61.4 0.00E+00 1.28E+10 6.24 
elongation factor 1-alpha 25 61.5 0.00E+00 1.19E+10 6.19 
cholinesterase 1-like 25 44.7 0.00E+00 1.65E+10 6.10 
translationally controlled tumor 12 39.9 0.00E+00 7.06E+09 5.64 
D-arabinitol dehydrogenase 1-like 16 51.2 5.65E-214 7.10E+09 5.13 
glutathione S-transferase-like 6 18.2 1.55E-174 6.28E+09 5.16 
N-acetylneuraminate lyase-like 25 46.4 0.00E+00 7.30E+09 5.24 
fibrous sheath CABYR-binding 13 32.3 2.53E-295 3.95E+09 5.18 
multifunctional ADE2 13 55.4 3.04E-161 2.24E+09 5.06 
glutathione S-transferase 1-like 22 59.5 1.54E-196 6.86E+09 5.01 
esterase FE4-like 16 53.8 3.02E-224 5.71E+09 5.11 
cellular retinoic acid binding 12 22.2 0.00E+00 3.05E+09 5.17 
triosephosphate isomerase 21 26.2 0.00E+00 4.94E+09 4.92 
lambda-crystallin homolog 8 26.1 2.51E-101 8.00E+09 4.89 
trans-1,2-dihydrobenzene-1,2-diol dehydrogenase-like 4 47.2 9.89E-277 3.41E+09 4.69 
Tubulin alpha chain 23 46 1.36E-254 5.29E+09 4.68 
tubulin beta chain 18 59.1 0.00E+00 1.00E+10 4.43 
fructose-bisphosphate aldolase isoform X1 30 50.6 0.00E+00 1.24E+10 4.59 
immune-related Hdd1 14 45.1 3.38E-215 3.57E+09 4.64 
L-threonine ammonia-lyase-like 4 28.4 6.93E-31 1.89E+09 4.08 
arginine partial 5 9.8 8.02E-110 1.78E+09 4.02 
PREDICTED: uncharacterized protein LOC106129042 15 58.8 2.50E-224 3.61E+09 3.89 
aliphatic nitrilase 19 45.1 4.19E-244 3.41E+09 3.61 
glutamine synthetase 2 cytoplasmic-like 7 37 1.13E-44 1.07E+09 3.49 
Purine nucleoside phosphorylase 12 61.5 1.32E-146 8.16E+08 3.61 
enolase 5 16.7 1.12E-97 3.61E+09 3.39 
heat shock 90 20 41.9 1.36E-241 1.91E+09 3.49 
Profilin 21 32 4.84E-263 1.73E+09 3.18 
homeobox 2-like isoform X4 9 48.1 4.28E-288 2.65E+09 3.14 
glyceraldehyde-3-phosphate partial 3 15.2 3.72E-92 1.67E+09 3.15 
D-3-phosphoglycerate dehydrogenase 5 36.2 4.27E-39 9.54E+08 3.05 
Peptidyl-prolyl cis-trans isomerase 9 29.1 6.27E-93 2.15E+09 3.03 
circadian clock-controlled -like 9 35.5 6.41E-171 1.95E+09 3.01 
15-hydroxyprostaglandin dehydrogenase [NAD(+)]-like 29 44.9 0.00E+00 5.33E+10 2.70 
probable salivary secreted peptide 19 45.3 0.00E+00 4.41E+09 2.71 
cytosolic malate partial 19 28.2 7.32E-209 4.09E+09 2.90 
glutathione S-transferase 1-1-like 24 38 0.00E+00 4.14E+10 2.81 
cysteine ase inhibitor precursor 14 32 3.26E-82 1.01E+09 2.54 
isocitrate partial 6 38 2.66E-52 5.87E+08 2.50 
proliferation-associated 2G4 26 61.8 0.00E+00 5.31E+10 2.48 
ecdysteroid-regulated 16 kDa -like 7 34.3 2.22E-85 6.68E+08 2.96 
gustatory receptor candidate 59 13 31.2 7.71E-149 1.49E+09 2.19 
chemosensory 11 46.5 4.67E-148 1.45E+09 2.78 
uncharacterized protein Dmoj_GI19595 6 31.1 1.29E-32 7.59E+08 2.25 
cytosolic non-specific dipeptidase 5 36 2.31E-38 8.00E+08 2.23 
aldehyde dehydrogenase mitochondrial-like 6 21.3 2.40E-48 2.21E+08 2.61 
leukotriene A-4 hydrolase isoform X2 11 37.9 2.32E-85 1.68E+09 2.06 
N-acetylneuraminate lyase-like 18 30.9 3.56E-168 1.06E+09 2.03 
ejaculatory bulb-specific 3-like 14 57.3 0.00E+00 2.05E+10 2.13 
Peptidoglycan recognition 5 8.1 3.31E-26 1.69E+08 2.02 
Selenium-binding 1 6 24.8 7.89E-90 9.73E+08 2.05 
heat shock 8 57.7 3.46E-179 1.07E+10 1.98 
bifunctional purine biosynthesis PURH 16 29.2 1.29E-152 4.27E+09 1.75 
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ejaculatory bulb-specific 3-like 15 76.3 0.00E+00 1.80E+10 1.63 
aminopeptidase 5 20.9 3.12E-31 2.17E+08 1.65 
superoxide dismutase [Mn] mitochondrial 11 30.9 4.34E-90 1.12E+09 -1.52 
seroin-like isoform X2 2 57.7 1.94E-07 4.54E+08 -2.06 
Proteins shaded in grey at the end of the table were significantly downregulated in abundance upon 
inoculation with Cu-Phen (1).  
Peptides matched to the annotated protein, sequence coverage, PEP (Posterior Error Probability) and 
































Table 5.9 Identities and relative expression values for proteins that were identified as 
being significantly higher in abundance in the larvae inoculated with the LD50 dose of 
Cu-DPQ-Phen (2) in comparison to the negative control.  









aldehyde dehydrogenase mitochondrial-like 35 63.3 0.00E+00 1.65E+10 7.16 
lambda-crystallin homolog 25 61.5 0.00E+00 1.19E+10 6.76 
Selenium-binding 1 30 61.4 0.00E+00 1.28E+10 6.62 
tubulin beta chain 25 44.7 0.00E+00 1.65E+10 6.37 
D-arabinitol dehydrogenase 1-like 16 53.8 3.02E-224 5.71E+09 5.80 
cytoplasmic A3a 12 39.9 0.00E+00 7.06E+09 5.74 
N-acetylneuraminate lyase-like 6 18.2 1.55E-174 6.28E+09 5.69 
elongation factor 1-alpha 16 51.2 5.65E-214 7.10E+09 5.57 
serine cytosolic isoform X1 23 46 1.36E-254 5.29E+09 5.48 
D-3-phosphoglycerate dehydrogenase 13 32.3 2.53E-295 3.95E+09 5.27 
multifunctional ADE2 30 50.6 0.00E+00 1.24E+10 5.13 
15-hydroxyprostaglandin dehydrogenase [NAD(+)]-like 22 59.5 1.54E-196 6.86E+09 5.05 
glutamine synthetase 2 cytoplasmic-like 12 22.2 0.00E+00 3.05E+09 5.00 
cytosolic malate partial 25 46.4 0.00E+00 7.30E+09 4.97 
triosephosphate isomerase 21 26.2 0.00E+00 4.94E+09 4.96 
glutathione S-transferase-like 13 55.4 3.04E-161 2.24E+09 4.65 
probable enoyl- mitochondrial 14 45.1 3.38E-215 3.57E+09 4.61 
glyceraldehyde-3-phosphate partial 18 59.1 0.00E+00 1.00E+10 4.60 
glutathione S-transferase 1-1-like 15 58.8 2.50E-224 3.61E+09 4.60 
Tubulin alpha chain 4 47.2 9.89E-277 3.41E+09 4.60 
N-acetylneuraminate lyase-like 6 14.9 2.86E-59 1.49E+09 4.34 
probable phosphoserine aminotransferase 18 55.3 2.12E-160 8.79E+08 4.23 
trans-1,2-dihydrobenzene-1,2-diol dehydrogenase-like 19 45.1 4.19E-244 3.41E+09 4.17 
fructose-bisphosphate aldolase isoform X1 4 28.4 6.93E-31 1.89E+09 4.14 
thioredoxin 7 22.6 3.62E-44 1.78E+09 3.87 
tubulin alpha chain 9 76.9 1.73E-39 2.54E+09 3.85 
bifunctional purine biosynthesis PURH 5 9.8 8.02E-110 1.78E+09 3.70 
N-acetylneuraminate lyase-like 3 15.2 3.72E-92 1.67E+09 3.69 
ejaculatory bulb-specific 3-like 5 16.7 1.12E-97 3.61E+09 3.68 
cholinesterase 1-like 20 41.9 1.36E-241 1.91E+09 3.64 
immune-related Hdd1 19 28.2 7.32E-209 4.09E+09 3.58 
superoxide dismutase [Mn] mitochondrial 9 48.1 4.28E-288 2.65E+09 3.53 
small heat shock 5 24.4 2.12E-30 1.17E+09 3.46 
dihydropteridine reductase 9 29.1 6.27E-93 2.15E+09 3.40 
heat shock 90 21 32 4.84E-263 1.73E+09 3.36 
aminopeptidase 13 31.2 7.71E-149 1.49E+09 3.34 
L-threonine ammonia-lyase-like 18 30.9 3.56E-168 1.06E+09 3.30 
leukotriene A-4 hydrolase isoform X2 11 46.5 4.67E-148 1.45E+09 3.26 
ecdysteroid-regulated 16 kDa -like 6 38 2.66E-52 5.87E+08 3.23 
uncharacterized protein LOC106129042 24 38 0.00E+00 4.14E+10 3.23 
15-hydroxyprostaglandin dehydrogenase [NAD(+)]-like 15 41.8 3.49E-289 2.84E+09 3.22 
aliphatic nitrilase 26 61.8 0.00E+00 5.31E+10 3.19 
rab GDP dissociation inhibitor alpha 13 27.1 5.92E-159 9.52E+08 3.15 
Peptidyl-prolyl cis-trans isomerase 9 35.5 6.41E-171 1.95E+09 3.12 
cellular retinoic acid binding 29 44.9 0.00E+00 5.33E+10 3.06 
enolase 19 45.3 0.00E+00 4.41E+09 2.95 
fibrous sheath CABYR-binding 11 37.9 2.32E-85 1.68E+09 2.89 
ejaculatory bulb-specific 3-like 6 31.1 1.29E-32 7.59E+08 2.72 
argininosuccinate synthase 14 32 3.26E-82 1.01E+09 2.66 
takeout-like 13 22.1 2.70E-95 9.39E+08 2.33 
high mobility group D 4 9 1.77E-90 1.11E+09 2.27 
actin 14 57.3 0.00E+00 2.05E+10 2.22 
heat shock 16 29.2 1.29E-152 4.27E+09 2.20 
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uncharacterized oxidoreductase TM_0325-like 8 28.4 1.92E-235 3.18E+08 2.18 
isopentenyl-diphosphate Delta-isomerase 1 6 21.3 2.40E-48 2.21E+08 2.13 
staphylococcal nuclease domain-containing 1 11 21.4 8.04E-45 4.95E+08 2.13 
glutathione S-transferase omega 1 7 44.3 2.06E-108 6.78E+08 2.07 
arginine partial 15 76.3 0.00E+00 1.80E+10 2.04 
Serpin-2 9 21.5 1.83E-109 1.26E+09 2.00 
proliferation-associated 2G4 5 20.9 3.12E-31 2.17E+08 1.98 
Purine nucleoside phosphorylase 12 61.5 1.32E-146 8.16E+08 1.96 
uncharacterized protein Dmoj_GI19595 8 57.7 3.46E-179 1.07E+10 1.91 
fumarylacetoacetase 8 33.3 2.71E-34 1.54E+08 1.57 
chitin deacetylase 1 5 8.1 3.31E-26 1.69E+08 1.52 
probable salivary secreted peptide 7 50.7 5.52E-50 2.31E+09 -1.72 
gloverin-like 2 57.7 1.94E-07 4.54E+08 -2.50 
Peptidoglycan recognition 11 30.9 4.34E-90 1.12E+09 -4.02 
apolipophorins isoform X2* 1 13.8 1.22E-06 1.18E+09 -4.15 
Proteins shaded in grey at the end of the table were significantly down-regulated in abundance upon 
inoculation with Cu-DPQ-Phen (2).  
* Denotes protein also expressed in 2D PAGE analysis with a similar profile. Imaginal disc growth factor 
also detected in LFQ proteomics (down regulated with a fold change of -0.72 relative to the solvent 
control) and also present in 2D PAGE analysis in Table 4.4. Relative expression changes of proteins up 
regulated and down regulated after Cu-DPQ-Phen (2) exposure. Peptides matched to the annotated 

























Table 5.10 Identities and relative expression values for proteins that were identified as 
being significantly higher in abundance in the larvae inoculated with the LD50 dose of 
Cu-DPPZ-Phen (3) in comparison to the negative control. 









aldehyde dehydrogenase mitochondrial-like 35 63.3 0.00E+00 1.65E+10 8.05 
Selenium-binding 1 30 61.4 0.00E+00 1.28E+10 7.80 
lambda-crystallin homolog 25 61.5 0.00E+00 1.19E+10 7.55 
tubulin beta chain 25 44.7 0.00E+00 1.65E+10 7.41 
D-arabinitol dehydrogenase 1-like 16 53.8 3.02E-224 5.71E+09 6.85 
elongation factor 1-alpha 16 51.2 5.65E-214 7.10E+09 6.63 
15-hydroxyprostaglandin dehydrogenase [NAD(+)]-like 22 59.5 1.54E-196 6.86E+09 6.49 
cytoplasmic A3a 12 39.9 0.00E+00 7.06E+09 6.40 
N-acetylneuraminate lyase-like 6 18.2 1.55E-174 6.28E+09 6.38 
serine cytosolic isoform X1 23 46 1.36E-254 5.29E+09 6.36 
multifunctional ADE2 30 50.6 0.00E+00 1.24E+10 6.19 
cytosolic malate partial 25 46.4 0.00E+00 7.30E+09 6.16 
D-3-phosphoglycerate dehydrogenase 13 32.3 2.53E-295 3.95E+09 6.04 
glutathione S-transferase-like 13 55.4 3.04E-161 2.24E+09 5.99 
Tubulin alpha chain 4 47.2 9.89E-277 3.41E+09 5.90 
triosephosphate isomerase 21 26.2 0.00E+00 4.94E+09 5.87 
muscle-specific 20 17 45.4 2.07E-216 3.37E+09 5.73 
glutamine synthetase 2 cytoplasmic-like 12 22.2 0.00E+00 3.05E+09 5.41 
probable enoyl- mitochondrial 14 45.1 3.38E-215 3.57E+09 5.31 
glutathione S-transferase 1-1-like 15 58.8 2.50E-224 3.61E+09 5.22 
glyceraldehyde-3-phosphate partial 18 59.1 0.00E+00 1.00E+10 5.04 
peroxiredoxin- mitochondrial 8 28.5 9.37E-84 2.46E+09 4.96 
fructose-bisphosphate aldolase isoform X1 4 28.4 6.93E-31 1.89E+09 4.94 
15-hydroxyprostaglandin dehydrogenase [NAD(+)]-like 15 41.8 3.49E-289 2.84E+09 4.88 
tubulin alpha chain 9 76.9 1.73E-39 2.54E+09 4.85 
thioredoxin 7 22.6 3.62E-44 1.78E+09 4.81 
superoxide dismutase [Mn] mitochondrial 9 48.1 4.28E-288 2.65E+09 4.70 
trans-1,2-dihydrobenzene-1,2-diol dehydrogenase-like 19 45.1 4.19E-244 3.41E+09 4.70 
glutathione S-transferase 1-like 7 37 1.13E-44 1.07E+09 4.67 
bifunctional purine biosynthesis PURH 5 9.8 8.02E-110 1.78E+09 4.56 
rab GDP dissociation inhibitor alpha 13 27.1 5.92E-159 9.52E+08 4.55 
N-acetylneuraminate lyase-like 3 15.2 3.72E-92 1.67E+09 4.53 
probable phosphoserine aminotransferase 18 55.3 2.12E-160 8.79E+08 4.46 
aminopeptidase 13 31.2 7.71E-149 1.49E+09 4.39 
heat shock 90 21 32 4.84E-263 1.73E+09 4.33 
enolase 19 45.3 0.00E+00 4.41E+09 4.32 
L-threonine ammonia-lyase-like 18 30.9 3.56E-168 1.06E+09 4.27 
arginine partial 15 76.3 0.00E+00 1.80E+10 4.24 
tropomyosin-1 isoform X1 7 30.1 2.10E-145 8.84E+08 4.22 
actin 14 57.3 0.00E+00 2.05E+10 4.22 
aliphatic nitrilase 26 61.8 0.00E+00 5.31E+10 4.19 
troponin T 7 33.2 6.39E-37 6.43E+08 4.18 
annexin B9 isoform X4 8 31.1 8.55E-124 4.82E+08 4.15 
Peptidyl-prolyl cis-trans isomerase 9 35.5 6.41E-171 1.95E+09 4.13 
dihydropteridine reductase 9 29.1 6.27E-93 2.15E+09 4.13 
aldehyde dehydrogenase mitochondrial-like 8 22.5 3.21E-67 5.23E+08 4.05 
cholinesterase 1-like 20 41.9 1.36E-241 1.91E+09 4.02 
Purine nucleoside phosphorylase 12 61.5 1.32E-146 8.16E+08 3.97 
small heat shock 5 24.4 2.12E-30 1.17E+09 3.97 
troponin I 8 30.2 2.15E-110 5.84E+08 3.97 
takeout-like 13 22.1 2.70E-95 9.39E+08 3.97 
muscle-specific 20 9 19.1 1.46E-47 5.54E+08 3.78 
cellular retinoic acid binding 29 44.9 0.00E+00 5.33E+10 3.77 
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argininosuccinate synthase 14 32 3.26E-82 1.01E+09 3.74 
high mobility group D 4 9 1.77E-90 1.11E+09 3.74 
uncharacterized protein Dmoj_GI19595 8 57.7 3.46E-179 1.07E+10 3.65 
heat shock 16 29.2 1.29E-152 4.27E+09 3.64 
Profilin 6 24.8 7.89E-90 9.73E+08 3.64 
asteroid 8 32.5 7.54E-44 7.85E+08 3.62 
immune-related Hdd1 19 28.2 7.32E-209 4.09E+09 3.57 
antichymotrypsin-2-like isoform X2 9 21.5 1.83E-109 1.26E+09 3.56 
ejaculatory bulb-specific 3-like 5 16.7 1.12E-97 3.61E+09 3.52 
fibrous sheath CABYR-binding 11 37.9 2.32E-85 1.68E+09 3.46 
aminoacrylate peracid reductase 5 36 2.31E-38 8.00E+08 3.35 
staphylococcal nuclease domain-containing 1 11 21.4 8.04E-45 4.95E+08 3.16 
ubiquitin carboxyl-terminal hydrolase isozyme L3 5 21.7 3.36E-37 3.91E+08 3.14 
leukotriene A-4 hydrolase isoform X2 11 46.5 4.67E-148 1.45E+09 3.13 
PREDICTED: uncharacterized protein LOC106129042 24 38 0.00E+00 4.14E+10 3.13 
cytosolic non-specific dipeptidase 7 34.3 2.22E-85 6.68E+08 3.10 
S-Adenosyl-L-homocysteine partial 2 10.2 1.22E-15 2.61E+08 3.08 
C-1-tetrahydrofolate cytoplasmic isoform X2 4 77.3 8.26E-30 4.02E+08 3.03 
glutathione S-transferase omega 1 7 44.3 2.06E-108 6.78E+08 2.92 
troponin C 7 24.6 4.42E-81 3.70E+08 2.88 
uncharacterized oxidoreductase TM_0325-like 8 28.4 1.92E-235 3.18E+08 2.82 
phosphoglycerate mutase 1 7 14.1 6.98E-83 3.63E+08 2.82 
probable transaldolase 9 20.7 1.44E-106 5.93E+08 2.78 
ejaculatory bulb-specific 3-like 6 31.1 1.29E-32 7.59E+08 2.77 
cytosolic non-specific dipeptidase 8 34.2 6.01E-34 3.70E+08 2.77 
circadian clock-controlled -like 7 20.4 6.28E-38 2.91E+08 2.70 
ecdysteroid-regulated 16 kDa -like 6 38 2.66E-52 5.87E+08 2.64 
4-coumarate-- ligase 1-like 5 19.3 2.35E-30 4.16E+08 2.62 
isopentenyl-diphosphate Delta-isomerase 1 6 21.3 2.40E-48 2.21E+08 2.55 
uncharacterized oxidoreductase TM_0325-like 7 20.3 4.02E-72 3.15E+08 2.48 
glutathione-specific gamma-glutamylcyclotransferase 
2 6 15.6 1.85E-37 2.78E+08 2.37 
fumarylacetoacetase 8 33.3 2.71E-34 1.54E+08 2.35 
proliferation-associated 2G4 5 20.9 3.12E-31 2.17E+08 2.35 
seroin-like isoform X2 5 18.9 1.55E-139 3.06E+09 2.28 
ATPase inhibitor 3 11.6 8.88E-08 2.49E+08 2.28 
acyl- -binding homolog 4 27.1 2.52E-23 1.13E+09 1.99 
glyceraldehyde-3-phosphate partial 19 54.2 0.00E+00 1.32E+10 1.86 
multiple inositol polyphosphate phosphatase 1-like 5 22.1 1.51E-20 3.77E+08 1.86 
nucleoside diphosphate kinase 10 51.2 1.90E-115 2.79E+09 1.83 
elongation factor 1-beta 7 34.2 1.98E-101 4.50E+08 1.76 
hydroxypyruvate isomerase 15 36.3 9.02E-162 2.50E+09 1.76 
Proactivator polypeptide 6 16.9 4.40E-13 2.33E+08 1.74 
phosphotriesterase-related -like 8 23.3 1.23E-46 2.62E+08 1.71 
glyoxalase domain-containing 4 4 16 5.06E-25 1.01E+08 1.67 
L-threonine 3- mitochondrial 6 34.1 2.48E-11 1.50E+08 1.66 
Prostaglandin reductase 1 7 27.6 2.55E-53 4.96E+08 1.57 
chitin deacetylase 1 5 8.1 3.31E-26 1.69E+08 1.55 
chitinase EN03 (imaginal disc growth)* 22 53.8 0.00E+00 1.39E+11 -1.50 
probable salivary secreted peptide 7 50.7 5.52E-50 2.31E+09 -1.77 
vanin 2 isoform X1 7 25.4 3.05E-50 5.24E+08 -1.79 
homeobox 2-like isoform X4 33 67.9 0.00E+00 1.58E+10 -2.15 
apolipophorins isoform X2* 6 36.9 2.42E-38 2.00E+10 -2.24 
chymotrypsin-like elastase family member 2A 7 17.7 1.17E-41 4.45E+08 -2.30 
serine protease 42-like 3 40.2 5.25E-24 4.10E+08 -2.41 
probable salivary secreted peptide 3 14.5 7.38E-170 1.63E+09 -2.80 
gloverin-like 2 57.7 1.94E-07 4.54E+08 -2.96 
Peptidoglycan recognition 11 30.9 4.34E-90 1.12E+09 -3.28 
Proteins shaded in grey at the end of the table were significantly down-regulated in abundance upon 
inoculation with Cu-DPPZ-Phen (3).  
255 
 
* Denotes protein also expressed in 2D PAGE analysis with a similar profile. Transferrin (-0.6 fold 
change), juvenile like binding hormone (-0.76 fold change) and 27 kDa hemolymph protein (-0.62 fold 
change) were also detected in exposure to Cu-DPPZ-Phen (3) relative to the solvent control and were also 
present in the 2D PAGE analysis in Table 5.4. Relative expression changes of proteins up regulated and 
down regulated after Cu-DPPZ-Phen (3) exposure. Peptides matched to the annotated protein, sequence 
























Table 5.11 Statistically significant differentially abundant (SSDA) proteins between 
exposure to Cu-Phen (1), Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3) in comparison to 
the negative control. 





aldehyde dehydrogenase mitochondrial-like 2.19 7.16 8.05 
Selenium-binding 1 2.02 6.62 7.8 
lambda-crystallin homolog 4.89 6.76 7.55 
tubulin beta chain 4.64 6.37 7.41 
D-arabinitol dehydrogenase 1-like 5.24 5.8 6.85 
elongation factor 1-alpha 6.19 5.57 6.63 
15-hydroxyprostaglandin dehydrogenase [NAD(+)]-like 2.96 5.05 6.49 
cytoplasmic A3a 1.28 5.74 6.4 
N-acetylneuraminate lyase-like 5.17 5.69 6.38 
serine cytosolic isoform X1 0.63 5.48 6.36 
multifunctional ADE2 5.13 5.13 6.19 
cytosolic malate partial 2.81 4.97 6.16 
D-3-phosphoglycerate dehydrogenase 3.05 5.27 6.04 
glutathione S-transferase-like 5.18 4.65 5.99 
Tubulin alpha chain 4.68 4.6 5.9 
triosephosphate isomerase 4.92 4.96 5.87 
glutamine synthetase 2 cytoplasmic-like 3.61 5 5.41 
probable enoyl- mitochondrial 1.09 4.61 5.31 
glutathione S-transferase 1-1-like 2.78 4.6 5.22 
glyceraldehyde-3-phosphate partial 3.14 4.6 5.04 
fructose-bisphosphate aldolase isoform X1 4.59 4.14 4.94 
superoxide dismutase [Mn] mitochondrial -1.52 3.53 4.7 
trans-1,2-dihydrobenzene-1,2-diol dehydrogenase-like 4.69 4.17 4.7 
bifunctional purine biosynthesis PURH 1.75 3.7 4.56 
aminopeptidase 1.39 3.34 4.39 
heat shock 90 3.39 3.36 4.33 
enolase 3.49 2.95 4.32 
L-threonine ammonia-lyase-like 4.08 3.3 4.27 
arginine partial 4.02 2.04 4.24 
aliphatic nitrilase 3.61 3.19 4.19 
dihydropteridine reductase 6.24 3.4 4.13 
Peptidyl-prolyl cis-trans isomerase 3.03 3.12 4.13 
cholinesterase 1-like 6.1 3.64 4.02 
Purine nucleoside phosphorylase 3.49 1.96 3.97 
cellular retinoic acid binding 5.01 3.06 3.77 
argininosuccinate synthase 1.28 2.66 3.74 
uncharacterized protein Dmoj_GI19595 2.25 1.91 3.65 
immune-related Hdd1 4.43 3.58 3.57 
ejaculatory bulb-specific 3-like 2.05 3.68 3.52 
fibrous sheath CABYR-binding 5.16 2.89 3.46 
leukotriene A-4 hydrolase isoform X2 2.13 3.26 3.13 
PREDICTED: uncharacterized protein LOC106129042 3.89 3.23 3.13 
ecdysteroid-regulated 16 kDa -like 2.54 3.23 2.64 
isopentenyl-diphosphate Delta-isomerase 1 -1.01 2.13 2.55 
heat shock 1.98 2.2 2.4 
proliferation-associated 2G4 2.61 1.98 2.35 
seroin-like isoform X2 -2.06 1.37 2.28 
actin 1.63 4.22 1.99 
nucleoside diphosphate kinase -0.66 0.79 1.83 
chitin deacetylase 1 6.88 1.52 1.55 
contig19736_1_exp_NA 1.43 -1.62 -1.82 
homeobox 2-like isoform X4 3.15 -1.33 -2.15 
probable salivary secreted peptide 2.9 -1.72 -2.8 
gloverin-like 0.92 -2.5 -2.96 
Peptidoglycan recognition 2.03 -4.02 -3.28 
glutathione S-transferase 1-like 5.11 - 4.67 
Profilin 3.18 - 3.64 
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aminoacrylate peracid reductase -0.69 - 3.35 
cytosolic non-specific dipeptidase 2.23 - 3.1 
circadian clock-controlled -like 3.01 - 2.7 
4-coumarate-- ligase 1-like 1.16 - 2.62 
multiple inositol polyphosphate phosphatase 1-like 1.14 - 1.86 
isocitrate partial 2.7 - 1.48 
esterase FE4-like 5.06 - -1.18 
thioredoxin - 3.87 4.81 
rab GDP dissociation inhibitor alpha - 3.15 4.55 
probable phosphoserine aminotransferase - 4.23 4.46 
small heat shock - 3.46 3.97 
takeout-like - 2.33 3.97 
high mobility group D - 2.27 3.74 
staphylococcal nuclease domain-containing 1 - 2.13 3.16 
glutathione S-transferase omega 1 - 2.07 2.92 
fumarylacetoacetase - 1.57 2.35 
hydroxypyruvate isomerase - 1.1 1.76 
apolipophorins isoform X2* - -4.15 -0.72 
chitinase EN03 (imaginal disc growth)* - -0.72 -1.5 
translationally controlled tumor 5.64 - - 
cysteine ase inhibitor precursor 2.71 - - 
gustatory receptor candidate 59 2.5 - - 
chemosensory 2.48 - - 
Serpin-2 - 2.00 - 
muscle-specific 20 - - 5.73 
peroxiredoxin- mitochondrial - - 4.96 
tropomyosin-1 isoform X1 - - 4.22 
troponin T - - 4.18 
annexin B9 isoform X4 - - 4.15 
troponin I - - 3.97 
asteroid - - 3.62 
antichymotrypsin-2-like isoform X2 - - 3.56 
ubiquitin carboxyl-terminal hydrolase isozyme L3 - - 3.14 
S-Adenosyl-L-homocysteine partial - - 3.08 
C-1-tetrahydrofolate cytoplasmic isoform X2 - - 3.03 
troponin C - - 2.88 
phosphoglycerate mutase 1 - - 2.82 
probable transaldolase - - 2.78 
ATPase inhibitor - - 2.28 
acyl- -binding homolog - - 1.99 
Proactivator polypeptide - - 1.74 
phosphotriesterase-related -like - - 1.71 
L-threonine 3- mitochondrial - - 1.66 
Prostaglandin reductase 1 - - 1.57 
vanin 2 isoform X1 - - -1.79 
chymotrypsin-like elastase family member 2A - - -2.3 
serine protease 42-like - - -2.41 
Relative fold changes are given for each test exposure in comparison to the solvent control.  
- denotes level of expression that was either absent or not detected.  
Shaded proteins were of particular interest and made a strong contribution to the discussion. 
Fold changes of ˂ 1.5 were included when expression in other test exposures was ≥ 1.5 fold change.  






Fig. 5.9 Principle component analysis (PCA) of haemolymph proteomic profiles of larvae inoculated with Cu-Phen (1), Cu-DPQ-Phen (2) and 
Cu-DPPZ-Phen (3) versus the solvent control. PCA of four replicates for the solvent control and three replicates for each of the test exposures. 






Fig. 5.10 Hierarchical clustering of haemolymph profiles of larvae inoculated with Cu-
Phen (1), Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3) versus the solvent control. Heat 
map generated using mean protein expression values of statistically significant 
differentially abundant proteins. Four replicates for the solvent control and three 













Fig. 5.11 Volcano plots highlighting proteins altered in abundance in haemolymph of G. 
mellonella larvae following inoculation with Cu-Phen (1) (A), Cu-DPQ-Phen (2) (B) 
and Cu-DPPZ-Phen (3) (C). Plots represent protein intensity differences (-log2 mean 
intensity difference (difference)) and significance in differences (-log P-value) based on 
a two sided t-test. Points above the curve are considered statistically significant (p < 
0.05). Points above the line and to the right are present at higher levels of abundance in 
the test exposure and have a fold change ≥ 1.5. Points above the line and to the left are 
present at lower levels of abundance in the test exposure and have a fold change ≥ 1.5. 
Proteins annotated represent an example of differentially expressed proteins following 
inoculation with the test complex in comparison to the solvent control. Volcano plots 









Fig. 5.12 Bar chart showing the different number of proteins present in a test exposure 
that is associated with selected biological processes (A) and molecular functions (B). 





Fig. 5.13 KEGG analysis of the metabolism of selected xenobiotics by cytochrome 
P450. Glutathione S-transferase (2.5.1.18) (pink) is shown to be significantly 




Fig. 5.14 KEGG analysis of significantly upregulated proteins in glycolysis/ 
gluconeogenesis (highlighted: blue, green, grey, orange and pink) between all test 










The aim of this study was to assess the response of G. mellonella larvae to novel copper 
phenanthroline-phenazine complexes as a means to determine their biological mode of 
action and therefore developmental potential. Larval mortality decreased as the ligated 
phenazine ligand in the [Cu(Phen)(N,N’)]2+ model was extended (Cu-Phen (1) > Cu-
DPQ-Phen (2) > Cu-DPPZ-Phen (3)). The mortality assay demonstrates that the 
complex series had superior toxicity at all timepoints to cisplatin with the exception of 
Cu-DPPZ-Phen (3) which, in comparison to Cu-Phen (1) and Cu-DPQ-Phen (2) was 
relatively non-toxic. Previous studies have confirmed the enhanced toxicity of copper 
complexes in comparison to platinum agents in G. mellonella larvae (McCann et al. 
2012). G. mellonella in this study function essentially as a ‘normal tissue’ model in the 
investigation of basic in-vivo biological responses and provide information regarding 
the potential effects and targeting information for mammalian in-vivo models. 
 
Immune priming often plays a large role in the larval response to foreign bodies, either 
chemical or pathological and alterations in the larval haemocyte density is one of the 
earliest markers of the invertebrate immune response (Browne 2014). Both controls and 
complex series induced a non-significant increase in the haemocyte response after 
complex exposure, which indicates that the novel Cu(II) complex series does not elicit a 
generalised cellular immune response. The non-stimulation of a non-specific immune 
response was also shown with the evaluation of the antimicrobial effects of 1,3-
dibenzyl-4,5-diphenyl-imidazol-2-ylidene silver(I) acetate (SBC3) in G. mellonella post 
infection with Staphylococcus aureus and Candida albicans (Browne et al. 2014). In 
contrast, other studies have shown a priming of the larval immune response with 
biologically derived echinocandines producing a resistance to subsequent infection 
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(Kelly and Kavanagh 2011). The priming of the immune response has been previously 
observed through amplification of immune-related genes (Volkoff et al. 2003; Bergin et 
al. 2006; Wojda and Jakubowicz 2007). This study in contrast shows significant 
decreases in IMPI and transferrin gene expression after exposure to the metallo-agents 
compared to the solvent control. Transferrin is typically increased following infection 
and based on functional homology with mammalian systems, sequesters biologically 
active iron from circulation to prevent it from being used as a microbial growth factor. 
IMPI was first identified in G. mellonella and is responsible for breaking down metal 
based proteases released by microbial pathogens (Wedde et al. 1998). Significantly, 
across the complex series there is no increase in either of these antimicrobial factors, 
indicating that at a cellular and mRNA level, the Cu(II) complexes are not indicating a 
larval immune response in a similar fashion to carbene silver(I) acetate (SBC3) 
exposure (Browne et al. 2014). In contrast, the larval exposure to caspofungin induces 
an immune priming reaction (Kelly and Kavanagh 2011). 
 
In this study, LFQ proteomics produced a high resolution analysis of the larval response 
to the complex series with the possibility of gaining an insight into the potential 
response in the mammalian system. Two-dimensional polyacrylamide gel 
electrophoresis (2D-PAGE) confirms many of the downregulated proteins using the 
LFQ proteomics method (Table 5.7) and supports the decrease in the immune related 
genes and the non-significant increase in the larval haemocyte response. 2D-PAGE 
analysis showed that imaginal disc growth factor and apolipophorin was downregulated 
in larvae treated with either Cu-DPQ-Phen (2) or Cu-DPPZ-Phen (3). Additionally, 
transferrin, juvenile like binding hormone and 27 kDa hemolymph protein was 
downregulated after exposure of larvae to Cu-DPPZ-Phen (3). All larvae were exposed 
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to the 24 h LD50 value of the 3 complexes but have a different number of proteins 
significantly altered in abundance. 
GST is a family of phase II detoxification enzymes that catalyses the conjugation of 
glutathione to a wide variety of endogenous and exogenous electrophilic compounds by 
making the exogenous molecule more hydrophilic, which aids in its elimination 
(Enayati et al. 2005; Bartolini et al. 2015). Studies have shown GST abundance to be 
elevated during oxidative stress in the mammalian system (Board and Menon 2013). 
Evidence has also linked the GST isozymes to anti-cancer drug resistance (Townsend 
and Tew 2003). The action of copper N-(2-hydroxy acetophenone) glycinate has shown 
promise in overcoming doxorubicin generated GST and MDR (Majumder et al. 2006). 
KEGG analysis of the metabolism of xenobiotics by cytochrome P450 (Fig. 5.13) 
highlighted the involvement of GST in detoxification of benzo-[a]-pyrene and 
napthalene both of which contain polycyclic aromatic rings which are present in the 
phenazine ligand in Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3). The upregulation of 
GST is also involved in the detoxification of cyclophosphamide and ifosfamide which 
are key therapeutic alkylating agents. Cu-Phen (1), Cu-DPQ-Phen (2) and Cu-DPPZ-
Phen (3) have previously been shown to have nuclease cleaving ability (Molphy et al. 
2014), and potentially interact with DNA through intercalation properties at the minor 
groove as seen with the ruthenium complex Λ-[Ru(phen)2dppz]2+ (Niyazi et al. 2012). 
 
Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3) have previously been shown to generate 
excellent SOD mimetic activity with a progressive Fenton reaction matching the 
cadence of the chemical nuclease capacity against pUC19 DNA (Molphy et al. 2014). 
Mitochondrial aldehyde dehydrogenase and mitochondrial superoxide dismutase have 
been shown to be closely associated with oxidative stress (McCord and Fridovich 1988; 
269 
 
Daiber 2004). The upregulation of activity of these proteins in both the Cu-DPQ-Phen 
(2) and Cu-DPPZ-Phen (3) treated larvae may be associated with increased oxidative 
stress. Aldehyde dehydrogenase in mammalian cells has been associated with tolerance 
to increased organic nitrates (Chen et al. 2002), which are known to produce oxidative 
stress. The upregulation of both aldehyde dehydrogenase and superoxide dismutase in 
the Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3) treated larvae rather than just the 
upregulation of aldehyde dehydrogenase in the Cu-Phen (1) may indicate that oxidative 
stress plays a stronger mechanistic role in the secondary phenazine ligands despite the 
lower LD50 value. Isocitrate dehydrogenase is only upregulated in Cu-Phen (1) exposure 
while malate dehydrogenase is only upregulated in Cu-DPQ-Phen (2) and Cu-DPPZ-
Phen (3) treated larvae. These dehydrogenase are closely linked to the TCA cycle and 
have an effect on NAD+/ NADH ratio, which has been the subject of renewed interest 
due to its capacity to alter/ ameliorate effects on aging and other complex disease 
phenotypes (Yang and Sauve 2016). An additional dehydrogenase present at increased 
levels of abundance in all exposures is 15-hydroxylprostaglandin 
dehydrogenase[NAD(+)] which has been shown to suppress eicosanoids such as 
prostaglandins and liposin, previously demonstrated to have anticancer properties 
(Tuncer and Banerjee 2015). 
 
KEGG analysis of glycolysis/ gluconeogenesis (Fig. 5.14) indicated upregulation of 
fructose bisphosphate, triose phosphate isomerase, glyceraldehydes-3-phosphate 
dehydrogenase and phosphopyruvate hydratase (enolase) after exposure to all 
complexes.   Previous studies have shown enolase to become up regulated in response 
to cellular stress (Ji et al. 2016). Based on the study conducted by Molphy et al. (2014), 
Cu(II) phenanthroline-phenazine complexes showed chemical nuclease activity in 
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pUC19 plasmid DNA. Chemical nuclease action on larval DNA may have contributed 
to cellular stress and related alterations in carbohydrate metabolism. Other proteins 
highlighted during this analysis were fructose-bisphosphate aldolase, triose-phosphate 
isomerase, glyceraldehyde-3-phosphate dehydrogenase. Glyceraldehyde-3-phosphate 
dehydrogenase is involved in the conversion of glyceraldehydes-3-phosphate to D-
glycerate. The non-enzymatic elimination of phosphate groups from glyceraldehyde-3-
phosphate can lead to the production of the cytotoxic methylglyoxal which is known to 
be a progenitor of advanced glycation end-products (Allaman et al. 2015). 
 
Purine metabolism from KEGG analysis (Fig. 5.15) indicated increased abundance of 
regulatory enzymes SAICAR, AICAR and other purine support enzymes. Changes in 
purine metabolism as a result of cellular stress states have promoted increased interest 
recently as a potential therapeutic target for new drug development (Chitrakar et al. 
2017). Among some of the new studies is evidence for the formation of a dynamic 
multi-enzyme complex (purinosome) proximal to the mitochondria and microtubules 
(Pedley and Benkovic 2017). The formation of this multimeric protein complex has 
been associated with the depletion of purines and the upregulation of heat shock 90 
protein (HSP90) which aids in higher order protein structure (Chitrakar et al. 2017). 
Based on the KEGG analysis, HSP90 was observed at higher levels of abundance in 
larvae treated with all test complexes highlighting the potential involvement of the 
newly described purinosome in the mechanistic response to nuclease active drugs due to 
accelerated DNA breakdown from the cleavage activity of the metal complexes.  
 
The GO analysis performed at level 4 ontology showed that for each of the grouped 
biological processes the percentage of proteins involved was largely unchanged between 
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the complex series when the total number of proteins was taken into account. The 
number of proteins in the following groups was markedly elevated: cellular nitrogen 
compound metabolic process, organonitrogen compound metabolic process, 
heterocyclic metabolic process, organic cyclic compound metabolic process, organic 
substance biosynthetic process and small molecule metabolic process associated 
proteins. The increased abundance of proteins associated with the complex series and in 
particular, Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3) are accompanied by a broad 
upregulation in detoxification and degradation pathways. The increased abundance of 
nitrogen containing, heterocyclic and small molecule related metabolism most likely 
reflects the cellular detoxification response to the complexes which peaks upon 
administration with Cu-DPQ-Phen (2) and Cu-DPPZ-Phen (3). The GO analysis of 
molecular function at level 4 ontology showed an elevated group of proteins indicative 
of DNA binding by all the test complexes; nucleotide binding and nucleoside phosphate 
binding. The upregulated activity of these groups of proteins may reflect an increased 
association with DNA damage and potential repair complexes. Radical hydroxyl attack 
is believed to be an effect of these complexes owing to their previously established 
Fenton chemistry (Molphy et al. 2014). The groups of protein associated with co-
enzyme binding and oxidoreductase action on CH-OH were associated only with Cu-
Phen (1) and with none of the other test complexes. Oxidoreductase and co-enzyme 
binding may be associated with the energy status of the organisms, with specific regard 
to the mitochondria where electron transfer plays a critical role in the homeostasis of 







Since the immune system of G. mellonella bears structural and functional similarities to 
the innate immune system of mammals, these larvae provide a vital pre-mammalian in-
vivo screening method in which to evaluate system wide changes in response to metallo-
drugs (Kellett et al. 2011b; McCann et al. 2012; Browne et al. 2014). For that reason, 
these insects were employed in this study to establish the in-vivo toxicity, immune 
related gene expression and proteomic effects induced by the novel Cu(II) 
phenanthroline-phenazine complex series without the necessity of mammalian testing. 
The immunogenicity of a therapeutic lead is an important consideration in the future 
development process. This model provides a basic analysis of the innate and humoral 
response and informs development and testing at the mammalian in-vivo level. 
 
This investigation showed that the extension of the phenazine π-backbone within the 
complex scaffold resulted in a decrease in both mortality and immune response in the 
larval model with the trend following Cu-Phen < Cu-DPQ-Phen < Cu-DPPZ-Phen. 
Interestingly, this trend in reactivity is in contrast to previous studies performed where 
enhanced nuclease activity, DNA binding and thermal melting stability were governed 
by the extended phenazine π-framework (Devereux et al. 2005; Slator et al. 2016). 
 
The label free quantitation (LFQ) mass spectrometry method produced a high resolution 
assessment of the proteomic changes occurring in the larvae in response to test 
complexes allowing for gene ontology (GO) analysis of both biological and molecular 
functions to be performed. The results indicated a prominent metabolic and 
detoxification response which may provide an opportunity to develop drug targeting to 
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this region but also to utilise the larval model to evaluate future therapeutic and 
targeting improvements. 
 
Overall, the analysis of these changes provides an additional evaluative tool for the 
synthetic process in medicinal inorganic chemistry. The results presented here highlight 
the detoxification, stress induction and metabolic proteins which have characterised the 
larval response to the complex series and provide a valuable insight into their likely 














































The development of metal-based drugs as alternative cancer therapeutics to cisplatin is a 
promising area of pharmaceutical development. The success of the platinum based drug 
cisplatin proved to be one of the major breakthroughs in chemotherapeutic treatment 
with therapeutic activity across a large range of solid tumours, significantly improving 
patient survival rates over recent decades. However, the many associated side effects, 
toxicities and cellular drug resistance have limited the long-term use in cancer patients. 
This limitation has accelerated the development of alternative metal-based drugs 
utilising different transition metals and ligands with the goal of meeting or exceeding 
the therapeutic activity of cisplatin, reducing or eliminating the adverse side-effects and 
removing the possibility of drug resistance, common to platinum therapies. The novel 
copper(II) phenanthroline scaffolds utilising phenazine π-backbone extensions has 
permitted customizable DNA intercalation capability along with the potent nuclease 
activity of copper(II) phenanthroline making them a strong therapeutic candidate. 
However, the biological modes of action of these drugs were unknown and therefore 
this study explored these mechanisms underlying their potential therapeutic response in 
cancer cells. 
 
The research used a range of in-vitro mammalian cells lines representing tumourigenic 
tissues; members of the NCI-60 therapeutic developmental panel and platinum resistant 
cell lines established the therapeutic cytotoxic values over both 24- and 48- h. The use 
of cisplatin sensitive and resistant cell lines allowed for the identification of activity of 
the Cu(II) phenanthroline-phenazine complexes that far exceeded cisplatin in specific 
cisplatin resistant SKOV-3, and A2780/ Cis cell lines. The activity profile of the Cu(II) 
phenanthroline-phenazine complexes across the range of cell lines demonstrated strong 
activity in the Cu-Phen (1) and Cu-DPQ-Phen (2) complexes. Figure 6.1 provides a 
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summary of the biological effect of the Cu(II) phenanthroline-phenazine complexes in 
both cisplatin sensitive and resistant cell lines. The Cu(II) complexes demonstrate a 
greater capacity to initiate DNA DSB formation, MoMP decay, mitochondrial related 
proteases transcription, mitochondrial fission/ fusion processes, increased apoptosis and 
increased expression of metabolic related proteins. Interestingly the DNA DSB marker 
γH2AX demonstrated higher levels of DSB formation in the cisplatin resistant, SKOV-3 
(Fig. 6.1). This coupled with the increased activity of apoptosis in the resistant cell lines 
compared to the sensitive cell lines after exposure to the Cu(II) phenanthroline-
phenazine complexes demonstrated that an alternative mechanism of action to the 
clinical drug control, cisplatin was responsible for their cytotoxic activity with the 
mitochondrial being a vital component of the intrinsic apoptotic process. The work 
described in Chapter 5 demonstrated that increased MoMP decay was generally 
observed in the resistant cell lines and was coupled with increased activity of 
mitochondrial protease (CLPP, LON, SPG7 and YME1L1) and fission/fusion (DRP1, 
MFN1, MFN2 and OPA1) regulators (Fig. 6.1). The loss of the mitochondrial outer 
membrane potential is strongly associated with mitochondrial toxicity and the activation 
of the intrinsic apoptotic pathway. The upregulation of mitochondrial proteases (CLPP, 
LON, SPG7 and YME1L1) and fission/fusion (DRP1, MFN1, MFN2 and OPA1) 
regulators may indicate that the Cu(II) phenanthroline-phenazine complexes have a role 
in disrupting mitochondrial protein homeostasis through oxidative damage which 
resulted in cellular apoptosis. The work described in Chapter 3 characterised the 
resultant proteome from the exposure of the Cu(II) phenanthroline-phenazine 
complexes to both a cisplatin sensitive and resistant cell lines. Both sensitive and 
resistant cell lines induced common increases in metal sequestration (Metallothionein-2, 
-1X), heat shock (HSP70) and ribosomal (40S) proteins however metabolic proteins 
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(glycolysis/ gluconeogenesis, fatty acid synthesis, purine metabolism) tended to 
dominate the repertoire of the resistant cells, potentially indicating the response of the 
cell to its energy status brought about by exposure to the Cu(II) phenanthroline-
phenazine complexes (Fig. 6.1). The work described in Chapter 4 used the in-vivo 
Lepidoptera model, G. mellonella to examine the activity of Cu-Phen (1), Cu-DPQ-Pen 
(2) and Cu-DPPZ-Phen (3). Importantly the copper complexes demonstrated higher 
toxicity in the larvae than cisplatin, which correlated with the results from the 
mammalian cell lines. The proteomics study demonstrated that metabolic (glycolysis/ 
gluconeogenesis and purine metabolism) and detoxification proteins (GST) were 
prominently expressed in the larvae exposed to the novel complex but in contrast to the 
in-vitro mammalian cells lines the toxicity did not increase with extension of the 
phenazine π-backbone within the complex scaffold. While this situation is contrasted to 
the profile of the mammalian cells, the common increase in metabolic proteins between 
both tests models and the addition of detoxification proteins in the in-vivo model may 
indicate that the Cu(II) phenanthroline-phenazine complexes strong DNA binding 
capabilities is not completely responsible for their mechanism of action.  
 
In conclusion, this project has demonstrated that Cu(II) phenanthroline-phenazine 
complexes are a promising therapeutic candidate with a complex mechanism of action 
that is highly effective against cisplatin resistant cells. Figure 6.2 gives an overview of 
the similar results across both biological models. Using both in-vitro mammalian cells 
and in-vivo G. mellonella models the mechanism of action of these complex has shown 
to be characterised by mitochondrial toxicity and subsequent activation of apoptosis and 
in the in-vivo model to be dominated by metabolic enzymes and detoxification 
processes which may be associated with mitochondrial action (Fig. 6.2). This thesis has 
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demonstrated for the first time the molecular mode of action of novel Cu(II) 
phenanthroline-phenazine complexes in both in-vitro and in-vivo biological models. 
Furthermore, the strong activity and mechanistic profile of this series of Cu(II) 
complexes against cisplatin resistant cells offers a potentially novel therapeutic avenue 
for treating cisplatin refractory cancers. The use of both cisplatin sensitive and resistant 
cell lines has evidently revealed different mechanistic pathways; however both 






Fig. 6.1 Summary of the biological effects of the Cu(II) phenanthroline-phenazine complexes in both cisplatin sensitive (MCF-7 and 











































The work described in the preceeding Chapters demonstrated the activity of Cu(II) 
phenanthroline-phenazine complexes in in-vitro mammalian models and the in-vivo 
model, Galleria mellonella. These results established the high degree of therapeutic 
activity in cisplatin resistant cells and strong DNA damage activity, which had been 
previously observed by Molphy et al. (2014) and (2015). Gene expression and 
proteomic analysis indicated that apoptosis and metabolic proteins played a prominent 
role in the mechanism of action. Further gene expression work established that 
mitochondrial proteases may play a role in the mitochondrial toxicity present after 
exposure to the complexes. The G. mellonella model indicated that metabolic process 
may have played a strong role in the mechanism of action at an in-vivo level. 
 
The future work of this project would include a more in-depth investigation of the 
mechanistic in-vitro analysis using PC-3 and A2780 cells. A major component of this is 
to confirm the type of apoptosis occurring (intrinsic or extrinsic). Using 
immundetection and flow cytometry methodologies, Annexin V (Annexin V-FITC 
Apoptosis Detection Kit) (Sigma, Ireland), Caspase 3 and 7 (intrinsic) (Vybrant FAM 
Caspase-3 and -7 Assay Kit), Caspase 8 (extrinsic) (Vybrant FAM Caspase-3 and -7 
Assay Kit) (Thermo, Ireland) and the mitochondrial marker, cytochrome c (Anti-
Cytochrome C antibody [37BA11]) (Abcam, USA) would be used to establish the 
nature of the apoptotic process. The proteomics work and identification of 
metallothioneins, heat-shock proteins and metabolic proteins would be validated using 
qPCR methods and western blotting to confirm gene expression and protein abundance 
changes. The data generated in this project demonstrated that the mitochondria may 
play a strong role in the mechanism of action. Based on the mitochondrial involvement, 
the Agilent Seahorse platform would be utilised to examine; basal respiration, ATP 
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production and maximal respiration using oligomycin, Carbonyl cyanide-p-
(trifluoromethoxy)phenylhydrazone (FCCP), antimycin A and Rotenone to examine the 
respiratory complexes during exposure to the Cu(II) complexes. Gene expression of 
mitochondrial proteases (LON, CLPP, SPG7, YME1L1) and fission regulator, DRP1 
demonstrated involvement in the response to the Cu(II) complexes. Western blotting 
and additional qPCR analysis would be used to provide additional information on their 
contribution to the mechanism of action. At present, the clear mechanism of action of 
the Cu(II) complexes centres on two process. The first is oxidative mediated DNA 
lesion formation (8-oxo-dG) from DNA intercalation of phenazine π-backbone extended 
complexes and the subsequent DSB formation and activation of p53 mediated 
apoptosis. The second is the generalised disruption of protein function, particularly the 
respiratory complex, which has consequences in cellular energy production. 
Mitochondrial proteases may also play a role in the eventual disruption of mitochondrial 
function resulting in the initiation of intrinsic apoptosis through the release of the 
mitochondrial permeability transition pore protein. 
 
The Cu(II) complexes have demonstrated excellent in-vitro activity in cisplatin resistant 
cell lines and proteomic studies in the in-vivo G. mellonella model has provided useful 
pre-mammalian in-vivo data to support use of in-vivo murine models. A high degree of 
activity was demonstrated after exposure to the Cu(II) complexes in the PC-3 and 
A2780 (A2780/ Cis) cell lines compared to cisplatin treatments. Based on these finding, 
in-vivo murine models utilising xenograft tumour models of PC-3 (prostate), A2780 or 
SKOV-3 (ovarian) in genetically modified hosts (murine) (Nude, SCID, NOD-SCID) 
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Appendix I: Reagents, solution constituents and experimental templates 
1.1 Cell Culture and MTT cytotoxicity assay 
1.1.1 Cell Culture Media: 
Roswell Park Memorial Institute (RPMI-1640) (Sigma, Ireland) (Cat# R8758) 500 ml 
solution supplemented with: 
 60 ml Foetal Bovine Serum (Cat# F2442) (Sigma, Ireland) 
 5 ml L-Glutamine (Cat# G7513) (Sigma, Ireland) 
 
1.1.2 Versene / EDTA (0.02 %) and trypsin solution 
 0.1 g of EDTA added to PBS (500 ml) and autoclaved prior to use. 
Trypsin 2.5 % v/v (100 ml) (Thermo, Ireland) (Cat# 15090046) added to Hank’s 
Balanced salt solution (HBSS) (Sigma, Ireland) (Cat# 9394) (1L). Solution aliquoted 
into 10ml and frozen to -20 °C until required. Upon thawing 10 ml aliquot combined 
with 10 ml Versene solution prior to application to cell culture.  
 
1.1.3 Freeze down procedure 
After each experiment was finished the cells were frozen down. This was performed to 
preserve the cells and protect them from genetic drift. The act of freezing cells down 
also limits the consumable necessary for the continuous culturing. They are preserved in 
the cryoprotectant DMSO (Sigma, Ireland) (cat# 276855) in cell culture media which 
was filtered prior to use with the cells. The initial procedure is performed at 4 °C with a 
stepwise decrease in temperature down to liquid nitrogen storage. This stepwise process 











Stock volume (ml) 
Cu-Phen (1) 547.97 9.12 2 
Cu-DPQ-Phen (2) 609.01 8.21 2 
Cu-DPPZ-Phen (3) 650.06 7.69 2 
Cu-DPPN-Phen (4) 736.15 6.79 2 
DMSO used as stock solvent. Solution stored in air tight sterile glass container. 
 
1.1.5 Cisplatin (Sigma, Ireland) (cis-Diamineplatinum(II) dichloride, CAS: 15663-27-1) 
(Cat# P4394) 
- Reconstituted to a stock concentration of 16.6 mM in DMSO wherein a working 
stock of 200 µM in RPMI-1640 cell culture media is generated. 
 
1.1.6 Doxorubicin (Sigma, Ireland) (Doxorubicin hydrochloride, CAS: 25316-40-9) 
(Cat# D2975000) 
- Reconstituted in 1 ml water (1 mM) and diluted to a stock of 20 µM in RPMI-1640 
cell culture media. 
 
1.1.7 Working solution make-up (Cu(II) phenanthroline-phenazine complexes) 
Make-up of working solutions of the Cu(II) phenanthroline-phenazine complexes for 










Volume (µM) from working stock made up in 5 ml cell culture 
media. Volume represented in µl 
































1.1.8 96-well plate set-up template 
96-well plate template for the Cu(II) phenanthroline-phenazine complexes exposure for 
MTT cytotoxicity test. “Neg” refers to the negative control (no exposure). 
Concentration range of the test Cu(II) complexes 0.25-10 μM replicated down multiple 
rows. 










C Neg 0.25 0.5 1 2.5 5 10 Neg Neg Neg 
D Neg 0.25 0.5 1 2.5 5 10 Neg Neg Neg 
E Neg 0.25 0.5 1 2.5 5 10 Neg Neg Neg 
F Neg 0.25 0.5 1 2.5 5 10 Neg Neg Neg 
G Neg 0.25 0.5 1 2.5 5 10 Neg Neg Neg 
H Blank 
 
1.1.9 Working solution make-up (cisplatin) 
Make-up of working solutions of cisplatin for the MCF-7, OE-33, SKOV-3, HeLa, HT-






(200 µM) (20 
ml) 
Volume (µM) from working stock made up in 5 ml cell culture 
media. Volume represented in µl 




240.96 µl 5000 µl 2500 µl 1250µl 250 µl 125 µl 25 µl 12.5 µl 
 
1.1.10 96-well plate set-up template 
96-well plate template for cisplatin exposure for MTT cytotoxicity test. “Neg” refers to 
the negative control (no exposure). Concentration range of cisplatin 0.5-200 μM 
replicated down multiple rows. 










C Neg 0.5 1 5 10 50 100 200 Neg Neg 
D Neg 0.5 1 5 10 50 100 200 Neg Neg 
E Neg 0.5 1 5 10 50 100 200 Neg Neg 
F Neg 0.5 1 5 10 50 100 200 Neg Neg 













1.1.11 Working solution make-up 
Make-up of Cu(II) phenanthroline-phenazine complexes and doxorubicin working 













Volume (µM) from working stock made up in 5 ml cell culture 
































































































1.1.12 Working solution make-up (cisplatin) 







(200 µM) (20 
ml) 
Volume (µM) from working stock made up in 5 ml cell culture 
media. Volume represented in µl 
























1.1.13 96-well plate set-up template 
96-well plate template for the Cu(II) phenanthroline-phenazine complexes exposure for 
MTT cytotoxicity test. “Neg” refers to the negative control (no exposure). 
Concentration range of the test Cu(II) complexes 0.156-10 μM replicated down multiple 
rows. 










C Neg 0.156 0.312 0.625 1.25 2.5 5 10 Neg Neg 
D Neg 0.156 0.312 0.625 1.25 2.5 5 10 Neg Neg 
E Neg 0.156 0.312 0.625 1.25 2.5 5 10 Neg Neg 
F Neg 0.156 0.312 0.625 1.25 2.5 5 10 Neg Neg 
G Neg 0.156 0.312 0.625 1.25 2.5 5 10 Neg Neg 
H Blank 
 
1.1.14 96-well plate set-up template 
96-well plate template for cisplatin exposure for the MTT cytotoxicity test. “Neg” refers 
to the negative control (no exposure). Concentration range of cisplatin 3.125-200 μM 
replicated down multiple rows. 










C Neg 3.125 6.25 12.5 25 50 100 200 Neg Neg 
D Neg 3.125 6.25 12.5 25 50 100 200 Neg Neg 
E Neg 3.125 6.25 12.5 25 50 100 200 Neg Neg 
F Neg 3.125 6.25 12.5 25 50 100 200 Neg Neg 
G Neg 3.125 6.25 12.5 25 50 100 200 Neg Neg 
H Blank 
 
1.1.15 96-well plate set-up template 
96-well plate template for doxorubicin exposure for the MTT cytotoxicity test. “Neg” 
refers to the negative control (no exposure). Concentration range 0.312-20 μM 
replicated down multiple rows. 










C Neg 0.312 0.625 1.25 2.5 5 10 20 Neg Neg 
D Neg 0.312 0.625 1.25 2.5 5 10 20 Neg Neg 
E Neg 0.312 0.625 1.25 2.5 5 10 20 Neg Neg 
F Neg 0.312 0.625 1.25 2.5 5 10 20 Neg Neg 
G Neg 0.312 0.625 1.25 2.5 5 10 20 Neg Neg 
H Blank 
 
1.1.16 MTT (Sigma, Ireland) (Cat# M5655) working solution (5 µg per 1 ml PBS) (100 
µl per well): 
 For 56 wells (one 96-well plate with 56 inoculated wells) 
 28 µg of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (CAS 
298-93-1) (Sigma, Ireland) in 5.6 ml PBS (Sigma, Ireland) (Cat# 806544) 
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 1:10 dilution of PBS solution with cell culture media for working MTT solution. 
 
1.1.17 Working protocol for MTT viability assay 
1. Cells were inoculated onto 24- and 48- h plates as described above. 
2. Cells were incubated as per usual conditions for 24 h to allow them to attach to 
the bottom of each well.  
3. Individual universal were made up of the specific copper complexes 
concentrations along with cisplatin concentrations.  
4. After the 24 h attachment and growth period the media is removed from the 
wells and 100 μl of the prepared copper complexes or cisplatin are added to the 
relevant wells. The plates were then incubated for 24 or 48 h. 
5.  Prior to the 24 or 48 h timepoint completion a suitable volume of working MTT 
solution is made up at a concentration of 5 mg/ml in PBS (Sigma, Ireland) (Cat# 
806544). The working solution is then sterilised by being passed through a 0.2 
μm nalgene filter (Thermo, Ireland) (Cat# 724-2020). 
6. At the 24- or 48-hour timepoint the cell culture media/ compound solution is 
carefully removed from the wells. 100 μl of the MTT working solution is then 
added to each well and the plate is incubated for 3 h.  
7. After the 3-hour incubation the MTT working solution is removed and each well 
is washed with sterile PBS (Sigma, Ireland) (Cat# 806544) solution 3 times. At 
the end of the last wash the residual liquid is carefully removed by tilting the 
plate and using the pipette from the corner of the cell taking care not to disturb 
the cells.  
8. 100 μl of DMSO is added to each well and the plate is placed on a plate shaker 
for 15 min. 
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9. The absorbance of the cells is read on spectrophotometer/ multiplate reader at 
595 nm wavelength to record viability. 
 
1.2 H2DCFDA assay (ROS assay) 

















































































































































































Cu(II) phenanthroline-phenazine complexes and cisplatin made up to 20 µM in supplemented RPMI-1640 
cell culture media and double diluted in plate as above.  
 
1.3 γH2AX staining protocol constituents: 
1.3.1 Fixing solution: 
2 % v/v paraformaldehyde (Sigma, Ireland) (Cat# F8775) in PBS 
 
1.3.2 Triton X-100 solution (0.25%): 
 2.5 µl of Triton X-100 (Sigma, Ireland) (Cat# T8787) 
 9997.5 µl of PBS. 
 
1.3.3 Blocking Solution: 
2 % Bovine Serum Albumin (w/v) (Sigma, Ireland) (Cat# A9418) in PBS 
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1.3.4 Primary antibody (Milipore, Ireland) (Anti-phospho-Histone H2A.X (Ser 139), 
clone JBW301) (Cat. # 05-636) (Lot # 2068177)): 
1:500 dilution made up in blocking solution 
 
1.3.5 Secondary antibody (Milipore, Ireland) (goat anti-mouse IgG Antibody, Alexa 
fluor 488 FITC conjugate)): 
1:200 dilution made up in blocking solution  
 
1.3.6 Counterstaining solution (1:1000): 
 1 µl of Propidium Iodide solution (1µg/ µl) (Sigma, Ireland) (Cat# P4864) 
 1000 µl of PBS 
 
1.3.7 Zeiss LSM510 Meta scanning and recording parameters: 
Images recorded at a resolution of 2048x2048 and sampled at 12-bit: 
 Green; pin hole 76, gain 573, amplifier offset -0.226, amplifier gain 1.01 
 Red; pin hole 80, gain 589, Amplifier offset 0.1, amplifier gain 2.81 
 Brightfield recorded 
 
1.4 Gene expression analysis of molecular targets: 
1.4.1 cDNA synthesis kit constituents (20 µl per reaction) (Quanta Biosciences, USA) 
(Cat# 733-1173) 
 1 µl qScript Reverse Transcriptase 
 4 µl qScript Reaction Mix 
 10 µl Nuclear-free water 
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Final 5 µl is sample RNA. All samples should have the same concentration of RNA 
before cDNA synthesis. 
 
1.5 Label-free quantitative whole cell proteomic analysis: 
1.5.1 Constituent solutions for the In-solution digestion protocol using ProteaseMax™  
 Cell lysis buffer: 6 M Urea, 2 M Thiourea, 0.1 M Tris-HCl (pH 8.0) (Cat# U5378, 
Cat# T8656, Cat# T3038): Prepare using MilliQ water. Aprotinin (10 mg/mL) 
(Cat# A6106), Leupeptin (Cat# L5793), Pepstatin (Cat# P5318) and TLCK (Cat# 
T7254) were added to the cell lysis buffer (10 µl of each protease inhibitor per 
1ml of cell lysis buffer). 
 50 mM ammonium bicarbonate (Sigma, Ireland) (Cat# 09830): Prepare fresh 
before use in MilliQ water 
 0.5 M DTT (Sigma, Ireland) (Cat# D0632): Prepare fresh before use in 50 mM 
ammonium bicarbonate (38.56 mg in 500 µl) 
 0.55 M IAA (Sigma, Ireland) (Cat# I4386): Prepare fresh before use in 50 mM 
ammonium bicarbonate and protect from light (101.728 mg in 1 ml) 
 ProteaseMAX stock (1 % (w/v)) (Promega, USA)  (Cat# V2071): Resuspend 1 
mg in 100 µl of 50 mM ammonium bicarbonate immediately before use and keep 
on ice prior to use. For storage, snap freeze 20 µl aliquots in liquid nitrogen and 
store at -20 °C.  
 Trypsin (0.5 µg/µl) (Promega, USA) (Cat# V5111): Resuspend sequencing grade 
trypsin vial (20 µg; V5111 Promega) with 40 µl of trypsin resuspension buffer. 
Keep on ice until ready for use. Snap-freeze any remaining trypsin and store at -




1.5.2 Bradford assay 
Bovine Serum Albumin standards (5-60 µg/ml) (Bio-Rad Munich, Germany) (Cat# G-
250), were made in 800 µl deionised water and 200 µl Biorad Bradford protein assay 
reagent (Bio-Rad Munich, Germany) (Cat# G-250)  and read on a spectrophotometer at 
595 nm (Eppendorf Biophotometer). A standard curve was prepared. Bradford protein 
assay reagent was prepared by diluting the stock 1:5 using deionised water. Protein 
samples were added (20 µl) to 980 µl of Bradford protein assay reagent. The samples 
were inverted, allowed to stand for 5 min and read spectrophotometrically. 
 
1.5.3 In-solution digestion working protocol using ProteaseMax™ 
1. Removed 60 µg of sample from lysate and perform an acetone, TCA/acetone 
(Sigma, Ireland) (Cat# T6399)/ (Cat# V800023) precipitation or 2D Clean up. 
2. Re-suspend samples (25 µl; 60 µg) in cell lysis buffer. Note try to keep volume 
at 15 µl even if conc. is lower than 60 µg. The pellet may take time to re-
suspend. Assist with vortex or pipetting. 
3. Ammonium bicarbonate (125 µl; 50 mM) (Sigma, Ireland) (Cat# 09830) was 
added to the samples. 
4. DTT (1 µl) (Sigma, Ireland) (Cat# D0632) was added to the samples, followed 
by incubation at 56 °C for 20 min. 
5. Samples were allowed to cool to room temperature and 2.7 µl of IAA (Sigma, 
Ireland) (Cat# I4386) was added, followed by incubation at room temperature 
for 15 min in the dark. 
6. Following reduction and alkylation 1 µl of ProteaseMAX stock and 1 µl (1 % 
(w/v)) (Promega, USA) (Cat# V2071) of trypsin were added to each of the 
samples, followed by incubation at 37 °C overnight.  
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7. The next day samples were spun briefly to collect any condensate and acidified 
by adding 1 µl of TFA (Sigma, Ireland) (Cat# 8.08260), vortexed briefly, and 
incubated at room temperature for 5 min (Some cloudiness can be visible at this 
point). 
8. Samples were centrifuged at 13,000 g for 10 min at room temperature. The 
supernatant was removed to a new tube.  
 Each sample was divided into 2 aliquots (the removal of 77.5 µl should 
yield c.30 µg). One aliquot for C18 clean up and the remaining aliquot was 
stored at -20 °C. 
 
1.5.4 C18 spin-column buffer constituents: 
Sample Buffer 1 (Urea/Protease Max procedure):  
 2 % TFA (Sigma, Ireland) (Cat# 8.08260) in 20 % Acetonitrile (ACN) 
(Sigma, Ireland) (Cat# 271004); Need 1 µl for every 3 µl of sample 
 200 µl ACN, 20 µl TFA and 780 µl ddH2O 
Activation Solution: 50% ACN, 50% ddH2O (2.5 ml ACN and 2.5 ml ddH2O) 
Equilibration Buffer: 0.5 % TFA in 5 % Acetonitrile; Need 400 µl per sample 
 4.725 ml ddH2O, 25 µl TFA and 250 µl Acetonitrile 
Wash Buffer: same as equilibration buffer; Need 600 µl per sample 
Elution Buffer: 70 % Acetonitrile; Need 60 µl per sample 
 700 µl ACN, 300 µl ddH2O 
Loading Buffer for Q Exactive: 0.05 % TFA in 2 % Acetonitrile (obtain from 
LCMS room); Need 20 µl per sample 




1.5.5 C18 spin-column (Thermo, USA) (Cat# 89870) working protocol: 
1. Columns were tapped to settle the resin and the caps were removed from either 
end. Columns were placed in 1.5 ml Eppendorfs. 
2. Urea/Protease Max Procedure: Samples were mixed with Sample Buffer 1 (3 
parts sample: 1 part Sample Buffer 1; e.g. 50 µl Sample + 18 μl Sample Buffer 1) 
to obtain a final 0.5 % TFA in 5 % acetonitrile. 
2. Activation Solution (200 µl) was added to the columns to rinse the walls of the 
column and wet the resin. Columns were centrifuged at 1500 g for 1 min and 
flow-through was discarded. Step was repeated. 
3. Equilibration Solution (200 µl) was added to the columns, centrifuged at 1500 g 
for 1 min and flow-through was discarded. Step was repeated. 
4. Samples (10-150 µl; up to 30 µg) were loaded to the top of the resin bed and the 
columns were placed in new receiver tubes. Samples were centrifuged at 1500 g 
for 1 min, the flow-through was recovered and re-applied to the column. This 
step was repeated twice more to ensure complete sample binding.  
5. Columns were transferred into new receiver tubes and 200 µl of Wash Buffer 
was added. The columns were centrifuged at 1500 g for 1 min and the flow-
through was discarded. This step was repeated twice more to remove high levels 
of contaminants. 
6. The columns were placed in new receiver tubes and 25 µl of Elution Buffer was 
applied to the top of the resin bed. The columns were centrifuged at 1500 g for 1 
min. This step was repeated twice more using the same receiver tube to collect a 
total ~75 µl of eluant.  




8. Samples were re-suspend in 32 µl of Loading Buffer for Q Exactive (2 % 
acetonitrile, 0.05 % TFA). Samples were placed in the sonication bath for 5 min 
to aid peptide re-suspension prior to MS/MS injection.  
9. Samples were centrifuged at 13,400 g for 5 min at room temperature to pellet any 
insoluble material, and the supernatants were transferred to vials for LC MS/MS 
analysis by the Q Exactive. 
 
1.5.6 MASCOT and SEQUEST search parameters: 
 Peptide mass tolerance at 20 ppm 
 Fragment mass tolerance at 0.02 Da 
 Up to 2 missed cleavages 
 Cysteine carboxymethylation set at static modification 
 Methionine oxidation at dynamic modification 
 MASCOT ion score at minimum of 40 
SEQUEST HT XCorr set at minimum 1.5 and FDR for PSMs and peptides set for strict 
at 0.01 and relaxed at 0.05 
1.6 Rhodamine 123 MMP assay 




















































































































































































1.7 Galleria mellonella study 
1.7.1 Make-up of working solutions for G. mellonella inoculation 
Dose (µg) (20 µl inoculation) Cisplatin inoculation make-up Cu(II) complex inoculation 
make-up 
Stock (5000 µg/ml H2O)   (1500 µg/ml H2O) 
100 (Cisplatin only) 1ml of stock + 0 ml H2O N.A 
30 N.A 1ml stock + 0 ml H2O 
20 N.A 0.666 ml stock + 0.334 ml H2O 
12 N.A 0.400 ml stock + 0.600 ml H2O 
10 0.1 ml stock + 0.9 ml H2O 0.333 ml stock + 0.666 ml H2O 
8 0.08 ml stock + 0.92 ml H2O 0.266 ml stock + 0.734 ml H2O 
6 0.06 ml stock + 0.94 ml H2O 0.200 ml stock + 0.600 ml H2O 
4 0.04 ml stock + 0.96 ml H2O 0.133 ml stock + 0.867 ml H2O 
2 0.02 ml stock + 0.98 ml H2O 0.066 ml stock + 0.934 ml H2O 
100 mg of cisplatin was weighed and dissolved in 1 ml DMSO. This was added to 19 ml H2O to make 
cisplatin stock. For Cu-Phen (1), Cu-DPQ-Phen (2), Cu-DPPZ-Phen (3) and Cu-DPPN-Phen (4) 15 mg 
was dissolved in 1 ml DMSO and then added to 9 ml H2O to make Cu-Phen (1), Cu-DPQ-Phen (2), Cu-
DPPZ-Phen (3) and Cu-DPPN-Phen (4) stock solutions. 
 
1.7.2 G. Mellonella 2D SDS-PAGE analysis of protein expression 
1-Dimension gel set-up and IEF buffer constituents 
The following constituents were added and dissolved in deionised water and stored in 2 
ml aliquots at -20 ºC until required. 
 Urea 8 M (Sigma, Ireland) (Cat# U5378) 
 Triton X-100 (BDH) 1 % (v/v) (Sigma, Ireland) (Cat# T8787) 
 CHAPS 4 % (w/v) (Sigma, Ireland) (Cat# C9426) 
 Tris-HCl 10 mM (Sigma, Ireland) (Cat# T3038) 








Prior to use DTT (65 mM) (Sigma, Ireland) (Cat# D0632) was added to the buffer and 
solubilised by vortexing. 
IEF rig program (EttanIPGphore II) 
 
1. 50 Volts, step and hold for 10 h 
2. 250 Volts, step and hold for 15 min 
3. 8000 Volts, gradient for 5 h 
4. 8000 Volts, step and hold for 8 h 
 
1.7.3 2-Dimension PAGE set-up 
Equilibration Buffer 
 Tris-base 50 mM (Sigma, Ireland) (Cat# TRIS-RO ROCHE) 
 Urea 6 M (Sigma, Ireland) (Cat# U5378) 
 SDS 2 % (w/v) (Sigma, Ireland) (Cat# 862010) 
 Glycerol 30 % (v/v) (Sigma, Ireland) (Cat# G5516) 
The solution was adjusted to pH 6.8 and aliquoted in 40 ml volumes prior to storage at -
20 ºC. For equilibration the buffer was modified as either reducing or alkylating. For 
reduction, DTT (0.01 g/ml) was added and dissolved thoroughly. For alkylation, IAA 
(0.025 g/ml) (Sigma, Ireland) (Cat# I4386) was dissolved thoroughly in the buffer. 
 
1.7.4 Separating gel composition 
 12.5 % Bis-Acrylamide solution (Sigma, Ireland) (Cat# A3574) 
 1.5 M Tris-HCl (pH 8.9) 3 ml (Sigma, Ireland) (Cat# T3038) 
 Deionised water 3.8 ml 
 30% Bis-Acrylamide 5 ml (Sigma, Ireland) (Cat# A2917) 
359 
 
 10% v/v SDS 120 μl (Sigma, Ireland) (Cat# 862010) 
 10% v/v APS 75 μl (Sigma, Ireland) (Cat# A3678) 
 TEMED 3 μl (Sigma, Ireland) (Cat# T9281) 
These volumes were sufficient to make 3 mini-gels and volumes were adjusted 
accordingly where a larger volume was required. 
 
1.7.5 5X Solubilisation Buffer for 1-D SDS–PAGE 
Solubilisation buffer was prepared by dissolving the following constituents to solubility. 
 Glycerol 8 ml (Sigma, Ireland) (Cat# G5516) 
 Deionised water 4 ml 
 10 % (w/v) SDS 1.6 ml (Sigma, Ireland) (Cat# 862010) 
 0.5 M Tris – HCl 1 ml (Sigma, Ireland) (Cat# T3038) 
 Bromophenol Blue (0.5 % w/v) 200 μl (Sigma, Ireland) (Cat# B8026) 
 2 – Mercaptoethanol 400 μl (Sigma, Ireland) (Cat# M6250) 
The buffer was gently mixed for 1 h at 4 ºC and aliquoted in 500 μl volumes prior to 
storage at -20 ºC. 
 
1.7.6 10 X electrode Running Buffer 
Running buffer (10 X), (electrode buffer), was prepared by adding; Tris Base 30 g/l, 
Glycine (Sigma, Ireland) 144 g/l and SDS 10 g/l dissolved using distilled water filled up 
to 1000 ml mark and the mixture was stirred until the solution was solubilised. 
Electrode running buffer (10 X) stock was diluted to 1 X concentration by making 1/10 





1.7.7 Coomassie Brilliant blue 
 0.25 % Coomassie blue (Sigma, Ireland) (Cat# B6529) 
 50 % MeOH (Sigma, Ireland) (Cat# 322415) 
 10 % HoAC (Sigma, Ireland) (Cat# A6283) 
 40 % H2O 
Leave gel in solution for 1 h followed by destaining for 1 h. Background will appear 
clear. 
 
1.7.8 Destaining solution 
 5 % MeOH (Sigma, Ireland) (Cat# 322415) 
 7.5 % HoAC (Sigma, Ireland) (Cat# A6283) 
 87.5 % H2O 
 
1.7.9 MASCOT program searching parameters 
MASCOT MS/MS Ions Search 
 Database – NCBInr/ Swissprot 
 Enzyme – Trypsin 
 Allow up to 2 missed cleavages 
 Quantitation – none 
 Taxonomy – Other Metazoa 
 Fixed Modifications – Carboxymethyl (C) 
 Variable Modifications – Oxidation (M) 
 Peptide tol. ± 2 Da  #13C=0 
 MS/MS tol. ± 1 Da 




 Data format – Mascot generic 
 Instrument – ESI-TRAP 
























Appendix II: Equipment 
2.1 Beckman COULTERTM Z1 coulter® particle counter (Beckman-Coulter, USA) 
2.2 1420 Multilabel Counter Victor3V spectrophotometer (PerkinElmer, USA) 
2.3 SpectraMax M3 Multi-Mode Microplate Reader (Molecular Devices, USA) 
2.4 MaestroNano™ spectrophotometer (Maestrogen, USA) 
2.5 Prime Thermal Cycler (Techne, UK) 
2.6 7500 fast Real-Time PCR System (Applied Biosystems, USA) 
2.7 Accuri C6 Plus (Beckman-Dickenson Bioscience, USA) 
2.7 LSM510 Meta (Zeiss, Germany) 
2.8 Q Exactive™ Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo Fisher 
Scientific, USA) 
2.9 SpeedyVac (Thermo Fisher Scientific, USA) 
2.10 EttanIPGphore II (Amersham Biosciences, USA) 














Appendix III: Raw data 
The following data refers to the MTT viability assay with raw data from the 
spectrophotometer normalized to the negative control. Each table represents normalized 
percentage values averaged from 3 independent assays.  





























































































































































































100 94.75555 94.4948 93.89969 92.81869 76.9958 18.25622 
 




















































































































































































































































































































































































































































































































































































































































































































































































100 100.6671 100.2722 95.48418 72.27852 55.0193 11.54096 
 



























































































































































































































































































































































































































94.99154 81.46438 71.01594 77.22821 57.29152 10.60494 
 











































































































































































































93.32276 71.41645 65.8557 56.5206 8.22556 6.627475 
 











































































































































































































89.5575 82.17032 80.64837 74.00164 61.26983 23.44599 
 











































































































































































































96.03157 85.36413 78.55079 56.22409 21.87502 6.311856 
 











































































































































































































97.33768 97.47567 90.70269 62.01643 37.59161 25.61939 
 











































































































































































































88.77194 78.41505 50.60406 23.34288 12.56878 12.50928 
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3.1.17 Dose-inhibition graphs 
 






































































































































































































































































































































































































































































































































































































3.2 ROS assay 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.3 γH2AX flow cytometry data 
3.3.1 MCF-7 24 MFI 
24 hour 1 2 3 minus unstained  average S.D 
unstained 279,596.
00 
   279,596
.00 








































































































3.3.2 MCF-7 48 MFI 















































































































3.3.3 MCF-7 24 % positive 
24 hour 1.00 2.00 3.00 minus unstained  average S.D 
unstained 0.02    0.02    
negative 7.14 2.49 1.16 7.12 2.47 1.14 1.81 0.94 
Cu-Phen 25.84 25.99 33.35 25.82 25.97 33.33 28.37 4.29 
Cu-DPQ-
Phen 
34.32 28.07 34.81 34.30 28.05 34.79 32.38 3.76 
Cu-DPPZ-
Phen 
6.48 31.83 27.61 6.46 31.81 27.59 29.70 2.98 
Cu-DPPN-
Phen 
18.26 26.39 40.25 18.24 26.37 40.23 28.28 11.12 










3.3.4 MCF-7 48 % positive 
48 hour 1.00 2.00 3.00 minus unstained  average S.D 
unstained 0.05 0.08   0.07    
negative 3.92 2.09 2.93 3.86 2.03 2.87 2.92 0.92 
Cu-Phen 17.39 24.41 24.28 17.33 24.35 24.22 21.96 4.02 
Cu-DPQ-
Phen 
18.02 23.67 19.11 17.96 23.61 19.05 20.20 3.00 
Cu-DPPZ-
Phen 
15.34 39.99 39.43 15.28 39.93 39.37 39.65 0.40 
Cu-DPPN-
Phen 
26.11 42.66 49.38 26.05 42.60 49.32 39.32 11.98 
Cisplatin 15.77 22.79 19.79 15.71 22.73 19.73 19.39 3.52 
 
3.3.5 SKOV-3 24 MFI 
24 hour 1 2 3 minus unstained  average S.D 
unstained 224,793.
20 
   224,793.
20 








































































































3.3.6 SKOV-3 48 MFI 
48 hour 1.00 2.00 3.00 minus unstained  average S.D 
unstained 165,113.
67 
   165,113.
67 

















































































































3.3.7 SKOV-3 24 % positive 
24 hour 1.00 2.00 3.00 minus unstained  average S.D 
unstained 0.03    0.03    
negative 6.43 7.70 6.79 6.40 7.67 6.76 6.94 0.65 
Cu-Phen 89.57 90.83 86.84 81.90 90.80 86.81 86.50 4.46 
Cu-DPQ-
Phen 
87.71 89.15 88.14 87.68 89.12 88.11 88.30 0.74 
Cu-DPPZ-
Phen 
51.60 84.10 62.13 51.57 84.07 62.10 56.84 7.45 
Cu-DPPN-
Phen 
91.83 94.90 95.62 91.80 94.87 95.59 94.09 2.01 
Cisplatin 74.18 60.14 59.88 74.15 60.11 59.85 64.70 8.18 
 
3.3.8 SKOV-3 48 % positive  
48 hour 1.00 2.00 3.00 minus unstained  average S.D 
unstained 0.04    0.04    
negative 6.41 11.59 10.00 6.37 11.55 9.96 9.29 2.65 
Cu-Phen 70.54 72.02 56.52 58.99 71.98 56.48 62.48 8.32 
Cu-DPQ-
Phen 
70.42 74.66 77.27 70.38 74.62 77.23 74.08 3.46 
Cu-DPPZ-
Phen 
41.62 38.61 33.87 41.58 38.57 33.83 37.99 3.91 
Cu-DPPN-
Phen 
70.88 69.27 71.51 70.84 69.23 71.47 70.51 1.16 






3.4 Gene expression data (Ct values and processing) 











Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 11.24 11.81    29.18 20.96 16.5 24.42 38.87 25.87   33.23 25.64 32.4 
Ct 2 11.71 11.61    29.3 20.66 21.71 23.93 41.99 25.33   34.21 27.29 31.99 
Ct 3 22.73                
Ct 4 22.26                
Ct 5                 









33.72 26.465 32.195 
Ref S.D 5.6352
84 
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Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 11.56 13.54    31.55 21.32 17.84 19.71 31.58 24.55   28.61 28.57 32.86 
Ct 2 11.96 13.37    32.72 21.5 19.66 16.91 31.8 24.46   30.69 28.82 32.5 
Ct 3 22.43                
Ct 4 21.92                
Ct 5                 









29.65 28.695 32.68 
Ref S.D 5.0029
38 































































































                 














































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 20.49 22.23    32.11 33.69 31.68 31.35 30.06 14.6    42.42 17.51 
Ct 2 21.26 21.79    31.16 32.92 31.5 31.06 31.02 14.7    42.35 17.69 
Ct 3 11.66                
Ct 4 11.2                
Ct 5                 











































































































                 










































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 12.68 13.81    29.01 21.87 20.54 25.17 39.79 25.79   35.64 27.64 33.5 
Ct 2 13.12 13.41    29.89 23.53 22.44 26.31 42.25 25.98   35.44 26.66 3.7 
Ct 3 23.99                
Ct 4 23.53                
Ct 5                 









35.54 27.15 18.6 
Ref S.D 5.4392
41 




























































































                 










































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 14.75 14    31.36 24.84 20.48 21.84 36.84 23.67   32.28 20.76 33.75 
Ct 2 14.58 14.25    32.68 24.95 18.48 21.6 38.83 23.45   32.97 21.31 32.6 
Ct 3 17.43                
Ct 4 18.54                
Ct 5                 









32.625 21.035 33.175 
Ref S.D 1.9045
99 
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Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 12.85 12.92    31.21 23.7 20.31 22.34 37.73 20.26   33.57 23 32.33 
Ct 2 12.92 13.12    29.12 23.3 20 22.57 37.45 19.92   33.3 23.93 31.91 
Ct 3 14.67                
Ct 4 15.51                
Ct 5                 









33.435 23.465 32.12 
Ref S.D 1.1388
9 

























































































                 








































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 12.91 13.62    27.59 23.42 21.25 19.67 35.62 22.42   28.33 19 30.52 
Ct 2 13.52 13.42    27.94 23.6 18.82 19.79 36.48 22.85   28.6 19.51 30.21 
Ct 3 17.66                
Ct 4 18.4                
Ct 5                 









28.465 19.255 30.365 
Ref S.D 2.4313
82 
























































































                 












































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 15.91 15.88    28.4 26.23 22.44 22.94 37.74 23.35   21.61 21.61 31.51 
Ct 2 16.16 18.88    28.47 26.64 20.79  39.18 23.99   20.98 20.98 32.1 
Ct 3 17.8                
Ct 4 17.58                
Ct 5                 









21.295 21.295 31.805 
Ref S.D 1.2370
57 































































































                 














































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 13.5 12.76    23.43 22.6 17.55 21.23 36.62 18.15   35.93 21.73 23.53 
Ct 2 14.9 13.52    22.76 23.87 17.85 21.78 41.85 18.21   30.7 22.2 22.81 
Ct 3 14.92                
Ct 4 14.73                
Ct 5                 









33.315 21.965 23.17 
Ref S.D 0.9153
31 
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Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 15.13 13.8    21.41 22.91 17.99 20.7 37.79 18.29   39.54 22.72 22.5 
Ct 2 13.98 14.82    21.67 23.33 17.73 20.87 38.99 18.48   37.4 23.55 22.39 
Ct 3 16.97                
Ct 4 16.36                
Ct 5                 









38.47 23.135 22.445 
Ref S.D 1.2706
64 































































































                 















































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 15.1 16.97    23.78 26.78 21.55 23.59 42.39 20.73   36.25 25.5 24.36 
Ct 2 17.65 17.01    23.94 26.36 21.77 22.97  20.94   34.67 25.17 24.01 
Ct 3 17.18                
Ct 4 17.22                
Ct 5                 









35.46 25.335 24.185 
Ref S.D 0.8931
01 





























































































                 












































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 13.87 14.19    20.82 24.9 19.96 20.45 36.77 18.03   33.83 21.9 21.56 
Ct 2 13.64 13.62    21.04 25.91 19.65 20.65 37.58 18.28   32.78 22.01 20.86 
Ct 3 14.93                
Ct 4 14.66                
Ct 5                 









33.305 21.955 21.21 
Ref S.D 0.5457
99 































































































                 














































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 16.24 14.25    25.31 24.29 19.7 21.38 36.41 19.49   30.75 22.83 25.7 
Ct 2 15.02 14.33    25.39 24.31 19.34 22.07 36.33 19.71   30.52 22.97 24.48 
Ct 3 16.61                
Ct 4 16.78                
Ct 5                 









30.635 22.9 25.09 
Ref S.D 1.1463
93 


































































0 0 0 
                 




1 1 1 

















































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 16.82 16.25    23.68 24.39 21.64 22.44 37.06 21.47   32.31 23.83 24.09 
Ct 2 16.54 16.36    23.75 24.29 20.84 22.5 37.93 21.73   30.71 23.79 24.84 
Ct 3 18.92                
Ct 4 18.36                
Ct 5                 









31.51 23.81 24.465 
Ref S.D 1.1394
46 































































































                 












































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 12.32 12.81    22.44 21.5 17.46 19.81 34.71 17.72   26.73 19.78 23.54 
Ct 2 12.24 12.74    22.68 21.18 17.48 20.39 33.85 17.8   26.1 19.76 23.81 
Ct 3 14.23                
Ct 4 13.79                
Ct 5                 









26.415 19.77 23.675 
Ref S.D 0.8096
77 






















































































                 











































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 13.34 14.82    20.87 23.95 19.53 19.81 36.96 19.53   30.52 22.16 22.44 
Ct 2 12.97 14.89    21.63 24.27 19.81 19.91 35.78 19.92   30.67 22.23 22.7 
Ct 3 15.87                
Ct 4 15.4                
Ct 5                 









30.595 22.195 22.57 
Ref S.D 1.1501
2 



























































































                 












































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 20.95 20.5    22.28 36.96 30.86 22.24 36.54 22.58   42.7 26.71 21.66 
Ct 2 21.52 25.82    22.14 42.14 31.44 22.77 37.25 22.67   37.71 28.47 22.4 
Ct 3 21.21                
Ct 4 20.38                
Ct 5                 









40.205 27.59 22.03 
Ref S.D 2.0487
26 






































































0 0 0 
                 




1 1 1 






















































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 28.7 42.52    23.6 41.39 36.35 28.91       33.02 
Ct 2 2.83 29.3      33  7     31.76  
Ct 3                 
Ct 4                 
Ct 5                 










































































































                 




































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 24.45 24.69    25.33 41.44 37.39 26.54 7.82 25.25    33.83 25.86 
Ct 2 23.78 23.48    24.82  35.49 25.83 41.37 25.07    31.83 25.55 
Ct 3 26.16                
Ct 4 26.46                
Ct 5                 











































































































                 






































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 24.46 23.91    24.68 41.63 37.49 25.4 15.93 27.4   37.69 32.78 28.47 
Ct 2 24.34 23.88    24.7 39.16 36.42 25.41  26.77   26.12 35.52 28.35 
Ct 3 27.93                
Ct 4 26.75                
Ct 5                 









31.905 34.15 28.41 
Ref S.D 1.7057
72 































































































                 











































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 21.59 21.32    22.54 34.98 30 22.72 42.98 23.47   40.7 27.7 22.73 
Ct 2 20.89 21.07    22.58 35.41 29.48 22.74 36.75 23.34    28.62 22.92 
Ct 3 22.29                
Ct 4 22                
Ct 5                 









40.7 28.16 22.825 
Ref S.D 0.5417
26 






































































0 0 0 
                 




1 1 1 






















































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 20.07 24.22    25.35 36.34       26.68 30.09 24.61 
Ct 2 18.64 28.53    24.03 37.67 33.6 26.95     11.36  28.56 
Ct 3                 
Ct 4                 
Ct 5                 













19.02 30.09 26.585 
Ref S.D 4.4568
64 


























































































                 






































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 24.28 25.05    26.18 37.94 32.54 23.53 38.42 24.38   36.6 33.41 25.69 
Ct 2 24 24.4    26.18 39.99 32.59 23.98  24.46   37.23 33.31 25.25 
Ct 3 24.6                
Ct 4 24.57                
Ct 5                 









36.915 33.36 25.47 
Ref S.D 0.3533
08 






























































































                 











































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 23.72 23.98    24.99 38.93 31.91 24.55  24.72   40.85 32.26 25.44 
Ct 2 23.63 24.32    25.26 38.22 32.31 24.43  25.23    33.37 25.38 
Ct 3 23.45                
Ct 4 24.47                
Ct 5                 











40.85 32.815 25.41 
Ref S.D 0.4026
62 




























































































                 







































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 21.48 22.58    33.66 30.64 27.14 29.45 32.71 29.79   34.46 33.23 30.54 
Ct 2 21.68 22.88    32.73 30.97 27.57 29.74 32.48 31.37   35.32 33.19 36.38 
Ct 3                 
Ct 4                 
Ct 5                 









34.89 33.21 33.46 
Ref S.D 0.6800
74 






































































0 0 0 
                 




1 1 1 






















































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 23.93 25.31    32.97 32.26 28.97 32.99 32.38 32.01   36.52 33.93 36.29 
Ct 2 23.92 24.93    33.35 32.32 29.36 32.88  32.11   35.33 34.62 31.6 
Ct 3                 
Ct 4                 
Ct 5                 









35.925 34.275 33.945 
Ref S.D 0.7071
72 






























































































                 















































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 20.37 21.35    32.61 30.14 25.97 26.41 30.8 27.61   34.24 32.35 29.97 
Ct 2 20.35 22.2    33.29 30.51 25.94 26.41 8.58 27.63   33.43 30.75 30.1 
Ct 3                 
Ct 4                 
Ct 5                 









33.835 31.55 30.035 
Ref S.D 0.8876
33 





























































































                 














































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 24.87 26.91    35.2 32.97 30.15 33.15 5.54 34.32   37.08 33.93 31.04 
Ct 2 24.74 26.03    35.79 32.32 29.93 33.88  32.84   36.44 33.45 31.15 
Ct 3                 
Ct 4                 
Ct 5                 









36.76 33.69 31.095 
Ref S.D 1.0275
98 






























































































                 
















































































































































Ref gene 4 IL-6 NF-KB PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 31.31 29.86    34.31 31.16 28.75 32.21 28.42 34.77   28.99 31.73 27.68 
Ct 2 30.27 30.67    35.49 31.68 28.91 31.92 30.72 34.5   30.11 30.78 27.95 
Ct 3                 
Ct 4                 
Ct 5                 









29.55 31.255 27.815 
Ref S.D 0.6176
5 










































































0 0 0 
                 




1 1 1 



















































































































Ref gene 4 IL-6 NF-KB PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 25.86 27.73    35.98 32.78 28.34 32.98 26.13 32.45   31.24 30.6 28.93 
Ct 2 26.04 27.69    34.88 32.91 28.9 32.7 29.79 33.69   29.99 30.42 32.86 
Ct 3                 
Ct 4                 
Ct 5                 









30.615 30.51 30.895 
Ref S.D 1.0189
21 
























































































                 




































































































































Ref gene 4 IL-6 NF-KB PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 30.4 30.92    35.85 34.51 29.37 32.14 1.75 35.52   9.37 30.42 29.97 
Ct 2 30.92 30.94    34.81 30.94 29.24 32.27 31.62 35.16   30.49 32.67 29.58 
Ct 3                 
Ct 4                 
Ct 5                 









19.93 31.545 29.775 
Ref S.D 0.2635
02 































































































                 































































































































Ref gene 4 IL-6 NF-KB PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 26.83 28.31    34.09 31.78 28.77 32.86 31.87 32.66   32.34 30.75 31.04 
Ct 2 26.52 27.05    34.55 31 29.35 32.6 27.59 34.61   31.05 31.43 31.15 
Ct 3                 
Ct 4                 
Ct 5                 









31.695 31.09 31.095 
Ref S.D 0.7856
79 
























































































                 






































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 18.47 15.48    26.75 28.07 23.3 21.38 40.81 17.74 27.755 22.754 31.14 23.02 26.85 
Ct 2 18.67 15.6    26.51 28.43 19.51 22.28  17.53 27.755 23.477 32.64 23.54 23.81 
Ct 3 15.615 17.58      35.95 22.151 38.867 22.103 27.702 22.43 32.373 25.994 30.939 
Ct 4 15.615 17.58       22.151 38.867 22.545 27.69 22.839 32.373 25.994 30.939 
Ct 5 15.99                























































































     delta delta Ct 0 0 0 0 0 0 0 0 0 0 0 
                 
     Normalized ddCt 1 1 1 1 1 1 1 1 1 1 1 

























































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 14.71 14.01    25.15 23.3 20.22 26.54  22.16 26.754 22.225 36.89 23.46 29.85 
Ct 2 14.76 13.55    26.24 24.37 21.29 23.88  21.94 27.044 22.633 33.62 24.53 29.79 
Ct 3 16.353 16.96    33 42.15  22.334 39.135 22.524 27.311 22.225 32.334 26.855 30.265 
Ct 4 14.927 17.24    26.02  32.31 20.596 38.685 27.227 26.85 21.818 32.759 26.855 30.11 
Ct 5 16.19                








































































































                 












































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 13.96 12.94    23.62 22.9 20.63 23.58 42.54 22.6 27.244 23.173 34.28 25.23 26.37 
Ct 2 14.27 13.2    22.38 23.96 21.55 23.52  22.9 27.819 23.015 36.1 26.62 26.37 
Ct 3 15.504 17.135    26.94 24.02  21.285 40.645 22.792 27.587 23.39 32.504 25.855 25.88 
Ct 4 17.975 16.942    26.17   6.034 40.645 22.229 27.026 23.267 33.842 26.7 25.277 
Ct 5 14.48                



















































































































                 











































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 15.31 14.19    26.62 24.81 21.25 21.87  20.27 27.731 22.844 36.63 25.94 29.91 
Ct 2 17.3 13.7    26.56 24.83 21.18 21.64  20.46 27.537 21.832 31.25 24.33 29.81 
Ct 3 30.19 18.938    26.43 21.78  20.324 39.934 23.819 28.056 22.969 32.279 26.406 30.345 
Ct 4 15.28      37.59 34.71 20.324 39.934 21.617 27.812 23.731 30.35 26.406 30.599 
Ct 5 15.88                



















































































































                 









































































































































   Target 
genes 




















































































































































































             
Ct 5 28.
64 
                            
Ct 6 27.
66 


































































































































































































































































































     delta delta 
Ct 
0 0 0 0 0 0 0 0 #D
IV/
0! 






0 0 0 
                              
     Normalized 
ddCt 
1 1 1 1 1 1 1 1 #D
IV/
0! 






1 1 1 

































































































































































































































































































































































































































































































































             
Ct 5 16.
56 
                            
Ct 6 16.
79 












































































































































































































































































































































































                              



























































































































































































































































































































































































































































































































































































              
Ct 5 14.
48 
                            
Ct 6 14.
44 









































































































































































































































































































































































                              













































































































































































































































































































































































































































































































































































              
Ct 4 15.
768 












              
Ct 5 15.
28 
                            
Ct 6 15.
85 




































































































































































































































































































































































                              







































































































































































































































































































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 23.79 21.67    24.66 40.5 32.13 22.73 42.54 23 26.291 31.696 33.6 28.89 23.78 
Ct 2 22.74 21.61    24.46 39.53 31.97 22.51  22.94 25.961 28.365  29.26 23.99 
Ct 3 21.717 22.599      33.09 22.382  25.544 25.82 26.054  24.785 26.989 
Ct 4 21.283 23.151       21.412  25.633 25.717 27.037  23.825 25.895 
Ct 5 23.03                




















































































     delta delta Ct 0 0 0 0 0 0 0 0 0 0 0 
                 
     Normalized ddCt 1 1 1 1 1 1 1 1 1 1 1 



















































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 22.77 21.53    24.72 36.58 32.37 23.22 40 25.42 24.54 24.379 32.71 30.83 26.26 
Ct 2 22.75 21.6    24.79 40.87 31.94 22.87 38.81 24.55 24.7 23.941  31.07 27.31 
Ct 3 20.318 21.728    22.44   19.602  23.873 24.446 23.757  22.126 24.417 
Ct 4 19.676 20.243    32.81  30.5 20.153  23.873 25.057 25.437  22.126 23.69 
Ct 5 19.58                











































































































                 









































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 21.89 20.22    22.85 37.98 32.9 21.2  21.97 24.723 26.98 34.78 28.84 23.83 
Ct 2 21.35 20.5    22.75 41.2 32.86 21.03  21.74 24.5 24.617  30.29 23.81 
Ct 3 22.93 21.667       20.721  24.712 24.795 25.545  22.532 24.83 
Ct 4 22.93 21.456      41.35 19.753  24.712 24.833 29.431  23.257 24.428 
Ct 5 20.62                




















































































































                 









































































































































Ref gene 4 IL-6 NF-
KB 
PARP Casp9 Casp3 SMAC BCL-2 BAX XIAP IAP1 IAP2 
Ct 1 21.62 20.71    23.52  31.88 22.52 38.57 23.98 25.04 23.843 40.26 30.07 27.61 
Ct 2 21.63 20.54    22.99  31.38 22.43 40.32 23.4 25.042 23.154  29.76 25.83 
Ct 3 20.397 22.798      13.38 39  24.313 24.51 24.788  22.025 23.982 
Ct 4 20.397 21.075       39  23.573 25.934 24.654  23.425 25.352 
Ct 5 20.43                
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Ct 5 23.
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Ct 6 22.
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     delta delta 
Ct 
0 0 0 0 0 0 0 #D
IV/
0! 






0 0 0 
                              
     Normalized 
ddCt 
1 1 1 1 1 1 1 #D
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Ct 4 19.
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   Target 
genes 








































































Ct 1 24.51 27.
43 
























     
Ct 2 24.48 27.
35 
      28.5
2 
  28.4 30.2
9 












25.8      
Ct 3 20.22 22.
28 
























     
Ct 4 20.63 21.
25 
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Ct 5                              

















































































































































































































































































































































                              
































































































































































































































































































































































































































Ct 1 24.98 26.
07 
















35.2       
Ct 2 23.96 25.
51 




















     
Ct 3 22.74 25.
74 




















     
Ct 4 22.5 24.
93 




















     
Ct 5                              

















































































































































































































































































































































































                              



































































































































































































































































































































































































































































Ct 1 12.43 17.
34 
















26      
Ct 2 12.88 17.
06 
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Ct 3 12.61 19.
44 






















     
Ct 4 11.93 17.
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Ct 5                              



















































































































































































































































































































































































                              
































































































































































































































































































































































































































































Ct 1 24.31 19.
83 
















     
Ct 2 27.94 26.
28 






















     
Ct 3 24.33 27.
79 




















     




















     
Ct 5                              
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Ct 2 17.53        30.0
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3.4.15 Galleria mellonella gene expression data (Ct values) 
 S7e  transferrin IMPI 
Undisturbed 13.65 12.16 12.59 13.51  17.4 19 18.11 18.63 14.57 15.15 14.31 15.73 
Sham-
inoculated 
12.47 13.77 14   17.37 17.68 16.7 39.27 14.96 15.26 15.44 14.25 
Solvent 
inoculated 
12.93 12.38 14.03 12.56  19.41 19.86 19.49 19.53 16.22 16.65 14.96 15.83 
Cu-Phen 14.01  13.3 13.37  20.43 20.74 21.57 36.86 18.29 18.92 18.73 18.5 
Cu-DPQ-Phen 14.69 14.67 13.13 12.51  21.68 22.6 21.73 21.91 20.07 19.65 20.58 20.06 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.6 Galleria mellonella mortality 
3.6.1 Cisplatin 
  24 
hours 
 mean % 
mortality 
S.D  48 
hour 
 mean % 
mortality 
S.D  72 hours  mean % 
mortality 
72h S.D % 
mortality 
Compound/ 











plate 3 %   plate 
1 % 
plate 2 % plate 3 %   
Cisplatin                
100ug (0.333uM) 90 100 70 86.67 15.2
7525 
90 100 70 86.67 15.2
7525 
100 100 70 90.00 17.3 
10ug (0.033uM) 0 0 0 0.00 0 10 10 0 6.67 5.77
3503 
10 10 0 6.67 5.8 
8ug (0.026uM) 0 0 0 0.00 0 0 0 0 0.00 0 0 0 0 0.00 0.0 
6ug (0.019uM) 0 0 0 0.00 0 0 0 10 3.33 5.77
3503 
0 0 10 3.33 5.8 
4ug (0.013uM) 0 0 0 0.00 0 0 0 10 3.33 5.77
3503 
0 0 10 3.33 5.8 
2ug (0.006uM) 0 0 0 0.00 0 0 0 10 3.33 5.77
3503 
0 0 10 3.33 5.8 
 
3.6.2 Cu-Phen (1) 
  4hr  mean 
% 
S.D  24h  mean 
% 
S.D  48h  mean 
% 






























Cu-Phen                     
30ug 100 100 100 100.0
0 
0 100 100 100 100.0
0 
0 100 100 100 100.0
0 
0 100 100 100 100.0
0 
0.0 
25ug 90 100 100 96.67 5.773
503 
100 100 100 100.0
0 
0 100 100 100 100.0
0 
0 100 100 100 100.0
0 
0.0 
20ug 80 90 90 86.67 5.773
503 
100 100 100 100.0
0 
0 100 100 100 100.0
0 
0 100 100 100 100.0
0 
0.0 
15ug 70 70 70 70.00 0 100 100 100 100.0
0 
0 100 100 100 100.0
0 
0 100 100 100 100.0
0 
0.0 
12ug 40 50 50 46.67 5.773
503 
100 100 100 100.0
0 
0 100 100 100 100.0
0 
0 100 100 100 100.0
0 
0.0 
10ug (0.018uM) 0 10 10 6.67 5.773
503 
80 70 100 83.33 15.27
525 
80 70 100 83.33 15.27
525 
80 70 100 83.33 15.3 
8ug (0.014uM) 0 0 0 0.00 0 20 30 0 16.67 15.27
525 
20 30 0 16.67 15.27
525 
20 30 0 16.67 15.3 
6ug (0.010uM) 0 0 0 0.00 0 0 0 0 0.00 0 0 0 0 0.00 0 0 0 0 0.00 0.0 
4ug (0.007uM) 0 0 0 0.00 0 0 0 0 0.00 0 0 0 0 0.00 0 0 0 0 0.00 0.0 
2ug (0.003uM) 0 0 0 0.00 0 0 0 0 0.00 0 0 0 0 0.00 0 0 0 0 0.00 0.0 
514 
 




























Cu-DPQ-Phen                     
30ug 100 100 100 100.0
0 
0 100 100 100 100.0
0 
0 100 100  100.0
0 
0 100 100 100 100.0
0 
0 
28ug 100 100 100 100.0
0 
0 100 100 100 100.0
0 
0 100 100  100.0
0 
0 100 100 100 100.0
0 
0 
24ug 70 80 80 76.67 5.773
503 
100 100 100 100.0
0 
0 100 100  100.0
0 
0 100 100 100 100.0
0 
0 
20ug 40 40 40 40.00 0 100 100 100 100.0
0 
0 100 100 100 100.0
0 
0 100 100 100 100.0
0 
0 
16ug 20 20 20 20.00 0 90 90 90 90.00 0 90 90 100 93.33 5.773
503 
90 100 100 96.67 5.773
503 
14ug 0 0 0 0.00 0 80 90 80 83.33 5.773
503 
90 100 80 90.00 10 90 100 80 90.00 10 
12ug 0 0 0 0.00 0 80 70 70 73.33 5.773
503 
80 70 70 73.33 5.773
503 
70 70 70 70.00 0 
10ug (0.016uM) 0 0 0 0.00 0 30 30 50 36.67 11.54
701 
30 30 50 36.67 11.54
701 
30 30 50 36.67 11.54
701 
8ug (0.013uM) 0 0 0 0.00 0 0 0 0 0.00 0 0 0 0 0.00 0 0 0 0 0.00 0 
6ug (0.0098uM) 0 0 0 0.00 0 0 0 0 0.00 0 0 0 0 0.00 0 0 0 0 0.00 0 
4ug (0.006uM) 0 0 0 0.00 0 0 0 10 3.33 5.773
503 
0 0 10 3.33 5.773
503 
0 0 10 3.33 5.773
503 

















3.6.4 Cu-DPPZ-Phen (3) 
  4hr  mean 
% 
S.D  24h  mean 
% 
S.D  48h  mean 
% 






























Cu-DPPZ-Phen                     
40ug 100 100 100 100.0
0 
0 100 100 100 100.0
0 
0 100 100 100 100.0
0 
0 100 100 100 100.0
0 
0 
30ug 100 100 100 100.0
0 
0 100 100 100 100.0
0 
0 100 100 100 100.0
0 
0 100 100 100 100.0
0 
0 
20ug 100 100 100 100.0
0 
0 100 100 100 100.0
0 
0 100 100 100 100.0
0 
0 100 100 100 100.0
0 
0 
12ug 100 60 70 76.67 20.81
666 
100 70 70 80.00 17.32
051 
100 70 70 80.00 17.32
051 
100 70 70 80.00 17.32
051 
11ug 80 60 80 73.33 11.54
701 
80 80 90 83.33 5.773
503 
          
10ug (0.016uM) 0 0 0 0.00 0 0 0 0 0.00 0 0 0 0 0.00 0 50 40 30 40.00 10 
8ug (0.013uM) 0 0 0 0.00 0 0 0 0 0.00 0 0 0 0 0.00 0 0 0 0 0.00 0 
6ug (0.0098uM) 0 0 0 0.00 0 0 0 0 0.00 0 0 0 0 0.00 0 0 0 0 0.00 0 
4ug (0.006uM) 0 0 0 0.00 0 0 0 0 0.00 0 0 0 0 0.00 0 10 0 0 3.33 5.773
503 



















3.6.5 Cu-DPPN-Phen (4) 
  4hr  mean 
% 
S.D  24h  mean 
% 
S.D  48h  mean 
% 






























Cu-DPPN-Phen                     
40ug 10 0 0 3.33 5.773
503 
30 0 20 16.67 15.27
525 
30 0 20 16.67 15.27
525 
30 0 40 23.33 20.81
666 
30ug 0 0 0 0.00 0 10 0 0 3.33 5.773
503 
20 10 20 16.67 5.773
503 
20 10 20 16.67 5.773
503 
20ug 0 0 0 0.00 0 20 0 10 10.00 10 20 0 20 13.33 11.54
701 
20 10 20 16.67 5.773
503 
12ug 0 0 0 0.00 0 0 30 30 20.00 17.32
051 
0 30 30 20.00 17.32
051 
0 30 30 20.00 17.32
051 
10ug (0.016uM) 0 0 0 0.00 0 0 0 0 0.00 0 0 10 10 6.67 5.773
503 
30 30 30 30.00 0 
8ug (0.013uM) 0 0 0 0.00 0 0 0 0 0.00 0 0 0 0 0.00 0 0 0 0 0.00 0 
6ug (0.0098uM) 0 0 0 0.00 0 0 0 0 0.00 0 0 0 10 3.33 5.773
503 
0 10 0 3.33 5.773
503 
4ug (0.006uM) 0 0 0 0.00 0 0 0 0 0.00 0 0 10 0 3.33 5.773
503 
10 0 0 3.33 5.773
503 











3.7 G. mellonella haemocyte count at LD50 exposure after 24 h 
Solvent/ 
negative     
average 
haemocyte 
count per ml 
average S.D 
1 86 93 94 79 88 4.40E+07 
  
 
86 79 72 99 84 4.20E+07 
  
2 75 65 50 65 63.75 3.19E+07 
  
 
59 77 63 64 65.75 3.29E+07 
  
3 56 65 76 67 66 3.30E+07 
  
 
66 83 86 85 80 4.00E+07 
  
4 75 62 43 64 61 3.05E+07 
  
 
64 55 60 71 62.5 3.13E+07 3.57E+07 5.396E+06 
Cu-Phen 
LD50 24h         
5 95 98 81 48 80.5 4.03E+07 
  
 
94 104 110 109 104.25 5.21E+07 
  
6 92 77 77 76 80.5 4.03E+07 
  
 
87 82 92 80 85.25 4.26E+07 
  
7 89 71 71 62 73.25 3.66E+07 
  
 
53 78 92 65 72 3.60E+07 
  
8 69 71 72 66 69.5 3.48E+07 
  
 




        
9 121 127 119 105 118 5.90E+07 
  
 
119 125 146 127 129.25 6.46E+07 
  
10 101 102 96 87 96.5 4.83E+07 
  
 
69 83 81 79 78 3.90E+07 
  
11 
        
         
12 58 50 65 60 58.25 2.91E+07 
  
 




        
13 150 113 128 84 118.75 5.94E+07 
  
 
122 122 121 141 126.5 6.33E+07 
  
14 57 55 59 64 58.75 2.94E+07 
  
 
46 37 54 56 48.25 2.41E+07 
  
15 96 94 84 100 93.5 4.68E+07 
  
 
93 106 118 106 105.75 5.29E+07 
  
16 73 58 73 65 67.25 3.36E+07 
  
 
80 57 73 89 74.75 3.74E+07 4.33E+07 1.439E+07 
Sham 
inoculation         
17 85 86 79 88 84.5 4.23E+07 
  
 
74 73 86 98 82.75 4.14E+07 
  





97 99 79 95 92.5 4.63E+07 
  
19 42 49 51 63 51.25 2.56E+07 
  
 
48 47 47 44 46.5 2.33E+07 
  
20 50 53 58 60 55.25 2.76E+07 
  
 
64 76 62 83 71.25 3.56E+07 3.57E+07 9.031E+06 
undisturbe
d         
21 
        
         
22 10 21 12 11 13.5 6.75E+06 
  
 
13 14 10 13 12.5 6.25E+06 
  
23 80 78 79 86 80.75 4.04E+07 
  
 
70 82 95 88 83.75 4.19E+07 
  
24 51 69 64 73 64.25 3.21E+07 
  
 
76 66 76 68 71.5 3.58E+07 2.72E+07 1.639E+07 
 
 
3.8 G. mellonella 2D-PAGE 
3.8.1 G. mellonella 2D-PAGE Progenesis SameSpot analysis output  




LD50 24 h 
Cu-DPQ-
Phen LD50 24 
h 
Cu-DPPZ-
Phen LD50 24 
h 
53 7.436e-004 6.4 7323.822 3935.175 1152.780 1684.348 
65 0.001 4.6 7577.226 9539.601 2073.979 2339.487 
8 0.006 2.4 3938.221 2922.647 1633.304 1761.574 
66 0.008 3.7 587.533 583.879 288.907 159.284 
29 0.011 5.1 203.019 489.475 681.113 1043.649 
36 0.016 1.9 2003.462 1108.715 1058.913 1101.398 
40 0.021 3.9 106.498 109.043 347.222 411.424 
27 0.031 2.7 5271.907 4582.039 1981.567 2568.498 
52 0.034 3.6 1036.671 1199.377 336.827 528.988 
18 0.034 1.8 1.999e+004 2.211e+004 1.233e+004 1.321e+004 
67 0.036 6.0 6869.326 6701.720 1375.526 1139.020 
13 0.038 2.5 1848.394 1490.794 750.606 807.622 
11 0.041 3.4 2122.252 3658.593 7143.887 5350.948 
60 0.042 4.6 258.385 855.154 807.837 1182.532 
50 0.047 2.5 2616.734 2071.074 1030.475 1352.780 
47 0.051 2.0 687.285 524.745 588.299 1061.341 
41 0.051 3.4 384.577 441.488 287.730 990.522 
39 0.052 7.0 43.642 28.937 86.487 202.319 
31 0.053 4.8 651.762 215.125 135.131 253.534 
12 0.055 2.6 887.524 1255.481 1814.490 2325.213 
62 0.057 21.2 69.578 101.674 1475.647 104.466 
45 0.066 2.2 7532.939 6618.067 3352.145 4817.492 
46 0.066 3.1 896.714 834.220 289.701 339.827 
23 0.069 1.7 1.975e+004 1.455e+004 1.183e+004 1.290e+004 
30 0.089 2.0 316.222 406.972 203.185 357.257 
519 
 
70 0.094 23.8 107.967 153.353 2565.508 170.794 
72 0.100 2.7 50.138 117.981 44.135 43.222 
5 0.117 4.4 627.053 1724.708 490.010 388.114 
44 0.117 24.1 91.295 78.375 1890.529 159.353 
4 0.128 2.1 3445.723 3441.988 1626.416 1712.553 
48 0.138 2.4 4526.798 2929.349 1880.411 3001.447 
56 0.138 2.5 3369.012 2270.598 1814.836 1374.868 
49 0.140 2.2 2837.915 2511.156 1302.332 1834.473 
34 0.142 2.0 1.977e+004 1.659e+004 9968.003 1.197e+004 
59 0.162 3.1 176.401 165.412 511.368 473.533 
38 0.168 5.3 67.279 65.405 151.448 343.382 
20 0.188 3.1 1124.548 2790.878 917.328 891.349 
33 0.219 2.0 2570.036 1486.672 3018.909 2888.208 
64 0.222 2.6 4155.465 3352.677 1597.735 1990.542 
57 0.222 17.6 38.441 56.343 613.663 34.918 
28 0.226 12.5 133.024 136.932 790.134 1662.759 
74 0.228 22.1 79.639 49.963 868.391 39.342 
71 0.228 2.4 342.703 569.514 265.289 232.605 
42 0.242 18.9 186.831 146.721 2766.168 1211.422 
43 0.257 17.9 93.909 83.787 1501.969 731.180 
9 0.258 1.6 1277.390 1199.383 1563.950 1937.297 
61 0.262 16.8 116.328 213.553 1950.766 389.116 
73 0.265 15.8 124.769 130.854 1977.515 166.480 
51 0.275 5.0 229.887 345.178 84.987 69.432 
75 0.282 19.4 143.635 43.087 837.767 72.479 
58 0.288 7.2 113.472 478.690 166.975 813.537 
32 0.297 22.7 35.910 27.161 588.544 615.879 
7 0.300 5.2 494.238 196.970 370.351 1018.925 
15 0.303 3.5 718.361 880.380 2148.315 2484.520 
69 0.319 2.7 504.724 1059.895 556.446 392.397 
14 0.340 13.1 246.157 3230.745 1037.657 478.838 
37 0.349 25.8 147.411 63.333 1631.806 1596.772 
22 0.361 2.3 524.162 275.472 517.235 645.903 
21 0.384 3.9 534.690 1053.363 362.497 1397.116 
68 0.402 24.7 113.215 223.228 2794.570 213.855 
63 0.440 16.8 134.658 160.518 2268.669 178.954 
54 0.465 2.5 725.627 495.541 284.561 449.127 
16 0.505 2.7 6349.447 4948.409 7817.841 1.337e+004 
35 0.526 1.9 1067.037 567.532 854.359 928.222 
17 0.545 2.3 1095.678 1530.519 2481.758 2076.828 
10 0.554 1.9 2919.251 4255.945 3274.193 2233.827 
1 0.597 5.8 549.099 876.387 149.986 270.128 
24 0.619 2.9 322.139 229.958 656.394 509.381 
3 0.627 1.7 4272.990 2729.826 4752.135 2724.785 
25 0.647 14.3 60.858 65.843 76.570 872.798 
2 0.724 3.4 1581.201 2688.157 1970.295 790.099 
6 0.829 4.1 223.799 921.343 334.794 474.664 
26 0.882 1.7 1887.232 2295.809 3282.388 2088.000 
520 
 
19 0.896 2.0 512.918 1029.904 652.866 531.966 
55 0.920 2.4 118.476 252.067 121.061 106.360 
 
3.8.2 Spots analysed using MASCOT from Progenesis SameSpot differential expression 
report (3.8.1) and presented in the thesis main body. 
Excised spots 
No. 




8 Not included 
36 Not included 
27 Not included 
52 Not included 
67 Not included 
11 3 
60 4 






49 Not included 
34 10 
58 Not included 
54 Not included 
26 Not included 
 
3.9 G. mellonella LFQ proteomics 







































































































































































































R1_contig19537_1.exp_gi|47607477|gb|AAT36640.1|imaginal disc growth 
























R2_contig07154_1.exp_gi|85726208|gb|ABC79625.1|imaginal disc growth 
R2_contig07154_1.exp_gi|85726208|gb|ABC79625.1|imaginal disc growth 
R2_contig07952_1.exp_gi|157927723|gb|ABW03225.1|beta actin [Mamestra 
R2_contig07952_1.exp_gi|157927723|gb|ABW03225.1|beta actin [Mamestra 







































































































































































































































































R1_contig19537_1.exp_gi|47607477|gb|AAT36640.1|imaginal disc growth 




R1_contig21466_1.exp_gi|134103857|gb|ABO60878.1|cationic peptide CP8 



















R2_contig07154_1.exp_gi|85726208|gb|ABC79625.1|imaginal disc growth 
R2_contig07154_1.exp_gi|85726208|gb|ABC79625.1|imaginal disc growth 
R2_contig07952_1.exp_gi|157927723|gb|ABW03225.1|beta actin [Mamestra 
R2_contig07952_1.exp_gi|157927723|gb|ABW03225.1|beta actin [Mamestra 
















































































































































































































































































R1_contig19537_1.exp_gi|47607477|gb|AAT36640.1|imaginal disc growth 




R1_contig21466_1.exp_gi|134103857|gb|ABO60878.1|cationic peptide CP8 






















R2_contig07154_1.exp_gi|85726208|gb|ABC79625.1|imaginal disc growth 
R2_contig07154_1.exp_gi|85726208|gb|ABC79625.1|imaginal disc growth 
R2_contig07952_1.exp_gi|157927723|gb|ABW03225.1|beta actin [Mamestra 
R2_contig07952_1.exp_gi|157927723|gb|ABW03225.1|beta actin [Mamestra 































































3.10 Progenesis QI for Proteomics output of mammalian in-vitro proteomics 
3.10.1 Exposure of MCF-7 cells at 24 h to Cu-Phen (1) and Cu-DPQ-Phen (2) against the negative control 
         Ne
g 
ctrl 
   Cu-
Phe
n 





























Description 1 2 1 3 ave
rag
e 
2 1 2 3 ave
rag
e 
































































































































Neg ctrl Cu-Phen Nucleoside diphosphate kinase B OS=Homo sapiens 













































































Protein disulfide-isomerase OS=Homo sapiens GN=P4HB 





































Neg ctrl Cu-Phen Rac GTPase-activating protein 1 OS=Homo sapiens 







































Thioredoxin domain-containing protein 5 OS=Homo 






































Cu-Phen Histone H2A type 1-B/E OS=Homo sapiens 






































































Neg ctrl Cu-Phen Purine nucleoside phosphorylase OS=Homo sapiens 













































































Neg ctrl 60S ribosomal protein L14 OS=Homo sapiens GN=RPL14 









































































60S acidic ribosomal protein P2 OS=Homo sapiens 







































Cu-Phen 60S ribosomal protein L8 OS=Homo sapiens GN=RPL8 






































Neg ctrl Cu-Phen CUGBP Elav-like family member 1 OS=Homo sapiens 













































































Neg ctrl Cu-Phen tRNA-splicing endonuclease subunit Sen34 OS=Homo 






































Cu-Phen Histone H2B type 1-D OS=Homo sapiens 






































Cu-Phen Neg ctrl BAG family molecular chaperone regulator 3 OS=Homo 















































































































Ubiquitin carboxyl-terminal hydrolase 10 OS=Homo 





































Neg ctrl Cu-Phen Ribosome biogenesis regulatory protein homolog 




































Cu-Phen Neg ctrl Thioredoxin reductase 1, cytoplasmic OS=Homo sapiens 













































































Neg ctrl Keratin, type I cytoskeletal 15 OS=Homo sapiens 








































Cu-Phen 60S ribosomal protein L23a OS=Homo sapiens 







































rRNA 2'-O-methyltransferase fibrillarin OS=Homo sapiens 







































Cu-Phen 60S ribosomal protein L35a OS=Homo sapiens 






































Heterogeneous nuclear ribonucleoprotein H2 OS=Homo 






































L-lactate dehydrogenase A chain OS=Homo sapiens 














































































Cu-Phen 40S ribosomal protein S6 OS=Homo sapiens GN=RPS6 








































Cu-Phen Histone H2B type 1-K OS=Homo sapiens 








































LIM and SH3 domain protein 1 OS=Homo sapiens 







































Leucine-rich repeat flightless-interacting protein 1 













































































Cu-Phen Chromobox protein homolog 1 OS=Homo sapiens 







































Fructose-1,6-bisphosphatase 1 OS=Homo sapiens 







































High mobility group protein B1 OS=Homo sapiens 








































Poly(U)-binding-splicing factor PUF60 OS=Homo sapiens 







































Cu-Phen D-3-phosphoglycerate dehydrogenase OS=Homo sapiens 














































































Cu-Phen 40S ribosomal protein S7 OS=Homo sapiens GN=RPS7 







































6-phosphogluconate dehydrogenase, decarboxylating 














































































Serine/threonine-protein phosphatase PP1-beta catalytic 














































































Cu-Phen Neg ctrl Ubiquitin-60S ribosomal protein L40 OS=Homo sapiens 





































Neg ctrl Cu-Phen Polypyrimidine tract-binding protein 1 OS=Homo sapiens 














































































Cu-Phen Protein LSM14 homolog B OS=Homo sapiens 







































Small glutamine-rich tetratricopeptide repeat-containing 








































Heterogeneous nuclear ribonucleoprotein A/B OS=Homo 














































































Acyl-CoA-binding protein OS=Homo sapiens GN=DBI 














































































Neg ctrl Cu-Phen Ubiquitin fusion degradation protein 1 homolog OS=Homo 




















































































































Neg ctrl DNA replication licensing factor MCM3 OS=Homo sapiens 















































































Neg ctrl 60S ribosomal protein L28 OS=Homo sapiens GN=RPL28 






































Cu-Phen Rab GDP dissociation inhibitor beta OS=Homo sapiens 
















































































Serine/arginine-rich splicing factor 1 OS=Homo sapiens 











































































Cu-Phen Mitochondrial import receptor subunit TOM34 OS=Homo 






































Isocitrate dehydrogenase [NADP], mitochondrial 






































Nucleosome assembly protein 1-like 1 OS=Homo sapiens 





































Neg ctrl Cu-Phen Phosphatidylethanolamine-binding protein 1 OS=Homo 







































Stress-70 protein, mitochondrial OS=Homo sapiens 






































Spliceosome RNA helicase DDX39B OS=Homo sapiens 



















































































Transcriptional repressor p66-alpha OS=Homo sapiens 








































Clathrin heavy chain 1 OS=Homo sapiens GN=CLTC 








































Adenylyl cyclase-associated protein 1 OS=Homo sapiens 





































Splicing factor U2AF 65 kDa subunit OS=Homo sapiens 













































































Heterogeneous nuclear ribonucleoprotein Q OS=Homo 








































Heterogeneous nuclear ribonucleoprotein D0 OS=Homo 







































































Cu-Phen Neg ctrl cAMP-dependent protein kinase type I-alpha regulatory 















































































Voltage-dependent anion-selective channel protein 2 








































Endoplasmic reticulum resident protein 29 OS=Homo 






































Cu-Phen Neg ctrl Golgin subfamily B member 1 OS=Homo sapiens 




































Cu-Phen 4F2 cell-surface antigen heavy chain OS=Homo sapiens 






































Serine/threonine-protein phosphatase PP1-alpha catalytic 







































Fructose-bisphosphate aldolase A OS=Homo sapiens 















































































Voltage-dependent anion-selective channel protein 1 





































Neg ctrl Cu-Phen Cytochrome c oxidase subunit 6B1 OS=Homo sapiens 
























































































































Cu-Phen Proteasome subunit alpha type-5 OS=Homo sapiens 








































RNA-binding protein EWS OS=Homo sapiens 






































Hepatoma-derived growth factor OS=Homo sapiens 





































Cu-Phen Neg ctrl 26S protease regulatory subunit 6A OS=Homo sapiens 






















































































































60S ribosomal protein L5 OS=Homo sapiens GN=RPL5 






































Cu-Phen Proliferating cell nuclear antigen OS=Homo sapiens 








































Cu-Phen Keratin, type II cytoskeletal 80 OS=Homo sapiens 







































DnaJ homolog subfamily B member 1 OS=Homo sapiens 





































Neg ctrl Cu-Phen Structural maintenance of chromosomes protein 1A 








































Chromobox protein homolog 5 OS=Homo sapiens 












































































Acidic leucine-rich nuclear phosphoprotein 32 family 







































60S ribosomal protein L10a OS=Homo sapiens 






































Neuroblast differentiation-associated protein AHNAK 






































S-adenosylmethionine synthase isoform type-2 OS=Homo 










































































Cu-Phen Macrophage migration inhibitory factor OS=Homo sapiens 













































































Phosphoglycerate mutase 1 OS=Homo sapiens 








































Cu-Phen Eukaryotic translation initiation factor 4H OS=Homo 














































































Cu-Phen Neg ctrl ATP-dependent 6-phosphofructokinase, platelet type 



































Neg ctrl Cu-Phen Methionine aminopeptidase 1 OS=Homo sapiens 





































Neg ctrl Cu-Phen Acidic leucine-rich nuclear phosphoprotein 32 family 







































































Ubiquitin carboxyl-terminal hydrolase 5 OS=Homo sapiens 







































ATP synthase subunit beta, mitochondrial OS=Homo 


















































































































Neg ctrl Cu-Phen Serine/arginine-rich splicing factor 5 OS=Homo sapiens 







































Neg ctrl Ubiquitin carboxyl-terminal hydrolase 14 OS=Homo 







































Protein CDV3 homolog OS=Homo sapiens GN=CDV3 







































Cu-Phen 40S ribosomal protein S8 OS=Homo sapiens GN=RPS8 







































Translationally-controlled tumor protein OS=Homo sapiens 






































Neg ctrl Actin-related protein 2 OS=Homo sapiens GN=ACTR2 













































































Neg ctrl T-complex protein 1 subunit alpha OS=Homo sapiens 






































Neg ctrl Cu-Phen Hematological and neurological expressed 1 protein 







































Neg ctrl Heat shock protein HSP 90-beta OS=Homo sapiens 







































Cu-Phen Proteasome subunit alpha type-2 OS=Homo sapiens 








































Cu-Phen Neg ctrl Ras GTPase-activating protein-binding protein 1 OS=Homo 






































Cu-Phen Serine/threonine-protein phosphatase 2A 65 kDa regulatory 























































































































S-formylglutathione hydrolase OS=Homo sapiens 





































Cu-Phen Neg ctrl 60 kDa heat shock protein, mitochondrial OS=Homo 








































Cu-Phen Nuclear mitotic apparatus protein 1 OS=Homo sapiens 





































Neg ctrl Heat shock protein HSP 90-alpha OS=Homo sapiens 








































Cu-Phen Hematological and neurological expressed 1-like protein 







































Cu-Phen 60S ribosomal protein L21 OS=Homo sapiens GN=RPL21 








































Heterogeneous nuclear ribonucleoprotein A0 OS=Homo 






































Protein disulfide-isomerase A3 OS=Homo sapiens 







































Glyceraldehyde-3-phosphate dehydrogenase OS=Homo 








































Chloride intracellular channel protein 1 OS=Homo sapiens 













































































Guanine nucleotide-binding protein subunit beta-2-like 1 










































Cu-Phen 60S ribosomal protein L24 OS=Homo sapiens GN=RPL24 











































































Neg ctrl Cu-Phen Histone H2B type 3-B OS=Homo sapiens 












































































N-alpha-acetyltransferase 10 OS=Homo sapiens 








































Anterior gradient protein 2 homolog OS=Homo sapiens 













































































Cu-Phen Aspartate aminotransferase, cytoplasmic OS=Homo sapiens 






































40S ribosomal protein S9 OS=Homo sapiens GN=RPS9 






































Cu-Phen Neg ctrl Bcl-2-associated transcription factor 1 OS=Homo sapiens 







































Neg ctrl Adenosylhomocysteinase OS=Homo sapiens GN=AHCY 















































































Cu-Phen 40S ribosomal protein S21 OS=Homo sapiens GN=RPS21 















































































Serine/arginine-rich splicing factor 2 OS=Homo sapiens 
















































































Cu-Phen 26S protease regulatory subunit 8 OS=Homo sapiens 






































Ras-related protein Rap-1b OS=Homo sapiens GN=RAP1B 






































Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit 






































Peptidyl-prolyl cis-trans isomerase A OS=Homo sapiens 







































Cu-Phen 60S ribosomal protein L13 OS=Homo sapiens GN=RPL13 








































Nuclear migration protein nudC OS=Homo sapiens 














































































Ubiquitin-40S ribosomal protein S27a OS=Homo sapiens 







































78 kDa glucose-regulated protein OS=Homo sapiens 





























































































































































Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 







































Cu-Phen Eukaryotic initiation factor 4A-III OS=Homo sapiens 







































10 kDa heat shock protein, mitochondrial OS=Homo 







































Elongation factor Tu, mitochondrial OS=Homo sapiens 
























































































































Calcyclin-binding protein OS=Homo sapiens 








































Na(+)/H(+) exchange regulatory cofactor NHE-RF1 















































































Cu-Phen Neg ctrl Heat shock 70 kDa protein 1B OS=Homo sapiens 








































Cu-Phen Cold-inducible RNA-binding protein OS=Homo sapiens 














































































Cu-Phen Neg ctrl Glucose-6-phosphate 1-dehydrogenase OS=Homo sapiens 







































Neg ctrl Proteasome subunit alpha type-1 OS=Homo sapiens 















































































Cu-Phen Heterogeneous nuclear ribonucleoproteins A2/B1 





































Neg ctrl Cu-Phen Transitional endoplasmic reticulum ATPase OS=Homo 








































Non-POU domain-containing octamer-binding protein 








































Cu-Phen T-complex protein 1 subunit eta OS=Homo sapiens 




































Neg ctrl Cu-Phen Heterogeneous nuclear ribonucleoprotein K OS=Homo 




















































































































































































3.10.2 Exposure of MCF-7 cells at 48 h to Cu-Phen (1) and Cu-DPQ-Phen (2) against the negative control 




  Cu 
Ph
en 




























Description 4 1 4 3 av
era
ge 
5 1 5 2 5 3 av
era
ge 
6 1 6 2 6 3 av
era
ge 








Cu Phen neg ctrl GTP-binding nuclear protein Ran 
























































neg ctrl Metallothionein-2 OS=Homo 





















































Cu Phen neg ctrl Tubulin beta-3 chain OS=Homo 




















































Cu Phen neg ctrl Phosphoglycerate kinase 1 
OS=Homo sapiens GN=PGK1 





















































Cu Phen neg ctrl Tubulin beta chain OS=Homo 




















































Cu Phen neg ctrl Tubulin beta-4A chain OS=Homo 

























































Cu Phen neg ctrl Annexin A2 OS=Homo sapiens 





















































Cu Phen neg ctrl Tubulin beta-6 chain OS=Homo 
























































Cu Phen Ubiquitin-40S ribosomal protein 
S27a OS=Homo sapiens 






















































Cu Phen Histone H2B type 1-K OS=Homo 






















































Cu Phen neg ctrl 40S ribosomal protein S7 
OS=Homo sapiens GN=RPS7 



















































Cu Phen neg ctrl Pyruvate kinase PKM OS=Homo 






















































neg ctrl Cu Phen Serum albumin OS=Homo sapiens 





















































neg ctrl Cu Phen Cold-inducible RNA-binding 
protein OS=Homo sapiens 






















































Cu Phen Protein RCC2 OS=Homo sapiens 



















































Cu Phen neg ctrl Heat shock 70 kDa protein 1B 
























































Cu Phen Proteasome subunit alpha type-1 
OS=Homo sapiens GN=PSMA1 


















































Cu Phen neg ctrl 60S acidic ribosomal protein P0 

























































Cu Phen Plectin OS=Homo sapiens 



















































Cu Phen neg ctrl Filamin-A OS=Homo sapiens 










































































Description 7 2 7 3 aver
age 
8 1 8 3 aver
age 

















Metallothionein-1X OS=Homo sapiens GN=MT1X 











































Metallothionein-2 OS=Homo sapiens GN=MT2A 










































Heat shock 70 kDa protein 6 OS=Homo sapiens 











































Heat shock 70 kDa protein 1B OS=Homo sapiens 










































Phosphoglycerate kinase 1 OS=Homo sapiens 










































Ubiquitin-40S ribosomal protein S27a OS=Homo 










































Tumor protein D54 OS=Homo sapiens 










































60S ribosomal protein L4 OS=Homo sapiens 








































Nucleoside diphosphate kinase B OS=Homo sapiens 



































































Carbonyl reductase [NADPH] 1 OS=Homo sapiens 









































Keratin, type I cytoskeletal 17 OS=Homo sapiens 

























































































































Tubulin alpha-1B chain OS=Homo sapiens 










































Histone H2B type 1-D OS=Homo sapiens 











































Heterogeneous nuclear ribonucleoproteins A2/B1 










































Importin subunit alpha-1 OS=Homo sapiens 



















































































ATP synthase subunit beta, mitochondrial 










































Polypyrimidine tract-binding protein 1 OS=Homo 









































Stress-70 protein, mitochondrial OS=Homo sapiens 









































Tubulin beta-4A chain OS=Homo sapiens 































































































































Nucleoside diphosphate kinase A OS=Homo sapiens 









































Thioredoxin-like protein 1 OS=Homo sapiens 









































60S ribosomal protein L24 OS=Homo sapiens 









































Histone H2B type 1-K OS=Homo sapiens 





















































































GMP synthase [glutamine-hydrolyzing] OS=Homo 










































40S ribosomal protein S7 OS=Homo sapiens 











































60S ribosomal protein L29 OS=Homo sapiens 








































Triosephosphate isomerase OS=Homo sapiens 









































































3.10.4 Exposure of SKOV-3 cells at 48 h to Cu-Phen (1) and Cu-DPQ-Phen (2) against the negative control 
         SKOV-3 
48 hr neg 
 SKOV-3 48 hr 
Cu-Phen 


































































Glyceraldehyde-3-phosphate dehydrogenase OS=Homo 










































48 hr neg 



































811 48 hr neg 48 hr Cu-
Phen 










































































Splicing factor 3B subunit 2 OS=Homo sapiens 









































48 hr neg 











































48 hr neg 
Phosphoglycerate kinase 1 OS=Homo sapiens GN=PGK1 












































Ubiquitin-40S ribosomal protein S27a OS=Homo sapiens 










































48 hr neg 












































48 hr neg 
Heat shock 70 kDa protein 1B OS=Homo sapiens 























































































Splicing factor, proline- and glutamine-rich OS=Homo 












































Protein disulfide-isomerase A3 OS=Homo sapiens 











































Proteasome subunit alpha type-1 OS=Homo sapiens 
























































































Tubulin beta-4A chain OS=Homo sapiens GN=TUBB4A 










































48 hr neg 
Triosephosphate isomerase OS=Homo sapiens GN=TPI1 










































48 hr neg 
Macrophage migration inhibitory factor OS=Homo sapiens 














































78 kDa glucose-regulated protein OS=Homo sapiens 












































Proliferation-associated protein 2G4 OS=Homo sapiens 












































Fructose-bisphosphate aldolase A OS=Homo sapiens 










































48 hr neg 













































Ran-binding protein 3 OS=Homo sapiens GN=RANBP3 









































48 hr neg 












































T-complex protein 1 subunit epsilon OS=Homo sapiens 











































Nuclear migration protein nudC OS=Homo sapiens 





















































































48 hr neg 
Histone H2B type 1-K OS=Homo sapiens 










































48 hr neg 












































Far upstream element-binding protein 1 OS=Homo sapiens 

































































































































60S ribosomal protein L13 OS=Homo sapiens GN=RPL13 










































Serine/arginine-rich splicing factor 1 OS=Homo sapiens 








































































































































T-complex protein 1 subunit zeta OS=Homo sapiens 





















































































KH domain-containing, RNA-binding, signal transduction-



















































































Heterogeneous nuclear ribonucleoprotein K OS=Homo 

































































































































DnaJ homolog subfamily A member 1 OS=Homo sapiens 












































Phosphoglycerate mutase 1 OS=Homo sapiens 











































Eukaryotic translation initiation factor 5 OS=Homo 



















































































48 hr neg 
Glucose-6-phosphate isomerase OS=Homo sapiens 












































40S ribosomal protein S28 OS=Homo sapiens GN=RPS28 











































Histone H2B type 3-B OS=Homo sapiens 












































Protein disulfide-isomerase OS=Homo sapiens GN=P4HB 






















































































Chromobox protein homolog 3 OS=Homo sapiens 









































48 hr neg 
Importin subunit beta-1 OS=Homo sapiens GN=KPNB1 










































Transitional endoplasmic reticulum ATPase OS=Homo 












































60S ribosomal protein L22 OS=Homo sapiens GN=RPL22 





















































































40S ribosomal protein S14 OS=Homo sapiens GN=RPS14 








































48 hr neg 











































Protein disulfide-isomerase A6 OS=Homo sapiens 










































48 hr neg 
Fructose-bisphosphate aldolase C OS=Homo sapiens 










































48 hr neg 
40S ribosomal protein S7 OS=Homo sapiens GN=RPS7 











































Neutral alpha-glucosidase AB OS=Homo sapiens 












































Epidermal growth factor receptor kinase substrate 8-like 



















































































48 hr neg 
Pre-mRNA-processing factor 19 OS=Homo sapiens 












































48 hr neg 
L-lactate dehydrogenase A chain OS=Homo sapiens 










































48 hr neg 










































Proteasome subunit alpha type-7 OS=Homo sapiens 










































48 hr neg 
Phosphoserine aminotransferase OS=Homo sapiens 












































Bcl-2-associated transcription factor 1 OS=Homo sapiens 









































48 hr neg 
Nucleoside diphosphate kinase B OS=Homo sapiens 










































48 hr neg 
Nucleoside diphosphate kinase A OS=Homo sapiens 










































Nucleosome assembly protein 1-like 4 OS=Homo sapiens 









































48 hr neg 
Tubulin beta-2A chain OS=Homo sapiens GN=TUBB2A 












































Serine/threonine-protein phosphatase 2A 65 kDa 
regulatory subunit A alpha isoform OS=Homo sapiens 





















































































48 hr neg 
Rab GDP dissociation inhibitor alpha OS=Homo sapiens 






















































































Heterogeneous nuclear ribonucleoprotein A0 OS=Homo 











































Probable ATP-dependent RNA helicase DDX17 















































Hematological and neurological expressed 1-like protein 











































Heterogeneous nuclear ribonucleoprotein D-like 











































GTP-binding nuclear protein Ran OS=Homo sapiens 










































Apoptotic chromatin condensation inducer in the nucleus 










































48 hr neg 
Microtubule-associated protein 1B OS=Homo sapiens 

































































































































Probable ATP-dependent RNA helicase DDX5 OS=Homo 









































48 hr neg 












































Polyadenylate-binding protein 1 OS=Homo sapiens 









































Cold-inducible RNA-binding protein OS=Homo sapiens 












































Heterogeneous nuclear ribonucleoprotein A1 OS=Homo 






















































































48 hr neg 












































Elongation factor 1-alpha 1 OS=Homo sapiens 












































Protein kinase C delta-binding protein OS=Homo sapiens 














































WASH complex subunit CCDC53 OS=Homo sapiens 








































48 hr neg 



































































































































Alanine--tRNA ligase, cytoplasmic OS=Homo sapiens 











































Tubulin beta-6 chain OS=Homo sapiens GN=TUBB6 











































ATP-dependent RNA helicase DDX3X OS=Homo sapiens 










































Scaffold attachment factor B1 OS=Homo sapiens 







































48 hr neg 
Ubiquitin-like modifier-activating enzyme 1 OS=Homo 











































60S ribosomal protein L15 OS=Homo sapiens GN=RPL15 











































Ran GTPase-activating protein 1 OS=Homo sapiens 






















































































PDZ and LIM domain protein 1 OS=Homo sapiens 























































































Protein AHNAK2 OS=Homo sapiens GN=AHNAK2 











































Proteasome subunit alpha type-6 OS=Homo sapiens 












































48 hr neg 
Prolyl 4-hydroxylase subunit alpha-2 OS=Homo sapiens 
























































































DNA replication licensing factor MCM7 OS=Homo 












































LIM and SH3 domain protein 1 OS=Homo sapiens 












































60S ribosomal protein L30 OS=Homo sapiens GN=RPL30 










































Thioredoxin domain-containing protein 5 OS=Homo 












































Vasodilator-stimulated phosphoprotein OS=Homo sapiens 












































Eukaryotic translation initiation factor 5A-1 OS=Homo 










































48 hr neg 
ATP-dependent 6-phosphofructokinase, liver type 











































ATP-dependent RNA helicase DDX1 OS=Homo sapiens 







































48 hr neg 
ATP-dependent 6-phosphofructokinase, platelet type 













































Macrophage-capping protein OS=Homo sapiens 





















































































Chromobox protein homolog 1 OS=Homo sapiens 










































Heterogeneous nuclear ribonucleoprotein D0 OS=Homo 









































48 hr neg 
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 












































Voltage-dependent anion-selective channel protein 1 
































































































































Eukaryotic translation initiation factor 6 OS=Homo 











































Actin-related protein 2 OS=Homo sapiens GN=ACTR2 










































60S acidic ribosomal protein P0 OS=Homo sapiens 









































Nuclear mitotic apparatus protein 1 OS=Homo sapiens 








































48 hr neg 













































Adenosylhomocysteinase OS=Homo sapiens GN=AHCY 










































60S ribosomal protein L3 OS=Homo sapiens GN=RPL3 











































Prohibitin OS=Homo sapiens GN=PHB PE=1 SV=1 
[MASS=29804] 
313
797
.2 
364
578
.4 
339
187
.8 
306
102
.8 
418
930
.8 
362
516
.8 
202
828
.6 
165
636
.4 
184
232
.5 
 
 
